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 1 ABSTRACT 
 People with diabetes suffer from an increased incidence of atherosclerosis, 
possibly due to the hyperglycaemia associated with this disease. Glucose may 
covalently modify proteins via glycation and glycoxidation reactions. Reactive 
aldehydes (e.g. methylglyoxal and glycolaldehyde) generated from these glycation and 
glycoxidation reactions, lipid peroxidation and other metabolic pathways may also 
modify proteins in glycation and glycoxidation reactions. These reactions can result in 
the formation of advanced glycation end-products, which are increased in diabetes and 
associated complications such as atherosclerosis. Low-density lipoproteins (LDLs) are 
the main source of lipid in atherosclerotic plaques, and the lipid-laden foam cells 
contained within. Modification of the single protein in LDL, apolipoprotein B-100 (apo 
B) by glucose and aldehydes may result in recognition of these altered LDL particles by 
macrophage scavenger receptors and cellular accumulation of cholesteryl esters; such 
accumulation is characteristic of atherosclerotic foam cells.  
The extent and nature of the modifications of LDLs that give rise to this 
behaviour have been poorly characterised, especially in regards to 
modification/oxidation of protein versus lipid components induced by glucose and low-
molecular-mass aldehydes. Therefore the aims of this project were to: 1) characterise 
LDL modification by glucose, methylglyoxal and glycolaldehyde; 2) examine the effect 
of these modified LDLs on arterial cells by monitoring cellular viability, proliferation 
and cholesterol and cholesteryl ester levels; and 3) examine macrophage handling of 
apo B from these modified LDLs. 
Glycolaldehyde induced more rapid and more extensive changes to LDL than 
methylglyoxal, which was significantly more modified than LDL exposed to glucose, in 
the presence or absence of Cu2+. LDL was modified by glycolaldehyde and 
methylglyoxal in a time- and concentration-dependent manner. These aldehyde-
modified LDLs were significantly more negatively charged relative (determined by 
changes in relative electrophoretic mobility), more aggregated (by SDS-PAGE) and lost 
more Arg, Lys and Trp residues (assessed by fluorescence-based assays) than glucose-
modified and control LDLs. Glucose-modified LDL had more modest increases in net 
negative charge, aggregation and only significantly lost Arg residues. Under the 
conditions examined none of the modified LDLs contained significant levels of the 
protein oxidation products DOPA and o-tyrosine, the lipid oxidation products 7-
 i i
 ketocholesterol and cholesteryl ester hydro(pero)oxides, nor marked depletion of the 
major antioxidant α-tocopherol or significant radical formation (EPR spectroscopy). 
Therefore these LDLs were glycated, but not (glyc)oxidised, and so allowed the cellular 
uptake of glycated LDL, rather than glycoxidised LDL, to be examined. 
These glycated LDLs had no effect on the cellular viability (assessed by LDH 
release), cell protein (BCA assay), and cholesterol and cholesteryl ester levels 
(quantified by reverse-phase HPLC) of endothelial and smooth muscle cells. The 
glycated LDLs also had no effects on human and mouse macrophage viability, protein 
and free cholesterol levels. However, exposure of macrophages to some of the glycated 
LDLs resulted in significant accumulation of cholesteryl esters and apo B. The greatest 
cellular accumulation of cholesteryl esters was in cells exposed to glycolaldehyde-
modified LDL, which occurred in a time- and concentration-dependent manner. Less 
cholesteryl ester accumulation was observed in cells exposed to methylglyoxal-
modified LDL, but some conditions resulted in significantly more cellular cholesteryl 
esters as compared to control LDLs, unlike glucose-modified LDL. Macrophages 
endocytosed significantly more apo B from glycolaldehyde-modified LDL labelled with 
125I on the apo B, than methylglyoxal-modified 125I-LDL. Apo B from methylglyoxal-
modified 125I-LDL was also endocytosed and degraded in greater amounts than control 
125I-LDLs, unlike glucose-modified 125I-LDLs. 
The glycation of LDL by some low-molecular-mass aldehydes have been shown 
to result in model foam cell formation as characterised by cholesteryl ester and apo B 
accumulation. This accumulation correlated with increases in net negative charge, 
aggregation and loss of Lys and Trp residues of the apo B in glycated LDL particles. 
However, the differences in cellular uptake of glycolaldehyde- versus methylglyoxal-
modified LDL were not completely resolved and it is postulated that this may arise from 
the extent or type of products formed on key amino acid residues, resulting in 
differential uptake by macrophage scavenger receptors, rather than loss of particular 
amino acids per se. Therefore these studies provide a potential mechanism to explain 
the increased atherosclerosis in people with diabetes, and a suitable model to examine 
the potential inhibition of the effects of glycated LDLs. This could provide potential 
therapeutic interventions to reduce diabetes-induced atherosclerosis. 
 
KHIJ 
 i i i
 LIST OF ABBREVIATIONS 
ABCA1   ATP-binding cassette transport-1 
ACAT    acyl coenzyme A: cholesterol acyltransferase 
ACE   angiotensin converting enzymes 
ACEH    acidic cholesteryl ester hydrolase 
AGE   advanced glycation end-product 
ANOVA  analysis of variance 
Apo   apolipoprotein 
ATP   adenosine triphosphate 
BCA   bicinchoninic acid 
BHT   butylated hydroxytoluene 
BSA   bovine serum albumin 
CEL   Nε-(carboxyethyl)lysine 
CML   Nε-(carboxymethyl)lysine 
DMPO   5,5’-dimethyl-1-pyrroline-N-oxide 
DNA   deoxyribonucleic acid 
DOPA   3,4-dihydroxyphenylalanine 
DTPA   diethylenetriaminepenta-acetic acid 
EDTA   ethylenediamine tetraacetic acid 
EPR   electron paramagnetic resonance 
FCS   foetal calf serum 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
HbA1c   glycated haemoglobin 
HBSS   Hank’s buffered saline solution 
HDL   high-density lipoprotein 
HMDM  human monocyte-derived macrophages 
HMG-CoA  3-hydroxy-3-methylglutaryl Coenzyme A reductase 
HPLC   high performance liquid chromatography 
HS   human serum 
HUVEC  human umbilical vein endothelial cells 
IDL   intermediate-density lipoprotein 
IGF-1   insulin-like growth factor 
IL   interleukin 
 i v
 LCAT   lecithin:cholesterol acyltransferase 
LDH   lactate dehydrogenase 
LDL   low-density lipoprotein 
LOX-1   lectin-like oxidised LDL receptor-1 
LPDS   lipoprotein deficient serum 
LPL   lipoprotein lipase 
LXR   liver X receptors 
mAU   milli absorbance units 
mRNA   messenger ribonucleic acid 
mT   millitesla 
NAD+   nicotinamide adenine dinucleotide, oxidised form  
NADH   nicotinamide adenine dinucleotide, reduced form 
NADPH  nicotinamide adenine dinucleotide phosphate, reduced form 
nCEH   neutral cholesteryl ester hydrolases 
NF-κB   nuclear transcription factor κB 
NIH   National Institute of Health (USA) 
p60   AGE binding receptor/protein of 60 kDa, 
p90   AGE binding receptor/protein of 90 kDa, 
PBN    N-tert-butyl-α-phenylnitrone   
PBS   phosphate-buffered saline 
PDGF   platelet derived growth factor 
PenStrep penicillin  (100 units/ml) and streptomycin (0.1 mg/ml) 
(Sigma-Aldrich, Castle Hill, NSW, Australia) 
PLTP   phospholipid transfer protein 
PPACK   D-phenylalanyl-L-arginine chloromethyl ketone 
PPAR   peroxisome proliferator-activated receptors 
PTB   N-phenacylthiazolium bromide 
RAGE   receptor for advanced glycation end-products 
REM   relative electrophoretic mobility 
RXR   retinoid X receptors 
SDS   sodium dodecyl sulphate 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SR   scavenger receptor 
SREBP  sterol regulatory element-binding protein 
 v
 TBARS  thiobarbituric acid reactive substances 
TCA   trichloroacetic acid 
TNF   tumour necrosis factor 
Tris   tris(hydroxylmethyl)aminomethane 
VCAM-1  vascular cell adhesion molecule-1 
VEGF   vascular endothelial growth factor 
VLDL   very-low density lipoproteins 
 
KHIJ  
 
 v i
 LIST OF FIGURES 
Figure 1.1 Metabolism of LDL in cells after uptake via the LDL receptor. ..................21 
Figure 1.2 Cholesteryl ester metabolism in macrophages after LDL uptake 
via scavenger receptor-mediated endocytosis. ..........................................22 
Figure 1.3 Pathways of AGE formation.........................................................................26 
Figure 1.4 Alternative pathways of the Maillard reaction from glucose, 
including formation of reactive aldehydes. ...............................................27 
Figure 1.5 Structure of glucose and some of the common aldehydes involved 
in glycation/glycoxidation reactions and the formation of 
AGEs. ........................................................................................................28 
Figure 2.1 Example of an agarose gel run with native and modified LDL to 
determine REM. ........................................................................................53 
Figure 2.2 HPLC chromatograph of cholesterol and cholesteryl esters 
detected at 205 nm.....................................................................................56 
Figure 2.3 HPLC chromatograph of a 7-ketocholesterol standard at 234 nm................57 
Figure 2.4 HPLC chromatograph of cholesterol and cholesteryl esters 
detected at 205 nm with a more polar mobile phase .................................63 
Figure 3.1 REM of LDL modified by glucose, in the presence or absence of 
Cu2+, for 14 days. ......................................................................................71 
Figure 3.2 REM of glucose-modified LDL over 8 weeks..............................................71 
Figure 3.3 SDS-PAGE of LDL modified by glucose over 8 weeks ..............................72 
Figure 3.4 Modification of Arg, Lys and Trp residues in apo B of LDL  
modified by glucose ..................................................................................74 
Figure 3.5 Levels of 7-ketocholesterol in LDL modified by glucose, in the 
presence or absence of Cu2+, for 14 days ..................................................77 
Figure 3.6 REM of LDL modified by methylglyoxal over time....................................83 
Figure 3.7 SDS-PAGE of LDL modified by methylglyoxal for up to 5 days................84 
Figure 3.8 Modification of Arg, Lys and Trp residues in apo B of LDL 
modified by methylglyoxal for up to 14 days ...........................................85 
Figure 3.9 Levels of 7-ketocholesterol in LDL modified by methylglyoxal 
for up to 14 days........................................................................................88 
Figure 3.10 EPR spectra, detected with the spin trap PBN,  of LDL modified 
by methylglyoxal for 5 days......................................................................89 
 v i i
 Figure 3.11 REM of LDL modified by glycolaldehyde for up to 14 days.....................93 
Figure 3.12 SDS-PAGE of LDL modified by glycolaldehyde, for up to 7 
days............................................................................................................95 
Figure 3.13 Modification of Arg, Lys and Trp residues in apo B of LDL  
modified by glycolaldehyde for up to 14 days. .........................................96 
Figure 3.14 Levels of 7-ketocholesterol in LDL modified by glycolaldehyde 
for up to 7 days..........................................................................................98 
Figure 3.15 EPR spectra, detected with the spin trap PBN, of LDL modified 
by glycolaldehyde for 7 days...................................................................101 
Figure 3.16 EPR spectra, detected with the spin trap DMPO, of LDL 
modified by glycolaldehyde for 7 days ...................................................102 
Figure 4.1 The effect of EDTA on J774A.1 macrophage viability and 
protein......................................................................................................112 
Figure 4.2 The effect of glucose, in the presence or absence of Cu2+, on 
J774A.1 macrophage viability and protein..............................................113 
Figure 4.3 The effect of methylglyoxal and glycolaldehyde on J774A.1 
macrophage viability and protein ............................................................114 
Figure 4.4 Protein concentration of glucose-modified LDL before and after 
column chromatography..........................................................................116 
Figure 4.5 Protein concentration of LDL modified by methylglyoxal before 
and after column chromatography...........................................................117 
Figure 4.6 Protein concentration of LDL modified by glycolaldehyde before 
and after column chromatography...........................................................118 
Figure 4.7 J774A.1 cell viability after exposure to acetylated LDL. ...........................121 
Figure 4.8 J774A.1 cell protein after exposure to acetylated LDL..............................122 
Figure 4.9 Quantification of free cholesterol, total cholesteryl esters and 
percent cholesteryl esters (of total sterol levels) detected in 
J774A.1 cells after exposure to acetylated LDL .....................................123 
Figure 4.10 J774A.1 cell viability after exposure to LDL modified by 
glucose, in the presence or absence of Cu2+ ............................................128 
Figure 4.11 J774A.1 cell protein after exposure to LDL modified by glucose, 
in the presence or absence of Cu2+ ..........................................................128 
 
 
 v i i i
  
Figure 4.12 Quantification of free cholesterol, total cholesteryl esters and 
percent cholesteryl esters (of total sterol levels) detected in 
J774A.1 cells after exposure to glucose-modified LDL, in the 
presence or absence of Cu2+. ...................................................................129 
Figure 4.13 The effect of LDL  modified by methylglyoxal for 24 hr on 
J774A.1 cellular viability, protein, free cholesterol levels, total 
cholesteryl ester levels and percent cholesteryl esters (of total 
sterol levels). ...........................................................................................133 
Figure 4.14 The effect of LDL modified by methylglyoxal for 5 days on 
J774A.1 cellular viability, protein, free cholesterol levels, total 
cholesteryl ester levels and percent cholesteryl esters (of total 
sterol levels). ...........................................................................................136 
Figure 4.15 The effect of LDL modified by methylglyoxal for 7 days on 
J774A.1 cellular viability, protein, free cholesterol levels, total 
cholesteryl ester levels and percent cholesteryl esters (of total 
sterol levels). ...........................................................................................137 
Figure 4.16 The effect of LDL  modified by methylglyoxal for 14 days on 
J774A.1 cellular viability, protein, free cholesterol levels, total 
cholesteryl ester levels and percent cholesteryl esters (of total 
sterol levels). ...........................................................................................138 
Figure 4.17 The effect of LDL modified glycolaldehyde for 24 hr on 
J774A.1 cellular viability, protein, free cholesterol levels, total 
cholesteryl ester levels and percent cholesteryl esters (of total 
sterol levels). ...........................................................................................145 
Figure 4.18 The effect of LDL modified by glycolaldehyde for 7 days on 
J774A.1 cellular viability, protein, free cholesterol levels, total 
cholesteryl ester levels and percent cholesteryl esters (of total 
sterol levels). ...........................................................................................147 
Figure 5.1 The effect of LDL modified by glucose, in the presence or 
absence of Cu2+ for 14 days, on HUVEC viability and cell 
protein......................................................................................................157 
 
 
 i x
  
Figure 5.2 The effect of LDL modified by glucose, in the presence or 
absence of Cu2+, for 14 days on HUVEC free cholesterol, total 
cholesteryl esters, and percent cholesteryl esters (of total sterol 
levels) ......................................................................................................158 
Figure 5.3 The effect of LDL modified by methylglyoxal for 5 days on 
HUVEC viability and cell protein ...........................................................161 
Figure 5.4 The effect of LDL modified by methylglyoxal for 5 days on 
HUVEC free cholesterol, total cholesteryl esters and percent 
cholesteryl esters (of total sterol levels) ..................................................162 
Figure 5.5 The effect of LDL modified by glycolaldehyde for 7 days on 
HUVEC viability and cell protein ...........................................................165 
Figure 5.6 The effect of LDL modified by glycolaldehyde for 7 days on 
HUVEC free cholesterol, total cholesteryl esters and percent 
cholesteryl esters (of total sterol levels) ..................................................166 
Figure 5.7 The effect of LDL modified by glucose, in the presence or 
absence of Cu2+, for 14 days on A7r5 smooth muscle cell 
viability, cell protein and free cholesterol levels.....................................171 
Figure 5.8 The effect of  LDL modified by glucose, in the presence or 
absence of Cu2+  for 14 days on serum-deprived A7r5 smooth 
muscle cell viability, cell protein and free cholesterol levels..................173 
Figure 5.9 The effect of LDL modified by methylglyoxal for 5 days on A7r5 
smooth muscle cell viability, cell protein and free cholesterol 
levels........................................................................................................175 
Figure 5.10 The effect of LDL modified by methylglyoxal for 5 days on 
serum-deprived A7r5 smooth muscle cell viability, cell protein 
and free cholesterol levels .......................................................................177 
Figure 5.11 The effect of LDL modified by glycolaldehyde for 7 days on 
A7r5 smooth muscle cell viability, cell protein and free 
cholesterol levels .....................................................................................179 
Figure 5.12 The effect of LDL  modified by glycolaldehyde  for 7 days on 
serum-deprived A7r5 smooth muscle cell viability, cell protein 
and free cholesterol levels .......................................................................181 
 x
 Figure 6.1 HMDM cell viability after exposure to LDL modified by 
acetylation, methylglyoxal, glycolaldehyde or glucose, in the 
presence or absence of Cu2+ ....................................................................189 
Figure 6.2 HMDM cell protein levels after exposure to LDL modified by 
acetylation, methylglyoxal, glycolaldehyde or 100 mM glucose, 
in the presence or absence of Cu2+ ..........................................................189 
Figure 6.3 Free cholesterol, total cholesteryl esters  and percent cholesteryl 
esters (of total sterol levels) for HMDM exposed to LDL 
modified by acetylation, methylglyoxal, glycolaldehyde or 
glucose, in the presence or absence of Cu2+ ............................................191 
Figure 6.4 Comparison of J774A.1 and HMDM free cholesterol, total 
cholesteryl esters and percent cholesteryl esters (of total sterol 
levels) after exposure to LDL modified by acetylation, 
methylglyoxal, glycolaldehyde or glucose, in the presence or 
absence of Cu2+ .......................................................................................198 
Figure 6.5 Comparison of levels of individual cholesteryl esters in J774A.1 
cells and HMDM, exposed to LDL modified by glycolaldehyde 
for 7 days. ................................................................................................199 
Figure 7.1 Comparison of the REM of 125I-LDL and unlabelled LDL used in 
HMDM experiments................................................................................204 
Figure 7.2 Cell protein levels in 125I-LDL HMDM studies..........................................206 
Figure 7.3 Cell death in 125I-LDL 24 hr chase studies, after HMDM exposure 
to modified LDL......................................................................................207 
Figure 7.4 HMDM surface binding, endocytosis, intracellular accumulation 
and degradation of apo B from acetylated LDL, control LDL or 
methylglyoxal-modified LDL. ................................................................210 
Figure 7.5 HMDM surface binding, endocytosis, intracellular accumulation 
and degradation of apo B from glycolaldehyde-modified LDL, 
glucose-modified LDL or glucose plus Cu2+-modified LDL..................211 
Figure 7.6 Comparison of HMDM surface binding, endocytosis, intracellular 
accumulation and degradation of apo B after 96 hr or 24 hr 
exposure to modified 125I-LDL................................................................212 
Figure 7.7  Rates of degradation of apo B, from modified 125I-LDL, by 
HMDM ....................................................................................................213 
 x i
 Figure 7.8 HMDM turnover of apo B after a 96 hr exposure to acetylated 
LDL, control LDL or methylglyoxal-modified LDL. .............................216 
Figure 7.9 HMDM turnover of apo B after a 96 hr exposure to 
glycolaldehyde-modified LDL, glucose-modified LDL  or 
glucose or Cu2+-modified LDL ...............................................................217 
Figure 7.10 HMDM turnover of apo B after a 24 hr exposure to modified 
125I-LDLs .................................................................................................219 
Figure 7.11 Comparison of percent apo B remaining after the 24 hr chase 
period for cells exposed to 125I-LDL for 24 or 96 hr...............................220 
 
KHIJ 
 x i i
 LIST OF TABLES 
Table 2.1 Response factors for cholesterol, cholesteryl esters and 7-
ketocholesterol used in HPLC quantification......................................…..57 
Table 3.1 Cholesterol  and cholesteryl estercomposition of LDL modified by 
glucose, in the presence or absence of Cu2+, for up to 14 days.................76 
Table 3.2 Cholesterol and cholesteryl ester composition of LDL modified by 
methylglyoxal for up to 14 days................................................................87 
Table 3.3 Cholesterol and cholesteryl ester  composition of LDL  modified 
by glycolaldehyde for up to 7 days.. .........................................................99 
Table 4.1 Levels of individual cholesteryl esters  in J774A.1 cells after 
exposure to acetylated LDL. ...................................................................124 
Table 4.2 Levels of individual cholesteryl esters in J774A.1 cells after 
exposure to glucose-modified LDL.........................................................130 
Table 4.3 Levels of individual cholesteryl esters  in J774A.1 cells after 
exposure to methylglyoxal-modified LDL..............................................140 
Table 4.4 Levels of individual cholesteryl esters  in J774A.1 cells after 
exposure to glycolaldehyde-modified LDL. ...........................................148 
Table 5.1 Levels of individual cholesteryl esters in HUVEC after exposure to 
glucose-modified LDL. ...........................................................................159 
Table 5.2 Levels of individual cholesteryl esters in HUVEC after exposure to 
methylglyoxal-modified LDL.. ...............................................................163 
Table 5.3 Levels of individual cholesteryl esters  in HUVEC after exposure 
to glycolaldehyde-modified LDL............................................................167 
Table 6.1 Levels of individual cholesteryl esters in HMDM after exposure to 
LDL modified by acetylation, glucose, methylglyoxal or 
glycolaldehyde.........................................................................................193 
 
KHIJ  
 x i i i
 PUBLICATIONS ARISING FROM THIS THESIS 
Research Papers 
Knott HM, Brown BE, Davies MJ and Dean RT. Glycation and glycoxidation of low-
density lipoproteins by glucose and low-molecular weight aldehydes: Formation of 
modified and oxidised proteins. Eur J Biochem 2003; 270: 3572-3582. 
 
Brown BE, Dean RT, and Davies MJ. Glycation of low-density lipoproteins by 
methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden 
foam cells. To be published in Diabetologia Feb 2005. 
 
Brown BE, Rashid I, van Reyk DM, and Davies MJ. Glycation of low-density 
lipoproteins results in the time-dependent accumulation of lipids and apolipoprotein B-
100 in human monocyte-derived macrophages and the formation of model foam cells. 
Still in preparation 2005. 
 
Conference Presentations (presenting author underlined) 
Brown BE, Dean RT, and Davies MJ. Glycation and Glycoxidation of Low-Density 
Lipoprotein and it’s role in Foam Cell Formation. Poster presentation at the Joint 
Scientific meeting of the Society for Free Radical Research (Australasia) and the 
Society for Free Radical Research (Japan) “Redox Processes in Chemistry, Biology and 
Medicine”, Sydney, NSW, Australia, 2001. 
 
Brown BE. The Role of Glycation and Glycoxidation of Low-Density Lipoproteins in 
Foam Cell Formation. Oral presentation at the Australian Atherosclerosis Society 
Annual Scientific Meeting, Sydney, NSW, Australia, 2002. 
 
Brown BE, Knott HM, Dean RT, and Davies MJ. The Role of Glycation and 
Glycoxidation of Low-Density Lipoprotein in Foam Cell Formation. Poster presentation 
at the Society for Free Racial Research Conference “Oxidative Pathways in Chemistry, 
Biology and Medicine”, Wollongong, NSW, Australia, 2002. Awarded a student poster 
prize for this presentation. 
 
 x i v
 Brown BE. Uptake of glycated low-density lipoproteins by arterial cell types: a 
mechanism for formation of lipid-laden foam cells in diabetics? Oral presentation at the 
Joint meeting of the Australian Vascular Biology Society and the Australian 
Atherosclerosis Society, Ballart, VIC, Australia, 2003. Awarded a student travel award 
to attend this conference. 
  
Brown BE, Dean RT and Davies MJ. Uptake of glycated low-density lipoproteins by 
arterial cell types. Poster presentation at the Joint meeting of the Australian Diabetes 
Society and the Australian Diabetes Educators Society, Melbourne, VIC, Australia, 
2003. 
 
Rashid I, Brown BE, van Reyk DM, and Davies MJ. Glycation of low-density 
lipoproteins results in the time-dependent accumulation of lipids and apolipoprotein B-
100 in human monocyte-derived macrophages and the formation of model foam cells. 
Poster presentation at the Joint meeting of the Australian Vascular Biology Society and 
the Australian Atherosclerosis Society, Barossa Valley, SA, Australia, 2004. 
 
Mahroof F, Cook N, Brown BE, van Reyk DM, and Davies MJ. Inhibition of glycation 
of low-density lipoproteins and model foam cell formation by hydrazine compounds. 
Poster presentation at the Joint meeting of the Australian Vascular Biology Society and 
the Australian Atherosclerosis Society, Barossa Valley, SA, Australia, 2004. 
 
Davies MJ, Mahroof F, Brown BE, and van Reyk DM. Inhibition of advanced glycation 
end-product generation and foam cell formation in diabetes-associated atherosclerosis. 
Poster presentation at the Joint meeting of the Australian Diabetes Society and the 
Australian Diabetes Education Society, Sydney, NSW, Australia, 2004. 
 
Nobecourt E, Davies MJ, Bonnet DJ, Curtiss LK, Brown BE, and Rye KA. Evidence 
that glycation alters the conformation of apolipoprotein A-I in discoidal reconstituted 
HDL and impairs their reactivity with LCAT. Poster presentation at the Joint meeting of 
the Australian Diabetes Society and the Australian Diabetes Education Society, Sydney, 
NSW, Australia, 2004. 
KHIJ
 xv
  
 
 
CHAPTER 1: INTRODUCTION 
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 1.1  General Introduction 
Increasing urbanisation, industrialisation and globalisation are bringing changes 
to Western societies which promote heart disease [1, 2]. Such changes in human 
behaviour and lifestyle factors include more sedentary lifestyles, overly rich nutrition 
and obesity [2]. This has led to global epidemics of diseases such as cardiovascular 
disease and diabetes [1, 3]. Over 17 million people die from cardiovascular disease per 
year, and it is predicted to become the single leading public health problem worldwide 
by 2020 [4]. In 2000 over 151 million people worldwide had diabetes and this is 
expected to increase by 46 % to 221 million by 2010 [2].  People with diabetes have an 
increased risk of cardiovascular disease, and other related diseases, leading to decreased 
life expectancy and quality of life [2, 3]. In fact a clinical term ‘Syndrome X’ (or 
‘Metabolic Syndrome’) has been coined as a term for a cluster of human pathologies 
that often occur together: android obesity, hypertension, glucose intolerance, insulin 
resistance and dyslipidaemia; leading to heart disease and diabetes [5, 6]. Due to the 
prevalence of these diseases much research has been performed, but the links between 
cardiovascular disease and diabetes are still not fully understood. This Chapter reviews 
background information and theories on the links between atherosclerosis and diabetes, 
which underlay the work covered in this thesis. Firstly the pathogenesis of 
atherosclerosis (a disease of the cardiovascular system) and then diabetes will be 
discussed, followed by evidence linking these two disease states together. 
 
1 .1 .1  Cardiovascular Diseases 
Cardiovascular diseases are those affecting normal functioning of the heart and 
blood vessels (for example coronary arteries and the cerebrovascular circulation). These 
encompass myocardial infarction, cardiomyopathies, rheumatic and congenital heart 
diseases, coronary artery disease, heart failure, hypertension, peripheral vascular 
disease, and stroke [1, 4]. In 2001 cardiovascular disease contributed to a third of global 
deaths and 80 % of these were from developing, low and middle income countries [1]. 
Russia has the highest death rate from cardiovascular diseases, followed by Ukraine, 
Romania, Hungary and Poland; whereas Japan has the lowest death rate, France the 
second lowest and Canada the third lowest [4].  
In 2002 Australia had the 6th lowest death rate from cardiovascular disease [4]. 
However, cardiovascular disease still kills more Australians than any other disease 
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 group, including cancers, and accounts for 37.6 % (or 50 000) of all deaths [7]. 
Coronary artery disease is the greatest single cause of death in Australia comprising 
approximately 19.5 % off all deaths in 2002 [7]. Currently 3.67 million Australians are 
affected by cardiovascular disease, with one-third disabled long-term [7]. Specific sub-
groups of Australians are more likely to die from cardiovascular disease than other 
groups. Death rates in men are 2-3 times those of females [4], and Aborigines and 
Torres Strait Islanders are 2.6 times more likely to die from cardiovascular disease 
compared to other Australians [7]. In 1993-1994 cardiovascular disease accounted for 
12 % ($3.9 billion) of total health care expenditure, making it one of the most costly 
diseases. The proportion of Australian adults with a least one risk factor for 
cardiovascular disease (such as being overweight/obese, inactive, hypertensive, 
hypercholesterolemic, a cigarette smoker, or diabetic) is very high at 90 % [7]. 
Therefore, even though death rates from cardiovascular disease are declining due to 
reductions in the prevalence of some risk factors, and improvements in disease 
management including new prescription drugs and medical treatment [4], it is still 
socially and economically very significant. 
 
1 .1 .1 .a  Pathogenesis of Atherosclerosis 
Atherosclerosis is the process which leads to the thickening of the artery walls 
and gives rise to the many pathologies that cause cardiovascular disease or coronary 
heart disease [1, 4]. The lesions of atherosclerosis are generally characterised by a soft, 
lipid-rich part (the ‘athere’ or porridge part) and a hard (sclerotic) fibrous or calcified 
part [8]. Atherosclerosis occurs mainly in medium and large sized arteries (diameter > 2 
mm), including the aortae, coronary arteries, iliac and femoral arteries, the internal 
carotids and the Circle of Willis arteries [8]. Lesions are often located where arteries 
branch, perhaps due to varying shear stresses [9]. The early stages of atherosclerotic 
lesions may begin in childhood [10, 11] and have been found in human foetal aortas 
[12]. Lesions generally increase in extent, severity, and prevalence up to the 4th decade, 
thus symptoms often manifest in later adult years due to the formation of advanced 
lesions [10, 11]. 
A number of groups have attempted to define the developmental stages of 
atherosclerotic lesions [10, 13-16]. However there is some controversy regarding such 
categorisations, with even the definition of a healthy artery not in universal agreement 
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 [8, 15]. In this thesis the developmental stages will be based on the relatively well 
accepted American Heart Association Medical/Scientific Statements [10, 15, 16]. These 
are basically an expansion on the earlier classifications terms of fatty streak, fibrous 
plaque and complicated lesions [13, 14]. The American Heart Association 
Medical/Scientific Statements lesion stages are designated by Roman numerals from I-
VI, indicating the usual sequence of lesion development determined by histology [10, 
15, 16].  
In a normal artery the intima is usually defined as the region between the 
endothelial surface at the lumen to the internal elastic lamina [8, 13, 15]. Under the 
endothelium the intima may be divided into 2 layers. The inner layer is called the 
proteoglycan layer as it contains ubiquitous proteoglycans as well as single-spaced 
smooth muscle cells and macrophages. The outer intima layer is the musculoelastic 
layer and has abundant smooth muscle cells and elastic fibres [8, 15]. Normal healthy 
arteries are a pinkish grey colour with a smooth, unblemished, surface, and often consist 
of a monolayer of endothelial cells with little area between them and the internal elastic 
lamina. However, in most arteries there are also areas where there is a layer of 
connective tissue between the endothelium and internal elastic lamina, termed intimal 
thickening. Prevalence of intimal thickening increases with age, hypercholesterolemia, 
hypertension [17], and areas of specific haemodynamic stresses [9]. It is unknown, and 
controversial, as to whether this intimal thickening is an adaptive change to normal 
vascular stresses or whether it is an atherogenic change. Nonetheless, atherosclerotic 
lesions are prone to develop in areas of intimal thickening [8, 15], and further 
atherosclerotic changes are usually accompanied by intimal thickening [18]. The 
internal elastic lamina denotes the beginning of the arterial media layer which is 
primarily composed of smooth muscle cells, elastin, collagen fibrils and proteoglycans 
[8, 13]. The outer layer of arteries is called the adventitia, it is highly vascularised and 
contains collagen and elastin fibrils, smooth muscle cells and lymph vessels [8]. One 
study reported vas vasorum neovascularisation in the adventitia layer, in a coronary 
artery model of experimental hypercholesterolemia, occurring before development of 
vascular lesions [19]. However, generally changes in the intimal thickness are 
considered to be more indicative of sites for potential atherosclerotic changes [8, 15].  
Type I, or initial, lesions consist of the first detectable lipid deposits. Most Type I 
lesions are not visible to the naked eye and are detected microscopically, chemically or 
by cell reactions associated with the lipid deposits. These lesions are most frequent in 
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 infants and children, but may be found in adults with little atherosclerosis or in areas of 
arteries that are lesion resistant [16]. The changes observed in these lesions are minor 
and consist of small groups of lipid droplet-containing macrophages or ‘foam cells’ 
present in areas of intimal thickening; the ‘lesion prone’ areas [20, 21]. These areas also 
correspond to where more developed lesions occur [16]. The accumulation of 
macrophage foam cells in the intima is often the initial cellular change observed in 
experimental animal models of hypercholesterolemia [22-24]. These lesions are only 
visible microscopically, and the changes are minimal. Therefore less investigative work 
has been performed in regards to these changes, and with more animal data than human 
data available, especially compared to the more advanced lesions [10, 16]. However, it 
is generally accepted that the presence of macrophage foam cells is an early cellular 
marker of accumulation of atherogenic lipoproteins, particularly in areas of intimal 
thickening [16]. 
Type II lesions include the macroscopically visible fatty streaks, which appear as 
yellow-coloured streaks, patches or spots on the intimal surface of arteries. As Type II 
lesions are determined by microscopic composition, not all of these lesions are fatty 
streaks and thus visible on the intimal surface [16]. Type II lesions consist mainly of 
intimal macrophage foam cells in layers and smooth muscle cells also containing lipid 
droplets [16]. Thus most of the lesion lipid is intracellular, with minimal extracellular 
lipid [16]. Type II lesions also contain more lipid-droplet free macrophages than Type I 
lesions or in healthy intima. T lymphocytes and mast cells are also present in Type II 
lesions, but not in numbers as great as macrophages. The smooth muscle cells present in 
such lesions have been postulated to have migrated from the media, but this is 
controversial as the phenotypes of the smooth muscle cells are dissimilar [16]. An 
absence of endothelial cells in human Type II lesions has been reported [25], however 
this may be artefactual due to long intervals between death and tissue fixation [16].  In 
laboratory animals, where this is not a problem, endothelial cells are present but 
possibly more metabolically active, without evidence of degeneration, necrosis or 
sloughing, regardless of lesion type or location [26]. It is now accepted that in early 
lesions the endothelium is intact, though dysfunctional [14]. Increased endothelial cell 
turnover, has also been reported, perhaps indicating that apoptosis, rather than necrosis, 
is occurring [27]. Other changes in the morphology, properties and functions of 
endothelial cells have been reported in animal studies or in vitro (reviewed in [16]) 
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 indicating endothelial function is impaired, but comprehensive human in vivo data is 
lacking [16, 27]. 
There has been some controversy in the past regarding whether Type II lesions 
are actually precursors to advanced atherosclerotic lesions [8]. The presence of 
atherosclerotic features, such as cholesterol clefts, have been shown to occur in both 
fatty streaks and advanced lesions, indicating a continuum of lesion progression [18]. 
Calcification, a feature of more advanced lesions, can also be detected in fatty streaks 
by electron microscopy, before it is visible macroscopically or by light microscopy [28]. 
Thus fatty streaks are considered as being an early stage in atherogenesis.  
Type III lesions are the transitional/intermediate lesions between fatty streaks and 
more advanced lesions, and are characterised by pools of extracellular lipid as well as 
fatty streak features. The presence of such lesions was under dispute, with the belief by 
some that atherosclerotic lesions progressed directly from fatty streaks to atheroma, 
however Type III lesions are now an accepted stage of plaque development [16]. 
Type IV lesions (atheroma) have a dense core of accumulated extracellular lipid 
that occupies a well-defined region of the intima. The small extracellular lipid pools in 
Type II lesions are considered to be the precursor to the lipid core found in Type IV 
lesions [10]. As this lipid core causes severe intimal disruption it is considered an 
advanced lesion. When the tissue between the lipid core and endothelium undergoes 
fibrous thickening (mainly from increases in collagen and smooth muscle cells) to form 
a fibrous cap, the lesion is classified Type V (or Type Va, or fibrous plaque). If the 
other parts of the lesion are calcified the lesions may be referred to as Type Vb. A Type 
Vc lesion is also classified, and this is where the lipid core is absent and lipid is minimal 
[10]. Type IV and V lesions that develop surface disruptions, haematoma or undergo 
haemorrhage are called Type VI lesions, or complicated lesions [10]. As well as 
narrowing the artery lumen and disrupting blood flow, these lesions are unstable and 
when they rupture can cause unstable angina, myocardial infarction and sudden death 
[8]. 
The cause(s) of lesion initiation, that is the first accumulation of macrophages and 
lipid, is controversial. There are 3 main hypotheses: the ‘response to injury’ hypothesis 
[14, 25, 29, 30], the ‘foam cell’ hypothesis [31], and the ‘response to retention’ 
hypothesis [16, 32-34]. Other hypotheses have included platelet and/or fibrin deposits 
on the intima as the initiation step in atherogenesis, and that a type of intimal thickening 
represented by a macroscopically visible gelatinous appearance, may be an initial 
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 atherosclerotic lesion [16]. However these latter hypotheses do not seem widely 
supported. 
The original response to injury hypothesis was based on the premise that 
endothelial denudation was the initial step in atherogenesis [25, 30], but a more recent 
model emphasises endothelial dysfunction rather than loss  [14, 29]. Injury to the 
endothelium results in responses that lead to endothelial cell dysfunction, such as 
increases in adhesiveness and permeability of the endothelium to leukocytes and 
platelets. This injury can cause the endothelium to become pro-coagulant and give rise 
to the release of cytokines and growth factors. If the cause of the endothelial 
dysfunction does not abate, the inflammatory response can stimulate migration and 
proliferation of smooth muscle cells and the movement of more macrophages into the 
intima and further release of hydrolytic enzymes, cytokines, chemokines and growth 
factors. This results in intimal remodelling and plaque formation [14, 29]. Though this 
model is consistent with the endothelial/inflammatory responses seen in vivo [29], in 
animal models that have had endothelial dysfunction induced by a variety of methods, 
the lesions do not reproduce the structure of human atherosclerotic lesions [16]. These 
models are, however, pertinent to restenosis induced by angioplasty or atherectomy 
[16]. The recent discovery of endothelial progenitor cells may lead to yet a further 
remodelling of the response to injury hypothesis regarding arterial wall repair and 
cardiovascular risk [35].  
The ‘foam cell’ hypothesis is another widely supported rationale for the lipid 
accumulation in atherosclerosis [31, 36]. The idea behind this hypothesis is that 
cholesterol is only trapped in the arterial wall if macrophages are present. This 
hypothesis also postulates that the lipid core in advanced atherosclerotic plaques is the 
result of cholesterol released from necrotic macrophage foam cells. However this 
hypothesis has been criticised on the basis of studies that have shown that retention of 
lipoproteins can occur before the appearance of macrophages [33, 37, 38], and that the 
lipid core composition does not match the composition of macrophage foam cell lipid 
droplets [31, 36]. 
The ‘response to retention’ hypothesis is probably the most widely accepted [16, 
32-34, 39, 40]. In this hypothesis, atherogenesis is postulated to occur as a result of the 
retention of plasma low-density lipoproteins, and other atherogenic lipoproteins (see 
Section 1.2), in the subendothelial matrix [39, 40]. Studies have indicated the presence 
of subendothelial lipoproteins in vivo. Tîrziu et al demonstrated that areas of intimal 
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 thickening in human aortae contain modified lipoproteins that were similar to those 
isolated from prelesional stage aortas of hyperlipidaemic rabbits and hamsters [41]. 
Work by Guyton and Klemp also supports the hypothesis that lipid accumulation in the 
human intima arises from interstitial lipoproteins rather than macrophage foam cell 
death, based on the lipid morphology [18, 37, 42]. Lipoprotein accumulation is more 
likely to occur in regions where mechanical forces favour an increased residence of the 
circulating atherogenic particles [16]. Once retained, specific biological responses to the 
lipoproteins can lead to changes that promote atherogenesis, for example endothelial 
cell alterations, chemotaxis, cholesterol loading of macrophages, smooth muscle cell 
migration and proliferation [39, 40]. Thus the entrapment of lipoproteins in the 
subendothelial matrix may lead to other alterations of the lipoproteins that promote 
plaque formation [43-45]. 
 
1 .1 .1 .a . i   Lipid Accumulation and Foam Cells 
Lipid accumulation is a significant event in atherogenesis. In normal intima the 
lipid content is approximately 2 % by mass and this increases to ~ 8 % by age 65.  In 
the newborn intima most of this lipid is phospholipid (~ 70 %) and cholesterol (~ 24 %), 
with triglycerides and cholesteryl esters making up the remainder. However, in fatty 
streaks, the lipid content increases to ~ 25 % by mass with cholesteryl esters (~ 80 %) 
and free cholesterol (~ 10 %) contributing towards most of this lipid content [46]. 
Guyton and Klemp have reported that the cholesteryl esters account for ~ 62 % of total 
cholesterol in fatty streaks [47].  
These increases in cholesteryl ester content in fatty streaks have been attributed 
to accumulation of lipid in macrophage foam cells [16, 22, 48, 49]. Macrophage foam 
cells are monocytes which have bound to the endothelium and then migrated into intima 
where they undergo transformation to become the macrophage foam cells observed in 
fatty streaks [8, 22]; these cells are the predominant cell type in these lesions [16, 50]. 
Studies using rabbit foam cells demonstrated that most of the free cholesterol was 
associated with lysosomes, and that most of the esterified cholesterol was in 
cytoplasmic lipid droplets with lesser amounts in lysosomes [49, 51]. These lipid 
inclusions accounted for half of the cytoplasmic volume [49]. A later study quantified 
the amount of cholesterol and cholesteryl esters and demonstrated that most of the 
cholesterol in foam cells is esterified [52]. The cholesteryl ester content of these foam 
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 cells was 1059 ± 445 μg/mg cell protein, and accounted for approximately 80 % of total 
cholesterol in these cells.  Mukhin et al enzymatically isolated cells from human intima, 
and found that cells from fatty streaks and more advanced lesions had at least 2-fold 
more free cholesterol and cholesteryl esters than normal intima. In cells from lesions up 
to 43 % of the lipid was cholesteryl esters, ~ 40 % were phospholipids, 10-13 % free 
cholesterol and up to 9 % of the lipid were triglycerides [53]. How macrophages 
accumulate this cholesterol and cholesteryl esters will be discussed in Section 1.2.1.c. 
As lesion development progresses towards more fibrous plaques, smooth muscle 
cell numbers increase [10, 50]. The expansion of fatty streaks to more developed lesions 
is associated with: a) the formation of multiple layers of foam cells comprising of both 
macrophages and smooth muscle cells; b) the hypertrophy of macrophage foam cells; c) 
increases in extracellular matrix; and d) plasma lipoprotein accumulation [23]. Changes 
also occur in the lipid composition of the lesions. Cholesteryl esters in these lesions 
account for 55 % of the total lipid, free cholesterol 23 %, phospholipid 17 % and 
triglyceride 5 % of total lipid by mass [46]. The cholesteryl esters in these types of 
lesions account for 46 % of total cholesterol levels [47]. As the lesions become more 
advanced, lipid can account for up to 60 % of total plaque mass with a slight decrease in 
cholesteryl ester content (to ~ 47 %) and a corresponding increase in free cholesterol (to 
~ 32%) [46]. 
Advanced lesions frequently contain cholesterol clefts, calcification and an 
acellular lipid core [8, 10]. Cholesterol clefts are holes in the connective tissue caused 
by cholesterol crystals [8]. The extracellular lipid in these lesions is either cholesterol-
rich vesicles (associated with cholesterol crystals) or cholesterol-rich oily droplets 
usually without crystals [54]. Death of macrophage foam cells was originally postulated 
as the source of this extracellular lipid, as dying macrophages are often seen around the 
lipid core, and the core itself can contain monocyte/macrophage immunohistochemistry 
markers [55]. However, this suggestion has been questioned, as these are cholesterol-
rich deposits, whereas foam cells contain mainly cholesteryl esters, and 90 % of the oily 
droplets in the lipid core are much smaller than foam cell lipid droplets  [42]. The lipid 
core is now postulated to result from extracellular lipid deposition from lipoproteins, 
rather than cell death [31, 36, 54], supporting the ‘response to retention’ hypothesis as 
discussed previously (see Section 1.1.1.a). Advanced plaques have been reported to be 
more likely to rupture if they have increased cholesteryl ester levels at their edges, and 
interestingly increased lipid content is often associated with diminished cap thickness 
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 above the lipid core. This increase in lipid may reflect macrophage activity [56], and 
demonstrates the significance of macrophages throughout atherosclerotic lesion 
development. Atherosclerotic lesion development is also affected by the presence of 
diabetes, which is discussed in the subsequent Sections. 
 
1 .1 .2  Diabetes Mellitus: Types, Prevalence and Pathophysiology 
Diabetes mellitus is a group of metabolic diseases characterised by 
hyperglycaemia arising from defects in insulin secretion and/or action [57]. The 
prevalence of diabetes worldwide for all age groups was 2.8 % in 2000 and is projected 
to be 4.4 % in 2030 (or 366 million people) [58]. The overall prevalence in Australia of 
diabetes is 7.4 %, with an additional 16.4 % having impaired glucose metabolism or 
being ‘pre-diabetic’ [59]. Diabetes prevalence in Australia has more than doubled since 
1981 [59]. The prevalence of diabetes determined in this study, by national sampling, 
was also double that of reported cases [7, 60]. There are 3 main types of diabetes 
mellitus: Type 1, Type 2 and gestational diabetes [57, 60]. Other types of diabetes 
include those in which a disease, drug/chemical or genetic defect cause the onset of 
diabetes and account for 1-2 % of all diagnosed diabetic cases [57, 60].  
Type 1 diabetes accounts for approximately 5-10 % of total cases worldwide [2, 
57], and approximately 10-15 % for the Australian population [60]. Type 1 diabetes, 
also termed immune-mediated diabetes, insulin-dependent diabetes or juvenile-onset 
diabetes, results from cell-mediated autoimmune destruction of the (insulin producing) 
β-cells in the Islets of Langerhans of the pancreas [57, 61]. There are two phases; firstly 
insulitis when leukocytes invade the islets and secondly diabetes; when there is 
insufficient insulin to regulate blood glucose levels. The time course of β-cell 
destruction can be quite variable between individuals. It is not known definitively what 
causes the β-cell destruction; autoimmune destruction of β-cells has multiple genetic 
predispositions and is also affected by environmental factors [57, 61]. People with Type 
1 diabetes need daily insulin injections to survive [57, 60]. In the case of acute insulin 
deficiency, symptoms of hyperglycaemia appear which include glucosuria, polyuria, 
polydipsia, weight loss sometimes occurring with polyphagia, blurred vision and life 
threatening, coma-inducing, ketacidosis and nonketotic hyperosmolar syndrome [57]. 
Diabetes means ‘syphon’ or ‘running through’ and mellitus means ‘sweet’, referring to 
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 the polyuria and glucosuria which occurs because the body cannot metabolise glucose 
as a result of insulin insufficiency. 
Type 2 diabetes is the most prevalent form, accounting for 90-95 % of cases 
worldwide [2, 57] and 85-90 % of diabetic cases in Australia [60]. Type 2 diabetes is 
extremely prevalent in some non-Europid populations such as Native American and 
Canadian communities, Pacific and Indian Ocean communities and Australian 
Aboriginals [2]. Diabetes prevalence rates in Aboriginal and Torres Strait Islander 
peoples have been reported to be as high as 30 % [60]. This form of diabetes is also 
known as non-insulin-dependent diabetes or adult-onset diabetes. Individuals with Type 
2 diabetes have insulin resistance and some degree of insulin insufficiency and do not 
need insulin injections for survival. Type 2 diabetes is strongly linked to obesity and 
lifestyle factors and can be managed by weight loss, exercise, dietary changes and/or 
oral hypoglycaemic medication. However sometimes the disease progresses to a degree 
where insulin injections are needed [2, 57, 60]. Specific aetiologies of Type 2 diabetes 
are not known, though there may be a genetic component in some cases [57, 62]. Of 
great concern is the increasing incidence of Type 2 diabetes in children; this is 
associated with increasing childhood obesity and sedentary lifestyles [2, 63, 64]. 
Gestational diabetes mellitus may occur in 1-14 % of pregnancies, depending on 
the population studied [57]. In Australia approximately 5 % of women are diagnosed 
with gestational diabetes, however the incidence can be as high as 20 % in Aboriginal 
and Torres Strait Islander women [60]. Complications arising from gestational diabetes 
include large babies and resulting complications in labour and delivery, hypertension, 
pre-term birth, uterine bleeding, foetal distress, pre-eclampsia and neonatal 
hypoglycaemia, respiratory distress and jaundice [60]. These mothers and babies are at 
an increased risk of developing diabetes later in life [60, 65]. 
Diabetes is associated with many long-term problems. People with diabetes have 
increased risk of microvascular complications in the retina, renal glomerulus and 
peripheral nerves, as well as the macrovascular disease of atherosclerosis in the heart, 
arms and legs [66, 67]. Thus, long term complications include retinopathy and loss of 
vision, nephropathy leading to renal failure, peripheral neuropathy problems such as 
ulcers and amputation, as well as autonomic neuropathy causing gastrointestinal, 
genitourinary, cardiovascular and sexual function problems [57]. The number of deaths 
worldwide attributed annually to diabetes is only 800,000 [3]. However this number 
does not take into account the large number of people with diabetes who die from other 
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 chronic conditions such as cardiovascular disease; a more plausible number is 4 million 
deaths per year. The World Heath Organisation estimates that direct health care costs of 
diabetes range from 2.5-15 % of annual health care budgets, but the cost of associated 
complications may increase these figures [3]. Thus, diabetes and associated 
complications have important health, societal and economic implications. 
 
1 .1 .3  Links between Atherosclerosis and Diabetes 
The World Health Organisation has reported that cardiovascular disease is 
responsible for 50 % of deaths among people with diabetes [3]. In 2002 in Australia 
diabetes was the 6th highest underlying cause of death at 2.5 % of all deaths. However, 
when the numbers of deaths with diabetes listed as an associated cause is combined 
with diabetes listed as an underlying cause of death, the total rises to 9 % [7]. In 
Australia, in 2002, if diabetes was listed as an underlying cause of death, 50 % of cases 
listed coronary heart disease as an associated cause. Where diabetes was listed as an 
associated cause of death, 24 % of cases listed coronary heart disease as the underlying 
cause of death [7]. Aronson et al reported that mortality rates in people with diabetes 
who have had an acute myocardial infraction are up to 2-fold higher than those for 
people without diabetes, using appropriate studies selected from the MEDLINE 
database [68]. The Framingham study showed for total coronary events, non-sudden 
coronary heart disease, sudden coronary heart disease, cerebrovascular incidents and 
other cardiovascular events the risk of mortality was 2-3-fold higher in people with 
diabetes than those without diabetes [69]. Haffner et al reported that patients with 
diabetes were at as great a risk of myocardial infarction as patients without diabetes 
with previous myocardial infarctions, and suggested patients with diabetes should be 
treated as aggressively as patients with a prior myocardial infarction [70]. The risk of 
coronary heart disease always appears to be higher in people with diabetes than those 
without diabetes, regardless of geographical variation in risk (for example Japanese 
people with diabetes have a higher risk of coronary heart disease, but they have a lower 
incidence of coronary heart disease compared to Western countries) [71]. The Multiple 
Risk Factor Intervention Trial (MRFIT) showed that, after adjustment for race, age and 
income group, the overall risk for cardiovascular disease mortality was 3-fold greater 
for patients with diabetes, and this increased with increasing incidence of other risk 
factors (raised cholesterol, blood pressure and cigarette smoking) [72]. The total 
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 mortality from cardiovascular disease has been reported from several groups to be 
higher for women than men [69, 73, 74], and women with diabetes can be at a greater 
relativerisk of cardiovascular disease and death, than men with diabetes, or women 
without diabetes [75].  
Various metabolic changes have been postulated to cause the increased 
incidence of atherosclerosis in people with diabetes. The following abnormalities of 
lipid metabolism associated with diabetes may promote atherosclerosis (reviewed in 
[74, 75]): increased plasma very low-density lipoproteins and lipoprotein(a), decreased 
plasma high-density lipoprotein, increased small dense low density lipoproteins and 
chylomicra, decreased activity of lipoprotein lipase and increased lipoprotein 
glycoxidation and oxidation. Haemostasis abnormalities that may promote 
atherosclerosis (reviewed in [74, 75]) include abnormalities of platelet function, 
elevated levels of factors VII and VIII, increased fibrinogen, increased plasminogen 
activator inhibitor, increased plasma thrombin-antithrombin complexes, decreased 
plasminogen and fibrinolytic activity, and decreased levels of antithrombin III, protein 
C and protein S. However, these abnormalities do not fully explain the increased 
cardiovascular disease observed in diabetes. The prevalent hyperglycaemia and 
hyperinsulinemia in people with diabetes could also potentially explain the increased 
risk of atherosclerosis (as discussed in the next 2 Sections). 
 
1 .1 .3 .a   Insulin 
Insulin levels in the body are normally determined by a feedback control system 
that is also responsive to plasma glucose levels [62]. Insulin is not only secreted in 
response to glucose, but also to amino and fatty acids and is regulated by neural and 
hormonal factors. Normally insulin secretion is rapid in response to glucose and shows 
a complex pulse profile. In people with Type 2 diabetes, where there is insulin 
resistance and β-cell dysfunction, insulin secretion may be delayed and diminished as 
well as having irregularities in the pulse profile [62]. People with Type 2 diabetes often 
have elevated plasma insulin levels due to insulin resistance and it has been postulated 
that this may contribute to atherosclerosis [74-76], and the occurrence of Syndrome 
X/Metabolic Syndrome [76]. 
Varying mechanisms have been postulated to link atherosclerosis and 
hyperinsulinemia. Increased levels of insulin stimulate mitogenic signalling pathways 
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 and increase DNA synthesis in endothelial and smooth muscle cells [75]. Insulin may 
also stimulate two atherogenic factors: endothelin and plasminogen activator inhibitor  
[75]. Insulin resistance in a mouse model induced dyslipidaemia and increased blood 
pressure, well known risk factors for atherosclerosis [74, 77]. Abe et al induced chronic 
hyperinsulinemia in rats by transplanting a second pancreas into the animals. These 
animals had increased cholesteryl ester levels in their arterial walls, without changes in 
blood pressure or plasma lipids; these animals however, did not develop atherosclerotic 
lesions [78]. Insulin has an endothelium-dependent vasodilatory effect and will decrease 
arterial stiffness in people with normal insulin sensitivity; however, this effect is not 
seen in obese people with Type 2 diabetes [74]. It has also been suggested that the 
atherosclerotic and growth effects of hyperinsulinemia may be mediated through an 
insulin-like growth factor (IGF-1) receptor. This may occur either by the action of IGF-
1 directly, or indirectly by the high levels of insulin as both IGF-1 and insulin are 
structurally similar, share receptors and have similar post-receptor signalling pathways 
[75, 76]. However, it should be noted that exogenous insulin used in the treatment of 
Type 1 diabetes has not been associated with increases in atherosclerosis [75]. 
Reduction of insulin levels also has not been linked to decreased cardiovascular disease 
[76]. Thus, hyperinsulinemia theories so far have not been widely supported.  
 
1 .1 .3 .b  Hyperglycaemia 
A popular theory is that the hyperglycaemia in diabetes contributes to the 
increased incidence of atherosclerosis [66, 67, 71, 74, 79]. A study by Sima et al in an 
experimental hamster model of diabetes indicated that hyperglycaemia alone was 
enough to induce atherosclerotic lesions [80]. An association between hyperglycaemia 
and cardiovascular disease has also been indicated in human studies. Glycated 
haemoglobin (HbA1C) concentration is an indicator of average blood glucose over the 
previous 3 months and may be used as a monitoring tool for diabetes [81]. A study on 
the Norfolk cohort of European Prospective Investigation of Cancer and Nutrition 
(EPIC-Norfolk) showed that men with known diabetes had increased mortality from all 
causes, cardiovascular disease and ischaemic disease, compared to non-diabetic 
controls. This study demonstrated that an increase of 1 % in HbA1C was associated with 
a 28 % increase in death, independent of age, blood pressure, serum cholesterol, body 
mass index and cigarette smoking after men with known diabetes, HbA1C concentration 
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 > 7%, or history of myocardial infarct or stroke were excluded [82]. HbA1C and other 
measures of hyperglycaemia have also been linked with increased mortality [83-86], 
cardiovascular disease/events [84-86], carotid artery stenosis [87], fatty streaks [86], 
and endothelial dysfunction [88]. A very recent study by McCarter et al also 
demonstrated that that individuals with a higher than predicted HbA1C were at greater 
risk of retinopathy and nephropathy [89]. Standl et al reported that deceased patients in 
their study, especially those from macrovascular causes, had significantly increased 
fasting blood glucose and HbA1C in baseline measurements taken 10 years previously 
[90]. Large vessel disease appears in people around the time of the first diagnosis of 
diabetes, therefore the pre-diabetic state, such as hyperglycaemia, may be important in 
the development of atherosclerosis [74].  
Strict hyperglycaemic control has not been conclusively linked with improved 
macrovascular outcomes, although there are clear micovascular benefits. The Diabetes 
Control and Complications Trial (DCCT), using Type 1 patients with diabetes showed 
that good blood glucose control reduced microvascular risk (of retinopathy) and 
suggested that tight blood glucose control might reduce cardiovascular events [71, 92]. 
However, the numbers used in this study were small and a relatively youthful 
population was studied [71]. The United Kingdom Prospective Diabetes Study 
(UKPDS) provided clear evidence that a decrease in HbA1C reduced microvascular 
complications, however there was not a significant decrease in the risk of macrovascular 
disease (p = 0.052) [71, 91]. A theory of ‘hyperglycaemic memory’ has been proposed, 
referring to the persistence or progression of hyperglycaemic-induced microvascular 
changes following periods of normal glucose metabolism [66]. Perhaps the effects of 
‘hyperglycaemic memory’ are more potent, in regards to macrovascular complications. 
There are many possible mechanisms as to how hyperglycaemia might induce 
atherosclerosis. In vitro experiments using endothelial cells exposed to high glucose 
levels have provided evidence for impaired cell replication [93], reductions in 
stimulated pentose phosphate shunt activity and in glutathione-dependent H2O2 
degradation, possibly due to an impaired NADPH supply [94]. Exposure of smooth 
muscle cells from aged rats to high media glucose levels results in greater induction of 
NF-κB (a nuclear transcription factor for several adhesion molecules), increased protein 
carbonyls and decreased apoptosis as compared to cells from young rats exposed to high 
glucose levels [95]. Smooth muscle cells exposed to high glucose conditions have also 
been shown to secrete significantly greater amounts of vascular endothelial growth 
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 factor (VEGF), which has been implicated in vascular permeability and monocyte 
migration [96]. Eaton and Dean (2000) reviewed possible reasons as to why 
hyperglycaemia may affect cell survival and proliferation or induce dysfunction, and 
suggested that activation of second messenger systems may play a role. The following 
appear to be important messenger systems that are activated by high glucose levels; 
diacylglycerol production, cytosolic phospholipase A2, protein kinase C, p21 (ras) and 
NF-κB, and p38 mitogen-activated kinase (p38 MAP kinase) [74]. Many of the 
metabolic disturbances in diabetes, including hyperglycaemia, may induce 
abnormalities in endothelial function by affecting the synthesis or degradation of nitric 
oxide, which is turn affects blood vessel vasodilation and production of molecular 
signals [67]. Brownlee has proposed four possible mechanisms for hyperglycaemia-
induced damage: increased polyol pathway flux, increased advanced glycation end-
product (AGE) formation, activation of protein kinase C, and increased hexosamine 
pathway flux. It was also suggested that these four mechanisms implicated in the 
pathogenesis of diabetic complications, may have a common element of overproduction 
of superoxide radicals by the mitochondrial electron-transport chain [66]. The rationale 
behind each of these proposed mechanisms is beyond the scope of this Introduction, 
however increased AGE formation has been very strongly implicated in the 
atherogenesis observed in patients with diabetes. AGEs may form on atherogenic 
lipoproteins; therefore, the next Section discusses cholesterol and lipoprotein 
metabolism, to aid discussion in Section 1.3 on the reactions leading to AGE formation 
and evidence for AGEs in atherosclerosis. 
 
1.2   Cholesterol and Lipoprotein Metabolism 
Cholesterol is essential for homeostasis and requires lipoproteins for in vivo 
transportation.  Eukaryotic cells require cholesterol in their membranes for fluidity, and 
cholesterol is also used for steroid hormone and bile production [97]. The properties of 
cholesterol that makes it localise in cell membranes, which includes its insolubility, 
makes it problematic to transport about the body and when it accumulates, such as in 
the artery wall it cannot be removed easily [97]. The transport of cholesterol in 
multicellular organisms occurs predominantly by esterifying the sterol with long chain 
fatty acids and transporting these (and triglycerides) in the hydrophobic core of 
lipoproteins, that are surrounded by polar lipids and apoproteins [97, 98].  
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 Different lipoproteins are classed according to increasing density: chylomicrons, 
chylomicron remnants, very low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL) 
[98]. Triglycerides, cholesterol and other lipids absorbed from the diet are transported 
away from the intestine in the form of chylomicrons [99]. The triglycerides in 
chylomicrons are hydrolysed by lipoprotein lipases, releasing fatty acids for cellular 
uptake, and leaving cholesterol-rich residues, or chylomicron remnants, that can be 
taken up by the liver. Cholesterol and triglycerides in excess of requirements of the liver 
are exported in the blood as VLDL. Triglycerides in VLDL can also be hydrolysed by 
lipases and thus IDL is formed. Half of the formed IDL particles are taken up by the 
liver, where the remainder become LDL [98, 99].  
The role of LDL is to transport cholesterol to peripheral tissues, whereas HDL has 
the opposite function. The structure of LDL is discussed in detail in the following 
Section (see Section 1.2.1). The main HDL lipoproteins are apolipoproteins (apo) A-I 
and A-II, but HDL particles may also contain apo A-IV, C, D, E and J. The surface of 
HDL also contains some of the plasma factors involved in remodelling of HDL, in its 
role of reverse cholesterol transport, such as lecithin:cholesterol acyltransferase (LCAT) 
and cholesteryl ester transfer protein (CETP) [100, 101]. Free cholesterol effluxed by 
cells is esterified by LCAT. This increases the size of the HDL particle, which is then 
able to exchange cholesterol and triglycerides with LDL and VLDL, mediated by 
CEPT. Smaller HDL particles can also accept free cholesterol and phospholipids via 
VLDL hydrolysis facilitated by lipoprotein lipase (LPL) and phospholipid transfer 
proteins (PLTP). Large HDL particles can then be degraded in the liver by hepatic 
lipase and the apo A-1 is recycled for further HDL formation [100, 101].  
The lipid accumulation observed in atherosclerotic lesions could be due to; 1) 
increased entry of lipid into the artery wall, 2) altered metabolism/flux of lipid in the 
artery wall and 3) decreased export/transport of lipid out of the intima. Greater entry of 
lipid into the intima may occur due to increased a): passive diffusion from elevated 
concentrations of lipid (LDL) in plasma; b) uptake and transport of lipid into the 
subendothelial space by endothelial cells; or c) uptake of lipid through intercellular 
spaces as a result of dysfunctional endothelium [36]. Decreased removal of lipid from 
the intima could occur if: a) the lipid is trapped in the intima (i.e. cannot pass through 
the internal elastic lamina); b) dysfunctional endothelium fails to transport intimal lipid 
back to the plasma; c) the lipid becomes sequestered in foam cells; d) lipid becomes 
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 bound to connective tissues components; e) the lipid becomes aggregated and physically 
trapped by lipoprotein components; or f) due to inefficient or insufficient removal of 
lipid by HDL [36]. 
 
1 .2 .1  Low Density Lipoproteins 
 
1 .2 .1 .a  Structure and Metabolism of Low-Density Lipoproteins 
LDL is the major carrier of cholesterol to the peripheral tissues in the blood. LDL 
can be separated by ultracentrifugation within a density range of 1.019-1.063 g/ml. LDL 
molecules are spherical particles 19-25 nm in size, with a mean molecular mass of ~ 2.5 
million [102]. LDL contains a lipophilic core of ~ 1600 cholesteryl ester molecules and 
~ 170 molecules of triglycerides, surrounded by a monolayer of ~ 700 phospholipid 
molecules and ~ 600 molecules of free cholesterol. The main phospholipid is 
phosphatidylcholine with others including sphingomyelin and lysophophatidylcholine.  
Embedded in the outer layer is a single LDL apoprotein, apolipoprotein B-100 (apo B). 
The molecular mass of apo B is ~ 550 kDa and consists of ~ 4536 amino acids. The 
approximate number of amino acid residues per apo B molecule are: Alanine (Ala) 266, 
Asparagine and Aspartic acid (Asx) 478, Arginine (Arg) 148, Cysteine (Cys) 25, 
Glutamine and Glutamic acid (Glx) 529, Glycine (Gly) 207, Histidine (His) 115, 
Isoleucine (Ile) 288, Leucine (Leu) 523, Lysine (Lys) 356, Methionine (Met) 78, 
Phenylalanine (Phe) 223, Proline (Pro) 169, Serine (Ser) 393, Threonine (Thr) 298, 
Tryptophan (Trp) 37, Tyrosine (Tyr) 152 and Valine (Val) 251 [102]. Approximately 8-
10 % of the apo B molecular mass is from N-linked oligosaccharides (mannose, 
galactose, glucosamine and sialic acid) [102]. For the particle as a whole, the 
contribution of various constituents are by mass: cholesteryl esters ~ 40 %, 
phospholipids ~ 20 %, protein (apo B) ~ 20 %, free cholesterol ~ 10 % and triglycerides 
< 10 % [102-107]. LDL also contains antioxidants, of which vitamin E (α-tocopherol) 
is the most abundant with 6-12 molecules/LDL particle [102, 108]. Other antioxidants 
found in LDL (at levels < 1 molecule/LDL particle) are γ-tocopherol, β-carotene, α-
carotene, lycopene, cryptoxanthin, cantaxanthin, lutein, zeaxanthin, phytofluene and 
ubiquinol-10 [102, 108]. The overall LDL plasma levels, and the levels of particular 
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 LDL components such as lipids and antioxidants, can vary greatly between individuals, 
with this due, at least partly, to dietary habits [102]. 
There is considerable evidence that LDL is important in atherogenesis, and that 
these particles are the main source of the lipid that accumulates in lesions. The 
Framingham study established that an elevated level of serum cholesterol, carried in 
LDL, is a major risk factor for the development of atherosclerosis [109-111]. Elevated 
cholesterol and LDL plasma levels are now well recognised risk factors for the 
development of atherosclerosis and so LDL lowering is a primary therapy for reducing 
the risk of coronary heart disease, in people with and without diabetes [112, 113]. 
Further animal studies have demonstrated the intimal uptake of LDL. In hyperlipidemic 
animals plasma LDL may be taken up by endothelial cells by two different mechanisms; 
endocytosis and trancytosis [38, 114]. Carew et al demonstrated that 40 % of total aortic 
degradation of LDL was carried out by intimal cells [115]. They also calculated that 
aortic retention of LDL averages < 0.01 % of the plasma pool/g aortic wet weight/day, 
and that the rate of LDL entry into the arterial wall (and exit) greatly exceeds its 
accumulation rate. Most lipoproteins are carried by transcytosis to the subendothelial 
space and in hypercholesterolemic animals this transport may be increased by 30-50 % 
[34, 38, 114]. However, the increased  risk of cardiovascular disease in patients cannot 
be explained by elevated LDL levels alone. The response to retention hypothesis (see 
Section 1.1.1.a) encompasses the facts that certain parts of the arterial tree are more 
susceptible to lipid deposition, and that also lipoprotein size, density, lipid composition 
and apolipoprotein complement may also be important in determining lipoprotein 
deposition [34].  
Retention of lipoproteins, not just supply is believed to be important in 
atherogenesis. Studies in animals and humans have suggested that retention of LDL in 
the subendothelial space is an early step in atherogenesis [16, 33, 34, 41, 103, 104] and 
even occurs before macrophage foam cells appear  [38, 116, 117]. Within 2 hours, after 
a bolus LDL injection, clustering of LDL microaggregates has been shown to occur in 
atherosclerosis-prone sites in rabbit intima [118], whereas macrophage appearance takes 
days [116, 117]. Skålén et al demonstrated that the expression of proteoglycans 
correlates with atherosclerotic lesions [33]. This study and others have led to the 
proposal that interactions with proteoglycans and other extracellular matrix components 
may lead to greater retention of lipoproteins (reviewed in [34, 39, 40]). Greater 
subendothelial retention of lipoproteins has also been reported in insulin-deficient 
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 rabbits [119], and perhaps also contributes to atherosclerosis in people with diabetes. If 
LDL is retained in the intima, there is greater chance of uptake by macrophages or other 
cells to yield lipid-laden foam cells, and it has been demonstrated that macrophages in 
vitro can accumulate LDL isolated from human atherosclerotic lesions [120]. 
 
1 .2 .1 .a . i  Receptor Mediated Endocytosis of Low-Density Lipoproteins 
LDL besides transporting cholesterol to peripheral tissues, is also a regulator of 
de novo cholesterol synthesis at these sites. Brown, Goldstein and colleagues have 
carried out extensive studies on how cells take up cholesterol from LDL and how this is 
regulated [97, 121-124]. Approximately 70 % of LDL uptake in the body occurs in the 
liver by receptor-mediated endocytosis [97], however other cells such as fibroblasts, 
smooth muscle cells, endothelial cells, adrenocortical cells and lymphocytes can also 
take up LDL in this manner [122]. The LDL receptor precursor is synthesised in the 
rough endoplasmic reticulum, with further modifications occurring in the Golgi 
apparatus [97]. Approximately 45 min after synthesis LDL receptors appear on the cell 
surface and gather in protein (clathrin) coated pits (Fig. 1.1). Between 50-80 % of all 
receptors are clustered over 2 % of the cell surface in such pits [122]. Within 3-5 min of 
their formation the coated pits invaginate to form coated endocytic vesicles and the 
clathrin coat disappears. Multiple endocytic vesicles then fuse to form endosomes. 
Proton pumps in the membrane cause the pH of the endosomes to fall below 6.5, and 
this acidic pH causes the LDL to dissociate from the receptor. The LDL receptor then 
returns to the surface, and thus is recycled. A LDL receptor can go through this cycle 
every 10 min, regardless if it is bound to LDL or not. The LDL that disassociates from 
the receptor is then delivered to the lysosome where the membranes of the endosome 
and lysosome fuse to form secondary lysosomes [97]. In lysosomes the protein 
component is hydrolysed to amino acids and the cholesteryl esters are hydrolysed by an 
acid lipase, releasing free cholesterol and fatty acids. These processes can occur within 
60 min of surface-bound LDL particles entering the cells [97]. 
This internalisation and breakdown of LDL is subject to internal regulation [97]. 
Excess free cholesterol generated from lysosomal lipases inhibits 3-hydroxy-3-
methylglutaryl Coenzyme A reductase (HMG-CoA), the rate limiting enzyme in 
endogenous cholesterol biosynthesis. Free cholesterol can also activate the cholesterol 
esterifying enzyme acyl Coenzyme A: cholesterol acyltransferase (ACAT), so that 
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 excess cholesterol is stored in the cytoplasm as cholesteryl ester droplets [97, 125]. 
Finally intracellular cholesterol levels can also suppress synthesis of LDL receptors [97, 
126]. Through these regulatory mechanisms cells can keep their free cholesterol levels 
constant despite great fluctuation in exogenous supply and cellular cholesterol 
requirements. 
 
 
Figure 1.1 Route of the LDL receptor in cells (from [97]). The receptor is synthesised in the endoplasmic 
reticulum, where it then travels to the Golgi complex, surface, coated pit, endosome and back to the 
surface. In lysosomes the apo B is hydrolysed to amino acids and the cholesteryl esters are hydrolysed by 
an acid lipase, freeing cholesterol and fatty acids. Cellular free cholesterol levels are regulated by 
decreasing 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA) and LDL receptor production, and 
by increasing acyl Coenzyme A: cholesterol acyltransferase (ACAT) activity to store excess cholesterol 
as cholesterol esters. See text for more detail. 
 
1 . 2 . 1 . a . i i  Macrophage Scavenger Receptors 
The tight regulation of intracellular cholesterol and cholesteryl esters, as 
described in Section 1.2.1.a.i does not account for the excessive cholesterol and 
cholesteryl ester accumulation observed in macrophage foam cells. When macrophages 
are incubated with high levels of LDL, mimicking hypercholesterolemia, they fail to 
accumulate cholesterol and cholesteryl esters, as observed in foam cells [127]. In 1979 
Goldstein, Brown, and colleagues demonstrated that LDL modified by acetylation 
resulted in significant macrophage accumulation of apo B, cholesterol and cholesteryl 
esters. They proposed that this occurred via a scavenger receptor pathway, not the 
classic LDL receptor pathway [127]. This accumulation of acetylated LDL has been 
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 also been demonstrated in vivo in white Carneau pigeons, where macrophage foam cells 
located on the arterial endothelium or intima accumulated acetylated LDL [24]. LDL 
enters the macrophage via receptor-mediated endocytosis and is delivered to the 
lysosome. In the lysosome the apo B is hydrolysed to amino acids, and the cholesteryl 
esters in LDL are hydrolysed by acidic cholesteryl ester hydrolase (ACEH). The free 
cholesterol leaves the lysosome and enters the cytoplasm where two fates are possible 
[128, 129]. Some of the LDL may be excreted in the presence of LDL acceptors such as 
HDL or apo E. Other excess free cholesterol is esterified by ACAT, which may result in 
the formation of cytoplasmic lipid droplets (Figure 1.2). Cholesteryl esters undergo a 
futile cycle of hydrolysis, mediated by neutral cholesteryl esters hydrolases (nCEH), 
and re-esterification, with up to 50 % of stored cholesteryl esters undergoing this 
process per day [129, 130]. These enzymes are believed to play a key role in reverse 
cholesterol transport as macrophages seem to be only able to excrete unesterified 
cholesterol [124, 128, 129]. 
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Figure 1.2 Cholesteryl ester metabolism in macrophages (adapted from [128, 129]). LDL enters the 
macrophage via receptor-mediated endocytosis and is delivered to the lysosome. In the lysosome the apo 
B is hydrolysed to amino acids and the cholesteryl esters in LDL are hydrolysed by acidic cholesteryl 
ester hydrolase (ACEH). Excess free cholesterol is esterified by acyl Coenzyme A: cholesterol 
acyltransferase (ACAT), which may result in the formation of cytoplasmic lipid droplets. In the absence 
of a cholesterol, acceptor (e.g. HDL), cholesteryl esters undergo a futile cycle of hydrolysis and re-
esterification. Neutral cholesteryl esters hydrolases (nCEH) hydrolyse the cholesteryl esters to 
cholesterol, which can be either excreted or re-esterified. For more details see text. 
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 Further studies have characterised multiple macrophage scavenger receptors, 
with varying affinities for different LDL modifications [131-135]. These scavenger 
receptors (SR) include SR-A, SR-B, SR-C, SR-D, SR-E, SR-F, SR-PSOX, FEEL-1 and 
FEEL-2.  Members of the SR-A class include: types I, II, III and MARCO; members of 
the SR-B class include CD-36 and SR-BI; SR-C: dSR-C1; SR-D: macrosialin/CD68; 
SR-E: Lectin-like oxidised LDL receptor-1 (LOX-1); and SR-F: SREC-1 (reviewed in 
[134, 136]). In a mouse model of atherosclerosis with a deficiency in SR-A class 
receptors decreased lesion sizes were found, and macrophages from these animals 
showed a decreased uptake of modified LDL in vitro [137]. A more recent study by 
Kunjathoor et al demonstrated that SR-A and CD36 account for 75-90 % degradation of 
LDL modified by oxidation or acetylation, indicating that these are the main scavenger 
receptors involved in modified LDL uptake in the system under study [138]. SR-B1 can 
act as an HDL receptor that mediates the selective uptake of HDL cholesteryl esters into 
cells, but can also facilitate the efflux of cholesterol from cells  [100, 132, 139-141]. 
LOX-1 and CD36 expression are both increased in high glucose conditions, potentially 
promoting foam cell formation in people with diabetes [142, 143].  
 More recent studies, and the discovery of different scavenger receptors, have 
meant additional mechanisms of intracellular cholesterol regulation have been 
elucidated. As cellular cholesterol levels increase, cholesterol biosynthesis (via HMG-
CoA) and receptor-mediated uptake via the LDL receptor expression is repressed 
through the sterol regulatory element-binding protein (SREBP) pathway [139, 141]. 
Therefore SREBPs can act to reduce intracellular cholesterol levels. ATP-binding 
cassette transport 1 (ABCA1) can transport free cholesterol and phospholipids to small 
HDL particles [100], as part of reverse cholesterol transport. Liver X receptors (LXR α 
and β) are members of a nuclear receptor family of ligand-dependent transcription 
factors that can induce transcription of specific target genes in response to the binding 
of oxysterols, in conjunction with retinoid X receptors (RXR) [139, 140]. LXR-RXR 
transcription factors regulate genes mediating macrophage cholesterol efflux (ABC 
transporters and apo E) and transport (SREBP, LPL, CETP) as well as bile metabolism 
[139-141]. Peroxisome proliferator-activated receptors (PPARs α, γ and δ) belong to a 
family of nuclear receptors that are activated by fatty acids, with PPARα able to 
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 increase the expression of apo A-I, SR-B1, ABCA1 and LPL. PPARγ can activate 
LXRα, resulting in induction of ABCA1 and decreased SR-A expression [141]. 
1 .2 .1 .b  Modification of Low-Density Lipoproteins and Atherosclerosis 
The classical studies by Brown and Goldstein and colleagues employed acetylated 
LDL [127, 144], and though cells will endocytose these particles, this type of LDL has 
little relevance to atherogenesis, except perhaps as a tool to study foam cell formation. 
It is now well recognised that modifications of LDL that induce an increased net 
negative charge on the particle, such as acetylation, succinylation or maleylation, can be 
recognised by macrophage scavenger receptors [127, 144-146]. However, in 1981 
Henriksen et al demonstrated that LDL oxidised by incubation with endothelial cells or 
smooth muscle cells was recognised by macrophage scavenger receptors [44, 105, 147-
150]. Many other modifications of LDL are now known that can lead to macrophage 
scavenger receptor recognition and foam cell formation. These LDL modifications 
include chemical adduction (e.g. 4-hydroxynonenal [151], or malondialdehyde [146, 
152]), oxidation [147, 153-155], aggregation [156, 157], enzymatic modification [31, 
43, 158] and complex formation, for example with dextran sulphate [159] or 
proteoglycans [160]. Macrophages stimulated by LDL immune complexes can also 
accumulate cholesteryl esters [161]. Other covalent modifications of LDL, such as those 
induced by glucose via glycation or glycoxidation reactions (see Section 1.3), can also 
result in modifications that are recognised by macrophage scavenger receptors, thus 
providing a possible explanation for the increased atherosclerosis observed in patients 
with diabetes [162-167]. 
Oxidation of LDL and its potential role in atherosclerosis has received much 
attention since it was discovered that LDL incubated with endothelial and smooth 
muscle cells [147, 148] was being oxidised [44, 105, 149, 150]. LDL that is recognised 
by macrophage scavenger receptors can also be produced in vitro by incubating LDL 
with metal ions to catalyse radical formation [102, 158]. Evidence has been presented 
for the presence of oxidised LDL in atherosclerotic lesions from both animal models 
and humans [168-170]. A number of studies have suggested that circulating levels of 
oxidised LDL are a risk marker of coronary artery disease [171, 172]. These studies 
support the oxidative modification hypothesis of atherogenesis, and much work has 
been performed examining the atherogenic effects of oxidised LDL [128, 158, 173-
175].  
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 Processes that may promote LDL oxidation include reactions catalysed by 
myeloperoxidase, other peroxidases and heme enzymes, lipoxygenases, reactive 
nitrogen species, oxygen radical reactions, metal-ion catalysed processes and 
glycoxidation [102, 173, 176-178]. Myeloperoxidase and H2O2 are produced by 
activated phagocytes and in the presence of Cl- ions produce HOCl. HOCl is a powerful 
oxidant capable of causing tissue damage [176, 179, 180]. Myeloperoxidase and 
markers of HOCl damage have been found in atherosclerotic lesions [181-184]. The 
reactive nitrogen pathway encompasses the reaction of nitric oxide with superoxide 
radicals to form peroxynitrite, another potent oxidant [176, 180]. A product of 
peroxynitrite reactions, 3-nitrotyrosine, has been detected in atherosclerotic lesions and 
on LDL [185, 186]. LDL oxidised by cells in the presence of glucose-enriched media is 
rapidly taken up by J774 macrophage-like cells [187]. It has also been shown that LDL 
oxidised by a mixture of glucose and iron is taken up by rat peritoneal macrophages 
[188]. These glycoxidation reactions of LDL have been strongly implicated in diabetes-
induced atherosclerosis [43, 74, 176, 189-191]. The chemical reactions that occur in the 
presence of excess glucose are discussed further in the next Section. 
 
1.3    Glycation and Glycoxidation Reactions 
Protein and sugars can interact in a variety of ways. Non-enzymatic reactions 
between carbonyl groups of carbohydrates and free amino groups on proteins, peptides, 
amino acids and organic amines can occur at physiological conditions of temperature, 
pH and concentration [192]. In 1987 Wolff and Dean demonstrated that the non-
enzymatic reaction of sugars with protein involves 3 components: 1) glycation– the 
non-oxidative, covalent, addition of sugar to the protein; 2) autoxidative glycosylation 
where free radicals, arising from glucose autoxidation, interact with proteins; and 3) 
autoxidation of protein-bound sugars formed as a result of glycation. The latter two 
oxidative processes are collectively termed glycoxidation [74, 193-195]. Therefore the 
hyperglycaemia seen in people with diabetes may lead to increased glycation and 
glycoxidation of proteins including LDL. 
 
1 .3 .1  Basic Mechanisms of Glycation and Glycoxidation Reactions 
The first step in the non-enzymatic glycation of proteins (or Maillard reaction) is 
the attachment of a sugar molecule to an amine group (or thiol [196]) via nucleophilic 
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 addition, resulting in the formation of unstable, chemically-reversible, Schiff base 
adducts. Schiff bases may exist in an open-chain aldimine form or a more stable 
glycosylamine ring form [190, 192]. These Schiff bases can undergo a slow chemical 
rearrangement (Amadori rearrangement) into a chemically-reversible, 1-amino-1-
deoxy-2-ketose or ketamine (i.e. fructosyl-lysine or fructosamine). From these Amadori 
products Advanced Glycation End-products (AGE) are formed (Figure 1.3) [189, 190, 
196-198].  
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Figure 1.3 Pathways of AGE formation (from [198]). Glycation adducts are formed by the reaction of 
proteins with glucose, α-oxoaldehydes and other saccharide derivatives, which may include glycolytic 
and lipid peroxidation products. For more details see text. 
 
There are many possible AGEs that can be formed and some have been well 
characterised. The number of AGEs detected in tissues is now increasing at the rate of 
2-3 per year, partly due to advances in analytical techniques [196]. The alternative 
pathways of the Maillard reaction from glucose are depicted in Fig. 1.4. The formation 
of AGEs from reducing sugars may occur from the autoxidation of sugars, from the 
Schiff base or the Amadori compound [196]. From an initial adduct formed between 
glucose and protein, Nε-(fructose)lysine, the AGE of Nε-(carboxymethyl)lysine (CML) 
[199] and pentosidine [200] are formed. The formation of these species requires 
oxidative cleavage of the six carbon backbone of the sugar [199-201]. CML is a well 
characterised glycoxidation product formed during in vitro glycation as well as the 
 26
 major immunological product determined on glycated proteins [202-204]. However, 
CML may not be unique to sugar oxidation as there is evidence for formation of this 
species as a result of lipid peroxidation [205, 206]. The autoxidation of glucose also 
produces both glyoxal and arabinose that are precursors of CML and pentosidine 
respectively [207]. Formation of pyrraline and crosslines from glucose, is a non-
oxidative process, and crosslines (and vesperlysines) seem to be directly derived from 
glucose [196].  
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Figure 1.4 Alternative pathways of the Maillard reaction from glucose, including formation of reactive 
aldehydes (from [196]). The formation of AGEs are catalysed by oxidation and fragmentation of their 
adducts to proteins. Some of the above reactions are catalysed by reactive oxygen species [O2] and 
peroxynitrite [ONOO-]. 
 
1 .3 .1 .a  Aldehyde Reactions 
Glycation and glycoxidation reactions produce a range of aldehydes and ketones 
(Figure 1.4), adding to the complexity of these reactions and the products formed. These 
aldehydes and ketones include α-ketoaldehydes such as glyoxal, methylglyoxal and 3-
deoxyglucosone and glucosone [201, 208, 209] (Figure 1.5). These may be formed by 
reverse aldol, dehydration and intramolecular rearrangements, or by oxidation of sugar 
or sugar-protein adducts [208]. Methylglyoxal is produced from the autoxidation of 
sugars and lipids, from glycation, and spontaneous decomposition of triose phosphate 
intermediates from aerobic glycolysis [209-211]. For example, glyoxal, 3-
deoxyglucosone and methylglyoxal are formed during autoxidation of glucose and 
degradation of Nε-(fructose)lysine [209]. Characterised adducts produced from glyoxal 
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 include CML, the crosslink glyoxal-lysine dimer (GOLD) and imidazolone adducts. 
Glyoxal may also be a product of lipid peroxidation [206]. 3-deoxyglucosone is 
involved in the formation of CML, pyrraline, pentosidine and also perhaps specific 
imidazolone products [201, 208]. Adducts from methylglyoxal include the crosslink 
methylglyoxal-lysine dimer (MOLD), Nε-(carboxyethyl)lysine (CEL) as well as 
methylglyoxal-arginine adducts such as 5-hydro-5-methylimidazolone, 
tetrahydropyrimidine and argpyrimidine. Lys-Arg crosslinks have also been reported 
from the reactions of α-ketoaldehydes, such as glucosepane, N6-(2-([(4S)-4-ammonio-
5-oxido-5-oxopentyl]amino)-5-[(2S)-2,3-dohyroxypropyl]-3,5-dihydro-4H-imidazol-4-
ylidene)-L-lysinate (DOGDIC), N6-(2-([(4S)-4-ammonio-5-oxido-5-oxopentyl]amino)-
5-3,5-dihydro4H-imidazol-4-ylidene)-L-lysinate (MODIC) and N6-(2-([(4S)-4-
ammonio-5-oxido-5-oxopentyl]amino)-3,5-dihydro-4H-imidazol-4-ylidene)-L-lysinate 
GODIC [212]. Methylglyoxal also reacts rapidly with the sulfhydryl group of Cys to 
form S-lactoylcysteine [201, 208, 210]. Recently, a new AGE has been determined from 
the reaction of Cys residues with glyoxal to form S-(carboxymethylcysteine) (CMC) 
[196]. 
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Figure 1.5 Structure of glucose and some of the common aldehydes involved in glycation/glycoxidation 
reactions and formation of AGEs (from  [163, 208, 209]).   
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 Another important, very reactive, aldehyde is glycolaldehyde, which is an 
immediate precursor in the formation of CML, but the subsequent AGE products 
generated by this species do not seem to be well characterised [213]. Glomb and Pfahler 
demonstrated that from glyoxal and glycolaldehyde reactions N6-{2-[(5-amino-5-
carboxypentyl)amino]-2-oxoethyl}lysine (GOLA) and N6-glycoloyllysine (GALA) are 
formed [214]. Recently it was demonstrated that glycolaldehyde is also formed from the 
reaction of dehydroascorbic acid (an ascorbic acid oxidation product) with the Lys ε-
amino group, with the product 1-(5-ammonio-5-carboxypentyl)-3-oxido-4-
(hydroxymethyl)pyridinium formed [215]. 
 
1 .3 .1 .b  Other Reactions Occurring Concurrently with Glycation and 
Glycoxidation 
Other reactions may occur along with those of glycation and glycoxidation, 
especially in the presence of metal ions which catalyse oxidation reactions. 
Autoxidation of sugars may produce superoxide radicals, H2O2, hydroxyl radicals and 
1-hydroxyalkyl radicals [176, 193, 216]. All these are capable of producing tissue 
damage [177]. In 1998 Fu et al showed that glycation reactions can be accompanied by 
the formation of amino acid oxidation products in incubation mixtures containing 
collagen and glucose. CML and Nε-(fructose)lysine formation was apparent as well as 
the presence of  3,4-dihydroxyphenylalanine (DOPA), o- and m-Tyr, dityrosine and 
leucine and valine hydroxides. These products are characteristic of metal-ion-catalysed 
(Fenton) oxy-radical systems and these may arise from the formation of sugar-, protein-
bound sugar-, and protein-derived radicals [217]. Lipid peroxidation may also occur 
during glycoxidation of LDL as the polyunsaturated fatty acids of cholesterol esters, 
phospholipids and triglycerides are subject to free radical initiated oxidation [208]. As 
mentioned previously, both glyoxal and CML may be formed during lipid peroxidation, 
as well as other aldehydes such as malondialdehyde, acrolein and 4-hydroxy-2-alkenals 
(for example 4-hydroxy-2-nonenal). These aldehydes can subsequently form amino acid 
adducts on proteins [205, 208]. Reactive aldehydes may also be generated from the 
myeloperoxidase-H2O2-Cl- system of phagocytes (see Section 1.2.1.b) or HOCl. Thus 
with Ser as the substrate, HOCl generates high levels of glycolaldehyde, and when 
ribonuclease A is exposed to Ser and HOCl, CML is produced [218]. A similar system 
involving Thr produced 2-hydroxypropanal and its dehydration product, acrolein [219]. 
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 Peroxynitrite (see Section 1.2.1.b) can also induce the formation of CML, via cleavage 
of Amadori products, and induce the formation of glucosone and glyoxal from glucose 
[220] (Fig. 1.4). Therefore, glycation and glycoxidation reactions can occur 
concurrently with other types of oxidative and adduction reactions, making this a 
complex area with the mechanisms, and resulting glycoxidation/AGE products 
incompletely characterised [74].  
 
1 .3 .2  In Vitro effects of Glycation and Glycoxidation 
The in vitro effects arising from the formation of Schiff bases, Amadori products 
and AGEs are many. The Maillard reaction leads to characteristic browning of the 
solutions, increases in chromophores and fluorophores, and protein crosslinking [194, 
221]. In the presence of metal ions (Cu2+) and glucose, human serum albumin 
undergoes fragmentation [222]. Collagen incubated with glucose over time results in 
increases in crosslinks [221]. It has been shown that the protein fragmentation and 
conformational changes brought about by the reaction of proteins with glucose are 
dependent upon the hydroxylating/oxidising agents produced, in the presence of metal 
ions, from the H2O2 arising from glucose autoxidation and ketoaldehyde formation, or 
similar processes [194, 223]. Fluorescence increases, Arg and Lys modification, and net 
negative charge increases have also been reported for bovine serum albumin (BSA) 
reacted with glucose, glyoxal, methylglyoxal and glycolaldehyde, with the magnitude of 
these changes dependent on which modifying agent is used [224]. In the study of Nagai 
et al CML levels were high on glyoxal-modified BSA, low on glycolaldehyde-modified 
BSA and were undetectable on methylglyoxal-modified BSA, and a similar pattern was 
also seen for antibodies against non-CML structures. The fluorescence spectra of the 
modified proteins were similar in all cases except for glyoxal-modified BSA, where 
they were weak, and all had similar changes in negative charge. However, only glucose- 
and glycolaldehyde-modified BSA were taken up by receptor-mediated endocytosis by 
a macrophage-type cell line [224].  
 
1 .3 .3  In Vivo Evidence for, and Effects of, Glycation and Glycoxidation 
Glycation and glycoxidation reactions are of relevance in vivo, especially in 
diabetes and associated complications. HbA1C (glycated haemoglobin; an indicator of 
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 average blood glucose over the previous 3 months) in people with diabetes is elevated 
and may reach values of up to 10 %, compared to values of approximately 5 % in 
controls [82, 166]. Methylglyoxal [225-227], 3-deoxglucosone [228], CML [203, 229-
232] and pentosidine [232], have been shown to be elevated in diabetic tissues, plasma 
or urine. AGE formation and accumulation is implicated in diabetic and age-related 
ocular disease [233], diabetic neuropathy [234] and endstage renal disease [198]. AGE 
levels have also been shown to be increased in haemodialysis patients [198]. Thornalley 
et al recently published a comprehensive study of AGEs in human blood cells, plasma 
and urine, as well as in diabetic rats [198]. They demonstrated that for all of the AGEs 
examined the concentrations were higher in cellular protein than in plasma protein, and 
that the highest levels of AGE were found for the hydroimidazolones (Nδ-(5-hydro-5-
methyl-4-imidazolon-2—yl)-ornithine and those derived from 3-deoxyglucosone), with 
these accounting for 1-3 % of total Arg residues. They reported that human serum 
albumin contains approximately 3 % hydroimidazolones residues. Individual AGE 
concentrations range from 0.8 nM to 147 nM in the plasma, with up to 10-fold increases 
observed in renal failure patients. Fructosyl-lysine, hydroimidazolones, CML and CEL 
were > 1 μM in control urine, with large increases again observed in renal failure 
patients. In rat tissues the hydroimidazolones were again the most abundant AGEs, with 
specific AGE increases observed in the retina, nerve, plasma protein and renal 
glomeruli. 
It has been shown that moderately oxidised proteins are more sensitive to 
proteolytic attack [177, 235], and are endocytosed more quickly than native proteins, 
which in turn are more quickly removed than heavily oxidised proteins [236-238]. This 
may explain the accumulation of oxidised proteins seen over time in some tissues and 
disease states (age, atherosclerosis, diabetes) and contribute to their pathologies [239]. 
Similar behaviour may occur with glycated/glycoxidised proteins. A number of studies 
have examined the glycation/glycoxidation of collagen, as it is a long-lived protein in 
the body, found in connective tissue such as that in the artery wall and other smooth 
muscle-containing tissues, and may therefore be likely to accumulate modification and 
oxidative damage. Chemical modification of rat tail collagen with glucose shows 
increased levels of CML and pentosidine [221], as well as the amino acid oxidation 
products DOPA, o- and m-Tyr, dityrosine and valine and leucine hydroperoxides [217]. 
Other studies with skin collagen have shown that extracellular levels of CML, 
pentosidine, CEL, methionine sulphoxide and o-Tyr increased with age and, in most 
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 cases, diabetes [210, 229-232]. CML has also been detected in the aortic collagen of 
streptozotocin-induced diabetic rats [240]. Thus, there is considerable evidence for the 
accumulation of AGE products in vivo; the situation with regard to atherosclerotic 
lesions is discussed in more detail in the following Section. 
 
1 .3 .3 .a  Presence of Glycation, Glycoxidation and Advance Glycation End 
Products in Atherosclerosis 
Glycoxidation products and AGE have been detected in atherosclerotic tissue, that 
is both early and late stage products from the reactions of sudgars with proteins. Kume 
et al found AGE in 12/22 human intimal lesions of aortic atherosclerosis using a 
monoclonal antibody, 6D12, specific for AGE [241]. This antibody is positive for AGE 
proteins, AGE polylysine, and AGE-Lys derivatives, but negative for early stage 
products, proteins, polylysine, Lys derivatives, monoaminocarboxylic acids and 
pentosidine and AGE monoaminocarboxylic acids. This group demonstrated that AGE 
accumulation occurred in macrophages, smooth muscle cells and their associated foam 
cells and was marked in the diffuse intimal thickening and fatty streak lesions [241]. 
Stitt et al reported AGE-immunoreativity in human atherosclerosis lesions, as well as 
the presence of AGE receptors [242]. Fluorescent techniques have also been used to 
demonstrate AGE products in human atherosclerotic plaques [243]. Schleicher et al 
reported age-dependent CML accumulation in the heart, arteries, foam cells and 
atherosclerotic plaques of humans, and accelerated accumulation in people with 
diabetes [229]. Another study by Sakata et al reported that in fatty streaks CML-
epitopes accumulated mainly in the cytoplasm of foam cells, while other non-CML 
AGEs were found in extracellular spaces [244]. As the lesion severity progressed CML-
epitopes were still found in macrophages but more were found extracellularly. Sima et 
al found AGE-proteins immunolocalised in the shoulders and caps of atherosclerotic 
plaques of hamsters, that were distributed extracellularly in a diffuse manner, or within 
macrophage-foam cells and smooth muscle cells [80]. Evidence of AGE products has 
also been obtained, using immunological techniques, in atherosclerotic plaques from 
rabbits [245]. A glycolaldehyde-derived pyridine has been detected in the cytoplasm of 
foam cells and extracellularly in the central region of human atheroma [246]. Therefore 
glycation/glycoxidation reactions, and the accumulation of AGE, appear to occur during 
the development of atherosclerotic lesions. 
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 1 .3 .3 .b  Role of Oxidative and/or Carbonyl Stress in Atherosclerosis 
It has been proposed that people with diabetes are subject to heightened oxidative 
reactions and/or oxidative stress [74, 94, 193, 247-250]. Oxidative stress refers to the 
situation of an imbalance between the production of free radicals and the antioxidant 
defence, possibly leading to tissue damage [248]. Antioxidants such as ascorbic acid, 
vitamin E, uric acid and glutathione, and possibly plasma total antioxidant power, have 
been reported to be decreased in plasma from people with diabetes compared to control 
[247]. Baynes (1991) proposed an ‘oxidative stress’ theory that encompassed the 
oxidative reactions, as well as the glycation/glycoxidation reactions, that may occur 
during diabetes [193]. Baynes proposed that possible sources of oxidative stress and 
protein damage include free radicals generated by oxidation of sugars and glycated 
proteins and by autoxidation of unsaturated lipids in plasma and membranes. The 
oxidative stress may be amplified by continuing cycles of metabolic stress, tissue 
damage and cell death leading to increased free radical production and compromised 
antioxidant defence and repair systems [193]. It was also suggested that much of the 
increase in collagen-linked fluorescence may be the result of a glycation-dependent 
enhancement of autoxidative reactions, that is the fluorescence of browned proteins may 
be due to secondary oxidation reactions [74].  
Dean and Kelly have also reviewed the evidence and mechanisms involved in 
enhanced oxidation in diabetes. This enhanced oxidation could arise from: a) the 
oxidants generated concurrently to reactions between sugars and proteins (discussed in 
Section 1.3.1.b); b) increased production of the superoxide radical in some cell types 
exposed to glucose; c) enhanced lipoxygenase-dependent oxidation in atherosclerotic 
plaque; and d) diabetes-associated mitochondrial dysfunction (for an example see 
Section 1.1.3.b) [74]. In contradiction to this, the susceptibility of LDL, from patients 
with atherosclerosis or diabetes, to copper-induced oxidation is not increased once the 
LDL vitamin E has been consumed [251-255]. These theories of increased oxidative 
reactions in diabetes are in dispute, however the glycation and glycoxidation of proteins 
may indeed lead to a state of ‘carbonyl stress’ [74]. A latter report by Baynes and 
Thorpe (1999) proposed a theory of ‘carbonyl stress’ over the earlier ‘oxidative stress’ 
theory, as some of the products from glycoxidation and lipoxidation, such as 3-
deoxyglucosone adducts to Arg and Lys residues, are formed independent of oxidation 
chemistry [256]. They proposed that the increased chemical modification of protein by 
carbohydrates and lipids in diabetes was the result of overload on metabolic pathways 
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 involved in detoxification of reactive carbonyl species from both oxidative and non-
oxidative processes. This could lead to increases in steady state levels of reactive 
carbonyls, and increased glycoxidation and lipoxidation of proteins in diabetic tissues, 
and thus carbonyl stress [74, 256, 257]. 
 
1 .3 .3 . c  Glycation and Glycoxidation Reactions with Low-Density Lipoproteins 
Schleicher et al in 1981 were the first to demonstrate the glycation of 
lipoproteins exposed to elevated glucose concentrations. They showed that glucose 
incorporation into apolipoproteins AI, AII, B, C and E was proportional to the time of 
the incubations and glucose concentration. These workers also demonstrated a 2-fold 
increase in the extent of glycation of apo B in LDL from people with diabetes as 
compared to control subjects and suggested that this glycation of lipoproteins may have 
important metabolic consequences [258]. Curtiss and Witztum later also demonstrated 
that apolipoproteins AI, AII, B, CI and E are glucosylated in hyperglycaemic patients, 
using immunological methods [259]. Lyons et al have reported that the degree of 
glycosylation of LDL from people with diabetes was 1.4 fold higher than controls [166]. 
Steinbrecher and Witztum reported up to 5 % of Lys residues in LDL from people with 
diabetes is glucosylated [260]. Klein et al, using affinity column chromatography, 
reported that the percentage of glycated LDL is higher in people with diabetes than 
controls (21 % and 5% respectively) [164]. Another study found serum AGE-apo B 
levels were significantly increased in older people (~ 1.4-fold increase), and in older 
people with atherosclerosis (~ 1.83-fold increase), when compared to younger control 
subjects [242]. Bucala et al, using AGE-specific antibodies, have identified epitopes 
near the LDL receptor binding site, as key AGE formation sites on apo B [261]. 
Glucosylation of LDL can affects its catabolism and degradation in vivo and in vitro 
[260, 262-265], and increases its proteoglycan binding properties [266]. Thus 
glycated/glycoxidised LDL may play a role in diabetes-associated atherosclerosis. 
Glycation and glycoxidation of the apo B protein of LDL, by glucose and other 
aldehydes gives rise to a range of modifications as observed with other proteins. These 
include increases in net negative charge, Lys and Arg modifications, fluorescence 
increases, crosslinks, presence of CML and fructosamine, malondialdehyde formation, 
peroxide formation as well as formation of TBARS (thiobarbituric acid reactive 
substances) and conjugated dienes from the lipid components [163, 167, 267-272]. 
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 CML has also been identified in glucose-modified LDL and in macrophage foam cells 
of atherosclerotic plaques [273, 274].  
It has been shown that the rate and extent of alterations to LDL are more 
apparent after incubation with reactive aldehydes, or when Cu2+ is added to the glucose 
and LDL reaction mixtures. One study compared different length aldehydes; 
glycolaldehyde, glyceraldehyde, erythrose, arabinose and glucose (2, 3, 4, 5 and 6 
carbons respectively). The lower the molecular mass of the aldehyde the more rapid and 
extensive the derivatisation of free amino groups and increases in negative charge [163]. 
Methylglyoxal also caused Lys and Arg modifications and increases in electrophoretic 
mobility and fluorescence. Mowri et al demonstrated that the oxidation of LDL by 
glucose is a metal ion-dependent oxidation process and involves increased metal ion 
reduction [268]. This effect of glucose on Cu2+-induced LDL oxidation was 
independent of superoxide radicals, even though superoxide radicals may play a role in 
Cu2+-induced oxidation without glucose [268, 271]. Another study also demonstrated a 
requirement for Cu2+ to stimulate glucose-mediated oxidation [271], but also showed 
that the glucose-mediated enhancement was partially blocked by superoxide dismutase 
and completely inhibited by butylated hydroxytoluene (BHT). Addition of a metal ion 
chelator also prevented any changes in lysine residue modification and TBARS. They 
suggested that glucose enhances LDL lipid peroxidation by an oxidative pathway 
involving superoxide radicals.  
 Glycation and glycoxidation of lipoproteins may render them immunogenic. 
Curtiss and Witztum demonstrated that LDL glycated in the presence of 
cyanoborohydride, which was heavily modified (60% of lysine residues glycated), was 
a potent immunogen, stimulating antibodies that did not interact with unmodified LDL 
[275]. When LDL was glycated with glucose alone (6% of lysine residues glycated) it 
was a less potent immunogen [275]. Differences in the antibody response and 
subsequent clearance were found to be dependent on the degree of modification. 
Therefore severely modified, glycoxidised LDL, which may be present in the artery 
wall, could behave as potent antigens and stimulate the formation of modified LDL-
containing immune complexes and thus play a role in the inflammation associated with 
atherosclerosis [265, 275]. It has also been shown that activation of macrophages, via 
ingestion of AGE, may lead to production of pro-inflammatory cytokines and promote 
local inflammatory reactions [74]. 
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 1 .3 .3 .d  Effects of Glycation and Glycoxidation Reactions on Arterial Cell Types 
Macrophages, in vitro, are capable of accumulating AGE-modified LDL and 
interact with in vivo glycoxidised lipoproteins. LDL from people with Type 1 diabetes, 
with significantly higher HbA1C, can stimulate more cholesteryl ester synthesis and 
intracellular cholesteryl ester accumulation in macrophages, than LDL isolated from 
control subjects [166]. LDL, from people with Type 1 diabetes, incubated with glucose 
in vitro can also stimulate more cholesteryl ester synthesis in human monocyte-derived 
macrophages (HMDM) than control LDL [166]. In another study by this group glycated 
LDL was separated from the non-glycated LDL using affinity chromatography [164]. 
The glycated LDL fraction was significantly more modified than the non–glycated 
fraction, and when this glycated fraction was incubated with HMDM, the extent of 
cholesterol and cholesteryl ester accumulation was significantly higher than that 
observed with the non-glycated LDL. The glycated LDL also significantly increased 
cholesteryl ester synthesis rates. Interestingly there were no significant differences in 
the rates of cholesteryl ester synthesis for glycated LDL obtained from people with or 
without diabetes [164]. 
In vitro glycation of LDL with glucose can also affect macrophages. One study 
has shown, using staining methods, that LDL glycated with glucose and iron can be 
taken up by mouse peritoneal macrophages, and also result in the production of 
superoxide radicals [267]. Lopes-Virella et al showed that incubating LDL with 
glucose, in the absence of metal ions, resulted in increased cholesteryl ester synthesis 
and cholesteryl ester accumulation in HMDM. They also showed that degradation of the 
modified LDL is enhanced by pathways other than the classic LDL receptor or 
scavenger receptor pathways [165]. Another group showed that human macrophages 
(that contain abundant scavenger receptors, but few LDL receptors) show increased 
rates of degradation of glycoxidised LDL when compared to control LDL, and that 
fibroblasts (that contain fewer scavenger receptors and more LDL receptors) show 
higher rates of degradation of native LDL than the glycated LDL. These HMDM also 
demonstrated enhanced uptake of modified LDL, whereas the fibroblasts showed 
enhanced uptake of the unmodified LDL [271]. Millican et al demonstrated that LDL 
glycoxidised with glucose and Cu2+ results in an increase in electrophoretic mobility 
that correlated with lipid oxidation, and that both of these correlated with the inhibition 
of DNA synthesis in P388D1 macrophage-like cells [269]. Albumin modified by 
pyrraline (an AGE derived from glucose [196]) has also been shown to accumulate in 
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 these cells, possibly due to decreased susceptibility of this modified protein to 
lysosomal degradation [276]. AGE products can also form on the lipid components of 
LDL, such as the amine groups of phospholipids [277, 278]. In glucose-modified LDL 
glucosylated phosphatidylethanolamines have been detected [278]. Enrichment of LDL 
with these glucosylated phosphatidylethanolamines can lead to increased LDL uptake, 
and cholesteryl ester and triglyceride accumulation, in macrophages [279]. 
Reactive aldehydes, such as methylglyoxal and glycolaldehyde, can also modify 
LDL in a way that it affects macrophage metabolism. Methylglyoxal-modified LDL has 
been shown in one study to cause significantly less cholesteryl ester synthesis in murine 
macrophages as compared to native, oxidised or acetylated LDL [167]. This is in 
contrast to glycolaldehyde-modified LDL which is specifically recognised, endocytosed 
and then degraded by the lysosome mainly via the macrophage scavenger receptor 
pathway [162]. This is an agreement with another study that showed that LDL modified 
with glycolaldehyde and glyceraldehyde is degraded more extensively by HMDM 
compared to LDL modified by longer chain aldehydes and native LDL, probably via the 
macrophage scavenger receptor pathway [163]. 
It has been suggested that people with diabetes are predisposed to endothelial 
dysfunction. Endothelial dysfunction refers to putative abnormalities such as increased 
vascular permeability, lack of normal endothelium-dependent relaxation of vascular 
smooth muscle and loss of anticoagulant function. This dysfunction may be caused by 
enhanced oxidation, from the effects of abnormal lipid metabolism on endothelial cells 
and increased endothelial free radical generation (reviewed in [74]). Endothelial cells 
may be exposed to AGE on both basal and luminal surfaces [280]. AGE-endothelial 
interactions may induce an oxidant stress, mediated by NF-κB which may result in 
increased endothelial vascular cell adhesion molecule (VCAM-1) expression and 
monocyte adhesiveness to endothelium [280, 281]. The binding of red blood cells (from 
people with diabetes) to endothelial cells can result in an increase in interleukin-6 (IL-6, 
an inflammatory cytokine) secretion. NF-κB activation may also lead to increased 
vascular permeability, which may be promoted by AGEs on serum albumin and red 
blood cells (reviewed in [280]). Receptors for AGE can provide a pathway for the 
delivery of glycoxidised proteins to the subendothelial space and AGEs may then 
crosslink with long-lived extracellular matrix components. Receptor engagement of 
AGE may also lead to a procoagulant state of endothelial cells, enhancement of the 
endothelial response to TNF (tumour necrosis factor- an inflammatory and possibly 
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 proatherogenic cytokine), and expression of a potent vasoconstrictor, endothelin-1 
(reviewed in [280]). Glycoxidised LDL has been shown to impair endothelial function 
more than oxidised LDL, possibly due to enhanced nitric oxide-inactivation by 
superoxide radicals [282], but another study using methylglyoxal-modified LDL 
demonstrated that this did not induce activation of human endothelial cells [167]. There 
are few other studies that have examined the effects of glycoxidised LDL on endothelial 
cells.  
Vascular smooth muscle cells may be exposed to subendothelial and circulating 
AGE by an increase in endothelial permeability [280]. Vascular smooth muscle cells 
show high levels of expression of receptors for AGE, which are unchanged by 
increasing age or the presence of vascular disease [283]. The functional significance of 
this is unclear, but the binding of AGE protein to smooth muscle cells can be associated 
with increased cellular proliferation, perhaps mediated by growth factors or cytokines 
[280, 284]. AGE-BSA has been shown to be endocytosed by smooth muscle cells, and 
also can induce chemotatic smooth muscle cell migration, but not their growth [285]. 
Glycoxidised BSA may also be cytotoxic to smooth muscle cells, possibly due to 
reactive oxygen species produced extracellularly by metal-ion induced glycoxidation 
[286]. Exposure of vascular smooth cells to glycated albumin has also been reported to 
result in increased activation of NF-κB, increased activity of mitogen activated kinases 
(MARK) and extracellular signal-regulated kinase (ERK), as well as increased 
expression of c-fos, c-jun, IL-6, and monocyte chemoattractant peptide (MCP-1) [287]. 
Glycated and glycoxidised LDL has also been shown to induce smooth muscle cell 
proliferation and migration [288, 289]. As with endothelial cells there seems to be little 
information of the effects of glycoxidised LDL on smooth muscle cells. 
 
1 .3 .3 . e  Receptors for Advanced Glycation End Products 
Of the scavenger receptors, discussed in Section 1.2.1.a.ii, many recognise AGE. 
These include SR-AI, SR-AII, CD36, SR-B1, LOX-1, FEEL 1 and FEEL-2 [134]. A 
study by Iwashima et al indicated that the expression of the genes which produce SR-
AI, CD-36, SR-BI and LOX-1 may be induced by the presence of AGEs [290]. 
Galectin-3/80K-H/OST48 complexes have also been shown to bind AGEs [134].  Two 
AGE binding proteins of 60 and 90 kDa, known as p60 and p90, have been identified 
from rat liver [291]. Subsequently p60 has been shown to be homologous to a 50 kDa 
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 component of the oligosaccharyltransferase complex (OST-48) and p90 to an 80 kDa 
phospho-tyrosine containing protein (80K-KH) [134, 292]. Galectin-3 is also a 
component of p90 [134, 293], and AGE-1, 2 and 3 may also refer to p60, p90 and 
Galectin-3 [294]. The receptors p60 and p90 have been detected in many human cells 
including endothelial cells, monocytes, macrophages, T-lymphocytes, neural tissue cells 
and smooth muscle cells [292]. Another receptor, Receptor for AGE (RAGE), is a well 
characterised member of the immunoglobin superfamily expressed on endothelial cells, 
mononuclear phagocytes and vascular smooth muscle cells in vitro and in vivo [295, 
296]. As cells can recognise AGEs, they may elicit a wide range of cell mediated effects 
that might contribute to the pathogenesis of diabetic complications and vascular and 
renal diseases [234, 280, 281, 283, 296]. 
The binding of AGE to RAGE has been reported to have pro-atherosclerotic 
effects. The effects of this interaction may include impaired barrier properties of 
endothelium, enhanced expression of VCAM-1, enhanced oxidation of polyunsaturated 
fatty acids, activation of NF-κB, induction of mRNA for oxygenase and IL-6, induction 
of pro-coagulant tissue factor and accelerated calcification in plaques (reviewed in 
[74]). Binding of AGE to RAGE has also been associated with chemotaxis of smooth 
muscle cells [285]. However a recent study using AGE-BSA suggested that AGE 
modification and high RAGE affinity binding are not always sufficient to generate pro-
inflammatory signalling molecules, and thus may not uniformly play a role in cellular 
activation [297]. Zhou et al have recently reported the RAGE/ligand interactions plays a 
role in neointimal formation after vascular injury, irrespective of diabetes status, as 
AGEs accumulate. In this study smooth muscle proliferation was suppressed by 
blockade of the RAGE/ligand interaction, both in vitro and in vivo [298]. Enhanced 
formation of vascular lesions was suppressed, in a genetically-modified mouse model of 
accelerated atherosclerosis with diabetes, when blockade of cell surface RAGE was 
achieved by infusion of a soluble, truncated form of the receptor [299]. This 
amelioration of atherosclerosis in these animals occurred without changes in plasma 
lipids or glycaemia. This suggests the possibility of a lipid- and glycaemia-independent 
mechanism of atherogenesis, such as the interaction of RAGE with its ligands [296]. A 
recent study in a diabetic mouse model demonstrated that treatment with a neutralising 
murine RAGE antibody reduced or ameliorated associated diabetic renal problems 
[300]. These latter studies also suggest novel ways of reducing diabetic complications, 
as well as supporting a role of AGE in atherogenesis. 
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 1 .3 .4  Inhibition of Glycation and Glycoxidation Reactions 
One of the most obvious ways to impede the potentially deleterious effects of 
glycation and glycoxidation reactions would be to reduce the hyperglycaemia seen in 
patients with diabetes. Hyperglycaemia may be controlled through diet, exercise, oral 
hypoglycemic agents (such as metformin, acarbose, sulfonylureas or glitazones) or 
insulin injections [6, 79, 301, 302]. The United Kingdom Prospective Diabetes Study 
(UKPDS) showed that patients with Type 2 diabetes subjected to intensified glycaemic 
control with sulphonylureas, diet, or insulin, lowered their HbA1C from 7.9 % to 7 % 
and this was associated with a clear benefit in microvascular disease, but interestingly 
not for macrovascular disease [91]. However, skin samples from subjects with Type 1 
diabetes in the Diabetes Control and Complications Trial with intensive hyperglycaemia 
treatment had 30-32 % lower furosine, 9 % lower pentosidine, 9-13 % lower CML, 24 
% higher acid-soluble collagen, and 50 % higher pepsin-soluble collagen, as well as a 
lower incidence of renal disease [303]. Therefore intensive hyperglycaemia treatment in 
patients with diabetes may reduce AGE formation, though any potential macrovascular 
benefits are not yet clear. A new trial, called The Action to Control Cardiovascular Risk 
in Diabetes (ACCORD), is targeted to examine the effect of glucose control on 
cardiovascular event rate and mortality [113]. 
Other treatments for patients with diabetes may also improve cardiovascular 
outcomes. In a recent review by Mazzone, current clinical trials evaluating the role of 
thiazolidinediones, angiotensin-converting enzyme (ACE) inhibitors and statins were 
discussed [113]. Thiazolidinediones have recently been approved in the United States to 
lower blood glucose levels, however they may also have atherosclerosis reducing 
effects such as decreasing platelet reactivity, fibrogen, IL-6, TNF, endothelial 
dysfunction, and increasing HDL [113]. Ramipril (an ACE inhibitor) has been reported 
to decrease AGE accumulation in diabetic animals [304], prevent lesion progression in 
mice and uptake of oxidised LDL by their macrophages in vitro [305], and decrease 
carotid stenosis [306]. The Heart Protection Study provided direct evidence that statin 
cholesterol-lowering therapy is beneficial for people with diabetes even if they do not 
have coronary artery disease or high serum cholesterol levels [307]. These types of 
drugs that have anti-atherosclerotic effects need to be investigated further to determine 
their mechanisms of action in people with diabetes. 
Agents that trap the reactive carbonyls, formed during glycation and 
glycoxidation reactions, or prevent such reactions, can also act as AGE inhibitors. These 
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 include hydrazines, such as aminoguanidine, hydralazine, isoniazid and gentamicins 
[308]. In vitro, aminoguanidine has been shown to inhibit the formation of AGE, AGE 
cross-linking of soluble proteins to matrix and AGE cross-linking of collagen [190]. In 
vivo, aminoguanidine can prevent increases in the AGE matrix content of aortas and the 
quantity of plasma proteins cross-linked to the matrix [190]. Aminoguanidine was the 
subject of Phase 2/3 clinical trials under the name Pimagedine, however these trials 
were ended due to serious complications [309, 310]. Other carbonyl scavengers and 
potential AGE inhibitors include carnosine [311, 312], D-pencillamine [313], 2,3-
diaminophenazine, tenilsetam, OPB-9195 [205], thiamine [93, 314, 315], pyridoxamine 
[314, 316-318], sodium sulfite and N-acetylcysteine [319], and metformin [320, 321].  
Prevention of oxidative reactions, by use of anaerobic conditions and metal ion 
chelators, can inhibit glycoxidation reactions. The formation of CML and amino acid 
oxidation products from AGE-collagen is prevented by anaerobic and antioxidative 
conditions (for example by use of 1mM diethylenetriaminepenta-acetic acid (DTPA) 
and phytic acid and under an atmosphere of nitrogen) [217]. DTPA also reduces the 
covalent attachment of glucose to BSA and glucose autoxidation [194]. Another study 
using collagen-AGE showed that chelators, sulfhydryl compounds, antioxidants and 
aminoguanidine also inhibited the formation of glycoxidation and fluorescence 
products, and crosslinking of collagen, without significant effects on the extent of 
glycation of the protein [221]. In this study, inhibitors of crosslinking included DTPA, 
dithiothretiol (reducing agent) and thiourea (which scavenges hydrogen peroxide and 
oxygen radicals). Tiron, a chelator and radical scavenger, promoted crosslinking 
(probably due to the cross-linking of hydroquinone radicals or o-quinones formed 
during the quenching of oxygen radicals), but was a potent inhibitor of CML, 
pentosidine and fluorescence development [221]. AGE inhibitors, such as 
aminoguanidine, pyridoxamine, carnosine, phenazinediamine, OPB-9195 and 
tenilsetam, have been reported to also have chelating or antioxidant activity [322]. 
Antioxidants, such as ascorbate, glutathione or α-tocopherol, may also aid in the 
protection against damage induced by glycation. There is some controversy regarding 
the prevention of glycation and glycoxidation reactions in LDL by α-tocopherol [255, 
323, 324], and generally the benefits of antioxidant use/supplementation in 
atherosclerosis prevention is unclear [173]. 
Finally a number of novel agents have been shown to prevent AGE formation 
and accumulation. N-phenacylthiazolium bromide (PTB) and ALT-711 have been 
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 shown to be capable of breaking/cleaving AGE-derived crosslinks [308, 325-327]. In 
vitro studies have shown the release of BSA from AGE-BSA, treated with PTB, in a 
time- and dose-dependent manner, whereas aminoguanidine had no effect [325]. PTB 
was shown to prevent AGE accumulation in blood vessels of streptozotocin-treated 
diabetic rats [328]. However, another study has shown no effect of PTB on tail collagen 
solubility (that is AGE crosslinks) in streptozotocin-treated diabetic rats, whereas 2,3-
diaminophenazine did have an effect. However, neither PTB nor 2,3-diaminophenazine 
affected urinary albumin clearance or the clearance of 125I-albumin in the eye [329]. 
Schwendler et al also investigated the effects of PTB in a murine diabetic model, and 
found that while PTB did decrease renal AGE accumulation, diabetic nephropathy was 
not ameliorated [330]. Rahbar and colleagues have also recently reported the design and 
synthesis of new possible AGE breakers [309].  Thornalley has also proposed that 
enhancing the activity or level of enzyme systems that suppress the physiological levels 
of glycation agents, and repair glycated proteins (such as glyoxalase I, aldehyde 
reductases and dehydrogenases, amadoriase and fructosamine 3-phosphokinase), could 
be utilised in possible therapies [331]. 
 
1 .3 .5  Problems with Studies Investigating Glycation and Glycoxidation of Low-
Density Lipoproteins 
Many of the studies on the effects of glucose and other aldehydes on LDL are 
partially contradictory and faults may be found in many of them. Often the native, and 
especially the modified, LDL used in these studies is poorly defined. For example, the 
net negative charge, as demonstrated by the mobility of the LDL on agarose gels, has 
often been the only, or the main, detail provided about the extent or type of LDL 
modification and there is little information on the contribution of lipid oxidation, 
protein oxidation or glycoxidation to the LDL modification, with most studies reporting 
only data on one or two markers of oxidative processes [162, 165, 166, 267-269]. The 
TNBS (2,4,6-trinitrobenzenesulfonic acid) assay has been often used for examining Lys 
or free amino group modification and LDL modification [162, 163, 271]. However a 
study looking at methylglyoxal and LDL showed that Arg residues are also modified 
[167], and such modification may also contribute to an increase in net negative charge. 
Protein oxidative products from Tyr have been detected in AGE-collagen [217], and 
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 therefore may be formed during the glycoxidation of LDL. This suggests that only 
monitoring Lys residue modification may be over-simplistic.  
A number of studies have also examined the occurrence of lipid peroxidation by 
indirect methods. Thus many studies have used TBARS, to examine the degree of lipid 
peroxidation [162, 163, 271]. TBARS only measure aldehydes that represent 5 % of 
LDL oxidation products [332]. Aldehydes are also products from sugar autoxidation 
and oxidation of the protein-bound sugars [208], and so are not exclusively generated 
by lipid peroxidation. Many of the assays used to assess TBARS are also known to have 
low specificity, to give significantly different values between different studies, and may 
be confounded by other oxidation reactions [102]. Conjugated dienes are often also 
measured, at an absorbance maximum of 234 nm, as an indication of lipid peroxidation 
[102, 271]. However, there are some problems with this method including possible large 
background absorbance  (for example arising from other chromophoric products such as 
those that may be generated by glycation and glycoxidation reactions) and how it is 
utilised in determining the lag phase of LDL oxidation and LDL ‘oxidisability’ [102, 
108].  
A number of the studies examining the effects of glycated and glycoxidised 
LDL on macrophages have also been less than ideal. Different studies/groups have used 
different LDL modifying conditions which may be the cause of conflicting results (for 
example [165, 271]), and as mentioned above the LDL is often poorly characterised, so 
this does not aid in determining reasons for these differences. Very few of the studies 
have quantified cholesteryl synthesis accumulation directly, with most studies using 
indirect methods such as staining [267] and radiolabels [162]. Endocytotic degradation 
of modified LDL has been widely examined using 125I-labelled LDL [162, 163, 165, 
167], though this only gives information of the fate of the protein components rather 
than lipid components. Direct measurements of lipid and protein oxidation are needed in 
conjunction with measures of LDL modification and AGE formation, with standardised 
modifications of LDL, to completely investigate the mechanisms of glycoxidation and 
the effects on macrophages. As already discussed there has also been little work 
performed investigating the effects of glycated/glycoxidised LDL on other arterial cell 
types, such as smooth muscle and endothelial cells. 
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 1.4  Project Aims 
There is evidence that protein-sugar reactions (glycation and glycoxidation) 
leading to AGE formation are strongly implicated in the increased atherosclerosis in 
people with diabetes. Glycation and autoxidation of the protein-bound sugars may occur 
along side those of glucose autoxidation, oxidant production from the phagocyte 
myeloperoxidase-H2O2-Cl- system and protein and lipid oxidation. Glycation and 
glycoxidation of LDL can turn these particles into a high uptake form for macrophages, 
thereby potentially promoting foam cell formation in diabetes. However, even though a 
number of these studies have examined the glycation and glycoxidation of LDL and the 
effect of these particles on macrophages, the LDL used has often been poorly 
characterised (especially in regards to protein versus lipid oxidation/glycoxidation), 
mechanistic detail is lacking, cellular cholesterol and cholesteryl esters accumulation 
has only been quantified indirectly, and sometimes the results are conflicting to those of 
other studies. There has also been little examination of the effects of such 
glycated/glycoxidised LDL on other cell types in the artery wall, such as endothelial 
and smooth cells, and no comprehensive work has been carried out on the prevention, or 
reversal, of the effects of glycoxidation on LDL, or the consequent uptake by foam 
cells. Therefore there is a need for a systematic and detailed examination of the 
alterations of LDL, caused by glycation and glycoxidation reactions, and the effect of 
these particles on different arterial cell types. With this information novel therapeutic 
and preventative strategies may be formulated to reduce the atherosclerosis seen in 
patients with diabetes. 
Therefore the aims of the studies in this thesis are to: 
1) characterise in vitro glycated/glycoxidised LDL for use in cell studies, with 
particular attention to apo B changes and quantification of protein and lipid 
oxidation products ; 
2) Examine the effect of such LDL on arterial cell types: macrophages, and endothelial 
and smooth muscle cells, with particular emphasis on the effects of 
glycated/glycoxidised LDL on: 
•  cell viability and protein,  
• cholesterol and cholesteryl ester accumulation, and 
• macrophage apo B uptake, degradation and accumulation. 
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 1.5  Thesis Outline 
The central aim of this project is to characterise LDL that has been glycated or 
glycoxidised in vitro and to examine the effects of this modified LDL on arterial cell 
types. The general materials and methods used in this thesis are described in Chapter 2. 
Chapter 3 contains the characterisation experiments for the glycated/glycoxidised LDL. 
Lipid and protein oxidation levels are determined, as well as changes to apo B, 
including charge, size and loss of key amino acid residues in the covalent modification 
of LDL by glucose, methylglyoxal and glycolaldehyde. The effects of these modified 
LDLs on murine macrophages (Chapter 4), human endothelial cells (Chapter 5) and rat 
smooth muscle cells (Chapter 5) is examined by quantifying cellular viability, protein, 
cholesterol, and cholesteryl ester accumulation. The effect of the modified LDLs on cell 
viability, protein and cholesteryl ester accumulation in human macrophages is also 
examined (Chapter 6). In Chapter 7 human macrophages are exposed to 125I-labelled 
LDL, that is modified  in a similar manner to the preceding experiments, to examine the 
cellular endocytosis, degradation, and accumulation of apo B from the modified LDLs. 
The thesis concludes with Chapter 8, which contains a general discussion of the results 
obtained and their implications, conclusions made, and possibilities for future studies. 
 
KHIJ 
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2 CHAPTER 2: GENERAL MATERIALS AND METHODS 
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 2.1  Introduction 
This Chapter contains descriptions of all the final methods that have been used in 
this project. Any changes from these methods are described in detail in the relevant 
result Sections or Figure legends. 
 
2 .2  Materials 
Methylglyoxal, glycolaldehyde, fatty acid free bovine serum albumin (BSA) from 
fraction V, chloramphenicol, butylated hydroxytoluene (BHT), ethylenediamine-
tetraacetic acid (EDTA), Dulbecco’s phosphate-buffered saline pH 7.4 (PBS), aprotinin 
(5-10 trypsin inhibitory units/ml), soybean trypsin inhibitor (Type 1-S, 1 mg inhibiting 
2.1 mg trypsin with an activity of 10 000 Nα-benzoyl-L-arginine ethyl esters unit/mg 
protein), trypsin (Type 1, ~10 000 Nα-benzoyl-L-arginine ethyl esters unit/mg protein), 
CaCl2, thrombin (3 200 NIH units/mg protein), acetic anhydride, sodium iodide, sodium 
iodate, Fat Red 7B, 2-mercaptoethanol, Coomassie Brilliant Blue G, 
phenanthrenequinone, fluorescamine, N-tert-butyl-α-phenylnitrone (PBN), sodium 
pyruvate, cholesteryl propyl ether, KOH, AgNO3, Triton X-100, and trichloroacetic acid 
(TCA) were from Sigma-Aldrich (Castle Hill, NSW, Australia). Glucose, KBr, sodium 
acetate, sodium barbitone, barbituric acid, glycerol, sodium dodecyl sulphate (SDS), 
and glacial acetic acid were obtained from BDH (Merck, Kilsyth, VIC, Australia). 
CuSO4, NaOH, bromophenol blue and 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) were 
from ICN (Seven Hills, NSW, Australia). NaCl, tris 
(tris(hydroxylmethyl)aminomethane) and glycine were from Amresco (Solon, OH, 
USA). NADH was from Roche (Castle Hill, NSW, Australia). D-phenylalanyl-L-
arginine chloromethyl ketone (PPACK, a protease inhibitor) was acquired from 
Calbiochem (Merck, Kilsyth, VIC, Australia). PD10 columns and Na125I (≥ 15 Ci/mg 
iodide) were from Amersham Biosciences (Castle Hill, NSW, Australia). Pre cast 4-15 
% SDS-polyacrylamide gels (Bio-Rad, Reagents Park, NSW, Australia) and 1 % (w/v) 
agarose gels (Helena Laboratories, Mt. Waverly, VIC, Australia) were used. All 
solutions were prepared with nanopure water (Milli Q system, Millipore-Waters, Lane 
Cove, NSW, Australia) and, if appropriate, treated with washed Chelex-100 (Bio-Rad, 
Reagents Park, NSW, Australia). All other chemicals were of analytical grade and all 
solvents were of HPLC grade from EM Science (Gibbstown, NJ, USA), except 
chloroform, which was from BDH (Merck, Kilsyth, VIC, Australia) and diethyl ether 
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 (Fluka, Castle Hill, NSW, Australia). Gases were from Linde (Yennora, NSW, 
Australia) and ≥ 99.9 % purity. 
 
2 .2 .1  Tissue Culture Materials 
DMEM, M199 and RPMI 1640 media were obtained from JRH Biosciences 
(CSL, North Ryde, NSW, Australia).  Added to all media, unless specified otherwise, 
were 2 mM glutamine (Trace Scientific, Melbourne, VIC, Australia) and 1 % (v/v) 
PenStrep containing 100 units/ml penicillin and 0.1 mg/ml streptomycin (Sigma-
Aldrich, Castle Hill, NSW, Australia) and 10 % heat inactivated (30 min at 60 °C) 
foetal calf serum (FCS; Gibco, Melbourne, VIC, Australia) or human serum (HS; 
Australian Red Cross Clarence St Blood Bank). Trypsin/EDTA 1:250, pH 7, and 
sodium pyruvate were obtained pre-prepared from Trace Scientific (Melbourne, VIC, 
Australia). Other chemicals and materials were from the following sources. Sigma-
Aldrich (Castle Hill, NSW, Australia): 1A collagenase (> 125 collagen digestion 
units/mg solid), Dulbecco’s phosphate-buffered saline (PBS) pH 7.4, Hanks balanced 
salt solutions (HBSS) pH 7.4; Axis-Shield (Oslo, Norway): Lymphoprep; BDH (Merck, 
Kilsyth, VIC, Australia): H2O2; Starrate  (Bethungra, NSW, Australia): endothelial cell 
growth promoter; Braun (Castle Hill, NSW, Australia): Gelofusine. For tissue culture 
purposes Baxter (Old Toongabbie, NSW, Australia) sterile, endotoxin free, water was 
used. 
 
2.3  Low-Density Lipoproteins 
 
2 .3 .1  Isolation and Preparation 
Plasma was obtained from healthy volunteers, with informed consent, by blood 
collection into 0.01 mM EDTA, 1 μl/ml aprotinin, 0.04 μM PPACK and 20 μg/ml 
soybean trypsin inhibitor per ml of whole blood [333]. The blood was spun at 1877 g 
for 20 min at 10 °C and the plasma supernatant removed. The plasma was then adjusted 
to density 1.24 by adding KBr at 0.3816 g/ml. LDL (density 1.02 – 1.05) was isolated 
by sequential density gradient centrifugation, through underlaying 9 ml of different 
nitrogen gassed density solutions with a wide bore needle (prepared from stock density 
solutions of 1.006 and 1.346, as described below). The different density solution were 
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 underlaid in the following order: 1.0247, 1.0538, 1.085, and finally 12-13 ml of the 
density adjusted plasma [333, 334]. Tubes were ultracentrifuged (L-80 Optima; 
Beckman, Palo Alto, CA, USA), using a vertical rotor (VTi50; Beckman, Palo Alto, 
CA, USA), at 10 °C for 2.5 hr (206 000 g average), with slow acceleration and 
deacceleration programs. This seperated the LDL from other lipoproteins (including 
lipoprotein(a)) and plasma constituents. The LDL fraction was then collected and 
washed by ultracentrifugation, using, nitrogen gassed, density 1.063 KBr solution, in an 
angle rotor (Ti70; Beckman, Palo Alto, CA, USA), for 20 hr (184 000 g average) at 10 
°C and then dialysed overnight at 4 °C, with 4 x 1 l changes of degassed PBS containing 
1 mg/ml EDTA and 0.1 mg/ml chloramphenicol. LDL was stored sterile (0.45 μm 
filtered) in the dark at 4 °C and used within 3 weeks of isolation. Before use EDTA was 
removed by passage of LDL through 2 successive PD10 columns as per manufacturer’s 
instructions, using chelexed PBS [335]. 
 
 Density 1.006 solution = 8.766 g NaCl, 1.0 g EDTA and 0.1 g chloramphenicol per l of 
water. 
 
Density 1.346 solution = 354.0 g KBr, 153.0 g NaCl, 1.0 g EDTA and 0.1 g 
chloramphenicol per l water. 
 
2 .3 .1 .a  Lipoprotein Deficient Serum Preparation 
Lipoprotein deficient serum (LPDS) was prepared from the LDL deficient 
infranatant of healthy male donors after density ultracentrifugation, as based on 
previous published methods [336]. The LDL deficient fraction was adjusted to density 
1.25 with KBr (see below equation) and mixed approximately with an equal volume of 
1.25 KBr density solution (see preparation below) and ultracentrifuged (Ti70 rotor, 
Beckman, Palo Alto, CA, USA) at 10 °C for 20 hr (184 000 g average), using maximum 
acceleration and deacceleration programs, to remove all other lipoproteins. Extensive 
dialysis (5 daily changes of 5 l 0.9 % w/v NaCl solution with 0.1 mg/ml 
chloramphenicol) was performed to remove KBr before clotting of the LPDS with 1 M 
CaCl2 and 55 units of thrombin, per 100 ml LPDS, at 37 °C. LPDS was then filtered to 
remove clots, using Whatman’s (Maidstone, England) No. 1 filter paper. LPDS was 
reincubated and refiltered until no more clots were observed, then heat inactivated (for 
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 30 min at 60 °C), sterile filtered (0.22 μM) and stored frozen, at ~ 20 mg protein/ml, at 
– 20 °C. 
 
KBr to add (g) =  
0.1631 * (1.25 – density of LPDS fraction) * 10 * volume of LPDS fraction (ml) 
 
Equation for preparation of density 1.25 from 2 base densities: 
 Vada + Vbdb = (Va + Vb)dc
where Va = volume of 1.346 solution (ml), da = 1.346, Vb = volume of 1.006 solution 
(ml), db = 1.6, dc =  required density (i.e. 1.25). 
 
2 .3 .2  Low-Density Lipoprotein Modifications 
 
2 .3 .2 .a  Acetylation 
To acetylate LDL an equal volume of saturated sodium acetate was added to the 
LDL and followed by the addition of 6 μl acetic anhydride per mg LDL protein [337, 
338]. Acetic anhydride was added in 2 μl aliquots every 10 min to the LDL and sodium 
acetate mixture, while being stirred gently on ice, in the dark. Excess reagents were 
removed by passage of LDL through 2 successive PD10 columns as per the 
manufacturer’s instructions using chelexed PBS (pH 7.4), as an eluent. Acetylated LDL 
was filter-sterilised (0.45 μM) and stored 1-3 days before addition to cells. 
 
2 .3 .2 .b  EDTA 
LDL (1 mg protein/ml) was incubated with 50 μM EDTA, under sterile 
conditions, in chelexed PBS (pH 7.4) at 37 °C, under 5 % (v/v) CO2, with the caps 
loosened. Incubations were from 0-14 days depending on experiment. 
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 2 .3 .2 . c  Glucose with, or without, Cu2+ 
LDL (1 mg protein/ml) was incubated, under sterile conditions, with 100 mM 
glucose, with or without, 1 μM CuSO4, in chelexed PBS (pH 7.4) at 37 °C, under 5 %  
(v/v) CO2, with the caps loosened [335]. Typical incubation length was 0-14 days. 
 
2 .3 .2 .d  Methylglyoxal 
LDL at 1 mg protein/ml was incubated, under sterile conditions, with up to 100 
mM methylglyoxal in chelexed PBS (pH 7.4) at 37 °C, under 5 % (v/v) CO2, with the 
caps loosened [335]. Incubations were from 0-14 days. 
 
2 .3 .2 . e  Glycolaldehyde 
Sterile 1 mg/ml LDL solutions were incubated with up to 100 mM 
glycolaldehyde in chelexed PBS (pH 7.4)   at 37 °C, under 5 % (v/v) CO2, with the caps 
loosened [335]. Incubations were from 0-14 days. 
 
2 .3 .2 . f  Labelling with 125I 
LDL was always iodinated before any other modifications, working in an 
iodination hood, using appropriate personal precautions.  LDL was labelled with Na125I 
using the iodine monochloride method [152, 339]. The iodine monchloride stock was 
prepared by first dissolving 0.1 g sodium iodide in 4.2 ml concentrated HCl, (2 ml of 
water was added to facilitate dissolving), and 0.07 g sodium iodate in 10 ml of water, 
and then combing these 2 solutions with 5.8 g NaCl in 40 ml of water. This solution 
was then extracted with 150 ml x 3 volumes of chloroform using a 250 ml extraction 
funnel. Excess chloroform was removed by nitrogen gassing and the final volume 
adjusted to 50 ml with water. Before iodination of LDL, an iodine monchloride working 
solution was prepared, by adding 50 μl of the iodine monochloride stock solution, to 
200 μl of 2 M NaCl and 9 parts LDL (~ 3 mg protein/ml) was mixed with 1 part x 10 
glycine buffer (70.0 g glycine, 22.0 g sodium hydroxide and 131.0 g NaCl per l water). 
For iodination ~ 0.5-1 mCi of Na125I was added per ml of the LDL/glycine buffer mix, 
followed by 50 μl of the iodine monochloride working solution. The iodinated LDL 
solution was gently mixed and left on ice for 1 min before removal of excess reagents 
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 (free iodine, salts), by passage of LDL through 2 successive PD10 columns as per 
manufacturer’s instructions using chelexed PBS, as an eluent. Protein concentration of 
the LDL was determined and it was stored in the dark, at 4 °C, after filter sterilisation 
(0.45 μm), for up to 14 days before use. Specific activity of iodinated LDL, in cpm/ng 
apo B protein was determined by dividing the counts (Cobra II, Packard, Downers 
Grove, IL, USA) of a known amount of LDL by the amount of protein. Typically 
specific activity was in the range of 50-100 cpm/ng apo B protein. 
 
2 .3 .3  Protein Determination 
The Pierce (Rockford, IL, USA) Bicinchoninic Acid (BCA) method and reagents 
were used to determine LDL and LPDS protein concentrations, where 1 part Reagent B 
(4 % (w/v) CuSO4) was mixed to 50 parts Reagent A (containing sodium carbonate, 
sodium bicarbonate, BCA and sodium tartrate in 0.1 N NaOH), as based on 
manufacturer instructions. This reagent combines the reduction of Cu2+ by protein to 
Cu1+, in alkaline conditions (biuret reaction), with colorimetric detection of the Cu1+ by 
BCA. Samples in 250 μl were mixed with 2 ml BCA working reagent then incubated 
for 60 min at 60 °C [152]. Absorbance was determined by transferring 200 μl aliquots 
to 96 well plates, and then reading at 562 nm on a Tecan Sunrise (Grödig, Austria) plate 
reader. The protein concentration, in mg/ml, was determined by comparison to a 0-50 
μg BSA protein standard curve, made up in the same solvent as the samples.  
 
2.4  Characterisation of Low-Density Lipoprotein Modification 
All of the charcteristaion experiments performed were carried out with modified 
LDL from 2 or more separate incubations. 
 
2 .4 .1  Apolipoprotein B Changes 
 
2 .4 .1 .a  Relative Electrophoretic Mobility 
10-15 μl of LDL (1 mg protein/ml) was loaded onto precast 1 % agarose gels. 
Samples were run for 45 min at 90 V, in a pH 8.6 barbitone buffer (20.6 g/l sodium 
barbitone, 3.68 g/l barbituric acid and 0.372 g/l EDTA) using the Ciba-Corning (Palo 
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 Alto, Ca, USA) system [154]. Gels were fixed for 30 sec with 100 % methanol and then 
stained with 2.8 g/l of Fat Red 7B in 95 % methanol, for 5-10 min, before destaining for 
5-10 min with 70 % methanol. Gels were then dried in an oven at 60 ºC. Relative 
electrophoretic mobility (REM) was determined by the ratio of modified LDL to native 
LDL, calculated from the relative distances moved by native and modified LDL [335]. 
Native LDL was given a REM of 1 (Fig. 2.1). 
Origin 
REM = 1 
N
at
iv
e 
LD
L 
R
EM
 
Modified LDL +ve 
- ve 
Figure 2.1 Example of agarose gel run with native and modified LDL to determine REM. Native LDL is 
given a REM of 1. 
 
2 .4 .1 .b  SDS-PAGE 
Equal volumes were mixed of LDL (1 mg protein/ml) and sample loading buffer 
containing 10 % (w/v) SDS, 10 % (v/v) glycerol, 2.5 % (v/v) saturated bromophenol 
blue and 5 % (v/v) 2-mercaptoethanol in 300 mM pH 6.8 tris-HCl buffer. Samples were 
heated at 100 °C for 5 min and then 25 μl of sample was loaded per well onto 4-15 % 
precast SDS-polyacrylamide gels. Gels were run at 150 V for 50 min using SDS tris-
glycine (300 g/l tris base, 288 g/l glycine and 10 g/l SDS) buffer in a Bio-Rad (Reagents 
Park, NSW, Australia) system. Bands were then visualised with Coomassie Brilliant 
Blue G (0.2 g/l in 10 % (v/v) isopropanol and 15 % (v/v) acetic acid in water), as 
described in [152, 340]. Gels were destained with 10 % (v/v) acetic acid and 12.5 %  
(v/v) isopropanol in water and fixed in 5 % (v/v) glycerol, 50 % (v/v) methanol in 
water, before scanning with a Bio-Rad Gel Doc 1000 (Hercules, CA, USA). Broad 
range molecular weight markers were included on gels (Bio-Rad, Reagents Park, NSW, 
Australia) containing (in daltons) myosin (200000), β-galactosidase (116250), 
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 phosphorylase b (97400), serum albumin (66200), ovalbumin (45000), carbonic 
anhydrase (31000), trypsin inhibitor (21500), lysozyme (14400) and aprotinin (6500).  
 
2 .4 .1 . c  Amino Acid Consumption 
 
2 . 4 . 1 . c . i  Arginine 
Arg residue consumption was assayed using 9, 10-phenanthrenequinone. This 
compound reacts with free Arg residues or Arg residues within proteins and produces a 
fluorescence product that may be used to quantitatively determine Arg concentrations in 
proteins [341].  The following reagents were added, in the given order to clean sample 
tubes: 25 μl 20 mM EDTA, 250 μl LDL (1 mg protein/ml), 725 μl PBS, 0.5 ml NaOH 
and 3 ml 120 μM phenanthrenequinone in ethanol. Immediately after mixing, and after 
3 hr of incubation, at 60 °C, 0.5 ml of sample was removed and the reaction stopped by 
the addition of 0.5 ml 1.2 mM HCl. The fluorescence was read at λex 312 nm and λem 
392 nm in a Perkin Elmer LS50B (Wellesley, MA, USA) luminescence spectrometer 
and the Arg dependent fluorescence was deemed to be the difference between the 0 and 
3 hr samples [335]. Results were expressed as a percentage of residues remaining 
compared to the LDL incubation control at that time-point. 
 
2 . 4 . 1 . c . i i  Lysine 
Lys residue consumption was measured using fluorescamine. The reaction of 
fluorescamine with primary amines produces a fluorescent compound that may be used 
quantitatively to determine Lys concentrations in proteins [342]. The following were 
added to clean glass sample tubes: 4 μl 20 mM EDTA, 40 μl LDL (1 mg protein/ml) 
and 710 μl 0.2 M, pH 9, borate buffer. 250 μl of 0.15 mg/ml fluorescamine in acetone 
was then added, whilst the tubes were being vortex mixed and the samples subsequently 
read at λex 390 nm and λem 475 nm in a Perkin Elmer (Wellesley, MA, USA) LS50B 
luminescence spectrometer [335]. Results were expressed as a percentage of residues 
remaining compared to the LDL incubation control at that time-point. 
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 2 .4 .1 . c . i i i  Tryptophan 
Trp was measured using its own native fluorescence. The following were added 
to clean sample tubes: 10 μl 20mM EDTA, 100 μl LDL (1 mg protein/ml) and 890 μl 
PBS and samples read at λex 280 nm and λem335 nm in a Perkin Elmer (Wellesley, MA, 
USA) LS50B luminescence spectrometer [335]. Results were expressed as a percentage 
of residues remaining compared to the LDL incubation control at that time-point. 
 
2 .4 .2  Lipid Changes 
 
2 .4 .2 .a . i  Cholesterol and Cholesteryl Ester Determination 
The following were added to clean glass sample tubes: 10 μl 200 mM EDTA, 10 
μl 0.2 mM BHT, 20 μl LDL (1 mg protein/ml) and 980 μl PBS [335, 343]. To extract 
lipid from the LDL, 2.5 ml methanol and 5 ml hexane were added to the tubes, and 
samples were mixed thoroughly and stored at –80 °C until processing. Samples were 
then centrifuged at 834 g for 5 min and 4 ml of the hexane layer was removed and dried 
down (Savant speedyvac system, Holbrook, NY, USA) [335, 343]. Samples were 
redissolved in 200 μl of appropriate HPLC mobile phase and transferred to HPLC vials. 
150 μl of these samples were then injected into the HPLC. Cholesterol and cholesteryl 
esters were quantified at 205 nm by reverse-phase HPLC [343] using a Supelco (Castle 
Hill, NSW, Australia) ODS LC-18 column (25 x 0.46 cm, 5 μm particle size) and a 2 
cm Pelliguard column (Sigma-Aldrich, Castle Hill, NSW, Australia) at 25 °C 
(Shimadzu, CTO-10AVP column oven) on a Shimadzu system (SPD-M10Aνρ diode 
array UV detector, SIL-10ADνρ auto injector and cooler, LC-10AT pump, SCL-10Aνρ 
system controller, PC running Class-VP software; Kyoto, Japan). 
Cholesterol and cholesteryl esters from LDL samples, were separated 
isocratically at 1 ml/min with 70 %  (v/v) isopropanol and 30 %  (v/v) acetonitrile, that 
was filtered and degassed prior to use and flushed with helium during the 20 min run 
[343]. The run was extended to 25 min to include an 80 % methanol wash. Cholesterol 
and cholesteryl esters (cholesteryl docosahexaenoate, cholesteryl arachidonate, 
cholesteryl linoleate, cholesteryl palmitate, cholesteryl oleate and cholesteryl stearate) 
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 levels were quantified relative to standards (Sigma, Castle Hill, NSW, Australia) 
products (Fig. 2.2 and Table 2.1), and expressed as nmoles/mg apo B.  
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Figure 2.2 HPLC standard of cholesterol and cholesteryl esters detected at 205 nm with mobile phase 
containing 70 %  (v/v) isopropanol and 30 %  (v/v) acetonitrile. Cholesterol esters include: cholesteryl 
arachidonate (CA), cholesteryl linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO) and 
cholesteryl stearate (CS). Cholesteryl docosahexaenoate is not included due to availability and stability 
problems, but appears ~ 8 min. 
 
2 . 4 . 2 . a . i i  Oxidation Products 
Detection of the oxidation product, 7-ketocholesterol (Fig. 2.3), was also 
attempted, using the above HPLC system with 54 %  (v/v) isopropanol, 44 %  (v/v) 
acetonitrile and 2 % (v/v) water mobile phase, 22 min run time and 234 nm detection 
[343, 344]. Conjugated dienes are well known to form in polyunsaturated fatty acids 
undergoing oxidation, and reproducible changes in diene formation occurs at 234 nm 
[343]. Samples were prepared as described in 2.4.2.a.ii, for determination of non-
oxidised cholesterol and cholesteryl esters. See Table 2.1 for the response factor, 
determined from a 7-ketocholesterol standard (Sigma-Aldrich, Castle Hill, NSW, 
Australia) that was used to convert the chromatographic peak area into nmoles/mg apo 
B protein. 
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Figure 2.3 HPLC of a 7-ketocholesterol standard at 234 nm, using 54 %  (v/v) isopropanol, 44 %  (v/v) 
acetonitrile and 2 % (v/v) water mobile phase. 
 
LIPID 
RESPONSE 
FACTOR 
(mAU/nmol) 
MOLECULAR MASS 
Cholesterol 119724 386.7 
Cholesteryl docosahexanoate 1475366 697.1 
Cholesteryl arachidonate 843066 673.1 
Cholesteryl linoleate 354764 649.1 
Cholesteryl oleate 155203 651.1 
Cholesteryl palmitate 118113 625.1 
Cholesteryl stearate 113389 653.1 
7-ketocholesterol  778038 400.6 
 
Table 2.1 HPLC response factors for cholesterol, cholesteryl esters and 7-ketocholesterol. Note that the 
response factor for cholesteryl docosahexanoate is based on cholesteryl arachidonate (x 1.75) due to 
availability and stability problems, and the response factor for cholesteryl stearate is based on cholesteryl 
palmitate (x 0.96) due to solubility problems [154, 343]. 
 
2 .4 .3  Free Radical Formation 
Free radicals were detected using Electron Paramagnetic Resonance (EPR) 
spectroscopy and the spin traps PBN or DMPO [345]. LDL incubations were carried out 
as described in Sections 2.3.2.b, 2.3.2.d and 2.3.2.e for 7 days and then passed through 1 
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 PD10 column to remove excess reagents with chelexed PBS as an eluent. For PBN 
experiments, 200 μl samples of the eluted LDL was incubated for up to 24 hr, at 37 °C, 
with 100 mM PBN, in either PBS or DMEM with 10 % FCS (to mimic J774A.1 cell 
experiments as described following), with a total volume of 1 ml. In DMPO 
experiments, 200 μl of eluted LDL was incubated, at 37 °C, either with 50 μl 1 M 
DMPO in 750 μl chelexed PBS or DMEM with 10 % FCS (to mimic J774A.1 cell 
experiments as described following). After 0 hr and 1 hr for DMPO experiments, and 0 
and 24hr for PBN experiments, a 400 μl aliquot of the LDL-spin trap incubation was 
removed and transferred to a flattened aqueous EPR sample cell (WG-813-SQ, Wilmad, 
Buena, NJ, USA). The cell was then inserted into a cylindrical ER 4103TM cavity, in a 
Bruker (Billerica, MA, USA) EMX X-band spectrometer with 100 kHz modulation and 
EPR spectra obtained at room temperature [346]. Typical EPR spectrometer settings 
were; 10 mT sweep width with a centre field of 348 mT, resolution 1024 points, 
receiver gain 1 x 106, modulation amplitude 0.1 mT, time constant 327.680 ms, sweep 
time 335.544 ms, conversion time 327.680 ms, power 25 mW and frequency 9.76GHz, 
with 4 scans averaged. Hyperfine coupling were measured directly from the field scan 
and confirmed using the program WINSIM [347]. 
 
2.5  Cell Culture 
All cells were cultured in humidified incubators, with 5 % (v/v) CO2 at 37 °C and 
in Falcon (Becton Dickinson, Franklin Lakes, NJ, USA) 175 cm2 tissue culture flasks, 
or 12 well tissue culture plates, with 22 mm diameter wells.  
 
2 .5 .1  J774A.1 Mouse Macrophage Cells 
J774A.1 mouse macrophages (TIB-67, ATCC, Manassas, VA, USA), were 
routinely grown in DMEM media and 10 % FCS, with supplements as described in 
Section 2.2.1. Cells were scraped into suspension and replated at 1:4 dilution every 3-4 
days. For experiments, J774.A1 cells were scraped at confluency and replated into 12 
well tissue culture plates at 0.5 x 106 cells/ml and left overnight before exposure to 
modified LDL. 
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 2 .5 .2  Human Monocyte-Derived Macrophages 
Monocytes were isolated from white cell concentrates by using counter current 
elutriation as based on [348, 349], within 24 hr of collection. The elutriation system 
consisted of a Beckman (Palo Alto, CA, USA) Avanti J-20XPI centrifuge equipped 
with a JE-5.0 elutriation rotor and a 4.2 ml elutriation chamber with a Masterflex 
(Barrington, IL, USA) peristaltic pump. The elutriation media used was HBSS, with 
phenol red and 0.01 % EDTA and without Ca2+ and Mg2+. Before use the system was 
rinsed, in the following order, with ~ 250 ml 70 % (v/v) ethanol, water, 30 % (w/w) 
H2O2, water, and finally HBSS. The white cell concentrates were diluted 1:2 in HBSS 
and then 30 ml of this diluted white cell concentrate was underlaid with 15 ml 
Lymphoprep and centrifuged at 2060 g for 40 min at room temperature. Peripheral 
blood mononuclear cells were then isolated from the Lymphoprep interface, washed 
once with HBSS and resuspended in 30 ml HBSS. The peripheral blood mononuclear 
cells were then loaded at a rotor speed of 2020 rpm, at room temperature with an initial 
flow rate of 9 ml/min. The flow rate was increased by 1 ml/min every 10 min and the 
cell fractions from 15, 16, 17, 18 and then the final flow rate of 40 ml/min were 
collected and combined. Presence of monocytes was confirmed microscopically, after 
cytospinning (Shandon, Astmoor, Runcorn, England) and staining with Diff Quik 
(Narrabeen, NSW, Australia). Cells were diluted to 1 x 106 cells/ml in RPMI 1640 (no 
serum) and 1 ml added per well of 12 well Costar (Corning, NY, USA) tissue culture 
plates and allowed to adhere for 1-2 hr. Cells were then washed and RPMI media, with 
10 % HS and supplements as described in Section 2.2.1 added. Media was usually 
changed after 3 days and then when appropriate. Matured human monocyte-derived 
macrophages (HMDM) were exposed to modified LDL 9-11 days after monocyte 
isolation. 
 
2 .5 .3  Human Umbilical Vein Endothelial Cells 
Cords were obtained, with informed consent, from the Labour Ward of King 
George V Memorial Hospital for Mothers and Babies (Camperdown, NSW, Australia), 
and collected in M199 media containing only Penstrep and glutamine. Within 3 hr of 
collection, one end of the umbilical vein was cannulated and then perfused with M199 
media, again containing only glutamine and Penstrep, to wash the cord and remove any 
blockages. Human Umbilical Vein Endothelial Cells (HUVEC) were then harvested 
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 enzymatically using type 1A collagenase, by incubating for 15 min at 37 °C, as based 
on [350]. Cell were then spun at 162 g for 5 min, resuspended, and established as 
primary cell cultures in M199 media containing 20 % HS, glutamine and PenStrep as 
described in Section 2.2.1, as well as 0.5 % endothelial cell growth promoter. When 
cells reached confluency, they were exposed to Trypsin/EDTA (1:250) for 5 min, at 
room temperature to detach cells from the flask and diluted 1:2 for replating. This was 
done 1-2 times a week, with a media change every 2-3 days. For experiments, cells 
were again trypsinised and diluted to 0.2 x 106 cells/ml and replated in 12 well plates 
overnight before exposure to modified LDL. Cells were only used up to passage 4 and 
all tissue culture flasks and plates were pre-treated with Gelofusine in PBS (1:250) 
before cells were replated. The Gelofusine plate pre-treatment was carried out by 
exposing the surface of the tissue culture plate or well to the Gelofusine for 10-15 min, 
in the tissue culture incubator, with residual solution removed by aspiration, before the 
addition of cells. 
 
2 .5 .4  A7r5 Rat Aortic Smooth Muscle Cells 
A7r5 rat aortic smooth muscle cells (CRL-1444, ATCC, Manassas, VA, USA) 
were routinely cultured in RPMI 1640 media and 10 % FCS, with supplements as 
described in 2.2.1, as well as 1mM sodium pyruvate and 3.5 g/l glucose. When cells 
reached confluency, they were exposed to Trypsin/EDTA (1:250) for 5 min, in the 
tissue culture incubator to detach cells from flask and diluted 1:3 for replating. This was 
done weekly with a media change in between. For experiments, cells were again 
trypsinised and diluted to 0.2 x 106 cells/ml and replated in 12 well plates overnight 
before exposure to modified LDL.  
 
2 .5 .4 .a  Serum Deprivation 
In serum deprivation experiments, cells were plated down at 0.1 x 106 cells/ml in 
12 well plates in 10 % FCS overnight and then exposed to 0.2 % FCS for 48 hr. The 
resulting sub-confluent cells were then incubated with the modified LDL. This ensures 
that cells are in the G0 phase, which mimics the in vivo smooth muscle cell and thus 
cells are in a state to determine if cellular proliferation can be stimulated by various 
agents [351, 352]. 
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 2.6  Low-Density Lipoprotein Cellular Metabolism 
 
2 .6 .1  Exposure of Cells to Modified Low-Density Lipoproteins 
J774A.1 and A7r5 cells were exposed to 0-200 μg protein/ml modified LDL for 
24 hr, in media containing 10 % LPDS. J774A.1 cell conditions were based on those 
previously determined to give cholesterol and cholesteryl ester level typical of foam 
cells using acetylated LDL [154]. HUVEC were exposed to modified LDL for 48 hr in 
media containing 10 % LPDS. HMDM were exposed to 0-100 μg/ml modified LDL for 
2 days, followed by another 2 days with more LDL in fresh media, to ensure enrichment 
of free cholesterol and cholesteryl esters typical of foam cells [353]. All experiments 
performed with primary cells used cells isolated from at least 2 different donors as well 
modified LDL from 2 separate incubations. After exposure to modified LDL, cells were 
exposed to an equilibrium media containing 1 mg/ml BSA instead of serum overnight 
for HMDM and 2 hr for all other cell types. Cells were then lysed in 1 ml water (20 min 
at 4 °C on a rocking platform and then scraped with 1ml syringe plunger); 800 μl of the 
resulting cell lysate was extracted for HPLC cholesterol and cholesteryl ester analysis 
and 200 μl was used for viability and protein assays.  
 
2 .6 .1 .a  Bio-Rad Assay on LDL Before and After Column Chromatography 
LDL was subjected to chromatography using a PD10 column due to the potential 
cytotoxicity of the high glucose and aldehyde concentrations. These high concentrations 
of reducing aldehydes and glucose could interfere with the Pierce BCA assay (see 
Section 2.3.3) [354]. Therefore to confirm that only minimal losses of LDL occurred 
during the column chromatography the Bio-Rad (Reagents Park, NSW, Australia) 
protein assay was used as it is based on the colour shift of the dye from 465 nm to 595 
nm when protein binding occurs. 200 μl of the Bio-Rad Dye Reagent Concentrate 
(containing Coomassie Brilliant Blue G-250, phosphoric acid and methanol) was added 
to 800 μl of sample; tubes were vortexed and left at room temperature for 5 min, before 
200 μl aliquots were transferred to 96 well plates and read at 595 nm on a Tecan 
Sunrise (Grödig, Austria) plate reader. The LDL protein concentration, in mg/ml, was 
determined by comparison to a 0-20 μg BSA protein standard curve, made up in the 
same solvent as the samples. It was found that the Bio-Rad assay gave ~ 3-fold lower 
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 concentrations of LDL, as compared to the Pierce BCA assay. Therefore a LDL (1 mg 
protein/ml) solution, determined by the BCA assay was then used in the Bio-Rad Assay 
standard curve. 
 
2 .6 .1 .b  Cell Viability 
The enzyme, lactate dehydrogenase (LDH), catalyses the reduction of pyruvate 
to lactate, using NADH as the co-factor. Therefore, in this assay, the substrates are 
added in excess so the enzyme is the limiting factor. Hence the NADH loss, measured at 
340 nm is proportional to the amount of enzyme present intra- and extra-cellularly 
[355]. 200 μl of a 0.15 mg/ml NADH and 2.5 mM sodium pyruvate PBS working 
reagent was added to10 μl samples of either cell lysates or cell media (after spinning at 
353 g for 5 min to remove cellular debris) and read at 340 nm every 5 min for 7 cycles 
on a Tecan Sunrise (Grödig, Austria) plate reader. The linear change of absorbance/min 
was used in the following equation to determine cell viability. 
 
 
Viability (%) = Δ 340 nm (cell lysate)                * 100  
 Δ340 nm (cell lysates) + Δ340 nm (cell media)  
 
 
2 .6 .1 . c  Cell Protein 
Cell protein in μg was determined using the method outlined in 2.3.3. 
 
2 .6 .2  HPLC Analysis of Cellular Cholesterol and Cholesteryl Esters 
The following were added to clean glass sample tubes: 10 μl 200 mM EDTA, 10 
μl 0.2 mM BHT, 800 μl cell lysates and 200 μl water. To extract lipid from the cell 
lysates, 2.5 ml methanol and 5 ml hexane were added, and then processed as described 
in Section 2.4.2.a.i for LDL samples, except for HMDM cell lysates. HMDM cell lysate 
cholesterol and cholesteryl esters, due to higher basal lipid levels, were separated 
isocratically at 1 ml/min with 54 %  (v/v) isopropanol, 44 %  (v/v) acetonitrile and 2 % 
(v/v) water [343], that was filtered and degassed prior to use and flushed with helium 
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 during the 70 min run. Eluted compounds were detected at 205 nm, using the same 
system as described in Section 2.4.2.a.i. The increased separation of cholesterol and 
cholesteryl esters is shown in Fig. 2.4. The run was extended to 75 min to include an 80 
% methanol wash. Cholesterol or cholesteryl ester chromatographic peaks were 
converted to nmoles lipid using the response factors in Table 2.1 and then corrected to 
give nmoles lipid/mg cell protein (using total cholesterol = free cholesterol + cholesterol 
esters). 
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Figure 2.4 Separation of a HPLC standard of cholesterol and cholesteryl esters detected at 205 nm with 
mobile phase containing 54 %  (v/v) isopropanol, 44 %  (v/v) acetonitrile and 2 % (v/v) water. 
Cholesterol esters include: cholesteryl arachidonate (CA), cholesteryl linoleate (CL), cholesteryl 
palmitate (CP), cholesteryl oleate (CO) and cholesteryl stearate (CS). Cholesteryl docosahexaenoate is 
not included due to availability and stability problems, but appears ~ 21 min. 
 
2 .6 .2 .a  Saponification of HMDM Cell Lysates 
To confirm that all cholesteryl esters, including any possible oxidised materials in 
HMDM cell lysates, were being accounted for, some samples were saponified [154, 
356].  The following were added to clean glass sample tubes: 10 μl 200 mM EDTA, 10 
μl 0.2 mM BHT, 100 μl 50 μg/ml cholesteryl propyl ether (in 95 % heptane and 5 % 
isopropanol, as an internal standard), 800 μl cell of lysates and 200 μl water. To extract 
lipid from the cell lysates 2.5 ml methanol and 5 ml hexane were added to the tubes and 
samples were mixed thoroughly and stored at –20 °C until processing. Samples were 
then centrifuged at 834 g for 5 min and 2 x 2 ml of the hexane layer was removed into 
separate tubes and dried down (Savant speedyvac system, Holbrook, NY, USA). One 
set of tubes were processed and run on the HPLC at 205 nm, as already described in 
Section 2.4.2.a.i, to determine free cholesterol levels. The other samples were 
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 redissolved in 2.5 ml diethyl ether and 2 ml of 20 % (w/v) KOH in methanol added. 
These tubes were vortexed and placed on a spinning wheel overnight. Saponification 
was stopped by the addition of 2 ml 20 % (v/v) acetic acid, then 2 ml of hexane was 
added and samples vortexed and spun at 834 g for 5 min and 4 ml of the hexane layer 
was removed and dried down (Savant speedyvac system, Holbrook, NY, USA). 
Samples were redissolved in 200 μl of appropriate HPLC mobile phase and transferred 
to HPLC vials; 150 μl injections were made into the HPLC column. These samples 
were separated isocratically at 1 ml/min with 54 %  (v/v) isopropanol, 44 %  (v/v) 
acetonitrile and 2 % (v/v) water that was filtered and degassed prior to use and flushed 
with helium during the 70 min run. Eluted compounds were detected at 205 nm, using 
the same system as described in Section 2.4.2.a.i. Free cholesterol and saponified 
cholesteryl esters all elute together at ~ 9 min and cholesteryl propyl ether at ~ 19 min. 
The difference between the saponified sample (total cholesterol) peak and the non-
saponified is equal to the amount of cholesteryl esters, determined in moles/mg cell 
protein as described above (Section 2.6.2).  
 
2 .6 .3  Apolipoprotein B Accumulation and Degradation 
HMDM were incubated with 50 μg protein/ml 125I-LDL that had been modified 
for 7 days, as described previously in Section 2.3.2, for up to 96 hr (including 125I-LDL 
in fresh media at 48 hr) in media containing 10 % LPDS, for accumulation experiments. 
At the appropriate times the cell media was collected (0.5 ml) and cells were washed 
twice with cold PBS. For cellular turnover/chase studies media 125I-LDL containing 
media was removed and cells washed with 1 ml warm PBS, and then media containing 
1 mg/ml BSA, and no 125I-LDL, was added onto the cells for 0 to 24 hr. At the 
appropriate times the media was again collected (0.5 ml) and cells washed twice with 
cold PBS. For both accumulation and turnover studies 1 ml 0.01 % (w/v) trypsin was 
added to tissue culture wells, for 60 min at 4 °C, to remove surface-bound ligand [152]. 
This was retained for radioactivity measurement and then 1 ml 0.1 % (v/v) Triton X-100 
was added for 30 min at 4 °C to lyse cells. Of the cell lysates, 0.5 ml was retained for 
radioactivity measurement (total intracellular radioactivity) and BCA protein 
determination (Section 2.6.1.c). The other 0.5 ml of cell lysate, and the 0.5 ml of the 
collected media were processed by adding 0.1 ml 30 mg/ml BSA and 1 ml cold 3 M 
TCA. Samples were then incubated for 20 min at 4 °C and then centrifuged for 10 min 
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 at 1500 g at 4 °C to pellet TCA-precipitable proteins. An aliquot of the supernatant (1 
ml) was removed and added to 0.25 ml AgNO3 (to precipitate free iodide) and samples 
were respun. Then an aliquot (1 ml) of this cell media or cell lysate iodide-free, TCA-
soluble supernatant, was kept for radioactivity counting [152]. The TCA-precipitable 
pellets were washed 3 times with 5 % (w/v) TCA before being counted for radioactivity. 
Samples were counted on Cobra II (Packard, Downers Grove, IL, USA) gamma counter 
and also included were known protein amounts of 125I-LDL to determine specific 
activity (to convert counts per second (CPS) into ng apo B protein). All samples were 
also corrected for cell protein to give final values as ng apo B protein/mg cell protein. 
Therefore the following cellular fractions were determined (as determined from [152]): 
• cell surface-bound apo B (0.01% trypsin removed material); 
• total intracellular apo B (untreated cell lysate); 
• extracellular degraded apo B (cell media, iodide-free, TCA-soluble supernatant); 
• extracellular non-degraded apo B or cell death (cell media, TCA-precipitate); 
• intracellular degraded apo B (cell lysate, iodide-free, TCA-soluble supernatant); 
• intracellular non-degraded apo B (cell lysate, TCA-precipitate); 
• endocytosed material (cell media, iodine-free, TCA-soluble, radioactivity + total 
intracellular radioactivity). 
 
2.7  Statistical analyses 
All results are expressed as the mean ± standard error of the mean (SEM) and 
results are from at least 3 separate experiments, consisting of samples assayed in 
triplicate, unless noted otherwise. Statistical analyses were carried out by Student’s t-
test if only 2 different conditions were being considered. Multiple comparisons were 
accomplished by one-way analysis of variance (ANOVA) with Tukey’s post hoc 
analysis for comparison of means; and multiple comparisons over different times or 
concentrations were carried out using two-way ANOVA and Bonferroni’s post hoc 
analysis in comparison of means, using Prism 4.0a for Macintosh (GraphPad Software, 
San Diego, CA, USA). Differences were considered significant if P < 0.05. 
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3 CHAPTER 3: CHARACTERISATION OF THE 
MODIFICATION OF THE PROTEIN AND LIPID 
COMPONENTS OF LOW-DENSITY LIPOPROTEINS 
INDUCED BY GLUCOSE, METHYLGLYOXAL AND 
GLYCOLALDEHYDE 
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 3.1  Introduction 
The non-enzymatic reaction of glucose with protein involves glycation reactions 
and glycoxidation events that include free radical damage to proteins from glucose 
autoxidation and oxidation of glycated proteins [74, 193-195]. Non-enzymatic reactions 
between carbonyl groups of carbohydrates and free amino groups occur on proteins, 
peptides, amino acids and organic amines at physiological temperatures, pH and 
concentration [192]. Glycation and glycoxidation reactions may also occur with lipids 
[196, 205, 277]. Thus many reaction mechanisms and products are possible in glycation 
and glycoxidation of proteins. Comprehensive reaction mechanisms and products are 
still not known, and there is an abundance of literature using poorly defined glycated or 
glycoxidised protein in tissue or cells studies. 
One of the consequences of glycation and glycoxidation reactions is the 
production of reactive aldehydes, such as glyoxal, methylglyoxal, glucosone, 3-
deoxyglucosone and glycolaldehyde [208, 209, 213]. Methylglyoxal is elevated in the 
diabetic state [225, 227], and is produced from the autoxidation of sugars and lipids, 
glycation, and spontaneous decomposition of triose phosphate intermediates from 
aerobic glycolysis [209, 210]. Glycolaldehyde has been shown to be formed in vitro 
during glycation and glycoxidation reactions [213] and in oxidation systems [215, 219]. 
Reaction of glycolaldehyde with the Lys side-chains of proteins can lead to the 
formation of the well-known AGE, CML [213]. These aldehydes have been shown to be 
much more reactive with protein targets than glucose  [162, 163, 210, 246, 357]. 
Glycation/glycoxidation of proteins have documented in vitro effects. For 
example, it has been shown that glycation and glycoxidation reactions can cause 
aggregation/cross-linking or fragmentation of proteins depending on the 
glycation/glycoxidation system used [221, 223, 357]. Oxidative events alone involving 
LDL, can also cause aggregation, or fragmentation, depending on what oxidant system 
the LDL is exposed to [358, 359]. 
Previous studies have shown that glycation/glycoxidation reactions target certain 
amino acid side chains, resulting in the loss or modification of these residues. On Lys 
side chains, for example, the formation of Nε-(fructose)lysine, CML and pentosidine has 
been documented [199, 201]. Loss and modification of Lys residues has been reported 
in glucose- and methylglyoxal-modified LDL [167, 246, 260]. Glycation and 
glycoxidation reactions also produce adducts on Arg residues such as glucosepane and 
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 3-deoxyglucosone-Arg imidazolone [196]. Schalkwijk et al reported up to an 85 % loss 
of Arg residues in methylglyoxal-modified LDL [167]. In the modification of BSA by 
glycolaldehyde loss of ~ 80 % Arg and Lys residues has been reported [246]. Trp 
residues contain a nitrogen atom which may also be subjected to glycation reactions 
[194], and they also can be targets for oxidation reactions [177, 359]. Yang et al found 
in copper ion-oxidised LDL the presence of kynurenine (a Trp oxidation product) [360]. 
In the glycoxidation of collagen or BSA using glucose, the formation of various amino 
acid oxidation products has been shown to occur, such as m-Tyr, dityrosine, DOPA and 
valine and leucine hydroxides [217]. Recently a product formed on cysteine has also 
been reported, S-(carboxymethyl)cysteine [196]. 
Lipids may be modified or oxidised during glycation and glycoxidation reactions 
[196, 205, 277]. As glycoxidative events may encompass oxidation reactions, classic 
LDL lipid oxidation changes may be observed during LDL glycoxidation. For example, 
during Cu2+-induced oxidation of LDL, the levels of cholesterol and cholesterol esters 
decrease as the concentration of oxysterols increase [102, 170, 343, 344]. Oxysterols 
such as 7-ketocholesterol (the most abundant oxysterol) and 7α- and 7β-
hydroxycholesterol, cholesterol α- and β- peroxides and 6β- hydroxycholesterol may be 
produced [155, 344]. However, most studies have not examined both protein and lipid 
modification/oxidation concurrently in the in vitro glycation and glycoxidation of LDL 
and then often limit the protein/lipid characterisation of the LDL to one or two 
parameters, such as relative electrophoretic mobility, fluorescence or TBARS (for 
example [162, 166, 167, 260, 267, 277, 282]). Thus the relative importance of lipid 
versus protein modification, or oxidation, to the non-enzymatic modification of apo B 
by glucose is unclear. 
A number of studies have shown that the modification of isolated proteins is 
dependent on, and/or catalysed, by metal ions [194, 195, 217]. This dependence has also 
been reported for the modification of lipid and protein in LDL by glucose [188, 268-
271, 361]. Therefore the presence and concentration of metal ions in incubations 
containing LDL and glucose can be of great importance in determining the extent and 
type of modification. 
 There is a pressing need for the detailed characterisation of the modification of 
LDL by glucose, and the low-molecular-mass aldehydes, methylglyoxal and 
glycolaldehyde. This characterisation needs to be completed under tightly controlled 
conditions (pH and absence/presence of metal ions) with particular attention to the roles 
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 of lipid and protein oxidation/modification. Thus in the following studies changes to the 
single protein in LDL, apo B, will be examined as well as the cholesterol and 
cholesteryl esters components of LDL.  
The apo B amino acid analysis experiments, described below, were carried out 
in collaboration with Dr. Heather Knott.  
 
3.2  Aims 
The aims of the experiments in this Chapter are to examine in detail the reactions 
of glucose, methylglyoxal and glycolaldehyde with LDL. This will include detailed 
examinations of the single protein in LDL, apo B, as well as cholesterol and cholesteryl 
esters, in regards to oxidation and modification. As the glucose reactions are well 
documented to be slow, and have been reported to be catalysed by metal ions, the effect 
of addition of copper ions was also investigated.  
 
3.3  Results 
 
3 .3 .1  Modification of Low-Density Lipoproteins by Glucose, in the Absence or 
Presence, of Copper. 
 
3 .3 .1 .a  Apolipoprotein B Changes 
 
3 .3 .1 .a . i  Relative Electrophoretic Mobility 
Relative electrophoretic mobility (REM) is a technique to examine the 
modification of overall charge of LDL. The overall charge is determined by the total 
contribution of Arg, Lys, protonated His residues, and the N terminus amine group 
relative to Glu, Asp and the C terminus carboxyl residues. For example glycation and 
glycoxidation reactions that result in the formation of CEL and CML, that is, the 
loss/modification of positively-charged Lys residues of apo B, the further the now more 
negative LDL, would move into the gel as compared to native LDL.  
  In these experiments LDL (1 mg protein/ml) was incubated with 100 mM 
glucose, in the presence or absence of 1 μM Cu2+, for up to 14 days at 37 °C, in PBS 
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 (see Section 2.3.2.c). This concentration of LDL was chosen as it is commonly used by 
other groups (for example [163, 167, 270, 344]) and is within physiological serum LDL 
levels. Thus, in a normolipidemic person serum LDL is ~ 3 mg/ml and assuming the 
apo B comprises 22 % by mass of the LDL molecule this gives a concentration of ~ 
0.66 mg apo B/ml [102]). All solutions were treated with chelex resin as appropriate, to 
remove free metal ions, to ensure that the only metal ions present were those that were 
added. These glucose-modified LDL particles were also compared to native LDL (LDL 
that was stored in the dark at 4 °C with EDTA and chloramphenicol, from isolation) and 
incubation control LDL, containing 50 μM EDTA (Section 2.3.2.b), as the 0 mM 
glucose condition. EDTA, as a chelator, is well known to prevent oxidation reactions 
[102, 362] and has also been reported to prevent glycation/glycoxidation reactions to a 
certain extent [221]. Therefore LDL incubated with EDTA should provide minimally-
modified incubated LDL and be suitable as an incubation control.  
Acetylated LDL, prepared using sodium acetate and acetic anhydride (as 
described in Section 2.3.2.a), was also included on all gels as a positive control. 
Acetylation of LDL leads to structural modification of Lys residues and a net increase 
in negative change [145]. Acetylated LDL should therefore migrate much further than 
native LDL [145].  
The first step to determine the REM of the modified LDL particles was to take 
an aliquot (15 μg protein) of the LDL. The LDL was then loaded in 2 μl applications 
onto precast 1 % agarose gels and then run in an agarose gel electrophoresis system for 
45 min at 90 V, as described in Section 2.4.1.a. After the agarose gel electrophoresis, 
LDL bands were fixed using a methanol wash, stained with Fat Red 7B and then 
destained with 80 % methanol. The REM value was then calculated by measuring the 
distance the modified and native LDL bands moved, and then expressing the distance 
moved by the modified LDL relative to the native LDL, which was given a REM of 1.  
The REM of LDL (1 mg protein/ml) modified by 100 mM glucose, in the 
presence or absence of 1 μM Cu2+, at 37 °C, in PBS, increased over time compared to 
native LDL. In Fig. 3.1 LDL modified by 100 mM glucose for 14 days at 37 °C, in the 
presence or absence of Cu2+, has a statistically higher REM (P < 0.05) as compared to 
native LDL and the LDL plus 50 μM EDTA incubation control (~ 0.5 increase). 
However, even though these changes were statistically greater than the REM changes 
seen for control LDLs, the changes were small and not as great as seen for acetylated 
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 LDL (AcLDL), i.e. REM of 4.93 ± 0.08 for AcLDL versus an REM of 2.24 ± 0.09 for 
glucose-modified LDL in the absence of Cu2+, or 2.39 ± 0.13 in the presence of Cu2+. 
There was no statistical difference (P > 0.05) betweens the REMs of glucose modified 
LDL, in the presence or absence of 1 μM Cu2+. Fig. 3.2 demonstrates how, over time, 
the REM of glucose-modified LDL increases from 1 at the start at the experiment (time 
0) to ~ 4 after 6-8 weeks of incubation at 37 °C, with a trend for the glucose-modified 
LDL to have a slightly higher REM than the LDL plus EDTA incubation control. The 
modification of LDL by glucose over time, in the presence or absence of Cu2+, therefore 
results in small, significant, changes in the net charge of the particle, when compared to 
native LDL or incubation control LDL. 
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Figure 3.1 REM of LDL (1 mg protein/ml) modified by 100 mM glucose with or without 1 μM Cu2+ for 
14 days at 37 °C. The REM of LDL modified by glucose, in the presence or absence of Cu2+ (gLDL), is 
compared to native LDL (nLDL), acetylated LDL (AcLDL) and LDL plus 50 μM EDTA (incubation 
control). Data are mean ± SEM from ≥ 16 individual agarose gels; columns with different superscripts are 
significantly different (P < 0.05) from one another, by one-way ANOVA. 
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Figure 3.2 REM of glucose-modified LDL over time. LDL (1 mg protein/ml) was incubated with 100 
mM glucose (gLDL) or 50 μM EDTA over time at 37 °C. Data are mean with range bars from single 
agarose gels where samples were run in duplicate. 
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 3 . 3 . 1 . a . i i  SDS-PAGE 
The charge of glucose-modified LDL is different to that of native LDL, as 
shown in the previous Section, suggesting the LDL is being glycated or glycoxidised. 
Therefore, the size of the particles may also differ. A method of looking at the size of 
LDL particles is SDS-PAGE [151, 152]. LDL samples (30 μg protein) were prepared 
under reducing conditions, as detailed in Section 3.3.1.a.i, before loading onto 4-15 % 
precast SDS-polyacrylamide gels. The gels were run at 150 V for 50 min, stained using 
Coomassie Brilliant Blue, destained and then fixed, before scanning using a Bio-Rad 
Gel Doc 1000 (see Section 2.4.1.b for more details). All gels included broad range 
molecular weight markers, native LDL, incubation control LDL (LDL plus 50 μM 
EDTA), as well as the LDL (1 mg protein/ml) modified by 100 mM glucose, in the 
presence or absence of 1 μM Cu2+, for up to 8 weeks, at 37 °C. 
SDS-PAGE of glucose–modified LDL over time indicated that the particles 
increased in mass during the modification period (Fig. 3.3). These studies show that 
after 2-4 weeks of incubation time, glucose-modified LDL did not move as far into the 
gel (lanes 7,8 and 10), and after 6-8 weeks of incubation the glucose-modified LDL 
barely migrated into the gel from the loading well (lanes 12 and 14). No significant 
changes were observed in native LDL (lane 1) or in the incubation control LDL (lanes 
6, 11 and 13). The modification of LDL by glucose therefore results in the formation of 
larger molecular mass particles, not seen in the corresponding incubation controls. 
Figure 3.3 SDS-PAGE of LDL (1 mg protein/ml) modified by 50 μM EDTA or 100 mM glucose, over 8 
weeks, at 37 °C. Lane 1: native LDL; lanes 2, 4, 6, 9, 11 and 13: LDL and EDTA samples at 0, 1, 2, 4, 6 
and 8 weeks respectively; lanes 3, 5, 7, 10, 12 and 14: LDL and glucose samples at 0, 1, 2, 4, 6 and 8 
weeks respectively; lane 8: 2 week LDL and glucose with 1 μM Cu2+; and lane 15 molecular weight 
markers in kD. A composite gel is presented, using representative lanes from samples run in triplicate on 
1-2 gels. 
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 3 .3 .1 .a . i i i  Amino Acid Loss/Modification   
The observed change in charge and mass of the glucose-modified LDL suggests 
that loss/modification of amino acid side chains may be occurring. Therefore to 
characterise what was happening at the level of individual side-chains, the potential loss 
of Arg, Lys and Trp side chains was studied, using fluorescence assays (Fig. 3.4). Arg 
residues were examined by incubating the modified LDL with 120 μM 
phenanthrenequinone in ethanol, under basic conditions, at 60 ° C. At 0 time and after 3 
hr of incubation aliquots were taken and neutralised with HCl before reading the 
fluorescence at λex 312 nm and λem 392 nm, and the Arg-dependent fluorescence was 
deemed to be the difference from the zero time control                   
(as described in Section 2.4.1.c.i). Lys residues were quantified (see Section 2.4.1.c.ii) 
by mixing the modified LDL with 0.15 mg/ml fluorescamine in acetone and the 
fluorescence of the samples read at λex 390 nm and λem 475 nm. Trp has its own native 
fluorescence and so samples were simply diluted in PBS and read at λex 280 nm and 
λem335 nm (see Section 2.4.1.c.iii). Results are expressed as a percentage of residues 
remaining compared to the LDL incubation control at that time-point. As the addition of 
1 μM Cu2+, failed to catalyse the reaction of glucose with LDL, and affect the apo B 
characteristics (as reported in Sections 3.3.1.a.i and 3.3.1.a.ii), this condition was not 
examined in these studies. 
Of the 3 amino acids examined, only Arg residues were affected by the 
modification of LDL (1 mg protein/ml) by 100 mM glucose over 14 days of incubation 
at 37 °C, in PBS. Significant loss of Arg residues was observed in the glucose-modified 
LDL when compared to the incubation control LDL (P < 0.05). By 7 days of incubation 
at 37 °C only 48 ± 2 % of the original number of Arg residues were found, and after 14 
days of incubation only 32 ± 3 % were present (Fig. 3.4A). However 14 days of LDL 
modification by 100 mM glucose with LDL did not result in significant loss of Lys or 
Trp residues when compared to the incubation control LDL (Fig. 3.4B and C). Thus 
overall, only Arg residues are lost in the modification of LDL by glucose and this is 
consistent with the observed small changes in REM and aggregation. 
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Figure 3.4 Modification of amino acid residues (Panel A: Arg; Panel B: Lys; Panel C: Trp) in apo B of 
LDL (1 mg protein/ml) modified by 100 mM glucose at 37 °C. LDL modified by glucose (gLDL) is 
compared to the LDL plus 50 μM EDTA incubation control. Data are mean ± SEM from 3 or more 
experiments with duplicate samples. * Indicates glucose-modified LDL is significantly different (P < 
0.05) from the incubation control at that time-point, using Student’s t-test. 
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3 .3 .1 .b  Lipid Changes 
Cholesterol and cholesteryl esters were quantified, to determine if they were 
being lost/modified during glycation/glycoxidation reactions, in similar incubation 
mixtures to those described in the preceding Section (Section 3.3.1). LDL cholesterol 
and cholesteryl ester composition was determined by first extracting the lipid with a 
methanol/hexane mixture and then by separating the peaks isocratically, with reverse 
phase HPLC, with 1 ml/min 70 % isopropanol and 30 % acetonitrile, over a 22 min run 
with detection at 205 nm, using the system described in Section 2.4.2.a.i. Cholesterol 
and cholesteryl esters (cholesteryl docosahexaenoate, cholesteryl arachidonate, 
cholesteryl linoleate, cholesteryl palmitate, cholesteryl oleate and cholesteryl stearate) 
levels were quantitated relative to standards products (Fig. 2.2 and Table 2.1), and 
expressed as nmoles/mg apo B.  
LDL (1 mg protein/ml) modified by 100 mM glucose, in the presence or absence 
of 1 μM Cu2+, for up to 14 days, at 37 °C, was compared to incubation control LDL 
(LDL plus 50 μM EDTA) and native LDL. Over the incubation periods examined no 
statistically significant (P > 0.05) loss of free cholesterol or cholesteryl esters 
(cholesteryl docosahexaenoate, cholesteryl arachidonate, cholesteryl linoleate, 
cholesteryl oleate, cholesteryl palmitate and cholesteryl stearate) was found (Table 3.1).  
7-Ketocholesterol is a known major LDL oxidation product [344], and detection 
of this material was also attempted in the modified LDL. 7-Ketocholesterol elutes at ~ 5 
min under the HPLC conditions employed and was detected by its absorption at 234 nm 
(see Section 2.4.2.a.ii). A 7-ketocholesterol standard was used to convert the 
chromatographic peak area into nmoles/mg apo B protein. Only minimal 7-
ketocholesterol levels were detected (Fig. 3.5), equating to < 1.5 nmoles/mg apo B or < 
0.1% of total sterol levels. No statistical differences (P > 0.05) were found between the 
different LDL modification systems examined. These results suggest that little or no 
cholesterol or cholesteryl ester modification, or oxidation, of the glucose-modified LDL 
is occurring, under the conditions employed. 
  Incubation time (days) 0 7 7 7 14 14 14 
Sterol 
(nmoles/mg apo B) nLDL  (% CE) LDL + EDTA gLDL gLDL +  Cu2+ LDL +EDTA gLDL gLDL +  Cu2+
Free chol 590 ±  38 585 ±  47 617 ± 97 527 ± 93 603 ± 43 644 ± 51 575 ± 50 
CD 15 ±  2 (1) 14 ±  2 12 ± 2 10 ± 2 15 ± 1 16 ± 2 12 ± 2 
CA 86 ±  7 (9) 108 ±   9 107 ± 14 91 ± 17 86 ± 7 79 ± 7 76 ± 7 
CL 636 ±  44 (55) 765 ±  56 740 ± 91 728 ± 134 719 ± 60 722 ± 59 696 ± 55 
CO 222 ±  17 (20) 320 ±  20 312 ± 7 318 ± 34 226 ± 17 245 ± 22 241 ± 18 
CP 147 ±  12 (15) 209 ±  11 203 ± 8 208 ± 30 155 ± 12 176 ± 18 162 ± 13 
CS 9 ±  1 (< 1) 12 ±  6 17 ± 4 4 ± 4 2 ± 1 3 ± 2 2 ± 1 
Total CE 1186 ±  82 1429 ± 41 1393 ± 114 1360 ± 208 1193 ± 94 1199 ± 104 1186 ± 82 
Total chol 1673 ±  103 2014 ± 72 2010 ± 203 1887 ± 299 1822 ± 118 1885 ± 118 1765 ± 119 
CE (%  of  total chol) 65 ±  2  71 ± 2  70 ± 2  72 ± 1   67 ± 1 66 ± 2  67 ± 2  
 
Table 3.1 Cholesterol (chol) and cholesteryl ester (CE) composition of LDL (1 mg protein/ml) modified by 100 mM glucose, in the presence or absence of Cu2+ (gLDL ± 
Cu2+), for 7 and 14 days, at 37 °C. The cholesteryl esters quantified by HPLC, with UV detection at 205 nm, were cholesteryl docosahexaenoate (CD), cholesteryl 
arachidonate (CA), cholesteryl linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Numbers in brackets besides native LDL 
(nLDL) are the cholesteryl ester values as a percentage of total cholesteryl esters. Data are mean ± SEM from at least 3 experiments. Data is compared to native LDL and the 
LDL plus 50μM EDTA incubation control. Statistical analysis by one-way ANOVA, for each parameter, showed no significant differences between the different LDL 
samples (P > 0.05). 
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Figure 3.5 Levels of 7-ketocholesterol after LDL (1 mg protein/ml) was modified by 100 mM glucose ± 
1 μM Cu2+ for 14 days at 37 °C. LDL modified by glucose (gLDL) is compared with native LDL (nLDL) 
and the LDL plus 50 μM EDTA incubation control. Data are mean ± SEM from 9 or more experiments. 
Statistical analysis, by one-way ANOVA, showed no statistical difference between the LDL 
modifications (P > 0.05). 
 
3 .3 .1 . c  Discussion 
Overall in the modification of LDL by glucose, in absence or presence of Cu2+, 
the only significant changes found were in the protein characterisation studies and not in 
the lipid component measurements, as compared to the control LDL. The first LDL 
protein parameter determined was REM.  REM is a simple, and commonly used, 
technique to examine the modification of overall charge of LDL [102, 145, 152, 162, 
163, 167, 224, 267, 269, 337]. The REM of glucose-modified LDL, in the presence or 
absence of Cu2+, increased over 2 weeks of incubation and was significantly increased 
from incubation control LDL, by ~ 0.5. This small increase, in the absence of Cu2+, is 
consistent with other published work where LDL was modified in a similar manner 
[269]. However, what is not consistent with this published work is the lack of difference 
between the REM of the glucose-modified LDL, in the absence or presence of Cu2+. In 
the Millican et al study they reported a 3-fold increase in REM modified by 100 mM 
glucose with 0.5 μM Cu2+, as compared to the LDL modified with glucose alone. In the 
current study the LDL was incubated with 1 μM Cu2+, and no statistical difference was 
seen from LDL modified by glucose alone. A possible explanation for this difference is 
the reported variance in the times of the lag and propagation phases of LDL Cu2+-
induced oxidation when LDL is obtained from different subjects [102, 108]. Other 
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 studies have shown greater REM increases over shorter incubation periods, but the 
incubations have included higher concentrations of metal ions, for example 60 μM Fe3+ 
[188, 267] or 10 μM Cu2+ [152].  
The increases in the REM of glucose-modified LDL continued over 6-8 weeks of 
incubation and were slightly elevated above control LDLs. The REM of glucose-
modified LDL after 6-8 weeks nearly reached the REM observed for acetylated LDL. 
The increases in the REM of the EDTA-modified LDL, over the same time points show 
the necessity of including native LDL and incubation control LDL in these experiments. 
The modification of LDL by glucose is not as great when compared to the incubation 
control LDL as compared to the native LDL and suggests some changes are occurring in 
the LDL due to the incubation process alone. Thus incubation control LDL was 
included in all experiments to determine whether any changes in the LDL were due to 
the presence of the glucose, or the incubation and handling methodologies. Acetylated 
LDL was also included in the REM experiments as acetylation is known to increase the 
negative charge of LDL due to Lys modification [145, 337], and thus acted as a positive 
control in determining REM. The REM of acetylated LDL (~ 5) compared to native 
LDL is similar to that determined for LDL acetylated in a similar manner by others 
[154, 337, 338]. 
The next parameter examined in the modification of LDL by glucose was the 
mass of the LDL particles using SDS-PAGE. Reducing SDS-PAGE is an established 
technique to determine the mass of proteins, including apo B [152, 340, 354, 357, 358]. 
Changes in the mass of apo B were predicted due to the crosslink products described in 
glycation and glycoxidation reactions [196, 201], and reports of either protein 
crosslinking/aggregation, or fragmentation, in glucose-induced modification of other 
proteins such as collagen and BSA [221, 222, 243]. Increasing the incubation time of 
LDL with glucose, in the absence or presence of Cu2+, led to increasing molecular mass 
of the apo B, with this occurring to a much greater extent and over shorter time periods, 
than with the control LDLs, suggesting aggregation or crosslinking was occurring. This 
phenomenon was also observed by Sakuri et al, thought at much shorter time points 
probably due to the addition of higher concentrations of metal ions (60 μM Fe3+) [188]. 
Otherwise the measurement of this parameter in the modification of LDL by glucose, 
has not been reported. 
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 The changes in charge and size of the glucose-modified LDL particles, suggest 
glycation/glycoxidation reactions are occurring, and so loss of targeted amino acid 
residues would be expected. Therefore the analysis of the amino acids residues, Arg, 
Lys and Trp was performed using standard fluorescence assays [335, 341, 342]. When 
the loss of amino acids residues in glucose-modified LDL were compared to values 
obtained in control LDLs, decreases were only detected for Arg residues and not Lys or 
Trp residues. The increased loss of Arg residues, compared to control LDLs, may 
account for the small, but significantly increased REM found in glucose-modified LDL, 
as compared to control LDL, and suggests that the crosslinking/aggregation reactions 
may be occurring as a result of modification of the Arg residues. The lack of loss of Lys 
residues has been reported by another group, where only 2-5 % of Lys resides were 
reported to be glucosylated after up to 9 days of incubation with 200 mM glucose [260]. 
Increased  levels of glucosylated Lys residues were only seen in this previous study if 
NaCNBH3 was added to the reaction mixtures. No loss of Trp resides was observed, 
however, loss of Trp fluorescence has been reported, for example, in glucose-modified 
BSA [194], or LDL exposed to a heavy oxidant insult [177, 359]. 
Further work in our laboratory, by Dr. Heather Knott, has shown that protein 
oxidation products are detected in glucose-modified LDL. These experiments were 
carried out using conditions where the ratio of LDL to glucose differed due to a lower 
concentration of LDL being used. LDL (0.4 mg protein/ml) incubated with 5-100 mM 
glucose and 1 μM Cu2+, showed significant increases in the protein oxidation products, 
DOPA and o-Tyr, with incubation times of 2 weeks or greater [335]. However, these 
changes were Cu2+ dependent, and not observed in the absence of Cu2+. With the 
appearance of these protein oxidation products, concurrent increases in the lipid 
oxidation products 7-ketocholesterol and cholesteryl ester hydro(pero)xides were 
observed, and decreases in α-tocopherol, free cholesterol, cholesteryl arachidonate and 
cholesteryl linoleate. 
In the current study, LDL (1 mg protein/ml) modified by glucose, in the presence 
or absence of Cu2+, for up 2 weeks (Section 3.3.1.b), did not show in any significant 
decreases in free cholesterol or any cholesteryl esters, or production of the lipid 
oxidation product 7-ketocholesterol. These sterols were examined using methods 
established previously by workers in our laboratory [343, 344]. Dr. Heather Knott 
reported, after 2 weeks of modification of LDL by glucose Cu2+, levels of 7-
ketocholesterol between 150-200 nmol/mg apo B [335]. In this Chapter levels of 7-
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 ketocholesterol were up to 1.5 nmoles/mg apo B (~ 100 fold less) and account for less 
than 0.1 % of total sterol levels, indicating minimal oxidative events. This difference to 
the work by Dr. Heather Knott may arise from the different ratio of LDL to glucose and 
the higher Cu2+ (2.5 fold less LDL is used). The data presented in Dr. Heather Knott’s 
work is from one donor, and it is known that there are variations in timing of the lag 
phases of LDL oxidation, antioxidant status, and pre-existing lipid peroxides between 
different donors [102, 108, 335].  
The values obtained for cholesterol and cholesteryl esters of the LDL used in this 
Chapter are comparable to those reported in other studies for native LDL. The LDL 
characterised in this Chapter had free cholesterol levels of ~ 600 nmoles/mg apo B and 
previous studies have reported range of values from 500-1100 nmoles/mg apo B [102, 
335, 344, 363]. Total cholesteryl esters levels of LDL in this Chapter were ~ 1200 
nmoles/mg apo B and again these are comparable to other reported values of 1600-3000 
nmoles/mg apo B [102, 344]. The cholesterol and cholesteryl ester components of LDL 
have been reported to be unchanged between LDL from people with and without 
diabetes, suggesting that the minimally-oxidised glucose-modified LDL characterised in 
this Chapter is consistent with in vivo glycated/glycoxidised LDL [166]. 
The individual cholesteryl ester profile of the LDL in this Chapter is also 
consistent with other studies, which have examined native LDL. Cholesterol lineolate 
and arachidonate are the most rapidly lost cholesteryl esters during Cu2+-induced LDL 
oxidation [102, 344]. Both of these, as there was no significant oxidation occurring, 
were unchanged. Cholesteryl linoleate values were ~ 700 nmoles/mg apo B and 
cholesteryl arachidonate values were ~100 nmoles/mg apo B, and these are both in the 
range of other reported work in our laboratory (800-1200 nmoles/mg apo B and 90-130 
nmoles/mg apo B for cholesteryl linoleate and arachidonate respectively) [335, 363]. 
Cholesteryl linoleate is the most abundant cholesteryl ester in LDL (at 55 % of total 
cholesteryl esters), as confirmed in other studies [103, 104]. The next abundant esters 
from highest to lowest were cholesteryl oleate (20 %), cholesteryl palmitate (15 %), 
cholesteryl arachidonate (9 %), cholesteryl docosahexaenoate (1 %) and cholesteryl 
stearate (< 1%). These percentages and patterns are in agreement with previously 
published work [103, 104]. 
The lipid characterisation work, in conjunction with the protein studies, 
demonstrates that even though the LDL is slightly modified during the incubation 
period with EDTA, this modification is not due to significant (lipid) oxidation. If 
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 significant amounts of oxidation were occurring greater increases in REM or apo B 
aggregation or fragmentation would be expected to be observed, as well as loss of 
cholesteryl esters and increases in oxysterols [102, 152, 344]. These lack of changes 
indicate that the incubation of LDL with 50 μM EDTA for the same time periods as the 
LDL modified by glucose in the presence or absence of Cu2+, provides a suitable 
minimally-modified and oxidised incubation control LDL. 
Thus modification of LDL by 100 mM glucose, whether in the presence or 
absence of Cu2+, leads to LDL that is slightly more negatively charged and possibly 
crosslinked/aggregated to a small extent, as compared to control LDL, in the absence of 
significant lipid modification or oxidation. Of the amino acids residues examined of the 
apo B protein, only Arg residues were significantly diminished in the modification of 
LDL by glucose, in the presence or absence of Cu2+. This loss of detectable Arg 
residues could explain the small increases in REM and aggregation of the glucose-
modified LDL, in the presence or absence of Cu2+. These changes could be due to AGE 
formation on the Arg residues [196, 201]. This loss of Arg was only seen with the 
supra-pathophysiological concentration of 100 mM glucose [335]. A similar extent of 
modification of LDL may be possible in vivo, for example if LDL is trapped in the 
arterial intima in a hyperglycaemic subject [33, 34, 39-41, 103, 104, 119]. These studies 
also demonstrate that the chelex resin treatment effectively removed contaminating 
metal ions as no significant oxidation was detected in the absence of Cu2+ and that the 
ratio of Cu2+ to apo B used (0.5:1) did not induce significant oxidation. Other work 
reporting a stimulatory effect of glucose on Cu2+-mediated LDL oxidation used higher 
ratios of Cu2+: LDL (ranging from 1.25:1 to 31:1) [268, 271, 335, 361]. The low levels 
of Cu2+ used in this Chapter may also be closer to in vivo levels of Cu2+ found in 
diseased and healthy artery walls (~ 7 and 2 pmol/mg tissue respectively) [364]. Thus 
the lack of oxidation in the glucose-modified LDL used in this Chapter, indicate that the 
LDL is glycated rather than glycoxidised, through covalent modification predominantly 
at Arg residues. 
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 3 .3 .2  Modification of Low-Density Lipoproteins by Methylglyoxal 
Methylglyoxal is elevated in the diabetic state [225, 227], and is known to be 
formed via several pathways [209, 210]. Previous studies have shown that this aldehyde 
is much more reactive than 3-deoxyglucosone, glucose, glyoxal and hydroxyacetone 
with protein targets [209, 210, 357, 365], and it was therefore hypothesised that this 
compound would modify LDL more rapidly and to a greater extent than glucose. To test 
this hypothesis LDL samples were incubated with 0-100 mM methylglyoxal, at 37 °C, 
in PBS, and the reaction mixtures analysed at various time points for REM, SDS-
PAGE, amino acid and lipid changes as employed in the previous Section (Section 
3.1.1). 
 
3 .3 .2 .a  Apolipoprotein B Changes 
 
3 .3 .2 .a . i  Relative Electrophoretic Mobility 
The REM of LDL (1 mg protein/ml) modified by 0-100 mM methylglyoxal, at 
37 °C was determined over 14 days, as for glucose-modified LDL. As can be seen in 
Fig. 3.6 there is a time- and concentration- dependent increase in REM in the 
methylglyoxal-treated samples compared to the incubation control. A statistically 
different (P < 0.05) REM of 2.07 ± 0.46, was found, in LDL modified by 100 mM 
methylglyoxal, by 6 hr, as compared to the REM of 1.09 ± 0.02, for the 0 mM 
methylglyoxal control LDL (Fig. 3.6A). By 24 hr 1, 10 and 100 mM methylglyoxal-
modified LDL had a statistically higher REM (P < 0.05) than LDL incubated without 
methylglyoxal (i.e. 2.57 ± 0.14, 3.21 ± 0.12 and 3.31 ± 0.24 respectively versus 1.24 ± 
0.10). After 7 days of incubation the REM of 10 mM methylglyoxal-modified LDL 
reached values of 4.60 ± 0.01 and the REM was significantly higher (P <0.05) for the 
100 mM methylglyoxal-modified LDL, at 5.89 ± 0.10 (Fig. 3.6B). After 14 days of 
incubation at 37 °C the REM of LDL modified with 10 and 100 mM methylglyoxal had 
continued to increase, with respective REM values of 6.12 ± 0.26 and 6.90 ± 0.20. 
However, the REM of the 10 mM condition was not significantly less (P > 0.05), than 
the REM of 100 mM methylglyoxal-modified LDL, at the 14 day time point. Overall 
these studies show that the REM of methylglyoxal-modified LDL particles increases 
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 over time and is dependent the on methylglyoxal concentration, especially at shorter 
incubation times. These REM changes are larger, and occur more quickly, than in the 
corresponding glucose studies. 
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Figure 3.6 REM changes of LDL (1 mg protein/ml) modified by 0-100 mM methylglyoxal over 24 hr 
(Panel A) or 14 days (Panel B) at 37 °C. Data are mean ± SEM from 3 or more experiments. * Indicates 
methylglyoxal modified LDL is significantly different (P < 0.05) from the incubation control (LDL plus 
50 μM EDTA, with 0 mM methylglyoxal), and # indicates the 100 mM condition is significantly different 
(P < 0.05) from the 10 mM condition at that time-point, using 2-way ANOVA and Bonferroni post hoc 
testing. 
 
3 . 3 . 2 . a . i i  SDS-PAGE 
  As the REM changes in methylglyoxal-modified LDL occurred more quickly, 
and to a greater extent, than with glucose-modified LDL, the changes in the mass of 
methylglyoxal-modified LDL particles were examined over a shorter time frame. LDL 
(1 mg protein/ml) incubated with 0, 1 or 100 mM methylglyoxal for 1-5 days, was 
examined using SDS-PAGE (Fig. 3.7). After 24 hr of incubation 100 mM 
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 methylglyoxal-modified LDL barely moved into the gels (lane 4); a similar pattern is 
also seen after 5 days of modification (lane 7). Analogous changes in the mobility of 
LDL modified by 10 mM methylglyoxal are also observed (lanes 3 and 6), as compared 
to native LDL (lane 1) and the incubation control LDL (lanes 2 and 5). These data show 
that methylglyoxal-modified LDL is heavily aggregated/crosslinked after 24 hr of 
incubation, especially with 100 mM methylglyoxal. These changes again appear more 
quickly, and to a greater extent, than in the corresponding glucose experiments. 
Figure 3.7 SDS-PAGE of LDL (1 mg protein/ml) modified by 50 μM EDTA or 10-100 mM 
methylglyoxal, for 1 or 5 days, at 37 °C. Lane 1: native LDL; lanes 2 and 5: LDL and EDTA at days 1 
and 5 respectively; lanes 3 and 6: LDL and 10 mM methylglyoxal at days 1 and 5 respectively; lanes 4 
and 7: LDL and 100 mM methylglyoxal at days 1 and 5 respectively; and lane 8: molecular weight 
markers in kD. A composite gel is presented, using representative lanes from samples run in triplicate on 
2 gels. 
 
3 .3 .2 .a . i i i  Amino Acid Loss/Modification 
As LDL REM changes and aggregation occur more rapidly with methylglyoxal 
than glucose it might be expected that modification of any individual amino acids 
residues in LDL would also be more rapid. This hypothesis was tested by examining the 
loss of Arg, Lys or Trp residues in methylglyoxal-modified LDL compared to the 
incubation controls. All 3 residues were lost in a time- and concentration-dependent 
manner.  
Arg residues appeared to be the most rapidly lost of the amino acid residues 
measured (Fig. 3.8A). After 24 hr of incubation only 53 ± 4 % and 66 ± 3 % of Arg 
remained for LDL (1 mg protein/ml), modified by 10 and 100 mM methylglyoxal 
respectively. The rate of Arg loss seemed then to slow and after 7 days of incubation at 
37 °C, 24 % of Arg residues remained, and after 14 days only 14 % remained, for LDL 
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 modified by 100 mM methylglyoxal. Statistically higher (P > 0.05) percentages of Arg 
residues remained for LDL modified by 10 mM methylglyoxal, with 53 % remaining 
after 7 days and 48 % after 14 days, as compared to the 100 mM condition.  
  
 
Figure 3.8 Modification of amino acid residues (Panel A: Arg; Panel B: Lys; Panel C: Trp) in apo B of 
LDL (1 mg protein/ml) modified by 0-100 mM methylglyoxal at 37 °C. LDL modified by methylglyoxal 
is compared to the LDL plus 50 μM EDTA (0 mM methylglyoxal) incubation control. Data are mean ± 
SEM from 3 or more experiments with duplicate samples. * Indicates methylglyoxal-modified LDL is 
significantly different (P < 0.05) from the incubation control and # indicates the 100 mM condition is 
significantly different (P < 0.05) from the 10 mM condition at that time-point, using 2-way ANOVA and 
Bonferroni post hoc testing. 
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For Lys residues a similar pattern was observed to the loss of Arg residues in the 
100 mM methylglyoxal condition (Fig. 3.8B), with 52 ± 3 % remaining after 24 hr, 40 ± 
4 % at 7 days and 21 ± 1 % after 14 days of incubation. The loss of Lys residues for the 
10 mM methylglyoxal condition was significantly less (P < 0.05) at each time point. 
The loss of Trp residues (Fig. 3.8C) was slower than for the losses of Arg and 
Lys residues, but followed a similar time- and concentration-dependent decline. After 7 
days of incubation, LDL modified by 100 M methylglyoxal had 43 ± 5 % of Trp 
residues remaining and after 14 days of incubation, this decreased to 24 ± 2 %. At each 
time point the 10 mM methylglyoxal condition had significantly more (P < 0.05) Trp 
residues remaining than the 100 mM condition, with 60 ± 6 % at 7 days and 40 ± 3 % at 
14 days still intact.  
Overall significant loss of Arg, Lys and Trp residues are observed in 
methylglyoxal-modified LDL in a time- and concentration- dependent manner. These 
changes, as with the REM and SDS-PAGE changes, occur to a much greater extent than 
observed with glucose-modified LDL particles. 
 
3 .3 .2 .b  Lipid Changes 
 
3 .3 .2 .b . i  Cholesterol and Cholesteryl Esters 
As large changes to the apo B protein seem to be occurring in methylglyoxal-
modified LDL, concurrent changes could also be occurring in the cholesterol and 
cholesteryl ester components. Therefore reverse-phase HPLC analysis was performed to 
determine the cholesterol and cholesteryl ester composition of LDL (1 mg protein/ml) 
modified by 10 and 100 mM methylglyoxal for up to 14 days at 37 °C, with this data 
compared to the incubation control (LDL plus 50 μM EDTA) and native LDL. Over the 
incubation period examined (0-14 days) no statistically-significant (P > 0.05) losses of 
free cholesterol or cholesteryl esters (cholesteryl docosahexaenoate, cholesteryl 
arachidonate, cholesteryl linoleate, cholesteryl oleate, cholesteryl palmitate and 
cholesteryl stearate) were found (Table 3.2). There was a trend for a loss of individual 
cholesteryl esters, total cholesteryl esters and as a percentage of total cholesterol levels, 
but this did not reach significance (P > 0.05), perhaps due to the (biological) variation 
between LDL donors [102, 108]. 
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Incubation time (days) 0 1 1 1 5 5 5 7 7 7 14 14 14 
Sterol 
(nmoles/mg apo B) 
nLDL 0 mM 10 mM 100 mM 0 mM 10 mM 100 mM 0 mM 10 mM 100 mM 0 mM 10 mM 100 mM 
Free chol 645 ± 33 646 ± 92 634 ± 120 642 ± 105 625 ± 45 648 ± 43 592 ± 43 699 ± 62 956 ± 12 816 ± 94 533 ± 121 615 ± 70 615 ± 54 
CD 18 ± 1 26 ± 5 23 ± 5 24 ± 4 16 ± 5 14 ± 2 14 ± 2 17 ± 1  17 ± 1 14 ± 2 17 ± 3 15 ± 6 11 ± 6 
CA 102 ± 6 107 ± 17 98 ± 23 102 ± 16 99 ± 5 85 ± 10 69 ± 8 133 ± 12 125 ± 8 98 ± 13 95 ± 13 70 ± 27 60 ± 21 
CL 768 ± 51 890 ± 142 853 ± 190 864 ± 139 800 ± 47 697 ± 92 532 ± 50 1032 ± 126 938 ± 79 685 ± 100 720 ± 97 489 ± 147 448 ± 86 
CO 250 ± 18 287 ± 41 279 ± 45 273 ±33 248 ± 19 202 ± 26 174 ± 17 382 ± 31 315 ± 22 240 ± 27 246 ± 37 163 ± 42 152 ± 23 
CP 176 ± 16 256 ± 65 239 ± 48 236 ± 53 172 ± 13 145 ± 15 126 ± 15 259 ± 25 216 ± 13 165 ± 21 183 ± 27 122 ± 32 117 ± 16 
CS 7 ± 1 1 ± 1 1 ± 1 1 ± 1 4 ± 1 4 ± 2 4 ± 1 19 ± 4 5 ± 5 1 ± 1 9 ± 5 10 ± 2 3 ± 3 
Total CE 1325 ± 83 1567 ± 238 1493 ± 270 1500 ± 206 1338 ± 77 1095 ± 111 970 ± 73 1842 ± 193 1616 ± 116 1203 ± 159 1270 ± 174 869 ± 255 791 ± 154 
Total chol 1970 ± 108 2213 ± 326 2126 ± 389 2142 ± 305 1963 ± 110 1742 ± 138 1562 ± 89 2541 ± 251 2572 ± 114 2019 ± 249 1803 ± 294 1484 ± 325 1406 ± 208 
CE (% of total chol) 67 ± 1 71 ± 1  70 ± 1  70 ± 1  68 ± 1  62 ± 2 62 ± 2   72 ± 1 63 ± 2 59 ± 1  71 ± 3 56 ± 6  59 ± 4  
 
 
Table 3.2 Cholesterol (chol) and cholesteryl ester (CE) composition of LDL (1 mg protein/ml) modified by 0-100 mM methylglyoxal, for up to 14 days, at 37 °C. The 
cholesteryl esters quantified by HPLC, with UV detection at 205 nm, were cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl linoleate (CL), 
cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Data are mean ± SEM from at least 3 experiments. Data is compared to native LDL (nLDL) 
and the LDL PLUS 50μM EDTA (0 mM methylglyoxal) incubation control. Statistical analysis by one-way ANOVA, for each parameter, showed no significant differences 
between the different LDL samples (P > 0.05). 
 
 
 Only very low levels of the cholesterol oxidation product, 7-ketocholesterol, and 
then at longer time points (Fig. 3.9), equating to < 1 nmole/mg apo B or < 0.05 % of 
total sterol levels, were seen. There appears to be trend of increased 7-ketocholesterol 
levels in the 7-day, 100 mM methylglyoxal-modified LDL, but this did not reach 
statistical difference when compared to control LDL (P > 0.05). These results suggest 
minimal changes are occurring in the cholesterol or cholesteryl ester components of 
methylglyoxal-modified LDL. 
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Figure 3.9 Levels of 7-ketocholesterol in LDL (1 mg protein/ml) modified by 10 or 100 mM 
methylglyoxal at 37 °C for 7 or 14 days. LDL modified by methylglyoxal is compared with native LDL 
(nLDL) and the LDL plus 50 μM EDTA incubation control. Data are mean ± SEM from 9 or more 
experiments. Statistical analysis by two-way ANOVA, showed no significant differences between the 
different LDL samples or an effect of time (P > 0.05).  
 
3 . 3 . 2 . b . i i  Free Radicals 
As the data in the previous Section suggests that there might be minor (albeit 
insignificant statistically) losses of cholesterol and cholesteryl esters in the long-term, 
high-methylglyoxal-concentration samples, further studies were carried out to determine 
whether significant amounts of free radicals (which might induce lipid peroxidation 
[108, 177] were being generated in these samples. EPR is method of detecting free 
radicals [345], and it was hypothesised that low levels of lipid modification of LDL by 
methylglyoxal might be occurring via a radical mechanism. 
To test this hypothesis LDL (1 mg protein/ml) was incubated with 50 μM EDTA 
or 100 mM methylglyoxal for 5 days at 37 °C, before removal of excess EDTA and 
methylglyoxal by column chromatography and examination by EPR spectroscopy, in 
the presence of the radical trapping agent (spin trap) PBN as described in Section 2.4.3.  
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Figure 3.10 EPR spectra of LDL (1 mg protein/ml) incubated with 50 μM EDTA (incubation control) or 
100 mM methylglyoxal for 5 days, at 37 °C, in PBS. After the incubation period the LDL was subject to 
column chromatography, to remove excess methylglyoxal, and the resulting modified LDL incubated 
with 50 mM PBN for 0 or 24 hr in either PBS or complete DMEM media with 10 % FCS, before 
scanning. Spectra A: 24 hr PBS and PBN control; B: 24 hr incubation of incubation control LDL with 
PBN in PBS; C: 24 hr incubation of methylglyoxal-modified LDL with PBN in PBS; D: 24 hr PBN and 
media control; E: 24 hr incubation of control LDL with PBN in media; and F: 24 hr incubation of 
methylglyoxal-modified LDL with PBN in media. Data are representative spectra from 1 experiment. 
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 Detection of free radicals was attempted by incubating the LDL-PBN mixture in 
both PBS and media for 24 hr (Fig. 3.10). Spectra A, B and C are from the PBS mixture 
studies, with A being the PBS plus PBN control, B containing the control LDL, and C 
the methylglyoxal-modified LDL. There were no observable differences between these 
spectra; the 4-line signal present in each of the spectra is known to be due to a spin trap 
degradation product [366]. This was again seen for the samples in media (Spectra D, E 
and F), with D being the PBN and media control, E containing the control LDL, and F 
containing the methylglyoxal-modified LDL in media. Due the lack of observed 
difference between methylglyoxal-modified LDL and incubation control LDL, no 
further experiments were carried out. It is concluded that free radical processes are not a 
major contributor to the modification of LDL by methylglyoxal, under the conditions 
employed. 
 
3 .3 .2 . c  Discussion 
The modification of LDL by methylglyoxal resulted in significant changes of apo 
B, and to a greater extent than glucose-modified LDL, as would be expected from other 
studies [209, 210, 224, 357]. The REM of methylglyoxal-modified LDL was 
significantly increased from control LDL within 6 hr for the 100 mM condition, and 
within 24 hr for LDL modified by methylglyoxal concentrations of 1-100 mM. This is 
in agreement with work by Schalkwijk and colleagues [167]. The REM of 
methylglyoxal-modified also continued to increase over the 14 days of measurement, to 
reach a REM higher than observed for acetylated LDL. This suggested that at least Lys 
and Arg residues were affected during the modification of LDL by methylglyoxal for 
the production of more negative particles. LDL modified by methylglyoxal for 24 hr or 
5 days also showed significant crosslinking/aggregation as compared to control LDL. 
At the highest concentration the mass of the apo B particle rendered them just able to 
move into the gel. Increases in molecular mass of proteins has also been observed in our 
laboratory when methylglyoxal is incubated with intracellular enzymes such as LDH 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [357] as well as by other 
groups examining other proteins [367, 368]. There has been little other work reported 
on the reaction of methylglyoxal with LDL for comparison with these results. 
The REM and SDS-PAGE experiments suggested that there would be a loss of 
Lys and Arg residues to account for the changes in these parameters. Reaction of LDL 
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 with 10 or 100 mM methylglyoxal did lead to significant losses in all three amino acid 
residues examined (Arg, Lys and Trp) over 5-14 days. Collaborative experiments with 
Dr. Heather Knott showed no such loss of amino acid residues with methylglyoxal 
concentrations less than 0.1 mM [335]. These results are comparable to Schalkwijk et al 
who examined Arg residues in LDL modified by methylglyoxal for up to 72 hr [167]. 
However, greater Lys residue loss was found in the current study than reported in the 
study by Schalkwijk et al, as they reported only minimal losses in Lys residues after 72 
hr incubation with methylglyoxal, but this may arise due to different detection methods 
(fluorescence assays versus hydrolysis and HPLC) and LDL donor differences [167]. 
Loss of Lys and Arg residues has also been reported during the modification of BSA 
[224, 369], GAPDH [357] and lysosome [370] by methylglyoxal. These results indicate 
in our system the possible formation of AGE products such as imidazolone adducts, 
arginyl-pyrimidine, CEL and MOLD (methylglyoxal-lysine dimer), which are increased 
in age and diabetes [198, 210]. Other groups have reported a loss of Trp fluorescence 
upon reaction of methylglyoxal with various proteins [367, 370-373], however it does 
not seem to be have been reported before for apo B. Reaction of methylglyoxal with 
other residues is also possible, for example cysteine, histidine, asparagine and glutamine 
[196, 373], and could provide the basis of further studies.                                                                     
Lipid analysis of methylglyoxal-modified LDL showed no significant losses of 
free cholesterol or cholesteryl esters, and no formation of 7-ketocholesterol. Further 
collaborative work with Dr. Heather Knott showed no indication of lipid oxidation, 
under the conditions employed. Other lipid oxidation products such as cholesteryl ester 
hydro(per)oxides not detected and no there was no loss of α-tocopherol, even in the 
presence of 1 μM Cu2+ [335]. As there was no detectable lipid oxidation, the detection 
of protein oxidation products was not performed as these are dependent on radical-
mediated processes [177, 374]. Lack of free radical processes was further confirmed by 
EPR, where no significant radical fluxes were observed. Schalkwijk et al also reported 
that methylglyoxal did not initiate lipid oxidation [167]. 
  The studies reported in Section 3.3.2 showed significant protein modification of 
LDL by methylglyoxal, without accompanying lipid oxidation/modification. The levels 
of methylglyoxal required to observe these changes in charge, LDL particle size and 
loss of amino acid residues were 10-100 mM. The level of methylglyoxal in blood or 
urine has been reported to be in the nM to μM range [225-227, 375, 376], with this 
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 elevated 2-3 fold in diabetics [225-227]. Therefore the concentrations of methylglyoxal 
used in this study are supra-pathophysiological, but as methylglyoxal is very reactive 
these in vivo values are likely to represent residual unreacted methylglyoxal, and not 
give a true indication of maximal concentrations nor fluxes. LDL has a lifetime of at 
least 2 days in human circulation [102] and so these studies have a relevant in vivo 
modification time. The entrapment of LDL in the sub-endothelium [33, 34, 39-41, 103, 
104, 119], may also allow the LDL to reach similar extents of modification if there is 
chronic long-term exposure to lower levels of methylglyoxal. Therefore the rapid 
reaction of LDL with methylglyoxal, seems to induce glycation reactions rather than 
oxidation reactions and results in the covalent modification of (at least) Arg, Lys and 
Trp residues. 
 
3 .3 .3  Modification of Low-Density Lipoproteins by Glycolaldehyde 
Glycolaldehyde is formed during glycation and glycoxidation reactions [213, 215, 
219, 246], and has been reported to be very reactive with LDL [162, 163]. 
Glycolaldehyde, as a low-molecular-mass aldehyde, may modify LDL to an extent such 
that it may be recognised by macrophage scavenger receptors [162, 163]. Therefore, 
considering the small extent of protein modification noted with glucose-modified LDL 
(Section 3.3.1), and the greater extent of modification observed in incubations with 
methylglyoxal (Section 3.3.1), the modification of LDL by glycolaldehyde was 
examined, under conditions similar to the methylglyoxal studies. 
 
3 .3 .3 .a  Apolipoprotein B Changes 
 
3 .3 .3 .a . i  Relative Electrophoretic Mobility 
The REM of LDL (1 mg protein/ml) modified by 0, 10 and 100 mM 
glycolaldehyde, at 37 °C, was determined at various time points for up to 14 days. Fig. 
3.11 shows that there is a time- and concentration-dependent increase in REM in the 
glycolaldehyde samples compared to the incubation control. The reaction of 100 mM 
glycolaldehyde with the LDL proceeded quickly; within 1 hr the REM of 2.82 ± 0.07 
was significantly different (P < 0.05) from the 0 mM glycolaldehyde value of 1.03 ± 
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 0.04 (Fig. 3.11A). By 24 hr, both the 10 and 100 mM conditions (REM of 3.09 ± 0.17 
and 5.36 ± 0.17 respectively) were significantly different (P < 0.05) from the incubation 
control value of 1.29 ± 0.06. The change in the REM of LDL modified by 1 mM 
glycolaldehyde was much less marked and did not achieve statistical difference (P < 
0.05) from the control LDL until day 14 (REM of 2.64 ± 0.05, compared to 1.41 for the 
0 mM glycolaldehyde condition; Fig. 3.11B). The REM for the 10 and 100 mM 
glycolaldehyde conditions continued to increase to day 5, to reach values of 5.38 ± 0.00 
and 5.96 ± 0.04 respectively, and then appeared to decline. After 14 days of incubation 
the REM were 3.80 ± 0.39 for the 10 mM condition and 3.89 ± 0.56 for the 100 mM 
condition. 
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Figure 3.11 REM changes in LDL (1 mg protein/ml) modified by 0-100 mM glycolaldehyde over 24 hr 
(Panel A) or 14 days (Panel B) at 37 °C. Data are mean ± SEM from 3 or more experiments. * Indicates 
glycolaldehyde-modified LDL is significantly different (P < 0.05) from the incubation control (LDL plus 
50 μM EDTA, with 0 mM glycolaldehyde) and # indicates the 1 and 10 mM conditions are significantly 
different (P < 0.05) from the 100 mM condition at that time-point, using 2-way ANOVA and Bonferroni 
post hoc testing. 
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 Significant concentration- and time-dependent changes were observed for 
glycolaldehyde-modified LDL, especially in the earlier time points, and these were 
much greater than those observed for glucose-modified LDL. The concentration-
dependent changes seem to diminish over time between the 1, 10 and 100 mM 
glycolaldehyde conditions due to the plateau/decline of the REM changes observed in 
the latter 2 conditions, though they were still increasing in the 1 mM condition. The 
initial REM changes over 24 hr were more rapid than with methylglyoxal, but after 5-7 
days of incubation comparable changes were observed. At day 14, lower REM values 
are observed in glycolaldehyde-modified LDL, compared to methylglyoxal-modified 
LDL at the same concentrations of aldehyde. For example, for the 100 mM aldehyde 
conditions, the REM values are 3.89 ± 0.56 for glycolaldehyde and 6.90 ± 0.20 for 
methylglyoxal. These differences may reflect different mechanisms of reaction between 
the two aldehydes. 
 
3 . 3 . 3 . a . i i  SDS-PAGE 
As the REM changes in glycolaldehyde-modified LDL appeared more quickly 
and to a greater extent compared to glucose-modified LDL, and over similar time 
periods to methylglyoxal-modified LDL, the changes in the mass of glycolaldehyde-
modified LDL particles were examined over 1-7 days. LDL (1 mg protein/ml) incubated 
with 0, 1, 10 or 100 mM glycolaldehyde for 1-7 days was examined using SDS-PAGE 
(Fig. 3.12). After 24 hr of incubation the 10 and 100 mM glycolaldehyde-modified LDL 
particles barely moved into the gels (lanes 4 and 5 respectively); a similar pattern was 
also seen after 7 days of modification (lanes 8 and 9 respectively). Less obvious 
changes were observed in the 24 hr 1 mM glycolaldehyde condition (lane 3), as 
compared to native LDL (lane 1) and the incubation control LDL (lane 2), but some 
increase in the size of the 1 mM glycolaldehyde particles was observed after 7 days of 
modification as compared to the incubation control (lane 6). On the basis of this data it 
is concluded that glycolaldehyde-LDL is heavily aggregated/crosslinked after 24 hr of 
incubation with 10 and 100 mM glycolaldehyde. These changes again appear more 
quickly and to a greater extent than those observed with glucose-modified LDL and 
perhaps methylglyoxal-modified LDL. 
 
 94
  
 2 3 4 5 6 7 8 9 10 1 
200 
116.25 
 
 
 
97.4 
 
Figure 3.12 SDS-PAGE of LDL (1 mg protein/ml) modified by 50 μM EDTA or 1-100 mM 
glycolaldehyde, over 1 and 7 days, at 37 °C. Lane 1: native LDL; lanes 2 and 6: LDL and EDTA at days 
1 and 7 respectively; lanes 3 and 7: LDL and 1 mM glycolaldehyde at days 1 and 7 respectively; lanes 4 
and 8: LDL and 10 mM glycolaldehyde at days 1 and 7 respectively; lanes 5 and 9: LDL and 100 mM 
glycolaldehyde at day 1 and 7 respectively; and lane 10: molecular weight markers in kD. A composite 
gel is presented, using representative lanes from samples run in triplicate on 2 gels. 
 
3 .3 .3 .a . i i i  Amino Acid Loss/Modification 
As there are rapid LDL REM and SDS-PAGE changes with glycolaldehyde it 
was hypothesised that the modification of individual amino acids residues in 
glycolaldehyde-modified LDL might also be more rapid. This hypothesis was tested by 
examining the loss of Arg, Lys or Trp residues in glycolaldehyde-modified LDL 
compared to the incubation controls. LDL (1 mg protein/ml) was modified by 0-100 
mM glycolaldehyde over 14 days, and modification was seen in all three amino acids 
examined, with time- and concentration-dependent changes seen for the Lys and Trp 
residues. 
For the100 mM condition, Arg residues were rapidly lost and were significantly 
less (P < 0.05) after 24 hr, at 52 ± 14 %, from the control (Fig. 3.13A). By 7 days only 
16 ± 8 % of Arg residues remained. However, no significant losses (P > 0.05) of Arg 
residues were observed with lower glycolaldehyde concentrations. 
Rapid loss of Lys residues was observed with all 3 concentrations of 
glycolaldehyde used, and by 24 hr the 1, 10 and 100 mM glycolaldehyde conditions 
were significantly different (P > 0.05) from the control at 83 ± 6 %, 34 ± 6 % and 7 ± 1 
% respectively (Fig. 3.13B). No further decrease was seen at longer time points for the 
100 mM samples. After 7 days the 10 mM condition (10 ± 1 %) was not significantly 
different from the 100 mM condition (P > 0.05). Lys residues for LDL modified by 1 
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 mM glycolaldehyde continued to decrease over the 14 days of incubation to 50 ± 7 % of 
the control, but remained significantly higher (P < 0.05) than the 10 and 100 mM 
conditions.  
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Figure 3.13 Modification of amino acid residues (Panel A: Arg; Panel B: Lys; Panel C: Trp) in apo B of 
LDL (1 mg protein/ml) modified by 0-100 mM glycolaldehyde at 37 °C. LDL modified by 
glycolaldehyde is compared to the LDL plus 50 μM EDTA (0 mM glycolaldehyde) incubation control 
(n=3-4). Data are mean ± SEM from 3 or more experiments with duplicate samples. * Indicates 
glycolaldehyde-modified LDL is significantly different (P < 0.05) from the incubation control and # 
indicates the 1 or 10 mM condition is significantly different (P < 0.05) from the 100 mM condition at that 
time-point, using 2-way ANOVA and Bonferroni post hoc testing. 
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Rapid loss of Trp residues was also observed for the 10 and 100 mM conditions 
after 24 hr of modification time, with values of 30 ± 5 % and 14 ± 1 % respectively, 
with these significantly less (P < 0.05) than the control (Fig. 3.13C). By 7 days there 
was no significant difference (P > 0.05) between the 10 and 100 mM glycolaldehyde 
concentrations with values reaching plateau levels of 16 ± 1 % and 13 ± 1 % 
respectively. The percent Trp residues remaining for the 1 mM condition remained 
higher than the 10 and 100 mM glycolaldehyde conditions after day 1, and was 
significantly different from the control for days 7-14, with 64 ± 9 % Trp residues 
remaining after 14 days of modification.  
Overall Arg residue loss was only significant in 100 mM glycolaldehyde, 
whereas rapid time- and concentration-dependent losses of Lys and Trp residues were 
observed. These modifications, or losses, of Lys and Trp residues were faster than that 
observed for methylglyoxal- and glucose-modified LDL. Methylglyoxal- and 
glycolaldehyde-induced losses of Arg were similar for the 100 mM conditions, but 
faster loss was observed in the 10 mM methylglyoxal condition. Both the methylglyoxal 
and glycolaldehyde changes were faster  than the glucose-induced changes in Arg 
residues, the only the amino acid measured that was affected in the glucose 
experiments. These differences between the modification of LDL by glucose, 
methylglyoxal and glycolaldehyde suggest dissimilar reaction mechanisms or kinetics. 
 
3 .3 .3 .b  Lipid Changes 
 
3 .3 .3 .b . i  Cholesterol and Cholesteryl Esters 
As large changes in the apo B structure, charge and amino acid composition, 
seem to be occurring in glycolaldehyde-modified LDL, concurrent changes could also 
be occurring in the cholesterol and cholesteryl ester components. HPLC analysis was 
performed to determine the cholesterol and cholesteryl ester composition of LDL (1 mg 
protein/ml) modified by 1, 10 and 100 mM glycolaldehyde for up to 7 days at 37 °C, 
and compared to incubation control (LDL plus 50 μM EDTA) and native LDL. Over 
the 7 days of incubation no statistically significant (P > 0.05) losses of free cholesterol 
or cholesteryl esters (cholesteryl docosahexaenoate, cholesteryl arachidonate, 
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cholesteryl linoleate, cholesteryl oleate, cholesteryl palmitate and cholesteryl stearate) 
were found (Table 3.3).  
Only very low levels of the cholesterol oxidation product 7-ketocholesterol were 
detected (Fig. 3.14), equating to < 1.5 nmoles/mg apo B or < 0.1 % of total sterol levels. 
This concurs with the non-significant loss of cholesterol observed. These results suggest 
little or no oxidation or modification was occurring in the cholesterol or cholesteryl 
ester components of glycolaldehyde-modified LDL. 
 
 
 
 Figure 3.14 Levels of 7-ketocholesterol in LDL (1 mg protein/ml) modified by 1-100 mM 
glycolaldehyde at 37 °C for 7 days. LDL modified by glycolaldehyde is compared with native LDL 
(nLDL) and the LDL plus 50 μM EDTA incubation control. Data are mean ± SEM from 6 or more 
experiments. Statistical analysis, by one-way ANVOA, showed no statistical difference between the LDL 
modifications (P > 0.05). 
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(nmoles/mg apo B) nLDL 0 mM 1 mM 10 mM 100 mM 0 mM 1 mM 10 mM 100 mM 
Free chol 688 ± 51 686 ± 125 636 ± 141 593 ± 130 576 ± 82 691 ± 84 669 ± 66 718 ± 50 703 ± 47 
CD 15 ± 2 19 ± 1 16 ± 0 17 ± 1 15 ±01 14 ± 2 14 ± 2 14 ± 2 13 ± 2 
CA 93 ± 9 90 ± 13 99 ± 15 85 ± 18 73 ± 17 100 ± 10 96 ± 11 95 ± 13 74 ± 8 
CL 709 ± 79 837 ± 198 964 ± 258 787 ± 251 684 ± 201 827 ± 116 740 ± 102 709 ± 98 620 ± 81 
CO 243 ± 26 271 ± 47 309 ± 108 260 ± 67 261 ± 61 273 ± 35 216 ± 28 198 ± 28 178 ± 19 
CP 155 ± 20 212 ± 51 187 ± 33 175 ± 38 189 ± 48 190 ± 25 126 ± 20 174 ± 35 134 ± 21 
CS 6 ± 1 9 ± 4 4 ± 4 7 ± 3 7 ± 2 5 ± 2 3 ± 1 4 ± 2 5 ± 2 
Total CE 1222 ± 132 1439 ± 310 1579 ± 418 1332 ± 377 1230 ± 320 1410 ± 185 1195 ± 155 1354 ± 248 1024 ± 122 
Total chol 1910 ± 166 2124 ± 430 2214 ± 559 1925 ± 507 1806 ± 401 2138 ± 257 1864 ± 202 2161 ± 338 1727 ± 152 
CE (% of total chol) 62 ± 2 67 ± 2 71 ± 1 68 ± 1  66 ± 4 65 ± 2  64 ± 2  60 ± 3 58 ± 3  
 
 
Table 3.3 Cholesterol (chol) and cholesteryl ester (CE) composition of LDL (1 mg protein/ml) modified by 0-100 mM glycolaldehyde, for 1 and 7 days, at 37 °C. The 
cholesteryl esters quantified by HPLC, with UV detection at 205 nm, were cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl linoleate (CL), 
cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Data are mean ± SEM from at least 3 experiments. Data is compared to native LDL (nLDL) 
and the LDL plus 50μM EDTA (0 mM glycolaldehyde) incubation control. Statistical analysis by one-way ANOVA, for each parameter, showed no significant differences 
between the different LDL samples (P > 0.05). 
 
  
3 . 3 . 3 . b . i i  Free Radicals 
Glycolaldehyde-induced modification of LDL may occur via free radical 
mechanisms. To this end LDL (1 mg protein/ml) was incubated with 50 μM EDTA or 
100 mM glycolaldehyde for 7 days at 37 °C, before removal of excess EDTA and 
glycolaldehyde by column chromatography, and analysis using EPR spectroscopy in the 
presence of the spin traps PBN or DMPO, as described in Section 2.4.3.  
Detection of free radicals was attempted by incubating the LDL-PBN mixture in 
both PBS and media for 24hr (Fig. 3.15). Spectra A, B and C are from the PBS mixture 
studies with A being the PBS and PBN control, B containing the control LDL, and C 
the glycolaldehyde-modified LDL. There are no differences between these spectra. This 
was again seen for the samples in media (Spectra D, E and F), with D being the PBN 
and media control, E containing the control LDL and F containing the glycolaldehyde-
modified LDL in media. The 4-line signal observed in these samples is known to be due 
to a spin trap degradation product [366].  
Detection of free radicals was also attempted by incubating the LDL-DMPO 
mixture in both PBS and media for 1 hr (Fig. 3.16). Spectra A-D were recorded from 
the PBS studies where A is the 1 hr DMPO and PBS control, B is the 1 hr DMPO and 
incubation-control LDL and D is the glycolaldehyde-modified LDL and 1 hr DMPO 
sample. Spectrum C is the 0 hr glycolaldehyde-modified LDL and DMPO sample. The 
differences between these spectra are slight and the lines in the spectra are building up 
over time. A similar pattern was again seen for the samples in media. Spectrum E was 
recorded from the 1 hr DMPO and incubation control LDL and Spectrum G from the 1 
hr DMPO with glycolaldehyde-modified LDL sample. Again the lines appear in the 
spectra as a function of time as they are not seen in the 0 hr DMPO and glycolaldehyde-
modified LDL sample (Spectrum F). The 4-line spectra detected in the DMPO 
experiments is due to DMPO-OH which can arise from a number of reactions, including 
the addition of hydroxyl radicals to the spin trap, but it can also arise from artifactual 
oxidation of the spin trap [345, 366]. As this signal is maximal in the control samples, 
artifactual reactions are the most likely source of this signal. Due to the lack of observed 
differences between glycolaldehyde-modified LDL and incubation-control LDL, further 
experiments were not attempted. It is concluded that free radical processes do not seem 
play a major role in the modification of LDL by glycolaldehyde. 
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Figure 3.15 EPR spectra of LDL (1 mg protein/ml) incubated with 50 μM EDTA (incubation control) or 
100 mM glycolaldehyde for 7 days, at 37 °C, in PBS. After the incubation period the LDL was subject to 
column chromatography and incubated with 50 mM PBN for 0 or 24 hr in either PBS or complete 
DMEM media with 10 % FCS, before scanning. Spectra A: 24 hr PBS and PBN control; B: 24 hr 
incubation of incubation-control LDL with PBN in PBS; C: 24 hr incubation of glycolaldehyde -modified 
LDL with PBN in PBS; D: 24 hr PBS and media control; E: 24 hr incubation of incubation control LDL 
with PBN in media; and F: 24 hr incubation of glycolaldehyde-modified LDL with PBN in media. Data 
are representative spectra from 1 experiment. 
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Figure 3.16 EPR spectra of LDL (1 mg protein/ml) incubated with 50 μM EDTA (incubation control) or 
100 mM glycolaldehyde for 7 days, at 37 °C, in PBS. After the incubation period the LDL was subject to 
column chromatography and incubated with 50 mM DMPO for 0 or 1 hr in either PBS or complete 
DMEM media with 10 % FCS, before scanning. Spectra A: 1 hr PBS and DMPO control; B: 1 hr 
incubation of incubation-control LDL with DMPO in PBS; C: 0 hr incubation of glycolaldehyde-
modified LDL with DMPO in PBS; D: 1 hr incubation of glycolaldehyde-modified LDL with DMPO in 
PBS; E: 1 hr incubation of incubation-control LDL with DMPO in media; F: 0 hr incubation of 
glycolaldehyde-modified LDL with DMPO in media; and G: 1 hr incubation of glycolaldehyde-modified 
LDL with DMPO in media. Data are representative spectra from 1 experiment. 
 
 
 
 3 .3 .3 . c  Discussion 
Glycolaldehyde caused the most rapid alternations to apo B and, as observed in 
the glucose and methylglyoxal studies this occurred without significant lipid oxidation. 
Most of these results are novel for apo B with a lack of other published data for 
comparison with these results. The REM of LDL was more rapidly affected by 
glycolaldehyde, as compared to glucose- and methylglyoxal-modified LDL. Both 10 
and 100 mM glycolaldehyde caused significant increases in REM after 1 hr of 
incubation. The REM of glycolaldehyde-modified LDL continued to increase until ~ 
day 5 and then the REM started to decrease in the 10 and 100 mM conditions, 
suggesting further modification of amino acid residues after the initial product 
formation. At days 1-7 for 100 mM glycolaldehyde, and days 5-7 for 10 mM 
glycolaldehyde, the REMs of these samples were comparable to acetylated LDL and 
methylglyoxal-modified LDL, suggesting Arg and Lys residue modification.  The 
decrease in REM could arise from further modifications to the Arg and Lys residues 
which render the LDL particles less negative, or the formation of adducts on other 
residues that contribute to an increased positive charge on the LDL molecule. However 
from the parameters measured in this study, a definitive answer is not possible on this 
point and perhaps future experiments should include total amino acid analysis using, for 
example, methanesulfonic acid hydrolysis with 9-fluorenylmethylchloroformate or o-
phthalaldehyde derivatisation [377] or product formation. 
The reaction of 10 and 100 mM glycolaldehyde with LDL also caused rapid 
crosslinking/aggregation. Within 24 hr, LDL modified under these conditions barely 
moved into the gel consistent with major alteration to the particles. Jinnouchi et al 
demonstrated crosslinking of glycolaldehyde-modified LDL with comparable LDL: 
glycolaldehyde ratios [162]. Crosslinking has also been reported in the modification of 
other proteins by glycolaldehyde [213, 357]. These results again indicate considerable 
amino acid residue modification. 
 Reaction of glycolaldehyde with LDL resulted in a faster loss of Lys and Trp 
than in the glucose and methylglyoxal experiments. Arg loss was more rapid than for 
glucose, but comparable to methylglyoxal for the 100 mM condition. LDL modified by 
10 mM glycolaldehyde resulted in little Arg loss, as compared to LDL modified by 10 
mM methylglyoxal. Jinnouchi et al reported a similar loss of Lys residues for 
comparable LDL: glycolaldehyde ratios, but did not examine time periods longer than 3 
days [162]. Modification of BSA by glycolaldehyde results in a more rapid modification 
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 of Lys residues, but a less rapid modification of Arg residues, as compared to 
modification induced by methylglyoxal [224], consistent with the current data. 
Formation of CML has been reported in the reaction of glycolaldehyde with proteins 
[213] and the formation of other AGE products is possible [196, 201, 214], however, 
the formation of such products has not been examined in the current study, though it 
would be advantageous to do so in future studies.  
Lipid analysis of glycolaldehyde-modified LDL showed no significant losses of 
free cholesterol or cholesteryl esters, and no formation of 7-ketocholesterol. 
Collaborative work with Dr. Heather Knott showed no indication of lipid oxidation in 
the absence of 1 μM Cu2+. Other lipid oxidation products, such as cholesteryl ester 
hydro(pero)xides, were not detected and no there was no loss of α-tocopherol [335]. 
However, in the presence of 1 mM glycolaldehyde and 1 μM Cu2+ significant lipid 
peroxidation occurred after 12 days, with loss of α-tocopherol, cholesteryl linoleate, 
cholesteryl arachidonate and concomitant increases in cholesteryl ester 
hydro(per)oxides [335]. From this it was suggested that Cu2+ may act as a catalyst for 
glycolaldehyde-mediated oxidation [335]. However, as the reactions of higher 
concentrations of glycolaldehyde were more rapid than glucose and methylglyoxal, 
addition of Cu2+ was not investigated. No significant generation of protein oxidation 
products was observed over 4 days of incubation in these studies, in the presence or 
absence of Cu2+ [335]. Lack of free radical processes and possible oxidative events, in 
the Cu2+-free glycolaldehyde conditions used in this Chapter, were confirmed by EPR, 
where no significant radical fluxes were observed. Other studies on the modification of 
LDL by glycolaldehyde have not quantified lipid changes/oxidation [162, 163]. 
 The studies reported in Section 3.3.3 showed significant protein modification in 
LDL by glycolaldehyde, without accompanying lipid oxidation/modification using 
glycolaldehyde concentrations of 10-100 mM; these conditions resulted in significant 
changes in charge, LDL particle size and loss of amino acid residues. The changes 
induced by glycolaldehyde, in general, were more rapid and resulted in a greater extent 
of modification. In vivo concentrations of this aldehyde have not been reported, so the 
physiological relevance of these levels cannot be judged. Overall, these studies show 
that the rapid reaction of LDL with glycolaldehyde, in the absence of Cu2+, induces 
glycation reactions rather than oxidation reactions, and results in the covalent 
modification of (at least) Arg, Lys and Trp residues. 
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 3 .3 .4   Conclusions 
In this Chapter, and in collaborative work with Dr. Heather Knott (the amino 
acid analysis), the reaction of glucose (in the presence or absence of Cu2+), 
methylglyoxal and glycolaldehyde with LDL has been examined. Glucose-modified 
LDL exhibited small increases in net negative charge, crosslinking/aggregation and a 
loss of Arg residues, over long incubation times. The addition of Cu2+ to the incubations 
did not significantly affect the rate or extent of these reactions. Reaction of 
methylglyoxal with LDL resulted in more rapid and more marked changes in net 
negative charge, crosslinking/aggreggation, and a significant loss of Arg, Lys and Trp 
residues. When LDL was incubated with glycolaldehyde, significant changes in REM 
were seen at earlier time points, and to a greater extent than with glucose- and 
methylglyoxal-modified LDL. Extensive crosslinking/aggregation was also observed 
and greater loss of Lys and Trp residues than for glucose- and methylglyoxal-modified 
LDL. The only parameter that changed more quickly in the methylglyoxal studies than 
in the glycolaldehyde studies was loss of Arg residues. This concurs with other 
published work that demonstrates Arg residues are a preferred target for methylglyoxal 
[167, 210, 373]. These changes to the apo B protein of LDL induced by glucose, 
methylglyoxal and glycolaldehyde occurred without accompanying lipid peroxidation. 
The LDL incubated with EDTA alone showed small changes in REM and aggregation 
and no detectable lipid oxidation, and was therefore a suitable minimally 
modified/oxidised incubation control. 
The studies reported in this Chapter have shown that it is possible to generate 
well-characterised LDL that has significant covalent modification or glycation, in the 
absence of (glyc)oxidation in vitro. These studies also suggest that metal ion-
independent glycation is an early event which occurs, under the conditions employed, 
before significant glycoxidation or protein/lipid oxidation; the latter only occur to a 
significant extent at longer modification times. These studies also indicate that the 
reaction of reactive low-molecular mass aldehydes with protein may be more important 
for the formation of AGE-modified proteins in disease states, than glucose. This well-
characterised glycated LDL can be used for further cell studies, to determine what effect 
glycation, as opposed to oxidation, has on the metabolism of LDL. Most previous 
studies have used, unfortunately, poorly characterised LDL for such studies. 
The accumulation of modified proteins has been implicated in aging and many 
diseases such as diabetes and atherosclerosis (reviewed in [177, 231, 233, 234, 239, 
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 257, 378]. Previous work has shown that the handling of oxidised proteins by cells can 
be impaired [236-238] and thus intracellular accumulation is possible. Intracellular 
accumulation of oxidised LDL has also been demonstrated in macrophages [152, 379, 
380]. The modifications of glycated LDL observed in this current study; increases in net 
negative charge, aggregation, and Arg and Lys modification, increase the likelihood that 
these modified lipoproteins will be recognised by macrophage scavenger receptors [43, 
145]. A family of scavenger receptors has also been described that recognise AGE-
modified  proteins (see Section 1.3.3.e) [134]. These macrophage scavenger receptors 
can take up modified LDL leading to the classic hallmark of atherosclerosis, cholesteryl 
ester laden foam cells [127]. In the following Chapter the well-defined glycated LDL 
characterised in this Chapter is used to investigate macrophage cholesteryl ester 
accumulation from these glycated, but minimally oxidised, LDLs. 
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4 CHAPTER 4: CELLULAR CHOLESTEROL AND 
CHOLESTERYL ESTER ACCUMULATION FROM LOW-
DENSITY LIPOPROTEINS MODIFIED BY GLUCOSE, 
METHYLGLYOXAL AND GLYCOLALDEHYDE IN J774A.1 
MOUSE MACROPHAGES 
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 4.1  Introduction     
The previous Chapter showed that modification of LDL occurred on exposure to 
glycation agents with the following general order of reactivity: glycolaldehyde > 
methylglyoxal > glucose. In this Chapter the effect of these glycated LDLs on 
macrophages is investigated. Macrophages have been postulated to play an important 
role in atherogenesis. In the development of atherosclerosis, the generation of fatty 
streaks is one the earliest events [22]. These fatty streaks are composed of foam cells 
[22], named thus because of their “ foamy” appearance [49, 50]. The progenitor of these 
cells are monocytes, which undergo transformation into macrophage foam cells in the 
arterial intima [22]. Macrophage foam cells are characterised by the accumulation of 
intracellular cholesterol and cholesteryl esters in lysosomal compartments, and 
cytoplasmic droplets primarily comprised of cholesteryl esters [51]. However, 
macrophage cells incubated with high levels of LDL in vitro fail to accumulate 
cholesterol. Goldstein et al demonstrated that macrophage cells will only become 
engorged with cholesteryl esters if the LDL is modified, such as by acetylation [127]. 
This unregulated cholesteryl ester accumulation did not occur via the normal LDL 
receptor and thus the existence of macrophage scavenger receptors was proposed [144].  
It now has been demonstrated that other modifications of LDL can also lead to 
macrophage scavenger receptor recognition and foam cell formation, characterised by 
large increases in intracellular cholesteryl esters. These LDL modifications include 
covalent modification (e.g. by 4-hydroxynonenal [151], or malondialdehyde [146, 
152]), oxidation [147, 153-155], aggregation [156, 157], complex formation (e.g. 
dextran sulphate) [159], and those processes leading to increased net negative charge of 
the LDL particles, such as succinylation or maleylation [144, 146]. Macrophages 
stimulated by LDL immune complexes will also accumulate cholesteryl esters [161]. It 
has been shown that macrophage scavenger receptors can recognise AGE-modified 
proteins [134] and glycated or glycoxidised LDL (see Section 1.3.3.e) [162-167]. Thus 
the hyperglycaemic state of people with diabetes, and potential LDL modification, may 
explain the increased incidence of atherosclerosis in these people, due to unregulated 
uptake of glycated/glycoxidised LDL.  
A number of groups have previously studied the effect of glucose-modified LDL 
on macrophages. Lopes-Virella et al showed that incubating LDL with glucose, in the 
absence of metal ions, can lead to increased cholesteryl ester synthesis and 
 108
 accumulation in macrophages [165]. Another group, using microscopic techniques, 
showed macrophage-mediated uptake of glycated LDL oxidised by iron [267]. Glucose-
modified LDL, in the presence of Cu2+, has also been reported to affect macrophage 
function, specifically DNA synthesis [269]. However in these studies direct 
quantification of cellular cholesterol and cholesteryl esters was not examined and the 
modifications induced on the LDL were not well quantified or characterised [165].  
Few studies have examined the effects of methylglyoxal- or glycolaldehyde-
modified LDL exposure on macrophages. Schalkwijk and colleagues reported that 
whilst methylglyoxal-modified LDL was recognised by macrophage scavenger 
receptors it did not lead to increased cholesteryl ester synthesis in murine macrophages 
[167]. Nagai et al demonstrated that glycolaldehyde-modified BSA is recognised by 
macrophage scavenger receptors [224], and two other studies have also shown that 
glycolaldehyde-modified LDL is recognised by macrophage scavenger receptors [162, 
163]. Again, in these studies direct quantification of cellular cholesterol and cholesteryl 
esters was not performed and the LDL used was not comprehensively characterised. 
However there have also been reports on the toxicity of glucose, methylglyoxal 
and glycolaldehyde. Methylglyoxal and glucose have been shown to induce apoptotic 
cell death in cell lines [95, 381, 382]. Dietary exposure to methylglyoxal can cause toxic 
effects in mice, such as the depletion of blood glutathione (GSH) [383]. Toxic effects 
are also apparent in Escherichia coli exposed to glycolaldehyde [384]. Decreased 
enzyme activity is observed in vitro systems when enzymes are exposed to 
methylglyoxal or glycolaldehyde [357]. Therefore in the studies reported here the 
effects of the concentrations of EDTA, glucose, methylglyoxal and glycolaldehyde used 
in the LDL modification procedures, on macrophage cells have been examined first, 
before exposing them to the modified LDLs.  
J774A.1 murine macrophage-like cells would appear to be a suitable cell line to 
examine potential cholesteryl ester accumulation from glycated LDLs, as they have 
been extensively used in LDL metabolism studies [154, 385-394]. J774 macrophages 
have the following macrophage-like characteristics; storage of cholesteryl esters in oil 
red O-positive droplets; adherence to plastic; phagocytosis of latex particles and 
antibody-coated sheep erythrocytes; positive staining for peroxidase and non-specific 
esterase; and contain β-glucuronidase and acid phosphatase [32]. J77A.1 cells have 
been reported to process acetylated LDL in an analogous fashion to other foam cell 
models, such as murine peritoneal macrophages and HMDM, even though there are 
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 individual cell type differences in the metabolism of acetylated LDL [395]. Cholesteryl 
esters in J774 cells also undergo continual hydrolysis as result of nCEH, and re-
esterification due to ACAT activity [395, 396], as in mouse peritoneal macrophages 
[129]. J774A.1 cells are useful when large cell numbers are needed, as in the following 
studies when a variety of conditions are examined. Obtaining large cell numbers can 
problematic with primary cell cultures, such as in mouse peritoneal macrophages and 
HMDM. 
Since previous studies examining foam cell formation have used poorly 
characterised glycated/glycoxidised LDL, or have only indirectly measured cellular 
cholesterol and cholesteryl ester levels, there is a need for the quantitative determination 
of cholesterol and cholesteryl ester levels in potential foam cells, formed from the 
possible uptake of glycated or glycoxidised LDL. This has been examined in the current 
study. 
 
4.2  Aims 
The aims of the experiments reported in this Chapter are to firstly examine the 
cytotoxicity of glucose, methylglyoxal and glycolaldehyde; and secondly to establish 
suitable conditions for model foam cell formation using acetylated LDL, in the murine 
macrophage-like cell line J774A.1. The third aim, using the established foam cell model 
system, is to examine the effects of the well-characterised glucose-, methylglyoxal- or 
glycolaldehyde-modified LDL, generated as described in Chapter 3, on J774A.1 
macrophages. In particular, J774A.1 cell viability, proliferation and levels of free 
cholesterol and cholesteryl esters are examined. 
 
4.3  Results 
 
4 .3 .1  The Cytotoxicity of EDTA, Glucose, Methylglyoxal and Glycolaldehyde on 
J774A.1 Macrophages 
This Chapter explores the effect of glucose-, methylglyoxal- and 
glycolaldehyde-modified LDL on J774A.1 cells using the LDL preparations described 
in Chapter 3. Cytotoxicity studies are necessary, as there have been reports of 
deleterious effects in regards to these aldehydes. Previous studies have employed LDL 
concentrations of 25-250 μg protein/ml LDL to examine foam cell formation [127, 154, 
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 165, 353]. It therefore was decided to use LDL (control and modified) in the 
concentration range of 50-200 μg protein/ml LDL to examine potential model foam cell 
formation. Thus LDL, at 1 mg protein/ml (with its modifying agents EDTA, glucose, 
Cu2+, methylglyoxal or glycolaldehyde) would need to be diluted 5-20 fold to achieve 
these concentrations. Dilutions of 4-fold and 16-fold of EDTA or glucose, in the 
presence or absence of Cu2+, in the LDL incubations were then used to determine any 
potential cytotoxic effects on J774A.1 cells. That is, 3.15 and 12.5 μM EDTA (50 μM 
EDTA used in LDL incubations) and 6.25 and 25 mM glucose (100 mM glucose used 
in LDL modifications).  
Before exposure to EDTA or glucose, J774A.1 macrophage cells were plated 
down at 5 x 105 cells/well in 12 well plates overnight, in complete DMEM with 10 % 
FCS (see Section 2.5.1). After this, cells were washed and exposed to EDTA or glucose, 
in the presence or absence of Cu2+, for 24 hr. After 24 hr, cell media samples were 
removed and stored on ice, the cells were washed again and 1 ml of water subsequently 
added for 20 min, on a rocking platform at 4 °C, for hypotonic lysis of the cells. After 
this the cell wells were scraped with a 1 ml syringe plunger and cell lysates transferred 
to tubes and stored on ice before assays were performed. The lysis with water was 
chosen for its simplicity and lack of effect on LDH activity [357] and the BCA protein 
assay [354]. Furthermore water would also not in interfere in later HPLC analyses, 
where detergent-based systems might. LDH activity in the media and cell lysates was 
determined by the loss of absorbance at 340 nm as the cofactor NADH is reduced to 
NAD+, in the conversion of pyruvate to lactate by LDH. As cell viability decreases, 
LDH is released into the media and thus percent cell viability can be calculated by 
comparing the activity of LDH in the media to total activity intracellularly and 
extracellularly (see Section 2.6.1.b). Cell protein, which is dependent on cell number, 
was determined using the BCA assay, as outlined in Section 2.3.3. 
EDTA (up to 12.5 μM), or glucose (up to 25 mM, in the presence or absence of 
0-0.25 μM Cu2+), did not result in significant changes in cell viability (Fig. 4.1A and 
Fig. 4.2A) or protein (Fig. 4.1B and Fig. 4.2B). As these concentrations are in the range 
to which the cells would be exposed to with the diluted, modified, LDL, and no effect 
on cell viability or protein was detected, further investigations were not carried out. 
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Figure 4.1 The effect of EDTA on J774A.1 macrophage viability (Panel A) and protein (Panel B). EDTA 
concentrations were determined by the 4- and 16-fold dilutions of the 50 μM EDTA used in LDL 
incubations. Cells were exposed to EDTA, for 24 hr, except for the control cells, before cell lysis. Cell 
viability was determined by the LDH assay, and cell protein by the BCA assay. Data are mean ± SD from 
a single experiment with triplicate samples. 
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Figure 4.2 The effect of glucose, in the presence or absence of Cu2+, on J774A.1 macrophage viability 
(Panel A) and protein (Panel B). The glucose and Cu2+ concentrations used were 4-and 16-fold dilutions 
of 100 mM glucose, or 1 μM Cu2+, used in LDL modifications. Cells were exposed to the stated 
concentrations of glucose ± Cu2+, for 24 hr, before cell lysis. Control cells were exposed to media alone. 
Cell viability was determined by the LDH assay, and cell protein by the BCA assay. Data are mean ± SD 
from a single experiment with triplicate samples. 
 
 
Next the effects of the more reactive aldehydes, methylglyoxal and 
glycolaldehyde, were investigated on J774A.1 macrophage viability and protein. 
Exposure of J774A.1 cells to concentrations of methylglyoxal and glycolaldehyde of 1 
mM or greater, for 24 hr resulted in loss of cell viability (Fig. 4.3A) and protein (Fig. 
4.3B). The lack of clear, concentration-dependent decreases in viability and protein at 
concentrations of 1 mM or greater may be due to the aldehydes themselves affecting the 
LDH enzyme activity [357] or interference with the BCA assay [354]. The 
concentrations of aldehyde used routinely in the LDL modification were 1-100 mM, and 
even diluted, the apparent cytotoxicity of the aldehydes at these concentrations are a 
problem, as well as the possible interferences on the protein and viability assays. Due to 
the effects of these compounds, they need to be removed before the modified LDL is 
added to the J774A.1 cells in the foam cell studies. A suitable way of removing these 
aldehydes from the LDL might be to use column chromatography. 
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Figure 4.3 The effect of methylglyoxal and glycolaldehyde on J774A.1 macrophage viability (Panel A) 
and protein (Panel B). Cells were exposed to the stated concentrations of methylglyoxal or 
glycolaldehyde for 24 hr, before cell lysis. Cell viability was determined by the LDH assay, and cell 
protein by the BCA assay. Data are mean ± SD from a single experiment with triplicate samples. 
 
4 .3 .1 .a  Loss of Protein from Column Chromatography of Modified Low-Density 
Lipoproteins 
Column chromatography is a way of separating low molecular mass molecules, 
such as methylglyoxal, from high molecular mass molecules, such as protein [354, 357]. 
As reactive aldehydes have been reported to interfere with LDH activity [357], the BCA 
assay [354] and affect J774A.1 cell viability and protein, at the concentrations used 
(Section 4.3.1), it would beneficial if we could remove the excess aldehydes before the 
glycated/glycoxidised LDL is added to the cells. However, in the preceding Chapter it 
was shown how high molecular mass crosslinks or aggregates are formed in the 
incubation of LDL with glucose, methylglyoxal or glycolaldehyde (Sections 3.3.1.a.ii, 
3.3.2.a.ii and 3.3.3.a.ii), and these may be too large to pass through the columns. 
Therefore the potential loss of protein during column chromatography was examined. 
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 LDL incubations were carried out, as described in the previous Chapter. That is, 
LDL (1 mg protein/ml) was incubated with 100 mM glucose, in the presence or absence 
of 1 μM Cu2+ for up to 2 weeks; or 10 or 100 mM methylglyoxal for 1 and 5 days; or 1, 
10 or 100 mM glycolaldehyde for 1 and 7 days, at 37 °C, in PBS. Appropriate 
incubation controls (LDL with 50 μM EDTA) were also included. After the applicable 
incubation times an aliquot of modified LDL was removed and the remainder was 
loaded onto prewashed PD10 columns and eluted with chelexed PBS. From the time of 
loading of the modified LDL onto the PD10 columns, 1 ml elution fractions were 
collected and retained. The Bio-Rad assay (as described in Section 2.6.1.a), which is 
known to not be affected by glucose or aldehydes [354], unlike the BCA assay, was 
used to determine protein concentrations of the modified LDL before being passed 
through the PD10 columns and then in each of the elution fractions. The total protein 
content in the eluted PD10 fractions (the majority of the protein was in fraction 4 and 
minor amounts in fraction 3 and 5) was compared to the pre-PD10 column value.  
Firstly, the potential loss of protein from glucose-modified LDL and control 
samples after column chromatography was examined. The LDL plus EDTA incubation 
(Fig. 4.4A) controls seem to lose less protein after column chromatography, when 
compared to the glucose-modified LDL (Fig. 4.4B), especially with incubation times of 
greater than 2 weeks. However, for the 2 week incubation samples the post PD10 
chromatography values for the incubation control and the glucose-modified LDL 
protein values were comparable (1.2 ± 0.1 and 1.0 ± 0.1 mg protein/ml respectively). 
The inclusion of Cu2+ in the modification of LDL by glucose trended towards increased 
loss of LDL protein, but the changes observed were within experimental variation. The 
pre-PD10 values were 0.9 ± 0.2 mg protein/ml for both samples, and after column 
chromatography whereas for the values were 1.0 ± 0.1 and 0.7 ± 0.1 mg protein/ml for 
control LDL and glucose plus Cu2+- modified LDL respectively.  
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Figure 4.4 Protein concentration of glucose-modified LDL before and after column chromatography. 
Panel A: LDL (1 mg protein/ml) with 50 μM EDTA and Panel B: LDL modified by 100 mM glucose 
over 8 weeks at 37 °C, PBS, before and after column chromatography. Panel C: comparison of LDL 
modified by 100 mM glucose in the presence of 1 μM Cu2+, to LDL incubated with 50 μM EDTA, for 2 
weeks at 37 °C, before and after column chromatography. LDL protein concentrations were determined 
using the Bio-Rad assay. Data are mean ± SD from a single experiment with triplicate samples. 
 
Column chromatography of methylglyoxal- and glycolaldehyde-modified LDL 
resulted in small, consistent losses of protein. Column chromatography of LDL 
modified with methylglyoxal for 24 hr (Fig. 4.5A) or 5 days (Fig. 4.5B) did not result in 
a large loss of protein. Loss of protein was also observed after column chromatography 
of LDL modified by glycolaldehyde for 24 hr (Fig. 4.6A) or 7 days (Fig. 4.6B). These 
losses were slightly higher than what was observed in the methylglyoxal and glucose 
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 experiments, but comparable to the glucose plus Cu2+ incubations, and did not follow a 
particular trend with glycolaldehyde concentration.  
Overall there is a small loss of LDL protein after PD10 column chromatography, 
but this was reasonably consistent across the different LDL modifications and 
incubation times. Therefore it appears that excess glucose, methylglyoxal and 
glycolaldehyde from the LDL incubations could be removed simply and rapidly by 
column chromatography, before addition of LDL to cells, thereby preventing associated 
cellular cytotoxicity and assay interference by methylglyoxal and glycolaldehyde. 
 
 
0.0
0.5
1.0
1.5
0 10 100
Before column chromatography
After column chromatography
0.0
0.5
1.0
1.5
0 10 100
Before column chromatography
After column chromatography
LD
L 
(m
g 
pr
ot
ei
n/
m
l) 
LD
L 
(m
g 
pr
ot
ei
n/
m
l) 
B 
A 
Methylglyoxal (mM) 
Figure 4.5 Protein concentration of LDL (1 mg protein/ml) modified by 10 and 100 mM methylglyoxal 
for 24 hr (Panel A), or 5 days (Panel B), before and after column chromatography. Methylglyoxal-
modified LDL concentrations are compared to the LDL plus 50 μM EDTA incubation control (0 mM 
methylglyoxal). LDL protein concentrations were determined by the Bio-Rad assay. Data are mean ± SD 
from a single experiment with triplicate samples. 
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 Figure 4.6 Protein concentration of LDL (1 mg protein/ml) modified by 1, 10 and 100 mM 
glycolaldehyde for 24 hr (Panel A) or 7 days (Panel B), before and after column chromatography. 
Glycolaldehyde-modified LDL concentrations are compared to the LDL plus 50 μM EDTA incubation 
control (0 mM glycolaldehyde). LDL protein concentrations were determined by the Bio-Rad assay. Data 
are mean ± SD from a single experiment with triplicate samples. 
 
4 .3 .1 .b  Discussion 
EDTA and glucose (in the presence or absence of Cu2+) did not significantly 
affect cell viability or protein. Other groups have used EDTA, for example to prevent 
cell-mediated LDL oxidation, at similar or higher concentrations than used in these 
studies, with no reported side effects [45, 362, 397, 398]. J774A.1 cells were exposed to 
glucose concentrations within pathophysiological ranges (25 mM) and thus perhaps it is 
not unexpected that there was no overt cell death within the 24 hr of exposure. Glucose 
has been shown to induce apoptotic cell death, but this was in vascular smooth muscle 
cells exposed to up to 25 mM glucose for 3 days [95]. High glucose may also promote 
foam cell formation. This may be through increases in scavenger receptor levels that 
may promote atherogenesis, for example increased CD36 [143], or LOX-1 expression 
[142]. High glucose levels have also been reported to lead to increased cholesteryl ester 
synthesis in THP-1 macrophages, during exposure to native or modified LDL [399], and 
in J774.2 macrophages lead to increased acetylated LDL uptake [400]. Thus removal of 
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 glucose before exposure of cells to the modified LDL may be advantageous, to ensure 
the effects observed are due solely to the glycated LDL. The concentrations of Cu2+ 
used in the modification of LDL by glucose, and subsequent dilution in macrophage 
exposure, was not significant enough to affect cell viability or protein. Ham’s F10 
medium contains 3 μM iron and 0.01 μM Cu2+ and has been used in macrophage-
mediated LDL oxidation studies with no reported side effects on the macrophages [102, 
349, 362, 401]. Heinecke et al used up to 10 μM Cu2+ to enhance smooth muscle cell 
mediated LDL-oxidation, and also did not report cytotoxicity [45]. 
Exposure of J774A.1 cells to methylglyoxal and glycolaldehyde led to losses in 
cell viability and protein. This is an agreement with other work reporting cytotoxic 
effects of these aldehydes in enzyme [357], cell [93, 94, 381, 384] or animal [383] 
systems. Aldehydes can also interfere with LDH activity [357] and the BCA assay 
[354]. Thus the excess aldehydes need to be removed from the LDL samples before 
addition to the cells to ensure that the effects of the glycated LDLs are being examined 
and not the effect of unreacted aldehydes on J774A.1 macrophages. 
 The column chromatography treatment of the glycated LDLs did result in small 
losses of LDL protein, nonetheless these were consistent for different modifications of 
LDL over different times, even though significant aggregation was observed in the 
methylglyoxal- and glycolaldehyde-modified LDL in Chapter 3. However longer 
incubation times, such as the 6-8 weeks for glucose-modified LDL, did result in greater 
losses of protein from column chromatography and it is hypothesised that this may be a 
greater problem if the aldehyde incubations were for longer. Therefore, for consistency 
LDL modified by EDTA, glucose (in the presence or absence of Cu2+), methylglyoxal 
or glycolaldehyde were all subjected to column chromatography before addition to 
J774A.1 cells. In the next set of studies the optimal LDL concentrations that induce 
foam cell formation in J774A.1 cells was determined, to resolve the concentrations of 
glycated LDLs (after column chromatography) that the macrophages would be exposed 
to. 
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 4 .3 .2  Quantification of Cholesterol and Cholesteryl Esters in J774A.1 
Macrophages after Exposure to Low-Density Lipoproteins Modified by 
Acetylation 
The studies described in the previous Section demonstrated that before exposing 
the cells to the glycated LDL the excess glucose and aldehydes need to be removed and 
a method using column chromatography was developed. The following experiments 
were designed to examine what concentrations of modified LDL are required to give 
rise to cholesterol and cholesteryl ester accumulation in J774A.1 cells. Of particular 
interest were the concentrations and types of modification required to give comparable 
cholesterol and cholesteryl ester levels to those found in atherosclerotic foam cells. 
Acetylated LDL, prepared using sodium acetate and acetic anhydride (as described in 
Section 2.3.2.a), is known to cause unregulated cellular accumulation of cholesterol and 
cholesteryl esters via uptake by macrophage scavenger receptors [127, 154, 402]. As the 
acetylation of LDL is easily accomplished it has become a useful standard for 
comparsion with other modifications of LDL, such as Cu2+-induced oxidation [154, 
155]. Previous studies have used macrophages cells exposed to acetylated LDL at 25-
250 μg protein/ml LDL for 24 hr to give rise to foam cells so similar levels were 
employed here [127, 154, 165, 353]. 
J774A.1 macrophage cells were plated down at 5 x 105 cells/well in 12 well 
plates overnight, in complete DMEM with 10 % FCS (see Section 2.5.1). The cells were 
then washed and exposed to acetylated LDL at 0-200 μg protein/ml media for 24 hr, in 
media containing 10 % LPDS. After 24 hr of cellular exposure to acetylated LDL, cells 
were then exposed to equilibrium media for 2 hr containing 1 mg/ml BSA rather than 
serum. This exposure to LDL-free media was designed to allow equilibration of 
cholesterol and cholesteryl esters between their subcellular pools [129, 130, 338], and 
thus reduce experimental variation in quantification of cellular cholesterol and 
cholesteryl esters. After 2 hr, cell media samples were removed, and stored on ice, and 
the cells washed again. 1 ml of water was then added for 20 min, on a rocking platform, 
at 4 °C, to induce hypotonic lysis of the cells. After this, the cell wells were scraped 
with a 1 ml syringe plunger and cell lysates transferred to tubes and stored on ice before 
the assays were performed.  
Of the cell lysates, 200 μl was used for the LDH and BCA assays and 800 μl of 
the lysates were extracted with methanol/hexane. The hexane (lipid-containing) layer 
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 was subsequently removed and evaporated to dryness, redissolved in appropriate mobile 
phase and transferred to HPLC vials for the determination of cellular cholesterol and 
cholesteryl esters, using the system as described in Sections 2.4.2.a.i. and 2.6.2. HPLC 
peaks from the cholesterol and cholesteryl esters were converted to nmoles lipid using 
the response factors in Table 2.1 and then corrected to give nmoles lipid/mg cell 
protein. Total cholesteryl esters were determined from the sum of free cholesterol plus 
cholesteryl esters, and the percent cholesteryl esters calculated from the amount of total 
cholesteryl esters compared to total sterol levels. 
 Exposure of J774A.1 macrophages to acetylated LDL did not result in any 
changes in cellular viability or protein. Cell viability values, for cells exposed to 
acetylated LDL at concentrations from 25 to 200 μg LDL protein/ml media, were not 
significantly different (P > 0.05) from the control cells value of 86 ± 1 % (Fig. 4.7). 
J774A.1 macrophages treated with acetylated LDL also did not have significantly 
different (P > 0.05) protein values, per tissue culture well, from the control values of 
167 ± 9 μg (Fig. 4.8).  
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Figure 4.7 J774A.1 cell viability after 24 hr exposure to acetylated LDL. Cells were exposed to 
acetylated LDL, for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before cell 
lysis and cell viability were determined by the LDH assay. Data are mean ± SEM from 11 or more 
experiments with triplicate samples. Statistical analysis, by 1-way ANOVA, showed that acetylated LDL 
had no effect on J774A.1 viability (P > 0.05). 
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Figure 4.8 J774A.1 cell protein (per well) after 24 hr exposure to acetylated LDL. Cells were exposed to 
the acetylated LDL, for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before 
cell lysis and cell protein were determined by the BCA assay. Data are mean ± SEM from 17 or more 
experiments with triplicate samples. Statistical analysis, using 1-way ANOVA, showed that the acetylated 
LDL had no significant effect on J774A.1 protein levels (P > 0.05). 
 
With these same concentrations of acetylated LDL, significant and 
concentration-dependent increases were seen in cellular levels of free cholesterol and 
cholesteryl esters (Fig. 4.9). Control values for free cholesterol were 50 ± 4 nmoles/mg 
cell protein, with this value increased significantly (P < 0.05) to 91 ± 6 nmoles/mg cell 
protein for cells exposed to 200 μg LDL protein/ml media (Fig. 4.9A). A significant 
increase in free cholesterol was not observed until ≥ 50 μg modified-LDL protein/ml 
media was employed, with levels of free cholesterol of 75 ± 4 nmoles/mg cell protein. 
In control cells no cholesteryl esters were detected, however in cells exposed to 
acetylated LDL at 50 μg protein/ml media these levels were significantly (P < 0.05) 
increased at 17 ± 3 nmoles/mg cell protein. In cells exposed to 200 μg protein/ml media 
these values reached 48 ± 8 nmoles/mg cell protein (Fig. 4.9B).  
A similar pattern was observed in the percentage of cholesteryl esters (of total 
sterol levels). For this parameter statistical significance (P < 0.05) was reached in cells 
exposed to acetylated LDL at 25 μg protein/ml media, with a value of 13 ± 3%, and this 
increased to 34 ± 3 % in cells exposed to the highest concentration of acetylated LDL 
(Fig. 4.9C).  
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Figure 4.9 Free cholesterol (Panel A), total cholesteryl ester (CE) (Panel B) and percent CE (of total 
sterol; Panel C) levels detected in J774A.1 cells, after exposure to acetylated LDL. Cells were exposed to 
the acetylated LDL, for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before 
cell lysis and lipid extraction. Cellular cholesterol and CE levels were determined by HPLC. Total 
cholesterol is the sum of individual CE and free cholesterol.  Data are mean ± SEM from 9 or more 
experiments with triplicate samples. Columns with different superscripts above them are statistically 
different (P < 0.05), by 1-way ANOVA using Tukey’s post hoc testing. 
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 Table 4.1 summarises the individual esters that were detected. Cholesteryl 
docosahexaenoate levels were not significantly increased (P > 0.05) from the control 
cell values. However, all the other esters showed concentration-dependent increases. 
The most abundant esters, when examining the 200 μg protein/ml media condition for 
acetylated LDL, were cholesteryl linoleate and cholesteryl oleate at ~ 16 nmoles/mg cell 
protein.  
Overall, it is concluded that J7741A.1 macrophages exposed to acetylated LDL 
concentrations ranging from 50-200 μg protein/ml media accumulate significantly 
elevated levels of cholesterol and cholesteryl ester, with no loss of cell viability or 
protein. At the highest concentration of acetylated LDL the macrophages contained 
percent cholesteryl ester levels similar to those observed in other model foam cell 
studies [152]. Therefore, it was concluded that this system could be used to determine if 
exposure of J774A.1 cells to glycated LDLs induced foam cell formation. 
 
 
 
   AcLDL (μg protein/ml media)  
Ester 0 25 50 100 200 (%) 
CD 0.00 ± 0.00a 0.40 ± 0.15a 0.61 ± 0.34a 1.15 ± 0.74a 0.92 ± 0.24 (2)a
CA 0.00 ± 0.00a 0.73 ± 0.30abc 0.76 ± 0.13b 1.40 ± 0.22c 2.82 ± 0.52 (7)d
CL 0.00 ± 0.00a 2.47 ± 0.90ab 4.66 ± 0.71b 8.04 ± 1.19b 15.67 ± 2.36 (34)c
CO 0.00 ± 0.00a 4.99 ± 1.69ab 6.96 ± 1.05b 10.98 ± 1.55bc  16.31 ± 3.05 (35)c
CP 0.00 ± 0.00a 2.14 ± 0.37ab 3.49 ± 0.64b 4.88 ± 0.93b 8.59 ± 1.69 (20)c
CS 0.00 ± 0.00a 0.15 ± 0.00ab 0.33 ± 0.10ab 0.47 ± 0.13b 0.75 ± 0.27 (2)b
 
Table 4.1 Levels of individual cholesteryl esters (nmoles/mg cell protein) in J774A.1 cells after exposure 
to acetylated LDL (AcLDL) at 0-200 μg LDL protein/ml media. Cells were exposed to the modified LDL 
for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before cell lysis, lipid 
extraction and then determination of cellular cholesterol and cholesteryl esters levels by HPLC. The 
esters examined were cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl 
linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Data are 
mean ± SEM from 9 or more experiments with triplicate samples. Numbers in brackets besides the 200 
μg LDL protein/ml media condition are the cholesteryl ester values as a percentage of total cholesteryl 
esters. Numbers with different superscripts are statistically different (P < 0.05), by 1-way ANOVA using 
Tukey’s post hoc testing. 
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 4 .3 .2 .a   Discussion 
Exposure of macrophages to acetylated LDL is a well known technique to induce 
foam cell formation, characterised by cellular cholesterol and cholesteryl ester 
accumulation, in both human and mouse macrophages, using either primary cells or cell 
lines [127, 154, 155, 166, 385, 388, 389, 395, 403]. In this Section it has been 
confirmed that J774A.1 cells accumulate intracellular cholesterol and cholesteryl esters 
when exposed to acetylated LDL (≥ 50 μg protein/ml media), without significant loss of 
cell viability or cell numbers. The free cholesterol levels (50-91 nmoles/mg cell protein) 
detected in these studies are in the range of other published work for J774A.1 cells. Free 
cholesterol levels for J774A.1 cells not exposed to LDL have been reported to be in the 
ranges of 30-93 nmoles/mg cell protein [154, 385, 388, 389, 394]. After exposure to 
acetylated LDL (50-100 μg protein/ml), free cholesterol levels have been reported in the 
ranges of 56-180 nmoles/mg cell protein [154, 385, 388, 389, 394].  
The cholesteryl ester values detected in this study are also within the range of 
other reported work. Levels of esterified cholesterol in the current studies ranged from 0 
for unloaded cells to 48 nmoles/mg cell protein for cells exposed to acetylated LDL.  
Cholesteryl esters, in J77A.1 macrophages after exposure to acetylated LDL have been 
reported to be in the range of 20-200 nmoles/mg cell protein, with minimal levels 
reported in unloaded cells [154, 385, 388, 389, 393, 394]. Cholesteryl esters levels as 
percentage of total sterol levels have been reported from 40-55 % [154, 385, 388, 394], 
and the value of ≤ 34 % detected here is comparable. The pattern of individual 
cholesteryl ester composition of the J774A.1 cells is also similar to previously reported 
work, with cholesteryl linoleate the most abundant ester, then cholesteryl oleate the next 
most abundant ester. The ester that is present at the third highest concentrations is 
cholesteryl palmitate, and the fourth, cholesteryl arachidonate. Other esters have been 
reported at low levels [154, 385, 386, 388]. 
Thus the values of free cholesterol and cholesteryl esters detected in this study are 
in agreement with previously published reports on J774A.1 foam cell models. The 
values of free cholesterol and cholesteryl esters are at the lower end of the range for 
previously published work and have lower cholesterol levels as a percentage of total 
sterol levels, compared to other published work. Variation from published results may 
arise from differences in the extent of modification during the LDL acetylation, with 
only some of the reported studies [154, 389] giving any indication of the degree of 
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 modification of the acetylated LDL. The study by Brown et al reported a similar REM 
of the acetylated LDL and similar cholesterol and cholesteryl esters values [154].  
Others differences may arise from the use of other cholesterol and cholesteryl ester 
detection methods, cell media and LDL exposure times. Another possible reason, for the 
differences amongst the studies, even with the use of acetylated LDL and the same cell 
line, is that the cell lines from the various groups have undergone different mutations or 
selective events [396]. Thus Khoo et al have reported variations in the susceptibilities of 
J774 cells, obtained from different groups, to form foam cells [396]. They named one 
J774 line “J774A.2” due to its increased ability to intracellularly esterify cholesterol 
from native LDL and achieve a 49-fold increase in cholesteryl esters (55 % of total 
cholesterol levels), compared to the J774A.1 cell line that had a 13-fold increase in 
cholesteryl ester levels (20 % of total cholesterol). Taba et al have reported that J774 
macrophages can accumulate large amounts of cholesteryl esters when incubated with 
unmodified LDL [32]. The study with the highest reported levels of cellular free 
cholesterol and cholesteryl esters after acetylated LDL exposure did in fact have the 
high rates of esterification of native LDL (22 % cholesteryl ester levels of total 
cholesteryl levels) [388]. An alternative explanation for the increased cholesteryl 
accumulation in J774 cells from unmodified LDL in these studies is that the LDL is not 
really ‘unmodified’, however due to a lack of LDL characterisation data this cannot be 
determined.  
In the following Sections potential foam cell formation from glycated LDLs is 
examined, using concentrations of LDL from 50-200 μg protein/ml, with the data from 
the modified LDL compared with well-characterised, minimally modified/oxidised, 
control LDL (LDL plus EDTA, as in Chapter 3). This comparison will ensure that any 
observed increased in cellular cholesterol esterification is due to the presence of 
glycated LDL and not just the LDL alone. Acetylated LDL was also employed as a 
positive control in these experiments, though the data from this material is omitted for 
clarity and was not significantly different from the data presented in the section. 
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 4 .3 .3  Quantification of Cholesterol and Cholesteryl Esters in J774A.1 
Macrophages after Exposure to Low-Density Lipoproteins Modified by 
Glucose, in the Presence or Absence of Cu2+ 
In the previous Chapter (Section 3.3.1) the protein and sterol changes in LDL 
that had been modified by glucose, in the presence or absence of Cu2+, was 
characterised. In this Section the effect of incubating J774A.1 macrophages with this 
glucose-modified LDL was examined with particular emphasis on cell viability and 
protein, and quantifying cellular cholesterol and cholesteryl ester levels. 
 LDL (1 mg protein/ml) was modified for 14 days with 100 mM glucose, in the 
presence or absence of 1 μM Cu2+, at 37 ºC, in PBS. This LDL was then subjected to 
column chromatography before J774A.1 cells were exposed to the glucose-modified 
LDL, at concentrations of 0-200 μg protein/ml of media, for 24 hr (as described in 
Section 2.6.1). This was followed by a 2 hr exposure to equilibrium media before cell 
lysis and analyses.  
Exposure of J774A.1 macrophages to this glucose-modified LDL led to no 
changes in cell viability, and protein content, or cholesterol and cholesteryl ester levels. 
J774A.1 cell viability after exposure to glucose-modified LDL was not significantly 
different (P > 0.05) from the control cell values of 88 ± 5 % (Fig. 4.10). There were also 
no significant differences (P > 0.05) between the control cell protein values of 135 ± 43 
μg and cells exposed to LDL (Fig. 4.11). Free cholesterol levels were not increased in 
macrophages exposed to glucose-modified LDL, as compared to the control cells, where 
free cholesterol levels were 63 ± 14 nmoles/mg cell protein (Fig. 4.12A). Total 
cholesterol ester levels (average values ≤ 7 nmoles/mg cell protein) were not 
significantly increased (P > 0.05) from the control values (Fig. 4.12B) resulting in 
percent cholesteryl esters levels (of total sterols) of < 7 % (Fig. 4.12C). Table 4.2 shows 
the amounts of individual cholesteryl esters found in the cells exposed to LDL at 200 μg 
protein/ml media. These values are low and are less than 4 nmoles/mg cell protein. 
Some of the ester levels (cholesteryl docosahexaenoate, arachidonate, linoleate and 
palmitate) were found to be significantly increased (P < 0.05) for cells exposed to the 
incubation control LDL, as compared to the cells exposed to no LDL. However the cells 
exposed to glucose-modified LDL did not have increased ester levels as compared to 
cells exposed to no LDL, or the incubation control LDL. 
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 Thus it is concluded that J7741A.1 macrophages exposed to LDL modified by 
glucose, in the presence or absence of Cu2+, do not give rise to significantly increased 
cholesterol and cholesteryl ester levels, under conditions that do not affect cell viability 
or protein. These results are consistent with the low levels of LDL protein modification 
reported in Section 3.3.1. 
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Figure 4.10 J774A.1 cell viability after 24 hr exposure to glucose-modified LDL. LDL (1 mg protein/ml) 
was modified by 50 μM EDTA or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± 
Cu2+), for 14 days at 37 °C and then subjected to column chromatography. Cells were exposed to the 
modified LDL, for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before cell 
lysis. Cell viability was determined by the LDH assay. Data are mean ± SEM from 3 or more experiments 
with triplicate samples. Statistical analysis, using 2-way ANOVA, showed that the modified LDLs had no 
significant effect on J774A.1 viability (P > 0.05). 
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Figure 4.11 J774A.1 cell protein (per well) after 24 hr exposure to modified LDL. LDL (1 mg 
protein/ml) was modified by 50 μM EDTA or 100 mM glucose, in the presence or absence of 1 μM Cu2+ 
(gLDL ± Cu2+), for 14 days at 37 °C, and then subjected to column chromatography. Cells were exposed 
to the modified LDL, for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before 
cell lysis. Cell protein levels were determined by the BCA assay. Data are mean ± SEM from 3 or more 
experiments with triplicate samples. Statistical analysis, using 2-way ANOVA, showed that the modified 
LDLs had no significant effect on J774A.1 protein levels (P > 0.05). 
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Figure 4.12 Free cholesterol (Panel A), total cholesteryl ester (CE) (Panel B) and percent CE (of total 
sterol; Panel C) levels in J744A.1 cells, after exposure to glucose-modified LDL. LDL (1 mg protein/ml) 
was modified by 50 μM EDTA or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± 
Cu2+), for 14 days at 37 °C, and then subjected to column chromatography. Cells were exposed to the 
modified LDL, for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before cell 
lysis, lipid extraction and then cellular cholesterol and CE levels determined by HPLC. Total cholesterol 
is the sum of individual CE and free cholesterol.  Data are mean ± SEM from 3 or more experiments with 
triplicate samples. Statistical analysis, using 2-way ANOVA, showed that the modified LDLs had no 
significant effect on J774A.1 cholesterol or cholesteryl ester levels (P > 0.05). 
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Ester Control LDL + EDTA gLDL gLDL + Cu2+  
CD 0.00 ± 0.00a 0.18 ± 0.07b 0.02 ± 0.01ab 0.06 ± 0.06ab
CA 0.00 ± 0.00a 0.46 ± 0.17b 0.04 ± 0.04ab 0.19 ± 0.19ab
CL 0.00 ± 0.00a 1.04 ± 0.30b 0.12 ± 0.12ab 1.05 ± 0.53 b
CO 0.00 ± 0.00a 3.63 ± 2.02a 0.36 ± 0.18a 3.30 ± 2.83a
CP 0.00 ± 0.00a 0.49 ± 0.01b 0.17 ± 0.17ab 0.00 ± 0.00ab
CS 0.00 ± 0.00a 0.02 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a
Table 4.2 Levels of individual cholesteryl esters (nmoles/mg cell protein) in J774A.1 cells after exposure 
to glucose-modified LDL at 200 μg protein/ml media. LDL (1 mg protein/ml) was modified for 14 days 
by 50 μM EDTA or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± Cu2+), at 37 °C, 
and then subjected to column chromatography. Cells were exposed to the modified LDL for 24 hr, 
followed by a 2 hr equilibrium period, before cell lysis, lipid extraction and cellular cholesterol and CE 
analysis by HPLC.  Control cells were exposed to media only for the same time periods. Total cholesterol 
is the sum of individual cholesteryl esters and free cholesterol. The cholesteryl esters examined were 
cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl linoleate (CL), cholesteryl 
palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Only the 200 μg/ml LDL loading 
condition is shown to reduce volume of data. Data are mean ± SEM from 3 or more experiments with 
triplicate samples. Numbers with different superscripts are statistically different (P < 0.05), by 1-way 
ANOVA using Tukey’s post hoc testing. 
 
4 .3 .3 .a   Discussion 
The exposure of J774A.1 macrophages to glucose-modified LDL, did not result in 
any significant changes in cell viability, protein or intracellular free cholesterol and 
cholesteryl esters levels, when compared to cells exposed to control LDL (LDL plus 
EDTA). Cells exposed to control LDL did not have increased free cholesterol levels 
when compared to cell exposed to no LDL at all. The free cholesterol and cholesteryl 
ester levels detected in these studies are within the range of results in Section 4.3.2 and 
previously reported studies for J77A.1 cells not exposed to LDL [154, 385, 388, 396]. 
However some studies have reported increases in free cholesterol and cholesteryl esters 
upon exposure of cells to unmodified LDL [32, 396]. This has been attributed to a 
‘J774A.2’ variant derived from either mutation or a selection event that results in these 
cells to be able to esterify cholesterol at a greater rate, with exposure to unmodified-
LDL resulting in up to 55 % percent of total sterols as cholesteryl esters. In the current 
studies exposure to cells to the minimally-modified control LDL (LDL plus EDTA) 
resulted in < 7 % of total sterols being cholesteryl esters. 
 Increased cholesteryl ester synthesis was not seen in J774A.1 cells exposed to 
glucose-modified LDL, in the presence or absence of Cu2+, and thus a lack of foam cell 
formation. This lack of cholesterol and cholesteryl ester accumulation is consistent with 
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 the low level of observed protein and lipid modification (see Section 3.3.1). The only 
significant effect found in glucose-modified LDL, compared to control LDL, was a 
greater loss of Arg residues. These changes probably explain the observed 
crosslinking/aggregation and the small increases in the negative charge of the particles. 
However, this extent of aggregation does not appear to promote foam cell formation 
[43]. Lys residue modification of > 16 %, rather than the net charge of the LDL particle, 
has been postulated as being necessary for macrophage scavenger receptor recognition 
of modified LDL [145]. No significant loss of Lys residues was found in Section 
3.3.1.a.iii, and thus, on the basis of the above hypotheses, foam cell formation would be 
unexpected. Other published reports using other macrophage sources have also reported 
no increases in cellular cholesteryl esters [263, 264].  
There were no differences in the measured cellular parameters in the handling of 
LDL modified by glucose, in the presence or absence of Cu2+. This is not surprising in 
view of the results in Section 3.3.1 where no significant differences were found between 
these two conditions in terms of protein modification. In previous studies it has been 
reported that glucose may enhance metal ion mediated LDL oxidation [268, 271, 335, 
361], however due to the lower ratio of apo B to Cu2+ used, no such effects were 
observed under the conditions employed in the current studies. Millican et al have 
reported that glucose and Cu2+-modified LDL inhibited DNA synthesis in the 
macrophage-like cell line P388D1. However, in this study no overt changes in cell 
viability, number, or cholesterol in cholesterol or cholesteryl ester accumulation were 
detected, though other perturbations in cell metabolism could be occurring. This could 
be an area worthy of further examination. 
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 4 .3 .4  Quantification of Cholesterol and Cholesteryl Esters in J774A.1 
Macrophages after Exposure to Low-Density Lipoproteins Modified by 
Methylglyoxal 
The previous Section (Section 4.3.3) examined the effect of glucose-modified 
LDL on J774A.1 macrophages and showed that exposure of these cells to LDL 
modified for 14 days by 100 mM glucose did not cause model foam cell formation. 
However in the LDL characterisation studies, reported in Chapter 3, methylglyoxal was 
found to induce a greater extent of protein modification in LDL than glucose and it was 
hypothesised that this could lead to increased macrophage scavenger receptor 
recognition. Therefore in this Section the effect of methylglyoxal-modified LDL on 
J774A.1 macrophages was studied, with particular emphasis on cell viability and 
protein, and quantifying cholesterol and cholesteryl ester levels. 
 LDL (1 mg protein/ml) was modified for up to 14 days with 10 or 100 mM 
methylglyoxal, at 37 ºC, in PBS, as described in Section 3.3.2. This LDL was then 
subjected to column chromatography before incubation with J774A.1 cells, at 
concentrations of 0-200 μg LDL protein/ml media, for 24 hr (as described in Section 
2.6.1). This was followed by a 2 hr exposure to equilibrium media before cell lysis and 
analyses.  
The exposure of J774 macrophages to LDL modified by methylglyoxal for 24 hr 
led to no changes in cell viability and protein, or cholesterol and cholesteryl ester levels. 
Thus the treated macrophages did not have significantly different (P > 0.05) cell 
viability from the control values of 89 ± 6 % (Fig. 4.13A). Similarly, there were no 
effects of methylglyoxal-modified LDL on total protein per well from the control values 
of 149 ± 55 μg after 24 hr incubation (Fig. 4.13B). Macrophages exposed to the 
modified LDL did not have significantly increased (P > 0.05) free cholesterol levels 
from the control values of 37 ± 8 nmoles/mg cell protein (Fig. 4.13C) and total 
cholesterol and percent cholesteryl ester levels in all conditions were under 2 
nmoles/mg cell protein and 2 %, respectively (Fig. 4.13D and Fig. 4.13E). Table 4.3 
shows that individual esters were all less than 1 nmole/μg cell protein with no statistical 
differences (P > 0.05) found between the conditions examined. 
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Figure 4.13 The effect of LDL (1 mg protein/ml) modified by 0–100 mM methylglyoxal for 24 hr, at 37 
°C, on J774A.1 cells. LDL was subjected to column chromatography before cells were exposed to the 
modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, and the various analyses. 
Control cells were exposed to media alone for the same time periods. Panel A: cell viability; Panel B: cell 
protein; Panel C: cellular free cholesterol levels; Panel D: total cholesteryl esters (CE) and Panel E: 
percent CE of total cholesterol. Total cholesterol is the sum of individual CE and free cholesterol. Data 
are mean ± SEM from 3 experiments with triplicate samples. * Indicates statistical difference (P < 0.05) 
from the LDL + EDTA control cells, at that concentration of LDL, using 2-way ANOVA and Bonferroni 
post hoc testing. 
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We hypothesised that an increased incubation time in the modification of LDL 
by methylglyoxal might lead to significant effects on the macrophage cell line, in light 
of the data reported in Section 2.3.3, demonstrating increased modification of LDL by 
methylglyoxal over time. However, LDL modified by 10 or 100 mM methylglyoxal for 
5 days also did not affect J774A.1 macrophage viability, protein or cellular cholesterol 
and cholesteryl ester levels. Viability and cell protein values for cells exposed to 
methylglyoxal-modified LDL were not significantly different (P > 0.05) from control 
cell viability of 85 ± 4 % (Fig. 4.14A) or control cell protein of 93 ± 29 μg (Fig. 4.14B). 
Methylglyoxal-modified LDL also did not lead to significant increases (P > 0.05) in free 
cholesterol levels from control levels of 58 ± 14 nmoles/mg cell protein (Fig. 4.14C). 
Cells exposed to 100 mM methylglyoxal-modified LDL at 200 μg protein/ml media 
trended towards increased cellular cholesteryl accumulation, however due to the 
variation between experiments this did not achieve significance (P > 0.05). Total 
cholesteryl esters for cells exposed to LDL modified by 100 mM methylglyoxal were 15 
± 11 nmoles/mg cell protein, as compared to the incubation control LDL values of 4 ± 2 
nmoles/mg cell protein (Fig. 4.14D). This equates to 13 ± 8 % cholesteryl esters for the 
cells exposed to the highest concentrations of methylglyoxal-modified LDL and 4 ± 2 % 
for cells exposed to incubation control LDL (Fig. 4.14E). Table 4.3 shows the levels of 
individual cholesteryl esters detected under these conditions. Individual levels are all 
less than 5 nmoles/mg cell protein, and levels in the cells exposed to methylglyoxal-
modified LDL were not significantly different (P > 0.05) from those of the controls. 
As there was a large variation in the effect of LDL modified by methylglyoxal 
for 5 days on cellular cholesterol and cholesteryl esters detected, further experiments 
were carried out with an incubation time of 7 days. This time point was chosen to 
facilitate comparison with the effect of 7 day modification of LDL by glycolaldehyde 
on J774A.1 cells (see Section 4.3.5 following). LDL modified by methylglyoxal for 7 
days did not affect J774A.1 viability or protein, but significant changes were found in 
cellular cholesterol and cholesteryl ester accumulation. Cells exposed to this 
methylglyoxal-modified LDL did not have significantly different viability (P > 0.05) 
from the control cell values of 96 ± 1 % (Fig. 4.15A) or cell protein amounts from the 
209 ± 14 μg control value (Fig. 4.15B). Free cholesterol levels in cells exposed to 
methylglyoxal-treated LDL were also not significantly different from the control cell 
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 levels of 56 ± 4 nmoles/mg cell protein (Fig. 4.15C). In contrast, cells exposed to 100 
mM methylglyoxal-modified LDL at 200 μg protein/ml media had significantly more (P 
< 0.05) total cholesteryl esters than the LDL incubation control cells (14 ± 2 and 2 ± 1 
nmoles/mg cell protein respectively; Fig. 4.15D). The percent cholesteryl esters values 
were also significantly increased (P < 0.05) to 11 ± 2 % for cells exposed to 100 mM 
methylglyoxal-modified LDL compared with 2 ± 1 % for cells exposed to incubation 
control LDL (Fig. 4.15E). Cells exposed to 10 mM methylglyoxal-modified LDL for 7 
days did not accumulate significantly greater quantities of cholesteryl esters than 
incubation controls. Table 4.3 shows the levels of individual cholesteryl esters detected 
in methylglyoxal-modified LDL. In the 100 mM condition cholesteryl arachidonate, 
linoleate, oleate and palmitate were significantly increased as compared to the control. 
Cholesteryl oleate levels were the highest at ~ 6 nmoles/mg cell protein followed by 
cholesteryl linoleate, palmitate at ~ 3 nmoles/mg cell protein and cholesteryl 
arachidonate at 0.43 nmoles/mg cell protein. 
The percent cholesteryl ester values achieved in macrophages exposed to 7 day 
methylglyoxal-modified LDL are lower than the levels achieved when J774A.1 cells are 
exposed to acetylated LDL (see Section 4.3.2). Therefore the incubation time of 
methylglyoxal with LDL was further increased to 14 days to see if higher cholesteryl 
ester loading was observed. LDL modified by methylglyoxal for 14 days did not affect 
J774A.1 viability or protein, but significant changes were found in cellular cholesterol 
and cholesteryl ester accumulation. Cells exposed to methylglyoxal-modified LDL did 
not have significantly different viability (P > 0.05) from the control cell value of 90 ± 5 
% (Fig. 4.16A) or cell protein amounts from the 162 ± 2 μg control value (Fig. 4.16B). 
Free cholesterol levels in cells exposed to methylglyoxal were also not significantly 
different from the control cell levels of 74 ± 6 nmoles/mg cell protein (Fig. 4.16C).  
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Figure 4.14 The effect of LDL (1 mg protein/ml) modified by 0–100 mM methylglyoxal for 5 days, at 37 
°C, on J774A.1 cells. LDL was subjected to column chromatography before cells were exposed to the 
modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, and the various analyses. 
Control cells were exposed to media alone for the same time periods. Panel A: cell viability; Panel B: cell 
protein; Panel C: cellular free cholesterol levels; Panel D: total cholesteryl esters (CE) and Panel E: 
percent CE of total cholesterol. Total cholesterol is the sum of individual CE and free cholesterol. Data 
are mean ± SEM from 4 experiments with triplicate samples. Statistical analysis, using 2-way ANOVA 
and Bonferroni post hoc testing, showed no significant effects (P > 0.05). 
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Figure 4.15 The effect of LDL (1 mg protein/ml) modified by 0–100 mM methylglyoxal for 7 days, at 37 
°C, on J774A.1 cells. LDL was subjected to column chromatography before cells were exposed to the 
modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, and the various analyses. 
Control cells were exposed to media alone for the same time periods. Panel A: cell viability; Panel B: cell 
protein; Panel C: cellular free cholesterol levels; Panel D: total cholesteryl esters (CE) and Panel E: 
percent CE of total cholesterol. Total cholesterol is the sum of individual CE and free cholesterol. Data 
are mean ± SEM from 3 experiments with triplicate samples. * Indicates statistical difference (P < 0.05) 
from the LDL + EDTA control cells, and # indicates statistical difference (P < 0.05) from the 10 mM 
condition, at that concentration of LDL, using 2-way ANOVA and Bonferroni post hoc testing. 
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Figure 4.16 The effect of LDL (1 mg protein/ml) modified by 0–100 mM methylglyoxal for 14 days, at 
37 °C, on J774A.1 cells. LDL was subjected to column chromatography before cells were exposed to the 
modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, and the various analyses. 
Control cells were exposed to media alone for the same time periods. Panel A: cell viability; Panel B: cell 
protein; Panel C: cellular free cholesterol levels; Panel D: total cholesteryl esters (CE) and Panel E: 
percent CE of total cholesterol. Total cholesterol is the sum of individual CE and free cholesterol. Data 
are mean ± SEM from 3 experiments with triplicate samples. * Indicates statistical difference (P < 0.05) 
from the LDL + EDTA control cell, and # indicates statistical difference (P < 0.05) from the 10 mM 
condition, at that concentration of LDL, using 2-way ANOVA and Bonferroni post hoc testing. 
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However, cells exposed to 100 mM methylglyoxal-modified LDL at 100 and 
200 μg protein/mg cell protein had significantly more (P < 0.05) cholesteryl esters as 
compared to the LDL incubation control cells (43 ± 9 and 8 ± 2 nmoles/mg cell protein 
respectively, for LDL at 200 μg protein/ml media; Fig. 4.16D). The percent cholesteryl 
esters values were also significantly increased (P < 0.05) to 26 ± 3 % for cells exposed 
to 100 mM methylglyoxal-modified LDL and 7 ± 2 % for cells exposed to incubation 
control LDL at 200 μg protein/ml media (Fig. 4.16E). There was also a significant 
difference (P < 0.05) for the 100 μg protein/ml media condition. Interestingly, cells 
exposed to 10 mM methylglyoxal-modified contained significantly less (P < 0.05) 
cellular cholesteryl esters (1.14 ± 0.58 %) as compared to the cells exposed to 
incubation control LDL (6.7 ± 1.7 %). However at each LDL concentration examined 
the cells exposed to the 100 mM methylglyoxal-LDL had significantly more cholesteryl 
esters than cells exposed to 10 mM methylglyoxal-modified LDL. 
Table 4.3 shows the levels of individual cholesteryl esters detected in 
methylglyoxal-modified LDL. In the 100 mM condition cholesteryl arachidonate, 
linoleate, oleate and palmitate were significantly increased as compared to the control. 
Cholesteryl oleate levels were the highest at ~ 18 nmoles/mg cell protein followed by 
cholesteryl linoleate at ~ 12 nmoles/mg cell protein, cholesteryl palmitate at ~ 9 
nmoles/mg cell protein and cholesteryl arachidonate at 1 nmoles/mg cell protein. All 
cholesteryl esters levels were higher in cells exposed to LDL modified by 100 mM 
methylglyoxal for 14 days compared to LDL modified for only 7 days. 
Overall, J774A.1 macrophage viability and protein are not significantly affected 
by exposure to methylglyoxal-modified LDL, whether the modification is for 24 hr or 
up to 14 days. No changes in cellular free cholesterol levels were observed under these 
conditions.  However significant cholesteryl ester accumulation was seen in cells 
exposed to LDL modified by methylglyoxal for 7 or 14 days. Shorter LDL modification 
times did not result in significant cholesteryl ester accumulation. Furthermore, J774A.1 
macrophages exposed to LDL modified by methylglyoxal for 7 or 14 days accumulated 
significantly more cholesteryl esters than in the analogous glucose experiments. This 
may be due to the increased extent of protein modification characterised in 
methylglyoxal-modified LDL, when compared to glucose-modified LDL (see Sections 
3.3.2 and 3.3.1 respectively), and thus increased macrophage scavenger receptor 
recognition. 
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Time 
(days)
0 5 5 5 7 7 7 14 14 14 
Sterol Control 0 mM 10 mM 100 mM 0 mM 10 mM 100 mM 0 mM 10 mM 100 mM 
CD 0.00 ± 0.00a 0.14 ± 0.12a 0.03 ± 0.04a 0.23 ± 0.21a 0.02 ± 0.02a 0.01 ± 0.01a 0.13 ± 0.03b 0.05 ± 0.05a 0.00 ± 0.00a 1.04 ± 0.41b
CA 0.00 ± 0.00a 0.29 ± 0.19a 0.00 ± 0.00a 1.23 ± 0.73a 0.07 ± 0.05a 0.05 ± 0.05a 0.43 ± 0.07b 0.13 ± 0.13a 0.03 ± 0.02a 1.39 ± 0.56b
CL 0.00 ± 0.00a 1.30 ± 0.99ab 0.13 ± 0.17a 5.32 ± 4.24b 0.56 ± 0.32a 0.84 ± 0.84a 3.22 ± 0.41b 1.20 ± 0.04a 0.41 ± 0.21a 11.46 ± 3.25b
CO 0.00 ± 0.00a 1.48 ± 0.72a 0.00 ± 0.00a 4.98 ± 3.17a 1.37 ± 0.74a 1.81 ± 1.81a 6.15 ± 0.37b 4.46 ± 1.03a 0.54 ± 0.27a 18.05 ± 3.11b
CP 0.00 ± 0.00a 0.35 ± 0.22a 0.00 ± 0.00a 2.77 ± 2.58a 0.30 ± 0.30a 0.69 ± 0.69a 3.36 ± 0.66b 2.21 ± 0.82a 0.10 ± 0.10a 9.31 ± 2.19b
CS 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.42 ± 0.52a 0.00 ± 0.00a 0.00 ± 0.00a 0.43 ± 0.43a 0.14 ± 0.14 a 0.00 ± 0.00a 1.21 ± 1.04a
 
 
 
Table 4.3 Levels of individual cholesteryl esters (nmoles/mg cell protein) in J774A.1 cells after exposure to methylglyoxal-modified LDL  at 200 μg protein/ml media. LDL 
(1 mg protein/ml) was modified for 0-14 days by 50 μM EDTA or 10-100 mM methylglyoxal, at 37 °C. LDL was subjected to column chromatography before cells were 
exposed to the modified LDL for 24 hr, except for the control cells, followed by a 2 hr equilibrium period, before cell lysis, lipid extraction and cellular cholesterol and 
cholesteryl ester levels analysis by HPLC. Total cholesterol is the sum of individual cholesteryl ester and free cholesterol. The esters examined were cholesteryl 
docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). 
Cholesteryl data for cells exposed to 24 hr methylglyoxal-modified LDL is omitted (no cholesterol esters were detected) and only the 200 μg/ml LDL loading condition is 
shown for clarity. Data are mean ± SEM from 3 or more experiments with triplicate samples. Numbers with different superscripts, from that incubation time period or control, 
are statistically different (P < 0.05), by 1-way ANOVA using Tukey’s post hoc testing. 
 4 .3 .4 .a  Discussion 
The potential of LDL modified by 10-100 mM methylglyoxal for up to 14 days to 
induce model foam cell formation was examined using J77A.1 macrophage cells. 
Regardless of which time period the LDL was modified for, cell viability or protein was 
unaffected. Thus, the cholesteryl ester accumulation results are not a result of 
significant cell death. 
Cells exposed to LDL modified by methylglyoxal for 24 hr did not have increased 
intracellular levels of free cholesterol or cholesteryl esters. Actually cells exposed to 
LDL modified by 10 or 100 mM methylglyoxal had significantly less cholesterol esters 
than observed for cells exposed to control LDL. At this time point the methylglyoxal-
modified LDL showed significant increases in REM and apo B 
crosslinking/aggregation. Significant losses of Arg and Lys residues were also observed 
in both 10 and 100 mM conditions, and a loss in Trp residues in the 100 mM 
methylglyoxal condition. However, macrophage scavenger receptor mediated uptake of 
methylglyoxal-modified LDL and cholesteryl ester accumulation, does not seem to have 
occurred. Less cholesteryl ester synthesis has also been reported in murine macrophage 
P338D1 cells exposed to methylglyoxal modified by 10 mM methylglyoxal for 3 days 
[167].  
Increasing modification times of LDL exposed to methylglyoxal led to increasing 
J774A.1 cholesteryl ester accumulation. Exposure of cells to LDL modified by 
methylglyoxal for 5 days trended towards increased cholesteryl esters but due to 
experimental variation this did not reach statistical significance. In contrast, J77A.1 
macrophages exposed to LDL modified by 100 mM methylglyoxal for 7 days, at the 
highest level of loading, did have statistically increased intracellular cholesteryl esters, 
compared to cells exposed to control LDL. After 14 days of LDL modification by 100 
mM methylglyoxal, cells accumulated cholesteryl esters to ~ 23 % of total sterol levels. 
This value is less than that observed for acetylated LDL (~ 34 %; see Section 4.3.2), but 
greater than those observed for J774A.1 cells exposed to glucose-modified LDL (see 
Section 4.3.3). However cells exposed to the 10 mM condition had significantly less 
cholesteryl esters, than cells exposed to control LDL. 
The increased cholesteryl ester accumulation observed in these cells suggests that 
the LDL modified by 100 mM methylglyoxal is recognised by the macrophage 
scavenger receptor. This is in accord with the data of Schalkwijk et al, who 
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 demonstrated that methylglyoxal-modified LDL is recognised by the macrophage 
scavenger receptor, even though LDL modified by 10 mM methylglyoxal resulted in 
decreased cholesteryl synthesis when compared to control cells [167]. It might have 
been expected that LDL modified by methylglyoxal would lead to significant 
cholesteryl ester accumulation at early time points due to the large changes in REM, 
SDS-PAGE and Arg, Lys and Trp loss detected after 5 days, or even 24 hr (see Section 
3.3.2). The level of modification is significantly less in the 10 mM condition, as 
compared to the 100 mM condition, which may explain the observed cholesteryl ester 
accumulation with one and not the other at the longer incubation times. By 5 days the 
extent of modification of the REM of 10 and 100 mM methylglyoxal was not 
significantly less than the REM observed for acetylated LDL, yet acetylated LDL 
caused significant cholesteryl ester accumulation, whereas 5 day methylglyoxal-
modified LDL did not. Within 24 hr ~ 50 % and by day 5 ~ 60 %, of Lys residues were 
lost, so based on the work of Haberland et al, macrophage maximal scavenger receptor 
recognition would be expected for incubations longer than this [145]. This group 
demonstrated, depending on the type of LDL modification, that 16-60 % of the Lys 
residues needed to be modified for maximal ligand binding, uptake and degradation. 
Vanderyse et al also presented data that indicated that even though modification of 
critical Lys residues was an indicator of cholesteryl accumulation, it didn’t explain the 
extent of intracellular cholesteryl ester accumulation with all LDL modifications [389]. 
This data indicates that prediction of cholesteryl ester accumulation in macrophages 
cannot be based on Lys modification alone. The following Section reports on similar 
studies with glycolaldehyde-modified LDL. 
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 4 .3 .5  Quantification of Cholesterol and Cholesteryl Esters in J774A.1 
Macrophages after Exposure to Low-Density Lipoproteins Modified by 
Glycolaldehyde 
Sections 4.3.3 and 4.3.4 examined the effect of glucose- and methylglyoxal-
modified LDL on J774A.1 macrophages. These studies showed that exposure of these 
cells to LDL modified for 14 days by 100 mM glucose will not cause model foam cell 
formation, whereas exposure to LDL modified by 100 mM methylglyoxal for 7 or 14 
days resulted in increased cellular cholesteryl ester accumulation. However in the LDL 
characterisation studies (see Section 3.3.3) glycolaldehyde induced more rapid protein 
modification in LDL than methylglyoxal, and greater modification than glucose. It was 
therefore hypothesised that increased extent of modification by glycolaldehyde would 
lead to increased macrophage scavenger receptor recognition and more rapid cholesterol 
and cholesteryl ester accumulation. In this Section the effects of glycolaldehyde-
modified LDL on J774A.1 macrophages were therefore examined in a similar manner to 
that described earlier in this Chapter for glucose-and methylglyoxal-modified LDL. 
 LDL (1 mg protein/ml) was modified for up to 7 days with 1, 10 or 100 mM 
glycolaldehyde, at 37 ºC, in PBS. This LDL was then subjected to column 
chromatography before incubation with J774A.1 cells, at concentrations of 0-200 μg 
protein/ml of media, for 24 hr (as described in Section 2.6.1). This was followed by a 2 
hr exposure to equilibrium media before cell lysis and analyses. 
LDL modified by glycolaldehyde for 24 hr did not affect J774A.1 cell viability 
or protein levels. Cells exposed to glycolaldehyde-modified LDL did not have 
significantly different viability (P > 0.05) from the control cell values of 90 ± 3 % (Fig. 
4.17A), or cell protein amounts from the 162 ± 19 μg control values (Fig. 4.17B). Free 
cholesterol levels in J774A.1 cell were not increased upon incubation with these types 
of glycolaldehyde-modified LDLs, however cholesteryl ester levels were. Thus, free 
cholesterol levels were not significantly different (P > 0.05) from the control cell levels 
of 67 ± 6 nmoles/mg cell protein (Fig. 4.17C), but cells exposed to 100 mM 
glycolaldehyde-modified LDL, at 100 and 200 μg protein/ml media, contained 
significantly more (P < 0.05) total cholesteryl esters when compared to the LDL 
incubation control cells (37 ± 10 and 2 ± 1 nmoles/mg cell protein respectively, for the 
200 μg protein/ml media condition; Fig. 4.17D). The 100 mM condition also had 
significantly more cholesteryl esters than the 1 and 10 mM conditions. Cells exposed to 
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 1 or 10 mM glycolaldehyde-modified LDL did not contain significantly increased (P > 
0.05) cellular cholesteryl esters as compared to the cells exposed to incubation control 
LDL. Percent cholesteryl esters values were also significantly increased (P < 0.05) in 
cells exposed to all concentrations of LDL modified by 100 mM glycolaldehyde. Thus 
these values reached 25 ± 5 % for cells exposed to 100 mM glycolaldehyde-modified 
LDL compared to 6 ± 1 % for cells exposed to incubation control LDL at the 200 μg 
protein/ml media condition (Fig. 4.17E).  
Table 4.4 shows the levels of individual cholesteryl esters detected in 
glycolaldehyde-modified LDL. For the 100 mM condition, cholesteryl arachidonate, 
linoleate, oleate and palmitate were significantly increased when compared to the 
control. Cholesteryl oleate levels were the highest at ~ 14 nmoles/mg cell protein 
followed by cholesteryl linoleate at ~ 11 nmoles/mg cell protein, cholesteryl palmitate 
at ~ 8 nmoles/mg cell protein and cholesteryl arachidonate ~ 2 nmoles/mg cell protein. 
The percent cholesteryl ester values achieved in macrophages exposed to 24 hr 
glycolaldehyde-modified LDL are higher than the levels achieved when J774A.1 cells 
are exposed to 24 hr methylglyoxal-modified LDL (see Section 4.3.4).  
The incubation time of glycolaldehyde with LDL was increased to 7 days to see 
if greater cellular effects were observed. LDL modified by glycolaldehyde for 7 days 
did not affect J774A.1 viability or protein. Cells exposed to glycolaldehyde-modified 
LDL did not have significantly different viability (P > 0.05) from the control cell values 
of 87 ± 6 % (Fig. 4.18A) or cell protein amounts from the 111 ± 72 μg control value 
(Fig. 4.18B). Free cholesterol levels in J774A.1 cells were not significantly increased, 
but cholesteryl esters were, upon exposure to this type of LDL. Free cholesterol levels 
in cells exposed to glycolaldehyde-modified LDL were also not significantly different 
from the control cell levels of 59 ± 7 nmoles/mg cell protein (Fig. 4.18C), but cells 
exposed to 100 mM glycolaldehyde-modified LDL at 100 and 200 μg protein/ml media 
had significantly more (P < 0.05) total cholesteryl esters as compared to the LDL 
incubation control cells (84 ± 23 and 4 ± 1 nmoles/mg cell protein respectively, for 
LDL at 200 μg protein/ml media; Fig. 4.18D). At the 200 μg protein/ml media 
concentration, the cells exposed to the 10 mM glycolaldehyde condition also had 
significantly increased total cholesterol esters levels (57 ± 24 nmoles/mg cell protein). 
LDL modified by 1 mM glycolaldehyde did not lead to macrophage cholesterol and 
cholesteryl ester accumulation.  
 144
 C
el
l p
ro
te
in
 (μ
g)
 B 0
20
40
60
80
100
0 50 100 200
Control
0 mM
1 mM
10 mM
100 mM
C
el
l v
ia
bi
lit
y 
(%
) A 
0
100
200
300
400
0 50 100 200
Control
0 mM
1 mM
10 mM
100 mM
0
10
20
30
40
50
60
0 50 100 200
Control
0 mM
1 mM
10 mM
100 mM
C
E
 (%
) 
LDL (μg protein/ml media) 
E 
# # ***
+ 
# 
++
0
20
40
60
80
100
120
0 50 100 200
Control
0 mM
1 mM
10 mM
100 mM
To
ta
l C
E 
(n
m
ol
es
/m
g 
ce
ll 
pr
ot
ei
n)
 
D 
#
#
**
+
+
Fr
ee
 c
ho
le
st
er
ol
 
(n
m
ol
es
/m
g 
ce
ll 
pr
ot
ei
n)
 
C 
0
20
40
60
80
100
120
140
0 50 100 200
Control
0 mM
1 mM
10 mM
100 mM
Figure 4.17 The effect of LDL (1 mg protein/ml) modified by 0–100 mM glycolaldehyde for 24 hr, at 37 
°C, on J774A.1 cells. LDL was subjected to column chromatography before cells were exposed to the 
modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, and the various analyses. 
Control cells were exposed to media alone for the same time periods. Panel A: cell viability; Panel B: cell 
protein; Panel C: cellular free cholesterol levels; Panel D: total cholesteryl esters (CE) and Panel E: 
percent CE of total cholesterol. Total cholesterol is the sum of individual CE and free cholesterol. Data 
are mean ± SEM from 4 experiments with triplicate samples. * Indicates statistical difference (P < 0.05) 
from the LDL + EDTA control cells, + indicates statistical difference (P < 0.05) from the 1 mM condition 
and  # indicates statistical difference (P < 0.05) from the 10 mM condition, at that concentration of LDL, 
using 2-way ANOVA and Bonferroni post hoc testing. 
 145
 Percent cholesteryl esters values were significantly increased (P < 0.05) to 45 ± 
8 % for cells exposed to 100 mM glycolaldehyde-modified LDL compared to 4 ± 1 % 
for cells exposed to incubation control LDL at 200 μg protein/ml media (Fig. 4.18E). 
There was also a significant difference (P < 0.05) for the 50 and 100 μg protein/ml 
media conditions. At the 200 μg protein/ml media condition 10 mM glycolaldehyde 
also caused a significant increase (P < 0.05) in percent cholesteryl esters at 34 ± 12 %. 
At each concentration of LDL there was no significant difference (P > 0.05) between 
the amount of cholesteryl esters in the 10 and 100 mM glycolaldehyde conditions, 
however the large variation in the 10 mM condition did not make it significantly 
different from the control LDL cells.  
Table 4.3 shows the levels of individual cholesteryl esters detected in 
glycolaldehyde-modified LDL. In the 10 and 100 mM conditions cholesteryl 
arachidonate, linoleate, oleate and palmitate were significantly increased as compared to 
the control. With the 100 mM condition cholesteryl linoleate levels were the highest at 
~ 30 nmoles/mg cell protein followed by cholesteryl oleate at ~ 26 nmoles/mg cell 
protein, cholesteryl palmitate at ~ 18 nmoles/mg cell protein and cholesteryl 
arachidonate at 6 nmoles/mg cell protein. All cholesteryl esters levels were higher in 
cells exposed to LDL modified by 100 mM glycolaldehyde for 7 days compared to LDL 
modified for only 24 hr. 
Overall J774A.1 macrophage viability and protein were not significantly 
affected by exposure to glycolaldehyde-modified LDL, whether the modification was 
for 24 hr or 7 days and no changes in cellular free cholesterol levels were observed.  
However significant cholesteryl ester accumulation was seen in cells exposed to LDL 
modified by 100 mM glycolaldehyde for 24 hr or 7 days, or LDL modified with 10 mM 
glycolaldehyde for 7 days. This cellular cholesteryl accumulation occurred more 
quickly, and to a greater extent, than when analogous cells were exposed to 
methylglyoxal-modified LDL. 
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Figure 4.18 The effect of LDL (1 mg protein/ml) modified by 0–100 mM glycolaldehyde for 7 days, at 
37 °C, on J774A.1 cells. LDL was subjected to column chromatography before cells were exposed to the 
modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, and the various analyses. 
Control cells were exposed to media alone for the same time periods. Panel A: cell viability; Panel B: cell 
protein; Panel C: cellular free cholesterol levels; Panel D: total cholesteryl esters (CE) and Panel E: 
percent CE of total cholesterol. Total cholesterol is the sum of individual CE and free cholesterol. Data 
are mean ± SEM from 3 experiments with triplicate samples. * Indicates statistical difference (P < 0.05) 
from the LDL + EDTA control cells, + indicates statistical difference (P < 0.05) from the 1 mM condition 
and  # indicates statistical difference (P < 0.05) from the 10 mM condition, at that concentration of LDL, 
using 2-way ANOVA and Bonferroni post hoc testing. 
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Time (days) 0 1 1 1 1 7 7 7 7 
Sterol Control 0 mM 1 mM 10 mM 100 mM 0 mM 1 mM 10 mM 100 mM 
CD 0.00 ± 0.00a 0.17 ± 0.07a 0.06 ± 0.06a 0.00 ± 0.00a 0.81 ± 0.43a 0.13 ± 0.10a 0.03 ± 0.03a 1.14 ± 0.72a 1.51 ± 0.82a
CA 0.00 ± 0.00a 0.36 ± 0.14a 0.21 ± 0.12a 0.00 ± 0.00a 2.39 ± 0.68b 0.51 ± 0.44a 0.14 ± 0.14a 4.65 ± 3.11b 6.20 ± 3.49b
CL 0.00 ± 0.00a 1.51 ± 0.46a 0.89 ± 0.13a 0.00 ± 0.00a 11.40 ± 2.89bb 1.14 ± 0.34a 0.31 ± 0.16a 20.77 ± 10.48b 29.75 ± 9.87b
CO 0.00 ± 0.00a 2.60 ± 0.50a 1.26 ± 0.01a 0.00 ± 0.00a 14.24 ± 3.45b 2.00 ± 0.42 a 0.39 ± 0.20 a 17.72 ± 3.46b 26.02 ± 3.15b
CP 0.00 ± 0.00a 1.24 ± 0.66a 0.14 ± 0.14a 0.00 ± 0.00a 7.52 ± 3.08b 0.45 ± 0.10a 0.22 ± 0.22a 10.99 ± 5.02b 17.54 ± 5.39b
CS 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.16 ± 0.16a 0.00 ± 0.00a 0.00 ± 0.00a 1.70 ± 1.10a 2.71 ± 1.21a
 
Table 4.4 Levels of individual cholesteryl esters (nmoles/mg cell protein) in J774A.1 cells after exposure to 200 μg/ml glycolaldehyde-modified LDL. LDL (1 mg protein/ml) 
was modified for 0-7 days by 50 μM EDTA or 1-100 mM glycolaldehyde, at 37 °C. LDL was subjected to column chromatography before cells were exposed to the modified 
LDL for 24 hr, followed by a 2 hr equilibrium period, before cell lysis, lipid extraction and cellular cholesterol and cholesteryl ester analysis by HPLC. Control cells were 
exposed to media alone for the same time periods. Total cholesterol is the sum of individual cholesteryl esters and free cholesterol. The esters examined were cholesteryl 
docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Only the 
200 μg/ml LDL loading condition is shown for clarity. Data are mean ± SEM from 3 or more experiments with triplicate samples. Numbers with different superscripts, from 
that incubation time period or control, are statistically different (P < 0.05), by 1-way ANOVA using Tukey’s post hoc testing. 
 4 .3 .5 .a  Discussion 
J774A.1 cells were exposed to LDL modified by 1-100 mM glycolaldehyde for 
up to 7 days to examine potential model foam cell formation. LDL modified by 
glycolaldehyde for 24 hr or 7 days, regardless of concentration, had no significant 
effects on cell viability or protein. Thus, the cholesteryl ester accumulation results are 
not a result of significant cell death. 
 Modification of LDL for 24 hr or 7 days by 100 mM glycolaldehyde induced 
significant cholesteryl ester accumulation in J774A.1 cells. This cholesteryl ester 
accumulation was greater than that observed with both methylglyoxal- and glucose-
modified LDL (see Sections 4.3.4 and 4.3.3 respectively). Cholesteryl esters were ~ 
25 % of total sterol levels for cells exposed to LDL modified by 100 mM 
glycolaldehyde for 24 hr. LDL modified by 1 or 10 mM glycolaldehyde for 24 hr did 
not result in significant cholesteryl esters as compared to cells exposed to control 
LDL. When cells were exposed to LDL modified by 100 mM glycolaldehyde for 7 
days cholesteryl ester levels increased to ~ 45 % of total sterol levels, and ~ 34 % for 
cells exposed to the 10 mM condition. Again no cholesteryl ester accumulation was 
observed in cells exposed to 1 mM glycolaldehyde. In cells exposed to acetylated 
LDL, the percentage of cholesteryl esters was ~ 34 % (see Section 4.3.2), so 
modification of LDL for 7 days by glycolaldehyde induced cholesteryl loading that 
was greater than that observed for acetylated LDL, and comparable cholesteryl ester 
loading to acetylated LDL for the 10 mM condition. Previous studies have 
demonstrated the recognition of glycolaldehyde-modified LDL by macrophage 
scavenger receptors [162, 163], and increased intracellular cholesteryl ester 
accumulation comparable to macrophages exposed to acetylated LDL [162]. 
Unlike the observations with methylglyoxal-modified LDL, REM, SDS-
PAGE and loss of Lys and Trp residues observed for this glycolaldehyde-modified 
LDL correlated better with J774A.1 cholesteryl ester loading. For the glycolaldehyde 
conditions a comparable REM to acetylated LDL resulted in cellular cholesteryl ester 
loading, unlike the observation with methylglyoxal-modified LDL. The conditions 
with extensive crosslinking/aggregation of glycolaldehyde-modified LDL induced 
foam cell formation as well. Complete consumption of available Lys and Trp residues 
occurred in the conditions that induced cholesteryl ester accumulation. Jinnouchi et al 
reported that > than 60 % Lys modification by glycolaldehyde was needed to induce 
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 foam cell formation [162], which is in agreement with the data in this Section. Loss of 
Arg residues, the only condition where faster kinetics were observed in the 
methylglyoxal experiments, did not correlate with foam cell formation in the 
glycolaldehyde studies. The only condition where significant loss of Arg residues was 
observed was in the 100 mM glycolaldehyde condition and cholesteryl ester 
accumulation was observed in cells exposed to 10 mM glycolaldehyde-modified 
LDL. Therefore not only were faster reaction kinetics observed with glycolaldehyde-
modified LDL, but the measured parameters also correlated better with cholesteryl 
ester accumulation, as compared to LDL modified by glucose or methylglyoxal. 
 
4.4  Conclusions 
At the start of the studies reported in this Chapter conditions were defined for 
examining the potential of glycated LDLs to induce model foam cell formation in the 
J774A.1 murine macrophage-like cell line. EDTA up to 12.5 μM, glucose up to 25 
mM, and methylglyoxal and glycolaldehyde at concentrations less than 1 mM, were 
shown not to significantly affect cell viability or protein. Concentrations of the 
aldehydes ≥ 1mM did significantly affect cell viability and protein. Aldehydes have 
been previously reported to affect LDH activity [357], thus potentially inferring with 
the measurement of cell viability, and to interfere with the BCA assay for cell protein 
[354]. It was therefore decided to remove excess reagents after the incubation periods 
using column chromatography; this treatment did not result it significant losses of 
LDL protein.  
The optimal range of LDL concentrations to induce model foam cell formation, 
using J77A.1 cells, was investigated with acetylated LDL at concentrations of 25-200 
μg protein/ml. These concentrations of acetylated LDL were shown to significantly 
increase intracellular free cholesterol and cholesteryl ester levels, in a concentration-
dependent manner. The free cholesterol and cholesteryl ester levels are in agreement 
with previously published work using acetylated LDL to produce a J774A.1 foam cell 
model  [154, 385, 388, 389]. Cholesteryl esters as a percent of total cholesterol 
averaged ~34 %. Thus suitable conditions for excess reagent removal after the LDL 
modification period, and exposure of macrophages were established; acetylated LDL 
and control LDL (LDL plus EDTA) were used as controls in subsequent experiments 
with glycated LDLs. 
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 J774A.1 viability and protein were not affected upon exposure to LDL modified 
by glucose, methylglyoxal or glycolaldehyde for up to 14 days. However different 
patterns were observed in cholesteryl ester accumulation upon exposure to these 
glycated LDLs. The greatest cholesteryl ester accumulation was observed in cells 
exposed to LDL modified by 100 mM glycolaldehyde for 7 days. Percent cholesteryl 
esters averaged ~ 45 %, 11 % higher than observed for cells expose to acetylated 
LDL. J774A.1 cells exposed to 7 day, 10 mM, glycolaldehyde-modified LDL resulted 
in average percent cholesteryl values (of total cholesterol) of 34 %, as seen in cells 
exposed to acetylated LDL. When cells were exposed to 100 mM, 24 hr, 
glycolaldehyde-modified LDL, cholesteryl ester levels were ~ 25 %. However LDL 
modified by 100 mM methylglyoxal for 14 days had cholesteryl ester levels only ~ 23 
% of total sterol levels. When J774A.1 cells were exposed to LDL modified by 100 
mM glucose, in the presence or absence of 1 μM Cu2+, no significant increases in 
cholesteryl esters were observed when compared to control cells (< 7 % of total sterol 
levels). Thus glycolaldehyde-modified LDL was a more potent inducer of model foam 
cell formation than methylglyoxal-modified LDL; in contrast glucose-modified LDL 
did not stimulate cholesteryl ester accumulation under the conditions used in this 
Chapter. 
These differences in behaviour in regard to the formation of model foam cells 
appears to be related, at least in part, to some of the LDL protein modifications 
reported in Chapter 3. Generally the greater the REM and crosslinking/aggregation 
observed in the SDS-PAGE experiments, the greater the extent of cholesteryl ester 
accumulation seen in the cells. These broad classifications explain the differences 
between glucose and the aldehydes, but not between methylglyoxal and 
glycolaldehyde. Consideration of the particular amino acid residue modified yields 
more significant information. Modification of Arg residues does not appear to be 
related to the cholesteryl ester accumulation in cells. This was the only residue 
measured that was lost in the glucose-modified LDL (over a 14 day incubation) and 
no cholesteryl ester accumulation was observed. With methylglyoxal and 
glycolaldehyde the loss of Trp and Lys residues seem to follow similar patterns, 
though the loss of Trp residues was slower. The greater the loss of these 2 residues the 
more significant the cholesteryl ester accumulation from the modified LDL appears to 
be. Thus more extensive and more rapid loss of Lys and Trp were observed in 
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 glycolaldehyde-modified LDL than methylglyoxal-modified LDL. Little work has 
been reported previously for Trp residues, however there seems to be a threshold of 
Lys modification that is necessary for macrophage scavenger receptor recognition and 
inducement of model foam cell formation, that varies between different LDL 
modifications [145, 146, 389]. This has been reported at 60 % Lys modification for 
glycolaldehyde-modified LDL [162], > 60 % for acetylation and succinylation of 
LDL [145] and > 16 % for malondialdehyde-modified LDL [145, 146]. Therefore it is 
possible that either the loss of Lys residues per se, or the products formed on the Lys 
residues, may be important for macrophage scavenger recognition and model foam 
cell formation. Modification of Lys and Arg residues, among others, is known to 
contribute to the increases in the negative charge of modified LDL particles, but as it 
is representative of overall charge, and not just Lys, REM values alone are not a 
conclusive indicator of potential model foam cell formation. 
Overall it appears that covalent protein modification (glycation) of LDL, in the 
absence of significant levels of oxidation, by the reactive aldehydes methylglyoxal 
and glycolaldehyde, can result in model foam cell formation. The reported results 
above outline a potential pathway to explain the increased atherosclerosis in people 
with diabetes. However, these studies have been carried out with a murine cell line, 
and not primary human cells, and other cell types in the arterial wall, for example 
endothelial and smooth muscle cells, have also been postulated to be involved in 
atherogenesis. The effects of these well-characterised glycated LDLs on these cells, as 
well as primary human macrophage cells, needs to be investigated and this forms the 
basis of the studies reported in the following Chapters. 
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5 CHAPTER 5: THE EFFECT OF LOW-DENSITY 
LIPOPROTEINS MODIFIED BY GLUCOSE, 
METHYLGLYOXAL AND GLYCOLALDEHYDE ON HUMAN 
UMBILICAL VEIN ENDOTHELIAL CELLS AND THE RAT 
AORTIC SMOOTH MUSCLE CELL LINE A7R5 
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 5.1   Introduction 
In previous Chapters the role of macrophages and the derived foam cells in 
atherosclerosis has been discussed. Endothelial and smooth muscle cells can also 
contribute to the development of atherosclerosis. Arterial endothelial cells form a 
selectively permeable barrier, a non–thrombogenic blood-tissue interface, regulate 
vascular tone, modulate immune and inflammatory reactions via cytokines and 
growth factors, produce intracellular matrix, and can modify lipoproteins and enhance 
foam cell formation by expressing adhesion molecules to trap monocytes (reviewed in 
[8, 14, 15]). Endothelial function is known to be altered by exposure to oxidised LDL, 
which can result in, for example, generation of reactive oxygen species [404], 
expression of adhesion molecules [405] and impaired anti-coagulant function [406, 
407]. Overall this endothelial dysfunction is considered atherogenic. Smooth muscle 
cells are important for vasoconstriction and arterial tone regulation, and in 
atherogenesis may migrate from the arterial media to intima and proliferate [10, 16, 
408], especially in response to inflammatory factors (such as oxidised LDL [409]). 
Smooth muscle cells also play a role in lipid metabolism by uptake and degradation of 
lipoproteins (reviewed in [8]). Smooth muscle cells have been reported to become 
foam cells in atherosclerotic lesions [241], and to be capable of accumulating large 
amounts of lipid in vitro, resulting in foam cell formation [8, 410-412]. Both 
endothelial and smooth muscle cells are also capable of modifying LDL [44, 148, 
149], such that it is recognised by macrophage scavenger receptors and can thereby 
contribute to foam formation [105, 147, 148]. 
 Endothelial and smooth muscle cell alterations/dysfunction have also been 
reported in diabetes [8]. The impairments in such cells exposed to high glucose levels 
may be due to the presence of glycation/glycoxidised products and/or AGE (see 
Sections 1.1.3.b and 1.3.3.d.). Receptors that bind AGE-modified proteins have been 
shown to be present on both endothelial and smooth muscle cells. Thus receptors for 
AGE (RAGE) are expressed on both endothelial and smooth muscle cells, both in vivo 
and in vitro [280, 285, 286, 294, 295]. AGE-endothelial interactions can induce 
expression of adhesion molecules and cytokines, vascular permeability and lead to a 
pro-coagulant state of endothelial cells (reviewed in [280]). Exposure of smooth 
muscle cells to AGE-modified proteins can lead to cytotoxicity and oxidant 
production and result in chemotaxic migration and activation of the smooth muscle 
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 cells [285-287]. AGEs have also been detected in both smooth muscle cells and 
associated foam cells of atherosclerotic lesions [241]. Therefore it is possible that 
AGEs may affect normal endothelial or smooth muscle cell function. 
Glycated or glycoxidised LDL have been reported to affect endothelial and 
smooth muscle cells. A study by Rabini et al demonstrated that endothelial cells 
exposed to LDL, from either healthy patients or people with diabetes, had decreased 
membrane fluidity, and cells exposed to diabetic LDL had altered function in regards 
to nitric oxide release, cytoplasmic Ca2+ levels, conjugated diene content and Na+-K+-
ATPase activity [413]. Exposure of aortic rings to oxidised or glycoxidised LDL, but 
not glycated LDL, significantly inhibited endothelium-dependent relaxation. Greatest 
inhibition was seen in rings exposed to glycoxidised LDL, and was attributed to 
increased superoxide radical production and resulting nitric oxide inactivation [282]. 
Studies using methylglyoxal-modified LDL however showed no activation of 
endothelial cells, as measured by the expression of monocyte chemoattractant protein-
1 and VCAM-1 [167]. Smooth muscle cell toxicity and apoptosis may be induced by 
exposure of these cells to glycated/glycoxidised BSA and LDL [286, 288]. Glycated 
and glycoxidised LDL has also been shown to induce smooth muscle cell proliferation 
and migration [288, 289]. 
Therefore glycated or glycoxidised LDL may lead to adverse changes in other 
arterial cell types, other than macrophages. This has been poorly investigated with the 
few reported studies not using well-characterised LDL [167, 282, 288, 289]. Most 
studies have also not looked at more than one cell type with similarly modified LDL 
for direct comparisons [282, 288, 289, 413]. Thus this Chapter examines the effect of 
well-characterised LDL (Chapter 3), prepared similarly to the previous macrophage 
studies reported in Chapter 4, on smooth muscle and endothelial cells. 
 
5.2  Aims 
  The aims of these studies were to examine the effect of LDL modified by 
glucose, methylglyoxal or glycolaldehyde on other arterial cell types besides 
macrophages, namely endothelial and smooth muscle cells. Cell viability, protein and 
cholesterol and cholesteryl ester content will be analysed, as in Chapter 4 with 
macrophages, using human umbilical vein endothelial cells (HUVEC) and the rat 
aortic smooth muscle cell line A7r5. 
 155
 5.3  Results 
 
5 .3 .1  Human Umbilical Vein Endothelial Cells 
 
5 .3 .1 .a  Exposure of Human Umbilical Vein Endothelial Cells to Low-Density 
Lipoproteins Modified by Glucose, in the Presence or Absence of Cu2+ 
HUVEC were isolated enzymatically by incubation with collagenase and 
cultured as described in Section 2.5.3. LDL (1 mg protein/ml) was prepared as 
previously, and modified, (see Sections 2.3.2.c and 3.3.1), for 14 days with 50 μM 
EDTA or 100 mM glucose, in the presence or absence of 1 μM Cu2+, at 37 ºC, in 
PBS. This LDL was then subjected to column chromatography before HUVEC were 
exposed to the glucose-modified LDL, at concentrations of 0-200 μg protein/ml of 
media, for 48 hr (as described in Section 2.6.1). These concentrations of LDL have 
been used in other studies with no reported cellular effects [404, 406, 413]. Cells were 
also exposed to acetylated LDL (as prepared in Section 2.3.2.a) or LDL free-media 
for the same time period (control cells). Exposure of cells to modified LDL was 
followed by a 2 hr exposure to equilibrium media before cell lysis (Section 2.6.1) and 
analyses. LDH and BCA assays were performed, to assess cell viability and protein, 
as described previously (see Sections 2.6.1.b and 2.3.3 respectively). HUVEC 
cholesterol and cholesteryl ester levels were determined by HPLC, as for the J774A.1 
macrophage experiments (see Sections 2.4.2.a.i and 2.6.2). 
  Exposure of HUVEC to glucose-modified LDL or acetylated LDL 
resulted in no significant differences in viability, cell protein, or cellular cholesterol or 
cholesteryl ester levels, as compared to cells incubated with no LDL, or LDL and 
EDTA. HUVEC viability or cell protein, regardless of which LDL the cells were 
exposed to, was not significantly different (P > 0.05) from the viability (87 ± 5 %; 
Fig. 5.1A) or the cell protein levels (35 ± 2 μg; Fig. 5.1B) of control cells. Free 
cholesterol levels in HUVEC were also not significantly different (P > 0.05) in cells 
exposed to modified LDL, when compared to cells exposed to no LDL, or LDL plus 
EDTA.  
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Figure 5.1 The effect of LDL (1 mg protein/ml) modified by 100 mM glucose, in the presence or 
absence of 1 μM Cu2+ (gLDL ± Cu2+), for 14 days, at 37 °C, on HUVEC viability (Panel A) and cell 
protein (Panel B). Cells were also exposed to LDL incubated with 50 μM EDTA (LDL + EDTA) or 
modified by acetylation (AcLDL). LDL was subjected to column chromatography before cells were 
exposed to the modified LDL for 48 hr, followed by a 2 hr equilibrium period, before cell lysis, and 
determination of cell viability by the LDH assay and cell protein by the BCA assay.  Control cells were 
exposed to media only for the same period. Data are mean ± SEM from 3 experiments with triplicate 
samples. Statistical analysis, by 2-way ANOVA, showed that LDL modification or concentration, had 
no significant effect (P > 0.05) on cell viability or protein. 
 
Free cholesterol levels in control cells were 109 ± 8 nmoles/mg cell protein 
(Fig. 5.2A). Cholesteryl ester levels trended to be higher in cells exposed to LDL, 
however, this did not reach significance. Total cholesteryl esters, in control cells, were 
5 ± 3 nmoles/mg cell (Fig. 5.2B), equating to 4 ± 2 % cholesteryl esters of total sterol 
levels (Fig. 5.2C).  Levels of cholesteryl esters in cells exposed to LDL reached 13 ± 
6 nmoles/mg cell protein or 8 ± 3 %. The cholesteryl ester content was comprised 
mainly of cholesteryl linoleate, with levels up to 6 nmoles/mg cell protein, and then, 
with levels up to 2 nmoles/mg cell protein, cholesteryl oleate and arachidonate (Table 
5.1). Minimal levels of cholesteryl docosahexaenoate, cholesteryl palmitate and 
cholesteryl stearate were detected. 
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 Overall, under the parameters examined, exposure of HUVEC to LDL 
modified by acetylation, EDTA or glucose, in the presence or absence of Cu2+, 
resulted in no significant changes in cell viability, protein, cholesterol or cholesteryl 
ester levels. 
Figure 5.2 The effect of LDL (1 mg protein/ml) modified by 100 mM glucose, in the presence or 
absence of 1 μM Cu2+, for 14 days, at 37 °C, on HUVEC free cholesterol (Panel A), total cholesteryl 
esters (CE) (Panel B), and percent cholesteryl esters (Panel C). Cells were also exposed to LDL 
incubated with 50 μM EDTA (LDL + EDTA) or modified by acetylation (AcLDL). LDL was subjected 
to column chromatography before cells were exposed to the modified LDL for 48 hr, followed by a 2 
hr equilibrium period, before cell lysis, lipid extraction and cellular cholesterol and cholesteryl ester 
content determined by HPLC.  Control cells were exposed to media only for the same period. Total 
cholesterol is the sum of free cholesterol and total cholesteryl esters. Data are mean ± SEM from 3 
experiments with triplicate samples. Statistical analysis, by 2-way ANOVA, showed that LDL 
modification or concentration, had no significant effects (P > 0.05) on cholesterol and cholesteryl ester 
levels as compared to the LDL + EDTA control. 
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 Ester Control LDL + EDTA gLDL gLDL + Cu2+  
CD 0.28 ± 0.14 0.86 ± 0.29 0.81 ± 0.32 0.54 ± 0.13 
CA 1.10 ± 0.70 2.50 ± 0.53 2.52 ± 1.06 1.65 ± 0.13 
CL 3.94 ± 2.89 5.91 ± 2.65 6.46 ± 2.45 5.03 ± 1.38 
CO 0.00 ± 0.00 2.30 ± 1.18 3.14 ± 1.85 2.10 ± 1.08 
CP 0.00 ± 0.00 0.54 ± 0.54 0.34 ± 0.34 0.23 ± 0.23 
CS 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 
Table 5.1 Levels of individual cholesteryl esters (nmoles/mg cell protein) in HUVEC after exposure to 
200 μg/ml modified LDL. LDL (1 mg protein/ml) was modified for 14 days by 50 μM EDTA (LDL + 
EDTA) or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± Cu2+), at 37 °C. After 
14 days of incubation all modified LDLs were subject to column chromatography. Cells were exposed 
to the modified LDLs for 48 hr, followed by a 2 hr equilibrium period, before cell lysis and cellular 
cholesterol and cholesteryl ester levels determined by HPLC. Control cells were exposed to media 
alone for the same time periods. The esters examined were cholesteryl docosahexaenoate (CD), 
cholesteryl arachidonate (CA), cholesteryl linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate 
(CO), and cholesteryl stearate (CS). Only the 200 μg/ml LDL loading condition is shown, and no 
acetylated LDL data, to reduce volume of data. Data are mean ± SEM from 3 or more experiments with 
triplicate samples. Statistical analysis, by 1-way ANOVA using Tukey’s post hoc testing, showed no 
significant difference (P > 0.05), in cholesteryl ester levels in cells exposed to modified LDL compared 
to control cells. 
 
5 .3 .1 .b  Exposure of Human Umbilical Vein Endothelial Cells to Low-Density 
Lipoproteins Modified by Methylglyoxal 
In the previous Section it was shown that exposure of HUVEC to LDL modified 
by acetylation, EDTA or glucose had no significant effects on cell viability, protein 
cholesterol or cholesteryl ester levels. In this Section the effect of LDL, modified by 
the more reactive species methylglyoxal, is examined. LDL (1 mg protein/ml) was 
prepared as previously (see Sections 2.3.2.d and 3.3.2), by modification for 5 days 
with 50 μM EDTA or 10 or 100 mM methylglyoxal, at 37 ºC, in PBS. This LDL was 
then subjected to column chromatography before HUVEC were exposed to the 
modified LDL, at concentrations of 0-200 μg protein/ml of media, for 48 hr. Cells 
were also exposed to acetylated LDL or LDL free media for the same time period 
(control cells). Exposure of cells to LDL was followed by a 2 hr exposure to 
equilibrium media before cell lysis and analyses. LDH and BCA assays were 
performed, for cell viability and protein, as described previously  (see Sections 2.6.1.b 
and 2.3.3 respectively). HUVEC cholesterol and cholesteryl ester levels were 
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 determined by HPLC, as in the J774A.1 macrophage experiments (see Sections 
2.4.2.a.i and 2.6.2). 
Exposure of HUVEC to LDL modified by methylglyoxal did not affect cell 
viability or protein levels. Cell viability, under all conditions was not significantly 
different (P > 0.05) from the control cell viability of 87 ± 8 % (Fig. 5.3A). Cell 
protein levels, under all conditions, were also not significantly different (P > 0.05) 
from the control cell values of 22 ± 6 μg/well (Fig. 5.3B). Free cholesterol content in 
HUVEC exposed to methylglyoxal-modified LDL was also unchanged, however there 
were variations in cholesteryl ester levels. Free cholesterol levels, in all conditions 
were not significantly different (P > 0.05) from the control cell values of 138 ± 15 
nmoles/mg cell protein (Fig. 5.4A).  
When cells were exposed to the modified and control LDL increased cholesteryl 
esters levels were detected (Fig. 5.4B). This was not seen in the previous glucose 
experiments, due to a large variation in the control cell cholesteryl ester levels. Total 
cholesteryl ester levels in the control cells were 2 ± 2 nmoles/mg cell protein and 
reached levels of 15 ± 5 nmoles/mg cell protein in cells exposed to acetylated LDL at 
200 μg protein/ml media. Levels of cholesteryl esters in cells exposed to LDL 
modified by acetylation, EDTA or 100 mM methylglyoxal were not significantly 
different (P > 0.05) from each other. However, in cells exposed to LDL modified by 
10 mM methylglyoxal at 50 and 200 μg protein/ml media the cholesteryl ester content 
was significantly lower (P < 0.05), with levels of 5 ± 1 nmoles/mg cell protein 
achieved. Cells exposed to LDL modified by 10 mM methylglyoxal at 100 μg 
protein/ml media did not have significantly less (P > 0.05) cholesteryl esters when 
compared to other cells exposed to modified LDL; however the values under this 
condition had greater variance. 
When examining percent cholesteryl esters the same patterns were observed, 
as for total cholesteryl esters (Fig. 5.4C). In cells exposed to acetylated LDL at 200 
μg protein/ml media percent cholesteryl esters reached levels of 10 ± 2 %, as 
compared to 1 ±1 % in control cells. The levels in cells exposed to LDL modified by 
acetylation, EDTA or 100 mM methylglyoxal were not significantly different (P > 
0.05) from one another, however there were significantly less (P < 0.05) percent 
cholesteryl esters in cells exposed to LDL modified by 10 mM methylglyoxal (2 ± 1 
%). 
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Figure 5.3 The effect of LDL (1 mg protein/ml) modified by 10-100 mM methylglyoxal (MG-LDL), 
for 5 days, at 37 °C, on HUVEC viability (Panel A) and cell protein (Panel B). Cells were also exposed 
to LDL incubated with 50 μM EDTA (LDL + EDTA) or modified by acetylation (AcLDL). LDL was 
subjected to column chromatography before cells were exposed to the modified LDL for 48 hr, 
followed by a 2 hr equilibrium period, before cell lysis, and determination of cell viability by the LDH 
assay and cell protein by the BCA assay.  Control cells were exposed to media only for the same 
period. Data are mean ± SEM from 3 experiments with triplicate samples. Statistical analysis, by 2-way 
ANOVA, showed that LDL modification or concentration, had no significant effect (P > 0.05) on cell 
viability or protein. 
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Figure 5.4 The effect of LDL (1 mg protein/ml) modified by 10-100 mM methylglyoxal (MG-LDL), 
for 5 days, at 37 °C, on HUVEC free cholesterol (Panel A), total cholesteryl esters (CE) (Panel B) and 
percent cholesteryl esters (Panel C). Cells were also exposed to LDL incubated with 50 μM EDTA 
(LDL + EDTA) or modified by acetylation (AcLDL). LDL was subjected to column chromatography 
before cells were exposed to the modified LDL for 48 hr, followed by a 2 hr equilibrium period, before 
cell lysis, lipid extraction and cellular cholesterol and cholesteryl ester content determined by HPLC.  
Control cells were exposed to media only for the same period. Total cholesterol is the sum of free 
cholesterol and total cholesteryl esters. Data are mean ± SEM from 3 experiments with triplicate 
samples. Statistical analysis, by 2-way ANOVA, showed that LDL modification or concentration, had 
no significant effects (P > 0.05) on cellular free cholesterol levels. * Indicates the 10MG-LDL 
condition is significantly different (P < 0.05) from the LDL + EDTA and AcLDL conditions. 
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 Table 5.2 shows the levels of individual cholesteryl esters in the 
methylglyoxal experiments. Cholesteryl linoleate levels were the highest in cell 
exposed to modified LDL, at approximately 6 nmoles/mg cell protein. The 
cholesteryl esters with the next highest levels were cholesteryl arachidonate and 
oleate and only minimal levels of cholesteryl docosahexaenoate, palmitate and 
stearate were detected. The levels of cholesteryl arachidonate and docosahexaenoate 
were significantly increased (P < 0.05) in HUVEC exposed to LDL modified by 
EDTA or 100 mM methylglyoxal, as compared to control cells or cells exposed to 
LDL modified by 10 mM methylglyoxal. 
HUVEC exposed to methylglyoxal-modified LDL did not show reductions in 
cell viability or protein. Free cholesterol levels in HUVEC are also not affected upon 
exposure to LDL. HUVEC exposed to LDL modified by acetylation or 100 mM 
methylglyoxal also did not have significantly increased cholesteryl ester levels from 
cells exposed to control LDL. However, HUVEC exposed to LDL modified by 10 
mM methylglyoxal, had significantly lower cholesteryl ester levels when compared to 
cells exposed to the other modified forms of LDL. 
 
 
Ester Control LDL + EDTA 10MG-LDL 100MG-LDL 
CD 0.00 ± 0.00a 0.57 ± 0.07b 0.23 ± 0.17ab 0.51 ± 0.12b
CA 0.24 ± 0.24a 2.39 ± 0.21b 0.71 ± 0.23a 1.94 ± 0.11b
CL 1.46 ± 1.46a 6.59 ± 0.66a 3.58 ± 1.09a 6.42 ± 1.90a
CO 0.00 ± 0.00a 3.40 ± 1.72a 0.00 ± 0.00a 0.59 ± 0.59a
CP 0.00 ± 0.00a 2.27 ± 1.61a 0.00 ± 0.00a 0.00 ± 0.00a
CS 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a 0.00 ± 0.00a
 
Table 5.2 Levels of individual cholesteryl esters (nmoles/mg cell protein) in HUVEC after exposure to 
200 μg/ml modified LDL. LDL (1 mg protein/ml) was modified for 5 days by 50 μM EDTA (LDL + 
EDTA) or 10-100 mM methylglyoxal (MG-LDL), at 37 °C. After 5 days of incubation all modified 
LDLs were subject to column chromatography. Cells were exposed to the modified LDLs for 48 hr, 
followed by a 2 hr equilibrium period, before cell lysis and cellular cholesterol and cholesteryl ester 
levels determined by HPLC. Control cells were exposed to media alone for the same time periods. The 
esters examined were cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl 
linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Only 
the 200 μg/ml LDL loading condition is shown, and no acetylated LDL data, to reduce volume of data. 
Data are mean ± SEM from 3 or more experiments with triplicate samples. Numbers with different 
superscripts are significantly different (P < 0.05), by 1-way ANOVA using Tukey’s post hoc testing. 
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 5 .3 .1 . c  Exposure of Human Umbilical Vein Endothelial Cells to Low-Density 
Lipoproteins Modified by Glycolaldehyde  
In the previous Section it was shown that exposure of HUVEC to LDL modified 
by methylglyoxal had no effect on cell viability, protein or free cholesterol. No 
changes in cellular cholesteryl esters were observed, except for cells exposed to LDL 
modified by 10 mM methylglyoxal, where less cholesteryl esters were detected. In 
this Section the effect of LDL, modified by glycolaldehyde, is examined. LDL (1 mg 
protein/ml) was prepared as previously (see Sections 2.3.2.e and 3.3.3), by 
modification for 7 days with 50 μM EDTA or 1-100 mM glycolaldehyde, at 37 ºC, in 
PBS. This LDL was then subjected to column chromatography before HUVEC were 
exposed to the modified LDL, at concentrations of 0-200 μg protein/ml of media, for 
48 hr. Cells were also exposed to acetylated LDL or LDL free media for the same 
time period (control cells). Exposure of cells to LDL was followed by a 2 hr exposure 
to equilibrium media before cell lysis and analyses. Cell viability, protein, free 
cholesterol, and cholesteryl ester levels were determined as described previously. 
Exposure of HUVEC to LDL modified by glycolaldehyde did not affect cell 
viability, protein or free cholesterol levels. Cell viability, under all conditions was not 
significantly different (P > 0.05) from the control cell viability of 86 ± 3 % (Fig. 
5.5A). Cell protein levels, under all conditions, were also not significantly different (P 
> 0.05) from the control cell values of 44 ± 5 μg/well (Fig. 5.5B). Free cholesterol 
levels, in all conditions were not significantly different (P > 0.05) from the control 
cell values of 80 ± 15 nmoles/mg cell protein (Fig. 5.6A).  
When cells were exposed to LDL increased cholesteryl esters levels were 
detected (Fig. 5.6B). Total cholesteryl ester levels in the control cells were 1 ± 1 
nmoles/mg cell protein and reached levels of ~ 9 nmoles/mg cell protein in cells 
exposed to LDL at 200 μg protein/ml media. Levels of cholesteryl esters in cells 
exposed to LDL modified by acetylation, EDTA or glycolaldehyde were not 
significantly different (P > 0.05) from each other. A similar pattern was also observed 
when examining percent cholesteryl ester levels, of total cholesterol (Fig. 5.6C). 
Percent cholesteryl esters were 1 ± 1 % in control cells and rose to ~ 8 % in cells 
exposed to LDL.  
  
 164
 0
20
40
60
80
100
0 50 100 200
Control AcLDL
LDL + EDTA 1GA-LDL
10GA-LDL
 
Figure 5.5 The effect of LDL (1 mg protein/ml) modified by 1-100 mM glycolaldehyde (GA-LDL), for 
7 days, at 37 °C, on HUVEC viability (Panel A) and cell protein (Panel B). Cells were also exposed to 
LDL incubated with 50 μM EDTA (LDL + EDTA) or modified by acetylation (AcLDL). LDL was 
subjected to column chromatography before cells were exposed to the modified LDL for 48 hr, 
followed by a 2 hr equilibrium period, before cell lysis, and determination of cell viability by the LDH 
assay and cell protein by the BCA assay.  Control cells were exposed to media only for the same 
period. Data are mean ± SEM from 3 experiments with triplicate samples. Statistical analysis, by 2-way 
ANOVA, showed that LDL modification or concentration, had no significant effect (P > 0.05) on cell 
viability or protein. 
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Figure 5.6 The effect of LDL (1 mg protein/ml) modified by 1-100 mM glycolaldehyde (GA-LDL) for 
7 days, at 37 °C, on HUVEC free cholesterol (Panel A), total cholesteryl esters (CE) (Panel B) and 
percent cholesteryl esters (Panel C). Cells were also exposed to LDL incubated with 50 μM EDTA 
(LDL + EDTA) or modified by acetylation (AcLDL). LDL was subjected to column chromatography 
before cells were exposed to the modified LDL for 48 hr, followed by a 2 hr equilibrium period, before 
cell lysis, lipid extraction and cellular cholesterol and cholesteryl ester content determined by HPLC.  
Control cells were exposed to media only for the same period. Total cholesterol is the sum of free 
cholesterol and total cholesteryl esters. Data are mean ± SEM from 3 experiments with triplicate 
samples. Statistical analysis, by 2-way ANOVA, showed that LDL modification or concentration, had 
no significant effects (P > 0.05) on cholesterol and cholesteryl ester levels as compared to the LDL + 
EDTA control. 
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 Cholesteryl lineolate was the most abundant cholesteryl ester at levels up to 4 
nmoles/mg cell protein (Table 5.3). The next most abundant esters were cholesteryl 
oleate and arachidonate; minimal levels of cholesteryl docosahexaenoate, palmitate 
and stearate were detected. 
Overall, the cell viability, protein and free cholesterol levels are unchanged 
when HUVEC were exposed to glycolaldehyde-modified LDL. Cholesteryl ester 
levels in HUVEC were not significantly increased in cells exposed to LDL modified 
or acetylation or glycolaldehyde, as compared to cells exposed to control LDL. 
 
 
 
Ester Control LDL + EDTA 1GA-LDL 10GA-LDL 100GA-LDL 
CD 0.10 ± 0.10 0.58 ± 0.06 0.55 ± 0.11 0.50 ± 0.13 0.43 ± 0.16 
CA 0.19 ± 0.19 1.65 ± 0.19 1.69 ± 0.49 1.68 ± 0.55 1.43 ± 0.49 
CL 0.59 ± 0.59 4.04 ± 0.53 4.09 ± 1.30 4.05 ± 1.25 3.58 ± 1.50 
CO 0.00 ± 0.00 1.91 ± 1.05 1.47 ± 0.80 1.51 ± 0.88 0.87 ± 0.51 
CP 0.00 ± 0.00 0.77 ± 0.77 0.26 ± 0.26 0.62 ± 0.62 0.00 ± 0.00 
CS 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 
Table 5.3 Levels of individual cholesteryl esters (nmoles/mg cell protein) in HUVEC after exposure to 
200 μg/ml modified LDL. LDL (1 mg protein/ml) was modified for 14 days by 50 μM EDTA (LDL + 
EDTA) or 1-100 mM glycolaldehyde (GA-LDL), at 37 °C. After 7 days of incubation all modified 
LDLs were subject to column chromatography. Cells were exposed to the modified LDLs for 48 hr, 
followed by a 2 hr equilibrium period, before cell lysis and cellular cholesterol and cholesteryl ester 
levels determined by HPLC. Control cells were exposed to media alone for the same time periods. The 
esters examined were cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl 
linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Only 
the 200 μg/ml LDL loading condition is shown, and no acetylated LDL data, to reduce volume of data. 
Data are mean ± SEM from 3 or more experiments with triplicate samples. Statistical analysis, by 1-
way ANOVA using Tukey’s post hoc testing, showed no significant difference (P > 0.05), in 
cholesteryl ester levels in cells exposed to modified LDL compared to control cells. 
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 5 .3 .1 .d  Discussion 
For in vitro studies of a vascular endothelial cell, HUVEC are a common and 
appropriate cell type to use [94, 294, 350, 404, 405, 413, 414].      HUVEC were 
exposed, as in the previous macrophage studies (Chapter 4), to LDL that was glycated 
as well as acetylated and control (incubated with EDTA) LDL. HUVEC were exposed 
to acetylated LDL, as this is a widely used and well-studied modification, and 
provides a basis for comparison with the macrophage experiments. Cells were also 
exposed to LDL that was incubated with EDTA for the same time periods that other 
LDL was incubated with glycation agents, as the studies reported in Chapter 3, that 
demonstrated that this LDL was minimally modified and suitable to use as incubation 
control LDL. 
 HUVEC viability or cell protein was not affected upon exposure to LDL 
modified by acetylation, EDTA, glucose, methylglyoxal or glycolaldehyde. Cell 
viability, determined by intracellular LDH release, was less than 20 % under all 
conditions. Cell protein, determined by the BCA assay, which was used as an 
indicator of cell number and to correct sterol values for inter-experimental variation, 
did not change regardless of which modification of LDL the cells were exposed to, or 
if they were exposed to LDL at all. This is in agreement with other published works 
which do not report any cytotoxicity of diabetic LDL [413], glycated/glycoxidised 
LDL [167] or oxidised LDL [404-406], at the concentrations utilised in these studies. 
Therefore, any observed differences in cellular lipid levels, after exposure to different 
glycated LDLs, cannot be attributable to significant losses in cell viability or number. 
Free cholesterol levels in HUVEC were not significantly affected by exposure 
to LDL, regardless of the extent or type of modification. Free cholesterol content in 
cells exposed to LDL was not significantly different to control cells that were not 
exposed to LDL. Cellular free cholesterol content was generally in the range of 100-
150 nmoles/mg cell protein. As these values are in the range of free cholesterol levels 
in control cells in previous macrophage studies these values seem plausible, as 
comprehensive HUVEC data seems to be lacking. 
Regardless of the modification of LDL, in nearly all conditions, an increase in 
cellular cholesteryl ester levels was detected The most abundant cholesteryl ester was 
cholesteryl linoleate; with the next most abundant esters being cholesteryl oleate and 
arachidonate. Minimal levels of cholesteryl docosahexaenoate, palmitate and stearate 
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 were detected. Levels of cholesteryl esters in control cells were up to 5 nmoles/mg 
cell protein (or 4 % of total sterol levels), and reached levels of 15 nmoles/mg cell 
protein (or 10 % of total sterol levels) in cells exposed to LDL. However, in most 
conditions the levels of cholesteryl esters in the cells exposed to LDL modified by 
acetylation, 100 mM glucose, 100 mM methylglyoxal or 1-100 mM glycolaldehyde 
were not significantly different from cells exposed to incubation control LDL (LDL 
plus EDTA). This suggests that these changes in the cholesteryl ester levels were a 
LDL effect and not related to the modification of the LDL, whether it was acetylation 
or glycation. Havekes et al reported no increases in cellular cholesterol ester levels 
upon exposure of HUVEC to native or acetylated LDL; however it is not clear 
whether the results reported were free cholesterol or total cholesterol levels (free 
cholesterol plus total cholesteryl esters) [415]. No other data on HUVEC cholesteryl 
ester levels, upon exposure to LDL, have been reported, as far can be ascertained.  
There was one situation in which the exposure of HUVEC to LDL did not result 
in an increase in cellular cholesteryl esters. Generally in cells exposed to LDL 
modified by 10 mM methylglyoxal cellular cholesteryl ester levels were not 
significantly different from control cells (that is cells exposed to no LDL) and were 
significantly lower than cells exposed to LDL modified by acetylation, 100 mM 
methylglyoxal or EDTA. This mimics a similar effect in J774A.1 cells (see Section 
4.3.4), also exposed to similarly modified LDL, which had decreased cholesteryl 
esters as compared to cells exposed to control LDL, perhaps due to differential 
receptor recognition. However, further investigation is needed to determine if this 
result is truly significant. 
These results indicate that HUVEC have receptors, or other uptake mechanisms, 
which recognise LDL, and perhaps to a limited degree differentiate between different 
modifications of LDL. Work by van Hinsberg et al indicated that approximately 70 % 
of HUVEC LDL uptake was via low-affinity endocytosis, 17 % by high-affinity 
endocytosis and 12 % via pinocytosis [416]. Kume et al demonstrated receptor 
mediated incorporation of 125I-LDL, modified by acetylation or oxidation, in HUVEC 
and suggested that these cells may have an additional receptor that recognise 
acetylated LDL, but not oxidised LDL [417]. Havekes et al also report data 
supporting receptor-mediated uptake of LDL by HUVEC. They also suggested that 
the binding of native LDL and acetylated LDL proceeded by 2 different high affinity 
receptors [415].   
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 Overall there appears to be little effect of glycated LDL on HUVEC, in terms of 
cell viability, protein or in cholesterol and cholesteryl ester levels. However HUVEC 
do appear to take up LDL to a limited extent and there could be other more subtle 
cellular effects. Many studies have reported endothelial dysfunction in atherosclerosis 
and diabetes (as described in the Introduction of this Chapter), such as changes in 
expression of cytokines and adhesion molecules, perturbations in anti-coagulant 
function, and generation of oxidants (that can further modify LDL for macrophage 
uptake). Such effects could be occurring in the studies reported here, but this was not 
investigated. 
 
5 .3 .2  Rat Aortic A7r5 Smooth Muscle Cells 
 
5 .3 .2 .a  Exposure of A7r5 Smooth Muscle Cells to Low-Density Lipoproteins 
Modified by Glucose, in the Presence or Absence of Cu2+ 
LDL (1 mg protein/ml) was prepared, as previously for HUVEC experiments 
(see Section 5.3.1.a), by modification for 14 days with 50 μM EDTA or 100 mM 
glucose, in the presence or absence of 1 μM Cu2+, at 37 ºC, in PBS. This LDL was 
then subjected to column chromatography before addition to A7r5 cells that had been 
plated down overnight at 2 x 105 cells/well (see Section 2.5.4). Cells were exposed to 
the glucose-modified LDL and appropriate control LDL, at concentrations of 0-200 
μg protein/ml of media, as in other cell experiments, for 24 hr (as described in Section 
2.6.1). Exposure of cells to modified LDL was followed by a 2 hr exposure to 
equilibrium media before cell lysis and analyses, as described for HUVEC 
experiments (Section 5.3.1.a). 
  Exposure of A7r5 cells to glucose-modified LDL or acetylated LDL resulted 
in no significant differences in viability, cell protein, or cellular free cholesterol 
levels, as compared to cells incubated with no LDL, or LDL plus EDTA. A7r5 cell 
viability or protein, was not significantly different (P > 0.05) from the viability (94 ± 
2 %; Fig. 5.7A) or the cell protein (174 ± 43 μg; Fig. 5.7B) of control cells. Free 
cholesterol levels in HUVEC were also not significantly different (P > 0.05) in cells 
exposed to modified LDL, when compared to cells exposed to no LDL, or LDL plus 
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 EDTA (Fig. 5.7C). Free cholesterol levels in control cells were 65 ± 14 nmoles/mg 
cell protein. No cholesteryl esters were detected under any conditions, irrespective of 
LDL modification, or not, or concentration. 
 The lack of changes in cell protein levels suggests that exposure of the cells to 
the glucose-modified LDL does not induce cell proliferation. However, it has been 
reported that if cells are in a subconfluent, serum-deprived state, that mimics the in 
vivo G0 phase, smooth muscle cell proliferation may be stimulated [351, 352], so 
further studies were undertaken using such conditions. 
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Figure 5.7 The effect of LDL (1 mg protein/ml) modified by 100 mM glucose, in the presence or 
absence of 1 μM Cu2+ (gLDL ± Cu2+), for 14 days, at 37 °C, on A7r5 smooth muscle cells; Panel A: 
viability, Panel B: cell protein and Panel C: free cholesterol levels. Cells were also exposed to LDL 
incubated with 50 μM EDTA (LDL + EDTA) or modified by acetylation (AcLDL). LDL was subjected 
to column chromatography before cells were exposed to the modified LDL for 24 hr, followed by a 2 
hr equilibrium period, before cell lysis, and determination of cell viability by the LDH assay, cell 
protein by the BCA assay, and cholesterol and cholesteryl ester levels by HPLC.  Control cells were 
exposed to media only for the same period. No cellular cholesteryl esters were detected under any 
conditions. Data are mean ± SEM from 3 experiments with triplicate samples. Statistical analysis, by 2-
way ANOVA, showed that LDL modification or concentration, had no significant effect (P > 0.05) on 
cell viability, protein or free cholesterol levels. 
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 5 .3 .2 .a . i  Serum-Deprived Cells 
It was hypothesised that if that the A7r5 cells were serum-deprived at a 
subconfluent level, smooth muscle cell proliferation might be stimulated, as reported 
in other studies using these cells [351, 352]. Therefore A7r5 cells were plated down at 
1 x 105 cells/well using 10 % FCS and then exposed to 0.2% FCS for 48 hr (as 
described in Section 2.5.4.a). The resulting subconfluent cells were then incubated 
with modified LDL that was prepared as described in Section 5.3.2.a and added to 
cells for 24 hr in media containing 10 % LPDS, followed by a 2 hr equilibrium period. 
Cells were then lysed and assayed as in Section 5.3.2.a. 
Exposure of serum-deprived cells to LDL modified by glucose, in the presence 
or absence of Cu2+, or acetylation, resulted in no changes in cell viability, protein or 
cellular free cholesterol, as compared to controls. Regardless of which modified LDL 
the cells were exposed to, and what concentration, cell viability and protein were not 
significantly different (P > 0.05) from control cell values of 93 ± 2 % for viability 
(Fig. 5.8A) and 109 ± 10 μg for protein (Fig. 5.8B). The control protein value is much 
less than the protein value of 174 μg in the non-serum-deprived cell experiments (see 
Section 5.3.2.a), confirming that the cells were in a subconfluent state, suitable for 
stimulation of proliferation. Cellular free cholesterol in any condition was not 
significantly different (P > 0.05) from control cell values of 58 ± 5 nmoles/mg cell 
protein (Fig. 5.8C), and no cholesteryl esters were detected. 
Serum deprivation of cells, before exposure to glucose-modified LDL, did not 
induce changes in cell viability, protein or free cholesterol content. The lack of 
changes in cell protein content per well suggest that cellular proliferation was not 
induced, as seen in some other situations. 
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Figure 5.8 The effect of LDL (1 mg protein/ml) modified by 100 mM glucose, in the presence or 
absence of 1 μM Cu2+ (gLDL ± Cu2+), for 14 days, at 37 °C, on serum-deprived A7r5 smooth muscle 
cells; Panel A: viability, Panel B: cell protein and Panel C: free cholesterol levels. Cells were also 
exposed to LDL incubated with 50 μM EDTA (LDL + EDTA) or modified by acetylation (AcLDL). 
LDL was subjected to column chromatography before serum-deprived cells were exposed to the 
modified LDL for 24 hr. This was followed by a 2 hr equilibrium period, before cell lysis, and 
determination of cell viability by the LDH assay, cell protein by the BCA assay, and cholesterol and 
cholesteryl ester levels by HPLC.  Control cells were exposed to media only for the same period. No 
cellular cholesteryl esters were detected under any conditions. Data are mean ± SEM from 3 
experiments with triplicate samples. Statistical analysis, by 2-way ANOVA, showed that LDL 
modification or concentration, had no significant effect (P > 0.05) on cell viability, protein or free 
cholesterol levels. 
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 5 .3 .2 .b  Exposure of A7r5 Smooth Muscle Cells to Low-Density Lipoproteins 
Modified by Methylglyoxal 
The previous Section investigated the effect of glucose-modified LDL on 
smooth muscle cells. In this Section the effect of methylglyoxal-modified LDL on 
A7r5 cells is examined, prepared similarly to the macrophage and endothelial cell 
experiments. LDL (1 mg protein/ml) was prepared, as previously, by modification for 
5 days with 50 μM EDTA or 10 or 100 mM methylglyoxal, at 37 ºC, in PBS (see 
Sections 2.3.2.d and 3.3.2). Cells were then incubated with this LDL, or appropriate 
control LDLs, followed by an equilibrium period, cell lysis and performance of the 
assays for cell viability, protein and cholesterol and cholesteryl ester levels, as 
described in Section 5.3.2.a. 
 Exposure of A7r5 cells to methylglyoxal-modified LDL resulted in no changes 
in cell viability, protein or free cholesterol. Cell viability was not significantly 
different (P > 0.05), in any cells exposed to LDL, from the control cell value of 95 ± 
1% (Fig. 5.9A). Likewise, cell protein in the control cells was 172 ± 8 μg, and this 
was not significantly different (P > 0.05) from any other condition (Fig. 5.9B), though 
there was a trend of decreasing cell protein with increasing concentration of 
methylglyoxal-modified LDL. Free cholesterol levels in cells exposed to 
methylglyoxal-modified LDL were not significantly different (P > 0.05) to the control 
cell values of 38 ± 12 nmoles/mg cell protein (Fig. 5.9C). No cholesteryl esters were 
detected in cells exposed to methylglyoxal-modified LDL. 
Exposure of A7r5 cells to methylglyoxal-modified LDL resulted in no 
significant changes of cell viability, protein or free cholesterol content, as compared 
to control cells. Methylglyoxal-modified LDL did not induce cellular proliferation 
under these conditions, as indicated by the cell protein levels. 
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Figure 5.9 The effect of LDL (1 mg protein/ml) modified by 10-100 mM methylglyoxal (MG-LDL), 
for 5 days, at 37 °C, on A7r5 smooth muscle cells; Panel A: viability, Panel B: cell protein, and Panel 
C: free cholesterol levels. Cells were also exposed to LDL incubated with 50 μM EDTA (LDL + 
EDTA) or modified by acetylation (AcLDL). LDL was subjected to column chromatography before 
cells were exposed to the modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell 
lysis, and determination of cell viability by the LDH assay, cell protein by the BCA assay, and 
cholesterol and cholesteryl ester levels by HPLC.  Control cells were exposed to media only for the 
same period. No cellular cholesteryl esters were detected under any conditions. Data are mean ± SEM 
from 3 experiments with triplicate samples. Statistical analysis, by 2-way ANOVA, showed that LDL 
modification or concentration, had no significant effect (P > 0.05) on cell viability, protein or free 
cholesterol levels. 
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 5 .3 .2 .b . i  Serum-Deprived Cells 
Serum-deprived cells were also exposed to methylglyoxal-modified LDL to 
see if proliferation or other changes could be induced. LDL was modified as in 
Section 5.3.2.b, and added to the serum-deprived cells (as described in Section 
5.3.2.a.i). 
Exposure of serum-deprived A7r5 cells to methylglyoxal-modified LDL, had 
no effect on cell viability, protein or cholesterol content. Cell viability, under any 
condition, was not significantly different (P > 0.05) from that seen in control cells (90 
± 2 %; Fig. 5.10A). Cell protein was also consistent throughout all conditions, with no 
cell protein values being significantly from the control cell value of 59 ± 12 μg (Fig. 
5.10B). The control protein value is 2-3 fold lower than the protein value of 172 μg in 
non-serum-deprived cell experiments (see Section 5.3.2.b), confirming the 
subconfluent state of these cells. The free cholesterol values were not significantly 
different from the control cell value of 104 ± 21 nmoles/mg cell protein (Fig. 5.10C). 
No cholesteryl esters were detected in cells in these studies. 
Serum-deprived cells exposed to methylglyoxal-modified LDL do not show 
significant changes in cell viability, protein or free cholesterol content. The lack of 
changes in cell protein values suggest no cellular proliferation was induced. 
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Figure 5.10 The effect of LDL (1 mg protein/ml) modified by 10-100 mM methylglyoxal (MG-LDL), 
for 5 days, at 37 °C, on serum-deprived A7r5 smooth muscle cells; Panel A: viability, Panel B: cell 
protein, and Panel C: free cholesterol levels. Cells were also exposed to LDL incubated with 50 μM 
EDTA (LDL + EDTA) or modified by acetylation (AcLDL). LDL was subjected to column 
chromatography before serum-deprived cells were exposed to the modified LDL for 24 hr. This was 
followed by a 2 hr equilibrium period, before cell lysis, and determination of cell viability by the LDH 
assay, cell protein by the BCA assay, and cholesterol and cholesteryl ester levels by HPLC.  Control 
cells were exposed to media only for the same period. No cellular cholesteryl esters were detected 
under any conditions. Data are mean ± SEM from 3 experiments with triplicate samples. Statistical 
analysis, by 2-way ANOVA, showed that LDL modification or concentration, had no significant effect 
(P > 0.05) on cell viability, protein or free cholesterol levels. 
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 5 .3 .2 . c  Exposure of A7r5 Smooth Muscle Cells to Low-Density Lipoproteins 
Modified by Glycolaldehyde  
The studies reported in the previous Sections have investigated the effect of 
glucose- and methylglyoxal-modified LDL on A7r5 smooth muscle cells. To 
complement these studies the effect of glycolaldehyde-modified LDL on A7r5 cells 
was also examined, using modified LDL prepared similarly to the macrophage and 
endothelial cell experiments. LDL (1 mg protein/ml) was prepared by modification 
for 7 days with 50 μM EDTA or 1-100 mM glycolaldehyde, at 37 ºC, in PBS (see 
Sections 2.3.2.e and 3.3.3). Cells were then incubated with this LDL, or appropriate 
control LDLs, followed by an equilibrium period, cell lysis and performance of the 
assays for cell viability, protein and cholesterol and cholesteryl ester levels, as 
described in Section 5.3.2.a. 
LDL modification by acetylation or glycolaldehyde had no significant on cell, 
viability, protein or free cholesterol levels, however in some instances there was an 
effect of LDL concentration. Cell viability under all conditions, regardless of LDL 
modification or concentration, was not significantly different from the control cell 
values of 96 ± 1% (Fig. 5.11A). Cell protein was not significantly affected (P > 0.05) 
by LDL modification, but was significantly decreased (P < 0.05) with increasing LDL 
concentrations (Fig. 5.11B). Control cells had a protein value of 167 ± 28 μg and with 
increasing LDL concentration cell protein decreased by up to 30-40 μg protein. Free 
cholesterol levels were not significantly affected by LDL modification but were 
significantly affected by LDL concentration (Fig. 5.11C). Free cholesterol levels in 
control cells were 52 ± 11 nmoles/mg cell protein and increased by 15-25 nmoles/mg 
cell protein, with increasing LDL concentrations the cells were exposed to. However 
as free cholesterol levels are expressed relative to the cell protein values, this effect 
may be due to the decreased values of the latter parameter. As with previous 
experiments no cholesteryl esters were detected. 
Overall, when A7r5 cells were exposed to glycolaldehyde-modified LDL, there 
was no effect of this modification on cell viability, protein or free cholesterol levels. 
Subsequent experiments examined the effect of serum deprivation on this system. 
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Figure 5.11 The effect of LDL (1 mg protein/ml) modified by 1-100 mM glycolaldehyde (GA-LDL), 
for 7 days, at 37 °C, on A7r5 smooth muscle cells; Panel A: viability, Panel B: cell protein, and Panel 
C: free cholesterol levels. Cells were also exposed to LDL incubated with 50 μM EDTA (LDL + 
EDTA) or modified by acetylation (AcLDL). LDL was subjected to column chromatography before 
cells were exposed to the modified LDL for 24 hr, followed by a 2 hr equilibrium period, before cell 
lysis, and determination of cell viability by the LDH assay, cell protein by the BCA assay, and 
cholesterol and cholesteryl ester levels by HPLC.  Control cells were exposed to media only for the 
same period. No cellular cholesteryl esters were detected under any conditions. Data are mean ± SEM 
from 3 experiments with triplicate samples. Statistical analysis, by 2-way ANOVA, showed that LDL 
modification or concentration, had no significant effect (P > 0.05) on cell viability. For cell protein and 
free cholesterol there was no significant effect of LDL modification (P > 0.05), but there was a 
significant effect of increasing LDL concentration (P < 0.05) decreasing cell protein values and 
increasing free cholesterol levels. 
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 5 . 3 . 2 . c . i  Serum-Deprived Cells 
Serum-deprived cells were exposed to glycolaldehyde-modified LDL to see if 
proliferation or other changes could be induced. LDL was modified as in Section 
5.3.2.c, and added to serum-deprived cells, as described in Section 5.3.2.a.i. 
Exposure of serum-deprived cells to LDL modified by glycolaldehyde, 
resulted in no changes in cell viability, protein or cellular free cholesterol, when 
compared to controls. Regardless of which modified LDL the cells were exposed to, 
and what concentration, cell viability and protein were not significantly different (P > 
0.05) from control cell values of 95 ± 1 % for viability (Fig. 5.12A) and 73 ± 7 mg for 
protein (Fig. 5.12B). The control protein value is ~ 2 fold lower than the protein value 
of 172 μg in non-serum-deprived cell experiments (see Section 5.3.2.c), confirming 
that the cells were in a subconfluent state. Cellular free cholesterol in any condition 
was not significantly different from control cell values of 70 ± 5 nmoles/mg cell 
protein (Fig. 5.12C).  Again, no cellular cholesteryl esters were detected. 
Overall, serum-deprived cells exposed to glycolaldehyde-modified LDL did 
not have significant changes in cell viability, protein or free cholesterol content. The 
lacks of changes in cell protein content per well suggest that no cellular proliferation 
was induced. 
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Figure 5.12 The effect of LDL (1 mg protein/ml) modified by 10-100 mM glycolaldehyde (GA-LDL), 
for 7 days, at 37 °C, on serum-deprived A7r5 smooth muscle cells; Panel A: viability, Panel B: cell 
protein, and Panel C: free cholesterol levels. Cells were also exposed to LDL incubated with 50 μM 
EDTA (LDL + EDTA) or modified by acetylation (AcLDL). LDL was subjected to column 
chromatography before serum-deprived cells were exposed to the modified LDL for 24 hr. This was 
followed by a 2 hr equilibrium period, before cell lysis, and determination of cell viability by the LDH 
assay, cell protein by the BCA assay, and cholesterol and cholesteryl ester levels by HPLC.  Control 
cells were exposed to media only for the same period. No cellular cholesteryl esters were detected 
under any conditions. Data are mean ± SEM from 3 experiments with triplicate samples. Statistical 
analysis, by 2-way ANOVA, showed that LDL modification or concentration, had no significant effect 
(P > 0.05) on cell viability, protein or free cholesterol levels. 
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 5 .3 .2 .d  Discussion 
A7r5 cell viability was not affected upon exposure to LDL modified by 
acetylation, EDTA, glucose (in the presence or absence of Cu2+), methylglyoxal or 
glycolaldehyde. Cell viability, in cells that were serum-deprived or not, was 
determined by extracellular LDH release and this was less than 10 % in all conditions. 
A study by Özer et al found no loss of cell viability in A7r5 serum-deprived cells 
upon exposure to 5 μg protein/ml native- or malondialdehyde-modified LDL [418]. 
Another study, using native and glycated LDL (by glucose) at 300 μg protein/ml, on 
porcine coronary artery smooth muscle cells, did not report losses in cell viability 
[289]. However another study, using human aortic smooth muscle cells, with an 
undefined concentration of LDL, reported apoptosis in cells exposed to LDL glycated 
or glycoxidised by glucose [288]. Measurements of apoptosis include assessment of 
DNA fragmentation and the use of commercial apoptosis kits [288, 381], however 
these effects were not exmined in the current studies. There are no reported studies of 
the effect of methylglyoxal- or glycolaldehyde-modified on smooth muscle viability. 
Therefore, any observed differences in cellular protein or lipid levels, after exposure 
to different glycated LDLs, cannot be attributable to significant losses in cell viability. 
 A7r5 are a rat aortic smooth muscle cell line used in studies of smooth muscle 
cell proliferation [351, 352, 418, 419]. A7r5 cells, serum-deprived or not, showed no 
significant changes in cell protein values, as compared to control cells, upon exposure 
to acetylated LDL, or LDL plus EDTA. These LDL modifications were included as 
controls. This suggests that incubating the cells with LDL induced no changes in cell 
numbers or proliferation. However, this is in contrast to the study by Özer et al, using 
serum-deprived A7r5 cells, that found a 1.6-fold increase in cell number after 
exposure to 5 μg protein/ml native LDL as compared to control cells [418]. Exposure 
of cells to malondialdehyde-modified LDL resulted in a 1.8-fold increase in cell 
number as compared to controls. No increase in cell protein was seen in cells exposed 
to LDL in the studies reported here, however the cells in this study were exposed to 
from 10- to 40-fold higher concentrations of LDL. Thus, any observed differences in 
cellular protein or lipid levels, after exposure to different glycated LDLs, cannot be 
attributable to significant effects of LDL modification, or its concentration, on cell 
protein. Thus any changes may be attributable to the presence of glycated LDL. 
 182
 A7r5 cells, serum-deprived or not, exposed to glucose-modified LDL, in the 
presence or absence of Cu2+, did not exhibit changes in cell protein levels, suggesting 
no cellular proliferation. This is in contrast with 2 other reported studies, using LDL 
modified by glucose, that found cell proliferation occurred on exposure to cells to this 
type of modified LDL [288, 289]. The LDL in one study was modified by 100 mM 
glucose for 70 hr, followed by dialysis to remove excess glucose and then added to 
porcine coronary artery smooth muscle cells, at 300 μg protein/ml for up to 96 hr 
[289]. LDL modification time, cell type, LDL concentration, and the time that the 
cells were exposed to this modified LDL may explain the differences found in these 
previous studies to those reported in this Chapter [289]. In the other previous study 
[288], the concentration and amounts of LDL the cells were exposed to are not clear 
and again different cell types (human aortic smooth muscle cells) were used, as 
compared to the studies in this Chapter. 
Serum-deprived smooth muscle cells, exposed to LDL modified by 
glycolaldehyde or methylglyoxal, did not show significant changes in cell protein per 
well. However, in the A7r5 cell experiments where the cells were not serum-deprived 
there were trends of decreasing cell protein upon exposure to increasing 
concentrations of LDL, or aldehyde that modified the LDL, suggesting subtle effects 
of methylglyoxal- or glycolaldehyde-modified LDL may be occurring in A7r5 cells. 
However there are no reported studies to compare this work to for confirmation. 
Perhaps examination of other markers of proliferation, such as protein kinase C [351, 
352, 418, 419] or platelet derived growth factor (PDGF) [280, 288, 409] or DNA 
synthesis [409], could have indicated if the glycated LDL was having true anti-
proliferative or proliferative effects. 
Free cholesterol levels in A7r5 smooth muscle cells were not significantly 
affected by exposure to LDL, regardless of modification. Free cholesterol content in 
cells exposed to any of the modified LDL was not significantly different to control 
cells, which were not exposed to LDL. Cellular free cholesterol content was generally 
in the range of 50-100 nmoles/mg cell protein. The free cholesterol levels of A7r5 
cells do not seem to have been measured directly previously, but as these values are in 
the range of free cholesterol levels in control cells in previous macrophage and 
HUVEC studies, they seem plausible. 
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 Smooth muscle cells have been reported to become foam cells in atherosclerotic 
lesions [8, 241]. However, in the studies in this Section the smooth muscle cells, when 
exposed to acetylated or glycated LDL, did not have increased cellular free 
cholesterol or cholesteryl esters. No cholesteryl esters were detected in smooth muscle 
cells under any conditions. Thus there may be more specific conditions needed for in 
vitro formation of model foam cells from smooth muscle cells.  One previous study 
found significant cholesterol and cholesteryl ester accumulation in irreversible 
synthetic smooth muscle cells (from rabbit aorta), and only when they were exposed 
to β-VLDL and not normal VLDL or LDL [410]. Minor et al converted cultured 
smooth muscle cells to foam cells by exposure to sonicated lipids droplets using an 
inverted culture technique [412] and another group produced lipid-laden smooth 
muscle cells by incubating them with lipid inclusions from macrophages [420]. Other 
work published demonstrates that cationised LDL (as characterised in [337]), but not 
native or acetylated LDL, can lead to cholesteryl ester synthesis in smooth muscle 
cells propagated from rat thoracic aorta [411]. In retrospect, the use of cationised 
LDL, in these studies, may have proved a useful positive control. As there is no 
reported work on cholesterol and cholesteryl ester accumulation in smooth muscle 
cells exposed to glycated LDL, and the glycated LDL used in these studies is more 
negatively charged (see Chapter 3), as opposed to positively charged cationised LDL, 
the lack of foam cell formation is consistent with these previous studies. 
 
5.4  Conclusions 
Under the conditions utilised in these studies, glycated LDL had no significant 
effect on HUVEC cell viability or protein. The lack of change in cell protein indicates 
that there is no marked cell death upon exposure to glycated LDL. HUVEC upon 
exposure to LDL modified by glucose, methylglyoxal or glycolaldehyde do not 
markedly altered levels of cellular free cholesterol. However, it has been shown that 
when HUVEC are exposed to LDL, regardless of the modification, increased cellular 
cholesteryl ester levels are observed (2-3 fold higher than those observed in control 
cells), in all cases except for cells exposed to LDL modified by 10 mM 
methylglyoxal. Otherwise there are no specific LDL modification differences in 
cellular cholesteryl ester levels. These results, and others [415-417], indicate that 
HUVEC can take up LDL and though a specific glycated LDL effect was not seen in 
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 the parameters examined, except in cells exposed to 10 mM methylglyoxal, other 
changes may be occurring that could explain endothelial dysfunction in diabetes-
associated atherosclerosis. 
 A7r5 rat aortic smooth muscle cells were not significantly affected by glycated 
LDL in terms of cell viability. Cells exposed to methylglyoxal- and glycolaldehyde-
modified LDL, but not glucose-modified LDL, were observed to lose cell protein with 
increasing aldehyde concentration and LDL concentration applied to the cells. 
However, these changes did not give a clear indication of whether the methylglyoxal- 
or glycolaldehyde-modified LDL had an anti-proliferative effect on smooth muscle 
cells. There were no changes in smooth muscle cell free cholesterol levels or 
detectable cellular cholesteryl esters after exposure to the (negatively-charged) 
modified-LDL. Thus there was no smooth muscle model foam cell formation. 
Previous studies have indicated that cationised LDL may have induced smooth 
muscle model foam cell formation. The anti-proliferative effects of glycated LDL 
may need further investigation. 
 The studies in this Chapter suggest that glycated LDL does not play a 
significant role in the cell death associated with atherosclerotic plaques, nor with 
smooth muscle foam cell formation. However, some of the results do indicate that 
glycated LDL may have a possible role in endothelial or smooth muscle cell 
dysfunction in diabetes-associated atherosclerosis. Further studies would need to be 
carried out to examine more specific indicators of endothelial or smooth muscle 
dysfunction before any true conclusions can be drawn regarding the effect of glycated 
LDL on these cell types. 
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6 CHAPTER 6: HUMAN MONOCYTE-DERIVED 
MACROPHAGES AND CELLULAR CHOLESTEROL AND 
CHOLESTERYL ESTER ACCUMULATION FROM LOW-
DENSITY LIPOPROTEINS MODIFIED BY GLUCOSE, 
METHYLGLYOXAL AND GLYCOLALDEHYDE 
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 6.1  Introduction 
It has been demonstrated that HMDM (human monocyte-derived macrophages), 
that is monocytes isolated by elutriation and then matured into macrophages, can 
metabolise glycated/glycoxidised LDL. HMDM exposed to LDL isolated from people 
with diabetes undergo increases in intracellular cholesteryl ester levels, as compared to 
LDL isolated from control subjects [166, 421]. This group have also shown that control 
LDL, or LDL from people with diabetes, that is glycosylated in vitro, by incubation 
with glucose, can lead to increased cholesteryl ester synthesis and intracellular 
accumulation in HMDM, with higher rates observed with LDL isolated from people 
with diabetes [165, 166]. “Glycated” LDL separated from “non-glycated LDL”, using 
column affinity chromatography, also led to increased cholesteryl ester synthesis rates 
in HMDM and intracellular LDL accumulation [164]. Studies by another group 
demonstrated that LDL modified by glycolaldehyde was more extensively degraded by 
HMDM than native LDL, or LDL modified by glucose, and that this increased uptake of 
glycolaldehyde-modified LDL may induce cellular lipid accumulation [163]. However, 
neither of these studies used LDL that had been comprehensively characterised with 
regard to changes in the protein and lipid components (that is, the extent and type of 
glycation and whether oxidation products were also present). 
As discussed in Chapter 4, many studies have used poorly characterised 
glycated/glycoxidised LDL in their model foam cell experiments, making conclusions 
on what modifications are needed to induce foam cell formation difficult. In Chapter 4 it 
was demonstrated that J774A.1 murine macrophage-like cells accumulate cholesteryl 
esters from glycolaldehyde-modified LDL more readily than from glucose- or 
methylglyoxal-modified LDL. In this Chapter the effect of these well-defined glycated 
LDLs on human, rather than mouse, macrophages is examined. 
 
6.2  Aims 
The aims of these experiments were firstly to quantify the cholesterol and 
cholesteryl ester accumulation, in HMDM, from LDL modified by glucose, 
methylglyoxal and glycolaldehyde, whilst confirming that cell viability and protein 
levels were not affected. Secondly to determine whether the cellular cholesterol and 
cholesteryl ester accumulation from the modified LDLs (as prepared and characterised 
in Chapter 3), occurs similarly in HMDM and J774A.1 murine-like macrophages. 
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 6.3  Results 
 
6 .3 .1  Cell Viability and Protein 
LDL (1 mg protein/ml) was modified for 7 days with 50 μM EDTA, 100 mM 
glucose, in the presence or absence of 1 μM Cu2+, 100 mM methylglyoxal or 100 mM 
glycolaldehyde at 37 ºC, in PBS (as in Chapter 3). These LDLs were then subjected to 
column chromatography before cells were exposed to the modified LDLs. Monocytes 
were isolated, as described in Section 2.5.2. These cells differentiated into human 
macrophages 9-11 days after isolation. These human monocyte-derived macrophages 
(HMDM) were exposed to LDL (modified or control) at concentrations of 0, 50 and 100 
μg protein/ml of RPMI media with 10 % LPDS, for 96 hr, with the media and modified 
or control LDL replaced at 48 hr. Cells were also exposed to LDL modified by 
acetylation (see Section 2.3.2.a). This loading protocol has been previously reported to 
ensure HMDM enrichment of cholesterol and cholesteryl esters, typical of foam cells 
[353]. The 96 hr loading time was followed by an overnight equilibrium period, with 
media containing 1 mg/ml BSA instead of serum (as described in Section 2.6.1). After 
this, cell media samples were removed, and stored on ice, and cells lysed as described in 
Section 2.6.1. Of the cell lysates 200 μl was retained for LDH and BCA assays, and the 
remaining 800 μl extracted for cholesterol and cholesteryl analysis by HPLC. The LDH 
assay and BCA assays were preformed as described previously (see Section 2.6.1.b and 
Section 2.3.3 respectively).  
HMDM viability was found to be not affected upon exposure to modified LDLs at 
0-100 μg protein/ml of media. Viabilities for cells exposed to the modified LDLs was 
not significantly different (P > 0.05) from the viability seen in control cells of 92 ± 1 % 
(Fig. 6.1).  
Similarly, cell protein per well was unaffected by exposure of HMDM to 
modified LDLs. Cell protein levels for cells exposed to the modified LDLs was not 
significantly different (P > 0.05) from the amounts of cell protein seen in control cells 
of 113 ± 26 μg (Fig. 6.2). These protein amounts are similar to those observed in 
J774A.1 experiments (Chapter 4). Thus it is concluded that exposure of human 
macrophages to LDL modified by glucose, methylglyoxal or glycolaldehyde does not 
result in significant loss of cell viability or protein, under the conditions employed. 
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Figure 6.1 HMDM cell viability after exposure to modified LDL. LDL (1 mg protein/ml) was modified 
by acetylation (AcLDL), 50 μM EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-LDL), 100 mM 
glycolaldehyde (GA-LDL) or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± Cu2+) 
for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to column 
chromatography. Cells were exposed to the modified LDLs (except for control cells) for 96 hr, with the 
media and LDL replaced at 48 hr, followed by an overnight equilibrium period, before cell lysis, with cell 
viability determined by the LDH assay. Control cells were not exposed to LDL. Data are mean ± SEM 
from 3 or more experiments with triplicate samples. Statistical analysis by two-way ANOVA showed no 
significant effect of LDL modification or concentration on HMDM viability levels. 
 
Figure 6.2 HMDM cell protein levels after exposure to modified LDL. LDL (1 mg protein/ml) was 
modified by acetylation (AcLDL), 50 μM EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-LDL), 
100 mM glycolaldehyde (GA-LDL) or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL 
± Cu2+) for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to column 
chromatography. Cells were exposed to the modified LDL (except for control cells) for 96 hr, with the 
media and LDL replaced at 48 hr, followed by an overnight equilibrium period, before cell lysis and cell 
protein determined by the BCA assay. Data are mean ± SEM from 3 or more experiments with triplicate 
samples. Statistical analysis by two-way ANOVA showed no significant effect of LDL modification or 
concentration on HMDM cell protein. 
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 6 .3 .2  Cellular Cholesterol and Cholesteryl Ester Accumulation 
HMDM cholesterol and cholesteryl ester accumulation was examined after 
cellular exposure to control LDL (LDL plus EDTA) or LDL modified by acetylation, 
glucose, methylglyoxal or glycolaldehyde. HMDM were exposed to the modified LDLs 
(except for control cells), at 0, 50, 100 μg protein/ml of media, for 96 hr, with media 
and LDL replaced at 48 hr, followed by an overnight equilibrium period, before cell 
lysis with water. The same cell lysate lipid extraction method and HPLC system were 
used as for the J774A.1 experiments described in Chapter 4, however a different (more 
polar) HPLC mobile phase was needed to increase the retention time of the lipids (see 
Sections 2.4.2.a.i. and 2.6.2.). This is necessary as HMDM have increased endogenous 
lipids making cholesterol and ester separation more difficult. To ensure all cholesteryl 
esters were accounted for, in several experiments half the cell lysates were extracted and 
saponified (see Section 2.6.2.a). Saponified esters elute with the cholesterol and give a 
total cholesterol value. The subtraction of free cholesterol from total cholesterol will 
give a total cholesteryl ester value. This saponification method did not give significant 
differences (P > 0.05) in the cholesteryl ester values and so this data is not discussed 
separately. 
 Cellular free cholesterol levels were not increased in HMDM, regardless of 
which modified LDL the cells were exposed too. These free cholesterol values were not 
significantly different (P > 0.05) from the control cell free cholesterol levels of 118 ± 33 
nmoles/mg cell protein (Fig. 6.3A).  
The different modifications of LDL had distinct effects on HMDM cellular 
cholesteryl ester accumulation. Increased cholesteryl ester levels were found in cells 
exposed to glycolaldehyde-modified LDL and to a lesser extent methylglyoxal-modified 
LDL, but not in cells exposed to glucose-modified LDL. Total cholesteryl ester levels 
for HMDM exposed to LDL modified by glucose, in the presence or absence of Cu2+, or 
EDTA, were not significantly different (P > 0.05) from the control levels of 3 ± 1 
nmoles/mg cell protein (Fig. 6.3B). Total cholesteryl ester levels were significantly 
elevated (P < 0.05) in cells exposed to LDL modified by acetylation or glycolaldehyde, 
with total cholesteryl esters levels reaching 150 ± 32 and 113 ± 34 nmoles/mg cell 
protein respectively.  Significant changes (P < 0.05) in total cholesteryl esters were also 
found in cells exposed to methylglyoxal-modified at 100 μg protein/ml of media (71 ± 
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 12 nmoles/mg cell protein), but not in cells exposed to lower concentrations of LDL (28 
± 10 nmoles/mg cell protein), when compared to control cells. 
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Figure 6.3 Panel A: free cholesterol, Panel B: total cholesteryl esters (CE) and Panel C: percent CE (of 
total cholesterol) for HMDM exposed to modified LDL. LDL (1 mg protein/ml) was modified by 
acetylation (AcLDL), 50 μM EDTA (LDL +EDTA), 100 mM methylglyoxal (MG-LDL), 100 mM 
glycolaldehyde (GA-LDL) or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± Cu2+) 
for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to column 
chromatography. Cells were exposed to the modified LDLs for 96 hr, with media and LDL replaced at 48 
hr, followed by an overnight equilibrium period, before cell lysis and analysis of cellular cholesterol and 
cholesteryl ester levels by HPLC. Control cells were exposed to media alone for the same time periods. 
Total cholesterol is the sum of individual CE and free cholesterol. Data are mean ± SEM from 3 or more 
experiments with triplicate samples. Columns with different letters above them are significantly different 
from each other (P < 0.05), using 2-way ANOVA and Bonferroni post hoc testing. 
 191
  192
Percent cholesteryl ester levels (of total cholesterol) followed the same pattern. 
Thus ester levels in cells exposed to LDL modified by glucose (± Cu2+) or EDTA, were 
not significantly different (P > 0.05) from the control levels of 3 ± 1 % (Fig. 6.3C). 
Total cholesteryl ester levels were however significantly increased (P < 0.05) in cells 
exposed to LDL modified by acetylation or glycolaldehyde, with percent cholesteryl 
esters levels of 41 ± 8 and 43 ± 10 % respectively.  These amounts were not 
significantly different (P > 0.05) from one another. Significant changes (P < 0.05) in 
percent cholesteryl esters were also found in cells exposed to methylglyoxal-modified 
LDL at 100 μg protein/ml of media (32 ± 4 %), but not in cells exposed to the lower 
concentration of LDL (16 ± 5 %), when compared to control cells. 
Table 6.1 shows the levels of individual esters in cells exposed to modified 
LDL. No significant increases (P > 0.05) in individual esters were observed in cells 
exposed to LDL modified by glucose (± Cu2+) or EDTA alone, or in cells exposed to 
methylglyoxal-modified LDL at 50 μg protein/ml media. Cells exposed to LDL 
modified by acetylation or glycolaldehyde, or methylglyoxal-modified LDL at 100 μg 
protein/ml media, showed significant increases in cholesteryl arachidonate, linoleate, 
oleate and palmitate, but not cholesteryl docosahexaenoate or stearate. For example, in 
HMDM exposed to acetylated LDL at 100 μg protein/ml media, cholesteryl linoleate (~ 
52 nmoles/mg cell protein) and palmitate (~ 39 nmoles/mg protein) were the most 
abundant esters. Next at slightly lower values, was cholesteryl oleate (~ 30 nmoles/mg 
cell protein), followed by cholesteryl arachidonate (~ 22 nmoles/mg cell protein). 
Thus HMDM, as seen with J774A.1 murine macrophages (Chapter 4), 
accumulate significant amounts of cholesteryl esters after exposure to LDL modified by 
acetylation or glycolaldehyde. Likewise accumulation of cholesteryl esters was 
detected, though at lower levels, in macrophages exposed to methylglyoxal-modified 
LDL. No accumulation was observed in cells exposed to LDL incubated with EDTA 
alone, or glucose, in the presence or absence of Cu2+. 
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       LDL (μg protein/ml)      
 0 50 50 50 50 50 50 100 100 100 100 100 100 
Ester Control AcLDL LDL + EDTA MG-LDL GA-LDL gLDL gLDL + Cu2+   AcLDL LDL + EDTA MG-LDL GA-LDL gLDL gLDL + Cu2+  
CD 0.35 ± 0.15 3.70 ± 1.68  2.79 ± 1.41 2.70 ± 1.26 6.64 ± 2.51 3.21 ± 0.43 3.20 ± 1.65 6.72 ± 2.58 1.65 ± 0.85 5.92 ± 2.62 5.54 ± 2.60 2.74 ± 1.49 2.37 ± 1.58 
CA 0.90 ± 0.37 10.07 ± 2.63* 5.11 ± 3.14 9.39 ± 3.85 15.69 ± 3.99* 6.13 ± 0.43 9.82 ± 5.80 21.72 ± 4.72* 4.43 ± 1.90 15.20 ± 1.46* 15.22 ± 5.99* 10.03 ± 5.71 8.32 ± 3.48 
CL 1.70 ± 0.43 27.71 ± 8.14* 6.38 ± 1.02 5.21 ± 1.13 27.48 ± 5.04* 0.00 ± 0.00 2.15 ± 0.81 52.82 ± 10.50* 3.83 ± 2.67 16.72 ± 1.38* 32.92 ± 7.45* 2.82 ± 1.64 4.78 ± 2.10 
CO 0.00 ± 0.00 22.11 ± 5.04* 0.00 ± 1.02 4.94 ± 1.37 19.76 ± 4.94* 1.12 ± 1.12 0.00 ± 0.00 30.09 ± 8.67* 0.00 ± 0.00 8.39 ± 3.64* 25.88 ± 3.88* 0.87 ± 0.51 1.34 ± 0.91 
CP 0.00 ± 0.00 26.89 ± 13.42* 0.00 ± 0.00 6.26 ± 3.37 32.05 ± 13.48* 0.66 ± 0.66 0.00 ± 0.00 38.60 ± 16.56* 0.00 ± 0.00 14.04 ± 6.87* 20.19 ± 16.76* 0.84 ± 0.50 0.93 ± 0.93 
CS 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 
Table 6.1 Levels of individual cholesteryl esters (nmoles/mg cell protein) in HMDM after exposure to 0-100 μg/ml modified LDL. LDL (1 mg protein/ml) was modified for 7 
days by 50 μM EDTA or 100 mM glucose (± 1 μM Cu2+), methylglyoxal or glycolaldehyde, at 37 °C, or by acetylation. After 7 days of incubation all modified LDLs were 
subject to column chromatography. Cells were exposed to the modified LDLs for 96 hr, with media and LDL replaced at 48 hr, followed by an overnight equilibrium period, 
before cell lysis and cellular cholesterol and cholesteryl ester levels determined by HPLC. Control cells were exposed to media alone for the same time periods. Total 
cholesterol is the sum of individual CE and free cholesterol. The esters examined were cholesteryl docosahexaenoate (CD), cholesteryl arachidonate (CA), cholesteryl 
linoleate (CL), cholesteryl palmitate (CP), cholesteryl oleate (CO), and cholesteryl stearate (CS). Data are mean ± SEM from 3 or more experiments with triplicate samples. * 
Indicates significant difference  (P < 0.05) from the control and the LDL + EDTA condition, by 1-way ANOVA using Tukey’s post hoc testing. 
 
 
 6.4  Discussion 
HMDM viability or cell protein was not affected upon exposure to LDL 
modified by acetylation, methylglyoxal, glycolaldehyde or glucose. Loss of cell 
viability, as determined by intracellular LDH release, was less than 20 % under all 
conditions. Cell protein, determined by the BCA assay, which was used as an 
indicator of cell number and to correct sterol values for inter-experimental variation, 
also did not change regardless of which modified LDL the cells were exposed too. 
This is an agreement with other published work which have not reported cytotoxicity 
of native or modified LDL to HMDM, at the concentrations utilised in these studies 
[163, 164, 421]. Therefore, the observed differences in cellular lipid levels, after 
exposure to different glycated LDLs, cannot be attributable to significant losses in cell 
viability or number. 
HMDM were exposed to acetylated LDL as a positive control, as this modified 
LDL is known to induce cellular lipid accumulation [127, 154, 402]. Free cholesterol 
levels were ~ 151 nmoles/mg cell protein and total cholesteryl esters 150 nmoles/mg 
cell protein in cells exposed to acetylated LDL at 100 μg protein/ml media. This 
equated to 41 % of total cholesterol that was esterified. These values are in agreement 
with other published work where free cholesterol levels were 122 nmoles/mg cell 
protein and total cholesteryl esters were 111 nmoles/mg cell protein, and the percent 
cholesteryl esters calculated to be ~ 48 % [166]. Thus exposing HMDM to acetylated 
LDL, at 100 μg protein/ml media, for 96 hr (with the media and LDL replaced at 48 
hr), induces increases in cellular cholesteryl ester levels as observed in atherosclerotic 
foam cells (as discussed in Section 1.1.1.a.i). These conditions also induce cellular 
cholesterol and cholesteryl ester changes comparable to previous reports for this foam 
cell model. This protocol therefore seemed suitable to determine if glycated forms of 
LDL could also induce foam cell formation. 
In HMDM experiments, as well as including acetylated LDL loaded cells as 
positive controls, cells were also exposed to LDL that had been incubated with EDTA 
for same time periods as LDL incubated with glycation agents; this condition 
therefore acted as a control for the incubation period and media changes employed. 
The results in Chapter 3 show that the LDL incubated with EDTA is minimally-
modified and so would not be expected to induce cellular sterol changes. As expected, 
HMDM exposed to LDL incubated with EDTA did not give rise to significant 
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 increases in free cholesterol or cholesteryl esters, as compared to cells exposed to 
media without LDL for the same time periods. Therefore any changes in cellular 
sterol levels as a result of exposure to glycated LDL have been ascribed to the 
presence of the glycated LDL, and not the incubation protocol. 
HMDM exposed to glycolaldehyde-modified LDL had the greatest changes in 
cellular sterol levels; methylglyoxal-modified LDL induced less pronounced changes 
in sterol levels (though these were still significantly elevated at the 100 μg protein/ml 
media level) and glucose-modified LDL did not induce any significant sterol changes. 
Glycolaldehyde-modified LDL led to significant increases in cellular cholesteryl ester 
levels, which were not significantly different to those seen in cells exposed to 
acetylated LDL. There are no reported studies on the effects of glycolaldehyde-
modified LDL on HMDM cholesteryl ester levels specifically, but other studies have 
reported that glycolaldehyde-modified LDL is recognised by macrophage scavenger 
receptors and can induce model foam cell formation [162, 163].  
Methylglyoxal-modified LDL only induced significant increases in cholesteryl 
esters at the highest concentration of LDL that was applied to the cells. At this 
concentration cholesteryl esters were 33 % of total sterol levels. As discussed in the 
previous Chapter there is little reported work on other macrophages to compare this 
data to. A previous study has shown that methylglyoxal-modified LDL is recognised 
by macrophage scavenger receptors, but decreased cholesteryl ester synthesis was 
seen [167]. However, the LDL used in this study was modified by 10 mM 
methylglyoxal, for 72 hr, and perhaps the higher concentration of 100 mM used in 
these experiments, as well as the longer incubation time (7 days) may explain the 
increased levels of cellular cholesteryl esters detected. 
Exposure of HMDM to glucose-modified LDL did not lead to model foam cell 
formation. Previous studies on HMDM have reported increased cholesteryl synthesis 
in cells exposed to LDL ‘glycated’ in vitro, with values approximately 2-fold greater 
than those seen in cells exposed to native LDL [165, 166]. In cells exposed to 
acetylated LDL a 6-fold increase in cholesteryl synthesis was reported in cells, as 
compared to native LDL, suggesting that the ‘glycated’ LDL was not as well 
recognised by macrophage scavenger receptors [165]. In this study increased levels of 
cholesteryl esters were also reported in HMDM exposed to ‘glycated’ LDL, but these 
values were again lower than those for cells exposed to acetylated LDL. This group 
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 reported that approximately 5 % of the Lys residues were modified, perhaps 
explaining the small increases in cholesteryl ester synthesis. This Lys modification 
may have resulted from glycoxidation of the LDL, rather than glycation, as oxidation 
reactions are well known to result in loss of Lys residues [102, 389]. 
2+Glucose has been reported to stimulate Cu -mediated LDL oxidation [268, 
361]; so the effect of LDL modified by glucose and 1 μM Cu2+, on HMDM, was also 
examined. The presence of Cu2+ did not lead to increased cholesteryl ester 
accumulation, compared to the non-copper samples. LDL oxidation induced by Cu2+ 
does lead to cholesteryl ester accumulation in macrophages, but those changes were 
detected with concentrations of Cu2+ 10-fold higher than those used in this study and 
only 5 % cholesteryl ester increase from control cell levels was seen [154]. In Chapter 
3 it was demonstrated that there was little oxidation occurring in LDL modified by 
glucose in the presence of Cu2+, therefore we would not expect the accumulation of 
cholesteryl esters in HMDM as a result of the presence of oxidised LDL. A possible 
explanation for the increased intracellular cholesteryl esters in HMDM exposed to 
glycated LDL in the study by Lopes-Virella et al discussed above was that oxidation 
reactions were occurring on their LDL not just glycation reactions [165]. Oxidation in 
their system is conceivable, as they did not state if metal ion-free solutions were used 
during the LDL modification or dialysis time. All solutions used in the LDL 
incubations in these current studies were treated with chelex resin to remove metal 
ions and prevent oxidation reactions. These differences may explain the discrepancies 
between these previous studies and the current study. Cholesteryl ester accumulation 
in HMDM exposed to glucose-modified LDL, may be dependent on the extent of 
oxidation or glycoxidation of the LDL, rather than the extent of glycation. Therefore 
the use of glycated LDL in these studies may explain the lack of cholesteryl ester 
accumulation in HMDM. 
When the results reported in the current Chapter are compared with those for 
the murine macrophage cell line discussed in Chapter 4, it can be seen that J774A.1 
mouse macrophages and HMDM followed comparable patterns of cholesteryl ester 
accumulation upon exposure to LDL that was modified under similar conditions. This 
occurred even though the cells were exposed to different concentrations of the 
modified LDL for different time periods (200 mg protein/ml LDL for 24 hr for 
J774A.1 cells, and 100 μg protein/ml for 96 hr for HMDM). Differences have been 
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 reported in the lipid metabolism of HMDM and J774A.1 cells; such as the presence in 
of hormone-sensitive lipase in J774 cells that is responsible for neutral ester 
hydrolytic activity, whereas with HMDM nCEH activity must reside in a distinct 
enzyme [422]. Thus it was unexpected to determine such similarities between the 
human and mouse macrophages.  In control cells (exposed to LDL free media for the 
same time periods as cells exposed to modified LDL) HMDM had significantly higher 
levels of free cholesterol, total cholesteryl esters and percent cholesteryl esters (Fig. 
6.4), suggesting that HMDM have higher endogenous levels of cholesterol and 
cholesteryl esters. HMDM trended towards higher free cholesterol on exposure to 
modified LDL, and this did reach significance in cells exposed to methylglyoxal- or 
glycolaldehyde- modified LDL (Fig. 6.4A). The only significant differences in 
cholesteryl esters between the cell types were found in cells exposed to no LDL, or 
methylglyoxal-modified LDL (Fig. 6.4B and Fig. 6.4C). In these cases increased 
levels of cholesteryl esters were found. The increased cholesteryl esters in HMDM 
exposed to methylglyoxal-modified LDL may occur due to the increased time the 
cells are exposed to this LDL. 
The pattern of individual cholesteryl ester accumulation in macrophages 
exposed to glycolaldehyde-modified LDL was also examined (Fig. 6.5). HMDM and 
J774A.1 macrophages accumulate, from highest to lowest levels, cholesteryl linoleate, 
cholesteryl oleate, cholesteryl palmitate, cholesteryl docosahexaenoate and 
cholesteryl stearate. For each ester there was no statistical difference between the 
J774A.1 macrophages and HMDM cholesteryl levels. Thus HMDM, besides having 
higher endogenous levels of free cholesterol and cholesteryl esters, accumulate 
cholesteryl esters, in a similar manner to J774A.1 cells, with the exception of the 
methylglyoxal-modified LDL. 
In these macrophage studies levels of cholesterol and cholesteryl esters have 
only been determined at one time-point and maximal accumulation of esters could 
occur at earlier time points and these studies do not give an indication of turnover of 
within cells. Levels of sterols may be also affected by accumulation/turnover of apo B 
protein/particles by cell machinery. This needs to be investigated further. 
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Figure 6.4 Comparison of J774A.1 and HMDM free cholesterol (Panel A), total cholesteryl esters (CE) 
(Panel B) and percent cholesteryl esters (of total cholesterol; Panel C) levels after exposure to modified 
LDLs. J77A.1 cells and HMDM were exposed to no LDL (control) or LDL modified by 50 μM EDTA 
(LDL + EDTA), 100 mM methylglyoxal (MG-LDL), glycolaldehyde (GA-LDL) or glucose (in the 
presence or absence of 1 μM Cu2+; gLDL ± Cu2+). The LDL was incubated for 7 days with the 
modifying reagent, and subjected to column chromatography. The LDL was then added to J774A.1 
cells at 200 μg protein/ml media for 24 hr or HMDM at 100 μg protein/ml media for a total of 96 hr 
(with media and LDL replaced at 48 hr). After exposure to LDL the cells were exposed to equilibrium 
media and then lysed, followed by lipid extraction, for HPLC analysis of cholesterol and cholesteryl 
esters. Total cholesterol is the sum of individual CE and free cholesterol. Data are mean ± SEM from 3 
or more experiments with triplicate samples. * Indicates the HMDM value is significantly different 
from the J774A.1 value (P < 0.05), by Student’s t-test. 
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Figure 6.5 Comparison of levels of individual cholesteryl esters (CE) in J774A.1 cells and HMDM, 
exposed to LDL modified by glycolaldehyde for 7 days. LDL was subjected to column 
chromatography, before addition to J774A.1 cells at 200 μg protein/ml media for 24 hr or HMDM at 
100 μg protein/ml media for a total of 96 hr (with media and LDL replaced at 48 hr). After exposure to 
LDL cells were exposed to equilibrium media and then lysed, followed by lipid extraction, for HPLC 
analysis of cholesterol and cholesteryl esters. The esters examined were cholesteryl docosahexaenoate 
(CD), cholesteryl arachidonate (CA), cholesteryl linoleate (CL), cholesteryl palmitate (CP), cholesteryl 
oleate (CO), and cholesteryl stearate (CS). Data are mean ± SEM from 3 or more experiments with 
triplicate samples. Analysis by Student’s t-test indicated that none of the HMDM values were 
significantly different (P > 0.05) from the J774A.1 values. 
 
6.5  Conclusions 
In this Chapter a suitable foam cell model has been established using HMDM 
and acetylated LDL. HMDM, as also seen with the J774A.1 macrophages, do not lose 
cell viability or cell numbers upon exposure to glycated LDL. However, whilst there 
is no significant cell death, the macrophages exhibit intracellular changes upon 
exposure to glycated LDL; this effect depends on the glycation agent which the LDL 
is modified by. Both HMDM and J774A.1 cells exhibit no significant increases in 
cellular cholesteryl levels after exposure to LDL modified by EDTA or glucose, in the 
presence or absence of Cu2+, as compared to cells exposed to no LDL. Conversely, 
HMDM and J774A.1 cells have been shown to accumulate increased levels of 
cholesteryl esters after exposure to methylglyoxal- or glycolaldehyde-modified LDL. 
However, whilst both the cell types have similar cholesteryl ester levels after 
exposure to glycolaldehyde-modified LDL, HMDM have significantly more 
cholesteryl esters after exposure to methylglyoxal-modified LDL. The methylglyoxal-
modified LDL seems to be less easily recognised by macrophage scavenger cells and 
the increased exposure time to this modified LDL in the HMDM experiments may 
explain the difference between the 2 cell types.  
The greatest cholesteryl ester accumulation was observed in cells exposed to 
glycolaldehyde-modified LDL, followed by methylglyoxal-modified LDL and lastly 
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 glucose-modified LDL. This is consistent with the pattern of reactivity of the glucose 
and the aldehydes, as discussed in Chapter 3. Potentially the greater the modification 
of the LDL, in terms of increases in negative charge, aggregation/crosslinking and 
modification/loss of Lys residues (and possibly Trp residues) the greater the 
recognition by macrophage scavenger receptors. This results in greater cellular 
cholesteryl ester accumulation, as discussed previously in greater detail, with J774A.1 
cell experiments (Section 4.4). 
In both of these models it has been demonstrated that exposure of macrophages 
to some glycated LDLs can lead to model foam cell formation. This may explain why 
people with diabetes suffer from an increased incidence of atherosclerosis. However, 
in this Chapter and the preceding ones, the focus has been on cellular cholesteryl ester 
accumulation from the glycated LDLs, not on the cellular handling of apo B from the 
glycated LDLs. Thus the next Chapter investigates the cellular handling of apo B. 
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7 CHAPTER 7: HUMAN MONOCYTE-DERIVED 
MACROPHAGE ENDOCYTOSIS, DEGRADATION, 
ACCUMULATION AND TURNOVER OF THE APO B 
PROTEIN OF MODIFIED LOW-DENSITY LIPOPROTEINS 
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 7.1  Introduction 
In Chapter 6 it was demonstrated that HMDM can accumulate cholesteryl esters 
when exposed to LDL modified by acetylation or glycolaldehyde, and to a lesser 
extent, LDL modified by methylglyoxal. No cholesteryl ester accumulation was 
observed in cells exposed to glucose-modified LDL, in the presence or absence of 
Cu2+. However the cellular handling of the protein component, apo B, was not 
examined in those studies. The protein and lipid components from the modified LDLs 
may not accumulate in synchrony due to differences in intracellular metabolism and 
turnover. Previous studies have demonstrated, using 125I-LDL and macrophages, 
increased cellular degradation and/or accumulation of apo B from LDL modified by 
acetylation [127, 145, 147, 162], glycolaldehyde [162, 163], malondialdehyde [145, 
146] or oxidation [147, 237], compared to native LDL. The glycated and /or oxidised 
LDL fraction from people with or without diabetes has also been reported to lead to 
increased cellular degradation and accumulation of apo B in HMDM [164]. Apo B, 
from in vitro glucose-modified LDL, has been studied with less consistent results.  In 
one study glucose-modified LDL has been reported to be less rapidly degraded than 
native LDL [163] and in another to be more rapidly degraded than native LDL [165]. 
However, these studies used different incubation times and concentrations of glucose, 
and the LDL was not comprehensively characterised, especially in regards to apo B 
protein changes, which may explain the differences between these studies. The effect 
of LDL modification by methylglyoxal, on the handling of apo B by macrophages has 
not been well studied in terms of cellular degradation rates and accumulation [167]. 
Many studies have either not investigated, or not compared, macrophage 
handling of apo B from well-defined glycated LDLs. In this Chapter, using similar 
cellular conditions to the HMDM cholesteryl ester studies (Chapter 6), the cellular 
handing of apo B from glycated LDLs is examined, using the well-characterised LDL 
described in Chapter 3. 
 
7.2  Aims   
The aims of the studies described in this Chapter were to investigate and 
quantify the cellular handling of apo B from LDL modified by glucose, methylglyoxal 
and glycolaldehyde. Specifically endocytosis, cell-surface binding, intracellular 
accumulation or degradation and turnover of apo B in HMDM, were examined.  
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 7.3  Results 
 
7 .3 .1  Characterisation of 125I-LDL 
LDL was isolated and then iodinated at the Tyr residues of the apo B protein, 
as described in Section 2.3.2.f. This LDL was then modified with various agents, as 
described in Section 6.3.1. Briefly, LDL (1 mg protein/ml) was modified for 7 days 
with 50 μM EDTA, 100 mM glucose (in the presence or absence of 1 μM Cu2+), 100 
mM methylglyoxal or 100 mM glycolaldehyde at 37 ºC, in PBS. Acetylated LDL was 
also prepared, for use as a positive control. However, unlike earlier the studies 
reported in this thesis, 2 different samples of acetylated LDL were prepared to aid in 
comparison with other published work [152]. LDL was acetylated by adding equal 
volumes of LDL and saturated sodium acetate, then acetic anhydride was added at 
either 2 or 6 μl/mg protein as described in Section 2.3.2.a. The LDL modified with 
less acetic anhydride would be expected to have a lower REM, due to a lower extent 
of Lys modification. 
To ensure that the iodination, and subsequent modification of the LDL, was 
not significantly different from the unlabelled LDL used in earlier experiments, the 
REM of the labelled LDL was determined and compared to unlabelled LDL. LDL 
was run on agarose gels using a barbitone buffer and then staining with the Fat Red 
7B (as described in Section 2.4.1.a and Section 3.3.1.a). Fig. 7.1 demonstrates that 
iodination of LDL, that is subsequently modified, does not result in significantly 
different (P > 0.05) REM values as compared to the modifications of unlabelled LDL. 
Methylglyoxal and glycolaldehyde have the highest REM values of ~ 6 and then 
acetylated LDL with REM values for the 2 extents of modification being ~ 4 and 5. 
LDL modified by glucose, in the presence or absence of Cu2+, had REM values of ~ 
1.8, which were slightly higher than the REM values seen LDL incubated with EDTA 
(~ 1.6). This data also demonstrates that the acetylation of LDL with different 
amounts of acetic anhydride affects the extent of protein modification and hence the 
mobility of the LDL. 
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125Figure 7.1 Comparison of the REM of I-LDL and unlabelled LDL used in HMDM experiments 
(Chapters 6 and 7). LDL was iodinated before modification and incubations were carried out as in the 
unlabelled experiments reported in Chapter 6. Thus, LDL (1 mg protein/ml) was modified by 50 μM 
EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-LDL), 100 mM glycolaldehyde (GA-LDL) or 
100 mM glucose, in the presence or absence of 1 μM Cu2+ 2+ (gLDL ± Cu ) for 7 days, at 37 °C. Two 
types of LDL acetylation were also used in these studies; modification by 2 μl acetic anhydride/mg of 
protein (AcLDL(2)), or the usual 6 μl acetic anhydride/mg protein (AcLDL(6)). REM was determined 
from the relative distances different LDLs moved compared to native LDL (nLDL), which was given a 
REM of 1. Data are mean ± SEM from 3 or more experiments, where individual gels were run. No 
significant difference (P > 0.05) was found between the labelled and unlabelled LDL employed, using 
Student’s t-test. 
 
The specific activity of the iodinated LDL was also determined for each 
experiment. Specific activity was calculated by dividing the radioactive counts of a 
known amount of LDL by the amount of protein in that sample. Average specific 
activity was 90 ± 18 cpm/ng apo B, with a range of 35-192 cpm/ng apo B. The 
iodinated control and modified LDLs were subjected to column chromatography 
before addition to cells, at a known specific activity. 
 
7 .3 .2  Cell Death and Protein in Endocytosis and Turnover Studies 
Cells were incubated with 125I-LDL at 50 μg protein/ml media (containing 10 
% LPDS) for up to 96 hr, with media and 125I-LDL replacement at 48 hr. In the 
endocytosis/accumulation studies the media was collected at 0, 24, 48, 72 and 96 hr 
and then cells were washed and exposed to 0.01 % trypsin to remove surface-bound 
ligand before cell lysis using 0.1% Triton (see Section 2.6.3), and determination of 
cell protein by the BCA assay (see Section 2.3.3). For turnover studies two conditions 
were examined. In the first set of turnover experiments, HMDM were exposed to 125I-
LDL for 96 hr, as with the cholesteryl ester experiments (Chapter 6), before a 24 hr 
chase period. In the second set of experiments HMDM were exposed to 125I-LDL 
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 modified by EDTA, glycolaldehyde, or LDL modified by 2 or 6 μl acetic 
anhydride/mg protein, for 24 hr. This was followed by a 24 hr chase period with 
media containing 1 mg/ml BSA instead of serum. These conditions were used to aid 
comparison with other published work [152, 165]. In the chase experiments, cell 
protein was determined at each time point using the BCA assay, and cell death was 
determined from the percentage of TCA-precipitable extracellular radioactive material 
in the chase media, as compared to total radioactive counts. This can be used as a 
maximal estimate of cell lysis [152]. 
Cell protein values were not affected by different modifications of 125I-LDL 
after exposure periods of up to 96 hr. However, in HMDM accumulation studies there 
was a significant (P < 0.05) decrease in cell protein over time (Fig. 7.2A). For 
example, in cells exposed to LDL incubated with EDTA the cell protein value 
dropped from 164 ± 35 μg at 0 hr to 125 ± 13 μg after 96 hr of exposure. Protein 
values in the chase after the 96 hr of HMDM exposure to 125I-LDL remained constant 
over time, with values of ~ 120 μg protein, and there were no significant (P > 0.05) 
effects due to the different modifications of 125I-LDL (Fig. 7.2B). When HMDM were 
exposed to 125I-LDL for 24 hr, followed by a 24 hr chase, cell protein values were not 
significantly affected (P > 0.05) by time or exposure to different modifications of 125I-
LDL, with values of ~ 130 μg (Fig. 7.2C). 
Cell death was less than 12 % in all chase studies, as determined by the 
appearance of non-degraded material in the media. In the chase period following 96 hr 
of exposure to 125I-LDL,  cell death increased significantly (P < 0.05) with time up to 
~ 12 %, but there was not a significant effect (P > 0.05) of 125I- LDL modification 
(Fig. 7.3A). When HMDM were exposed to 125I-LDL for 24 hr, followed by a 24 hr 
chase, again no significant effect (P > 0.05) of 125I-LDL modification was observed 
and cell death was less than 10 % (Fig. 7.3B). 
Some time-dependent losses in HMDM cell protein and increases in cell death 
were observed, regardless of which modification of 125I-LDL was used, potentially 
due to some of the extra handling steps the cells were exposed too. However, HMDM 
cell protein and death were not significantly affected upon exposure to different 
modifications of 125I-LDL by EDTA, methylglyoxal, glycolaldehyde, glucose (in the 
presence or absence of Cu2+) or acetylation.  
 205
  
0
50
100
150
200
250
0 24 48 72 96
AcLDL
LDL + EDTA
MG-LDL
GA-LDL
gLDL
gLDL +       
A 
C
el
l P
ro
te
in
 (μ
g)
 
Cu2+
0
50
100
150
200
250
0 1 6 24
AcLDL
LDL + EDTA
MG-LDL
GA-LDL
gLDL
gLDL +       
B 
C
el
l P
ro
te
in
 (μ
g)
 
Cu2+
0
50
100
150
200
250
0 24
AcLDL (6) AcLDL (2)
LDL + EDTA GA-LDL
C 
C
el
l P
ro
te
in
 (μ
g)
 
Time (hr) 
Figure 7.2 Cell protein in 125I-LDL HMDM studies; Panel A: cell protein during the 96 hr HMDM 
exposure to 125I-LDL (with media and 125I-LDL replaced at 48 hr); Panel B: cell protein during the 24 
hr chase following 96 hr of 125I-LDL exposure; and Panel C: cell protein at the end of a 24 hr chase 
following only 24 hr of HMDM exposure to 125I-LDL. Iodinated LDL (1 mg protein/ml) was modified 
by 50 μM EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-LDL), 100 mM glycolaldehyde (GA-
LDL) or 100 mM glucose, in the presence or absence of 1 μM Cu2+ 2+ (gLDL ± Cu ) for 7 days, at 37 
°C. After 7 days of incubation all modified LDLs were subject to column chromatography. Two types 
of LDL acetylation were used in these studies; modification by 2 μl acetic anhydride/mg of protein 
(AcLDL(2)), or the usual 6 μl acetic anhydride/mg protein (AcLDL or AcLDL(6)).Cells were exposed 
to the modified LDL  for up to 96 hr, with the media and LDL replaced at 48 hr, followed by a LDL 
free chase period of up to 24 hr, before cell lysis and cell protein determined by the BCA assay. Data 
are mean ± SEM from 3 or more experiments with triplicate samples. Statistical analysis by two-way 
ANOVA showed no significant effect of LDL modification on cell protein, under any conditions, 
however a significant effect (P < 0.05) of time was found in Panel A (but not Panels B or C). 
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Figure 7.3 Cell death in 125I-LDL 24 hr chase studies, for  HMDM exposed to a 96 hr loading period  
(Panel A) or a 24 hr loading period (Panel B). Iodinated LDL (1 mg protein/ml) was modified by 50 
μM EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-LDL), 100 mM glycolaldehyde (GA-LDL) 
or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± Cu2+) for 7 days, at 37 °C. After 
7 days of incubation all modified LDLs were subject to column chromatography. Two types of LDL 
acetylation were used in these studies; modification by 2 μl acetic anhydride/mg protein (AcLDL(2)), 
or the usual 6 μl acetic anhydride/mg protein (AcLDL or AcLDL(6)). Cells were exposed to the 
modified LDL for up to 96 hr, with the media and LDL replaced at 48 hr. This was followed a 24 hr 
exposure to LDL-free media, containing 1 mg/ml BSA instead of serum. Cell death was determined 
from the percentage of TCA-precipitable extracellular radioactive material in chase media, as 
compared to total radioactive counts. Data are mean ± SEM from 3 or more experiments with triplicate 
samples. Statistical analysis by two-way ANOVA showed no significant effect (P > 0.05) of LDL 
modification on HMDM cell protein, but a significant effect (P < 0.05) of chase time for Panel A, and 
statistical analysis by one-way ANOVA showed no effect of LDL modification (P > 0.05) on cell death 
in Panel B. 
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 7 .3 .3  Endocytosis, Degradation and Intracellular Accumulation of Modified 
Low-Density Lipoproteins by Human Macrophages 
In accumulation experiments HMDM were exposed to 125I-LDL for up to 96 
hr, with media and 125I-LDL replaced at 48 hr. At each time point the media was 
collected, then the cells were washed and exposed to 0.01 % trypsin to remove 
surface-bound ligand before cell lysis using 0.1% Triton. The collected media was 
mixed with BSA and TCA and spun to pellet TCA-precipitable material. Some of this 
supernatant was then removed and mixed with silver nitrate, and spun to precipitate 
free iodide. The resulting iodide-free, TCA-soluble supernatant was counted for 
cellular degraded material, as it is the low molecular mass iodinated material. Any 
material removed by the trypsin treatment represented cell surface-bound ligand. The 
cell lysate radioactive material was also counted to determine the amount of apo B 
that accumulated intracellularly. These counts were converted to ng apo B using the 
specific activity (see Section 7.3.1) and corrected for cell protein (values from Section 
7.3.2). The amount of material endocytosed was then calculated from the sum of 
degraded apo B and intracellular material (as described in Section 2.6.3). 
Fig. 7.4 and Fig. 7.5 show the kinetics of endocytosis, degradation and 
intracellular accumulation of apo B from modified 125I-LDLs.  Over the time points 
examined, cellular endocytosis and degradation of apo B increased linearly up to 48 
hr and then values generally plateau over the later time points (48-96 hr). At most 
time points the extent of degradation of apo B was less than the extent of endocytosis. 
Thus apo B appears to accumulate within the cells over the 96 hr of exposure of 
HMDM to modified LDLs.  These overall trends are observed with all conditions 
even though much higher rates of endocytosis, degradation and intracellular 
accumulation occur in cells exposed to LDL modified by acetylation (Fig. 7.4A), 
methylglyoxal (Fig. 7.4C) and glycolaldehyde (Fig. 7.5A), compared to cells exposed 
to LDL modified by EDTA (Fig. 7.4B) or glucose, in the absence or presence of Cu2+ 
(Fig. 7.5B and Fig. 7.5C respectively). The amount of apo B bound to the cell surface 
remained relatively constant over time and with the different modifications of LDL. 
A comparison of the HMDM apo B endocytosis, degradation, intracellular 
accumulation and surface-bound ligand levels, after 96 hr of exposure to modified 
LDLs is shown in Fig. 7.6A. The highest amounts of apo B endocytosed, degraded 
and accumulated intracellularly were found in cells exposed to acetylated LDL or 
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 glycolaldehyde-modified LDL. HMDM exposed to acetylated LDL degraded 90 ± 6 
ng apo B/μg cell protein and accumulated 7 ± 1 ng apo B/μg cell protein, after 
endocytosing 96 ± 7 ng apo B/μg cell protein. These values were not significantly 
different (P > 0.05) from HMDM exposed to glycolaldehyde-modified LDL which 
degraded 80 ± 6 ng apo B/μg cell protein and accumulated 7 ± 1 ng apo B/μg cell 
protein after endocytosing 87 ± 6 ng apo B/μg cell protein.  
Significantly increased rates of endocytosis and degradation were also seen in 
HMDM exposed to methylglyoxal-modified LDL, when compared to cells exposed to 
control LDL (Fig. 7.6A). HMDM exposed to methylglyoxal-modified LDL 
endocytosed 37 ± 3 ng apo B/μg cell protein and degraded 34 ± 3 ng apo B/μg cell 
protein, whereas cells exposed to LDL incubated with EDTA endocytosed 8 ± 2 ng 
apo B/μg cell protein and degraded 7 ± 2 ng apo B/μg cell protein.  
HMDM exposed to LDL modified by glucose, in the presence or absence of 
Cu2+, did not endocytose, or degrade, significantly (P > 0.05) more apo B than cells 
exposed to LDL incubated with EDTA. Cells exposed to LDL modified by 
methylglyoxal, EDTA or glucose, in the presence or absence of Cu2+, did not have 
significantly different (P > 0.05) amounts of apo B accumulated intracellularly. 
HMDM exposed to methylglyoxal-modified LDL trended to have higher intracellular 
apo B levels at 2.8 ± 0.3 ng apo B/μg cell protein, as compared to 1.5 ± 0.2 ng apo 
B/μg cell protein for cells exposed to LDL incubated with EDTA, or 1.3 ± 0.1 and 1.2 
± 0.1 ng apo B/μg cell protein for HMDM exposed to LDL modified glucose, in the 
presence or absence of Cu2+. HMDM, regardless of which modified LDL they were 
exposed to, did not have significantly different (P > 0.05) amounts of apo B bound to 
the cell surface, with average values of ~ 1 ng apo B/μg cell protein. 
125These parameters were also examined in HMDM exposed to I-LDL 
modified by acetylation, EDTA and glycolaldehyde for only 24 hr (Fig. 7.6B). The 
same trends were observed in these experiments, as compared to cells exposed to 125I-
LDL for 96 hr, except that the values were lower. LDL modified by acetylation with 
the usual 6 μl acetic anhydride/mg protein, or glycolaldehyde, did not have 
significantly different (P > 0.05) values for apo B endocytosed, degraded, 
accumulated intracellularly or surface-bound. Under these conditions ~ 40 ng apo 
B/μg cell protein was endocytosed, ~ 36 ng apo B/cell protein degraded and ~ 3 ng 
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 apo/μg cell protein accumulated intracellularly and ~ 1 ng apo B/μg cell protein was 
bound to the cell surface.  
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Figure 7.4 HMDM degradation, surface binding, intracellular accumulation and endocytosis of apo B 
from, acetylated LDL (Panel A), LDL + EDTA (Panel B) or methylglyoxal-modified LDL (Panel C). 
Iodinated LDL (1 mg protein/ml) was modified by incubation with 50 μM EDTA or 100 mM 
methylglyoxal for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to 
column chromatography. Acetylated LDL was prepared using 6 μl acetic anhydride/mg protein. Cells 
were exposed to the modified LDL for up to 96 hr, with the media and LDL replaced at 48 hr, before 
media collection, exposure of cells to 0.01 % trypsin for 60 min, and then cell lysis. Degraded material: 
iodide-free, TCA-soluble, media radioactivity; intracellular material: radioactivity associated with cell 
lysates; cell surface: radioactivity removed by trypsin action; and endocytosis: sum of cell degradation 
and intracellular material values at that time point.  Data are mean ± SEM from 3 or more experiments 
with triplicate samples. 
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Figure 7.5 HMDM degradation, surface binding, intracellular accumulation and endocytosis of apo B 
from, glycolaldehyde-modified LDL (Panel A), glucose-modified LDL (Panel B), glucose plus Cu2+-
modified LDL (Panel C). Iodinated LDL (1 mg protein/ml) was modified by 100 mM glycolaldehyde 
or glucose, in the presence or absence of 1 μM Cu2+, for 7 days, at 37 °C. After 7 days of incubation all 
modified LDLs were subject to column chromatography. Cells were exposed to the modified LDL for 
up to 96 hr, with the media and LDL replaced at 48 hr, before media collection, exposure of cells to 
0.01 % trypsin for 60 min, and then cell lysis. Degraded material: iodide-free, TCA-soluble, media 
radioactivity; intracellular material: radioactivity associated with cell lysates; cell surface: radioactivity 
removed by trypsin action; and endocytosis: sum of cell degradation and intracellular material values at 
that time point.  Data are mean ± SEM from 3 or more experiments with triplicate samples. 
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 LDL modified by acetylation with 2 μl acetic anhydride/mg protein had 
significantly (P < 0.05) higher values for endocytosis, degradation and intracellular 
accumulation of apo B, as compared to cells exposed to LDL incubated with EDTA 
(Fig. 7.6B). Exposure of HMDM to this acetylated LDL resulted in endocytosis 
values of 19 ± 2 ng apo B/μg cell protein, 17 ± 2 ng apo B/μg cell protein degraded, 
intracellular accumulation of ~ 2 ng apo B/μg cell protein, and 0.53 ± 0.04 ng apo 
B/μg cell protein was bound to the cell surface. Cells exposed to LDL incubated with 
EDTA endocytosed 2.28 ± 0.25 ng apo B/μg cell protein, degraded 1.73 ± 0.24 ng 
apo B/μg cell protein and accumulated intracellularly 0.54 ± 0.09 ng apo B/μg cell 
protein. Only 0.23 ± 0.07 ng apo B/μg cell protein was bound to the cell surface, in 
cells exposed to this control LDL. 
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Figure 7.6 Comparison of HMDM degradation, surface binding, intracellular accumulation and 
endocytosis of apo B after 96 hr (Panel A) or 24 hr exposure (Panel B) to modified 125I-LDL. Iodinated 
LDL (1 mg protein/ml) was modified by 50 μM EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-
LDL), 100 mM glycolaldehyde (GA-LDL) or 100 mM glucose, in the presence or absence of 1 μM 
Cu2+ (gLDL ± Cu2+) for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to 
column chromatography. Two types of LDL acetylation were used in these studies; modification by 2 
μl acetic anhydride/mg of protein (AcLDL(2)), or the usual 6 μl acetic anhydride/mg protein (AcLDL 
or AcLDL(6)). Cells were exposed to the modified LDL for up to 96 hr, with the media and LDL 
replaced at 48 hr, before media collection, exposure of cells to 0.01 % trypsin for 60 min, and then cell 
lysis. Degraded material: iodide-free, TCA-soluble, media radioactivity; intracellular material: 
radioactivity associated with cell lysates; cell surface: radioactivity removed by trypsin action; and 
endocytosis: sum of cell degradation and intracellular material values at that time point.  Data are mean 
± SEM from 3 or more experiments with triplicate samples. Columns with different superscripts are 
significantly different (P < 0.05) from one another for that cellular measurement, by one-way ANOVA 
and Tukey’s post hoc testing. 
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 Modification of 125I-LDL, by acetylation, EDTA, methylglyoxal, 
glycolaldehyde, or glucose resulted in significantly different (P < 0.05) HMDM 
degradation rates of apo B. LDL modified by acetylation (using 6 μl acetic 
anhydride/mg protein) or glycolaldehyde had the highest apo B degradation rates at 
1.61 ± 0.19 and 1.54 ± 0.08 ng apo B/μg cell protein/hr respectively (Fig. 7.7). LDL 
modified by acetylation (using 2 μl acetic anhydride/mg protein) or methylglyoxal 
had the next highest apo B degradation rates at ~ 0.7 ng apo B/μg cell protein/hr. 
These rates were significantly (P < 0.05) lower than the rates for acetylation (using 6 
μl acetic anhydride/mg protein) or glycolaldehyde, but still significantly (P < 0.05) 
higher than the degradation rates observed for LDL modified by EDTA or glucose, in 
the presence or absence of Cu2+. The HMDM apo B degradation rates for these 
modifications of LDL were not significantly different (P > 0.05) from one another and 
were ~ 0.09 ng apo B/μg cell protein/hr. 
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Figure 7.7 Rate of degradation of apo B, from modified 125I-LDL, by HMDM. Iodinated LDL (1 mg 
protein/ml) was modified by 50 μM EDTA (LDL + EDTA), 100 mM methylglyoxal (MG-LDL), 100 
mM glycolaldehyde (GA-LDL) or 100 mM glucose, in the presence or absence of 1 μM Cu2+ (gLDL ± 
Cu2+) for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to column 
chromatography. Two types of LDL acetylation were used in these studies; modification by 2 μl acetic 
anhydride/mg of protein (AcLDL(2)), or the usual 6 μl acetic anhydride/mg protein (AcLDL(6)). Cells 
were exposed to modified LDL for 24 hr before media collection and determination of amount of 
material degraded by the cells (iodide-free, TCA-soluble, media radioactivity) per hr. Data are mean ± 
SEM from 3 or more experiments with triplicate samples. Columns with different superscripts are 
significantly different (P < 0.05) from one another, by one-way ANOVA and Tukey’s post hoc testing. 
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 In summary, apo B from LDL modified by acetylation (using 6 μl acetic 
anhydride/mg protein) or glycolaldehyde had the highest levels of endocytosis, 
degradation and intracellular accumulation of apo B in HMDM. LDL modified by 
acetylation (using 2 μl acetic anhydride/mg protein) or methylglyoxal had lower 
levels of apo B endocytosis, degradation and intracellular accumulation, than LDL 
modified by glycolaldehyde or acetylation (using 6 μl acetic anhydride/mg protein), 
but higher values than cells exposed to control LDL. HMDM exposed to LDL 
modified by glucose, in the presence or absence of Cu2+, had similar levels of 
endocytosis, degradation and intracellular accumulation of apo B to cells incubated 
with LDL modified by EDTA.  
Overall these studies have shown that the apo B protein of LDL accumulates 
within cells after exposure to glycated LDLs and that the extent of accumulation 
differs markedly with the type and extent of prior modification to the apo B protein. 
These studies have not however examined the turnover of apo B in the absence of 
LDL; this was addressed in a further series of studies outlined below. 
 
7 .3 .4  Turnover of Endocytosed Modified Low-Density Lipoproteins by Human 
Macrophages 
The studies reported in the previous Section demonstrated increased 
degradation and accumulation of LDL modified by acetylation, glycolaldehyde, and 
to a lesser extent methylglyoxal, HMDM when compared to LDL incubated with 
EDTA. In the studies reported in this Section the turnover of this accumulated apo B 
was investigated. After cells were exposed to modified LDL for 24 or 96 hr, as 
described and examined in Sections 7.3.2 and 7.3.3, cells were exposed to LDL-free 
chase media, containing 1 mg/ml BSA instead of serum, for up to 24 hr. At each time 
point the media was collected, then cells were washed and exposed to 0.01 % trypsin 
to remove surface-bound ligand before cell lysis using 0.1 % Triton. The collected 
media was treated, as described in Sections 7.3.2 and 7.3.3, to obtain appropriate 
fractions. Material removed by the trypsin treatment represented cell surface-bound 
ligand, and it was unchanged between cells exposed to different modifications of LDL 
so it was omitted from the following Figures for clarity. The cell lysate radioactive 
material was also processed to obtain TCA-precipitable and iodide-free TCA-soluble 
fractions, instead of total cell lysate amounts reported in Section 7.3.3. The cell lysate 
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 TCA-precipitable fraction represents intracellular non-degraded material and the cell 
lysate iodide-free TCA-soluble fraction was counted to determine intracellular 
degraded material. These counts were converted to ng apo B using the specific 
activity (see Section 7.3.1) and corrected for cell protein  (as described in Section 
2.6.3).  
 The kinetics of the turnover of apo B was examined in HMDM exposed to 
125I-LDL for 96 hr before the chase period. Acetylated LDL (Fig. 7.8A) and 
glycolaldehyde-modified LDL (Fig. 7.9A), had the highest non-degraded intracellular 
apo B levels at the start of the chase, with ~ 7.5 and 9 ng apo B/μg cell protein 
respectively. These levels decreased slightly during the 24 hr chase period by ~ 1 ng 
apo B/μg cell protein for HMDM exposed to LDL modified by acetylation, and 
decreased by  ~ 3 ng apo B/μg cell protein for cells exposed to LDL modified by 
glycolaldehyde. These decreases in intracellular non-degraded apo B were matched 
by increases in intracellular and extracellular degraded apo B. HMDM exposed to 
methylglyoxal-modified LDL initially contained slightly higher levels of intracellular 
non-degraded apo B, as compared to the control LDL. Thus, non-degraded apo B 
levels for HMDM exposed to methylglyoxal-modified LDL were ~ 3.6 ng apo B/μg 
cell protein at the beginning of the chase and ~ 2.4 ng apo B/μg cell protein at the end 
of the chase period (Fig. 7.8C). This decrease in intracellular non-degraded apo B was 
matched by the increase in the amounts of degraded apo B intracellularly and 
extracellularly. Non-degraded apo B in HMDM exposed to LDL incubated with 
EDTA was ~ 2.2 ng apo B/μg cell protein at the start of the chase and ~ 1.4 ng apo 
B/μg cell protein at the end of the 24 hr chase period (Fig. 7.8B) with corresponding 
increases in the amount of apo B degraded. Similar trends and values as observed in 
cells exposed to LDL incubated with EDTA, were observed in the HMDM exposed to 
LDL modified by glucose, in the absence or presence of Cu2+ (Fig. 7.9B and Fig. 
7.9C). 
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Figure 7.8 HMDM turnover of apo B after a 96 hr exposure to acetylated LDL (Panel A), LDL + 
EDTA (Panel B) and methylglyoxal-modified LDL (Panel C). Iodinated LDL (1 mg protein/ml) was 
modified by 50 μM EDTA or 100 mM methylglyoxal for 7 days, at 37 °C. After 7 days of incubation 
all modified LDLs were subject to column chromatography. Acetylated LDL was prepared by the usual 
6 μl acetic anhydride/mg protein. Cells were exposed to the modified LDL for 96 hr, with the media 
and LDL replaced at 48 hr. This was followed by a 24 hr exposure to LDL-free chase media, 
containing 1mg/ml BSA instead of serum. Media was then collected and cells exposed to 0.01% trypsin 
for 60 min, before cell lysis. Degraded extracellular: iodide-free, TCA-soluble, media radioactivity; 
degraded intracellular: iodide-free, TCA-soluble, cell lysate radioactivity; and non-degraded 
intracellular: cell lysate TCA-precipitable radioactivity.   Data are mean ± SEM from 3 or more 
experiments with triplicate samples. 
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Figure 7.9 HMDM turnover of apo B after a 96 hr exposure to glycolaldehyde-modified LDL (Panel 
A), glucose-modified LDL (Panel B) or glucose and Cu2+-modified LDL (Panel C). Iodinated LDL (1 
mg protein/ml) was modified by 100 mM glycolaldehyde or glucose, in the presence or absence of 1 
μM Cu2+, for 7 days, at 37 °C. After 7 days of incubation all modified LDLs were subject to column 
chromatography. Cells were exposed to the modified LDL for 96 hr, with the media and LDL replaced 
at 48 hr. This was followed by a 24 hr exposure to LDL-free chase media, containing 1mg/ml BSA 
instead of serum.  Media was then collected and cells exposed to 0.01% trypsin for 60 min, before cell 
lysis. Degraded extracellular: iodide-free, TCA-soluble, media radioactivity; degraded intracellular: 
iodide-free, TCA-soluble, cell lysate radioactivity; and non-degraded intracellular: cell lysate TCA-
precipitable radioactivity.  Data are mean ± SEM from 3 or more experiments with triplicate samples. 
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 The turnover of apo B was also examined in HMDM that were exposed to 125I-
LDL for 24 hr, before the chase period. LDL modified by acetylation, using 6 μl 
acetic anhydride/mg protein, had the highest intracellular levels of non-degraded apo 
B with ~ 5.0 ng apo B/μg cell protein at the start of the start period and ~ 2.9 ng apo 
B/μg cell protein at the end of the 24 hr chase period (Fig. 7.10A). Over this time 
extracellular degraded apo B increased to 1.4 ng apo B/μg cell protein. HMDM 
exposed to glycolaldehyde-modified LDL also had high initial levels of non-degraded 
apo B (3.7 ng apo B/μg cell protein) with this decreasing to 1.7 ng apo B/μg cell 
protein at the end of the chase (Fig. 7.10D). Extracellular degraded apo B increased to 
1.3 ng apo B/μg cell protein over this time. Cells exposed to LDL modified by 
acetylation, using 2 μl acetic anhydride/mg protein, had 2.4 ng apo B/μg cell protein 
at the beginning of the chase period and this decreased to 1.5 ng apo B/μg cell protein 
over the chase (Fig. 7.10B). An increase of 0.3 ng apo B/μg cell protein appeared as 
degraded apo B in the media. Irrespective of whether LDL was modified by 
acetylation or glycolaldehyde, higher values were observed in these conditions, as 
compared to cells exposed to LDL incubated with EDTA. At the start of the chase 
period, HMDM exposed to LDL modified by EDTA had only 0.7 apo B/μg cell 
protein non-degraded intracellularly, which decreased to 0.4 apo B/μg cell protein 
over the 24 hr chase period (Fig. 7.10C). 
 Fig. 7.11 shows the percent remaining intracellular non-degraded apo B, of the 
original intracellular pool, at the end of the 24 hr chase period for cells exposed to 
125I-LDL for 24 or 96 hr. HMDM exposed to 125I-LDL for 24 hr modified by 
acetylation (using 6 μl acetic anhydride/mg protein) had 58 % of the non-degraded 
intracellular apo B remaining at the end of the chase. Similar values were also 
observed in HMDM exposed to acetylated LDL modified using 2 μl acetic 
anhydride/mg protein (65 %), and in HMDM exposed to LDL modified by EDTA (62 
%). However only 44 % of non-degraded apo B remained in cells exposed to 
glycolaldehyde-modified LDL at the end of the chase.  
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Figure 7.10 HMDM turnover of apo B after a 24 hr exposure to modified 125I-LDL. Two types of 125I-
LDL acetylation were used in these studies; the usual modification using 6 μl acetic anhydride/mg 
protein (Panel A) or modification by 2 μl acetic anhydride/mg of protein (Panel B). Iodinated LDL (1 
mg protein/ml) was also modified by 50 μM EDTA (Panel C), or 100 mM glycolaldehyde (Panel D), 
for 7 days, at 37 °C. After 7 days of incubation modified LDLs were subject to column 
chromatography. Cells were exposed to the modified LDL for 24 hr, with the media and LDL replaced 
at 48 h. This was followed by a 24 hr exposure to LDL-free chase media, containing 1 mg/ml BSA 
instead of serum. Media was then collected and cells exposed to 0.01% trypsin for 60 min, before cell 
lysis. Degraded extracellular: iodide-free, TCA-soluble, media radioactivity; degraded intracellular: 
iodide-free, TCA-soluble, cell lysate radioactivity; and non-degraded intracellular: cell lysate TCA-
precipitable radioactivity.   Data are mean ± SEM from 3 or more experiments with triplicate samples. 
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For the LDL modifications used in both the 24hr and 96 hr sets of studies 
there was a greater decrease (up to 20 %) in non-degraded intracellular apo B levels in 
the 24 hr studies, as compared to the 96 hr studies. This difference was significant (P 
< 0.05) for cells exposed to LDL modified by acetylation (using 6 μl acetic 
anhydride/mg protein) and glycolaldehyde, where 78 % and 67 % respectively, of the 
non-degraded apo B was remaining at the end of the chase after 96 hr of exposure to 
125I-LDL. The difference of ~ 12 % was not significant  (p = 0.08) in cells exposed to 
LDL incubated with EDTA, where there was 74 % remaining at the end of the chase 
after 96 of exposure to the 125I-LDL. These results suggest there was greater turnover 
of apo B in cells exposed to 125I-LDL for shorter time periods. HMDM exposed to 
methylglyoxal-modified LDL had 65 % non-degraded apo B remaining 
intracellularly, whereas LDL modified by glucose, in the absence or presence of Cu2+, 
had the highest percentages of apo B remaining at 85 % and 84 % respectively. 
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Figure 7.11 Comparison of percent apo B remaining after the 24 hr chase period for cells exposed to 
125I-LDL for 24 or 96 hr. Iodinated LDL (1 mg protein/ml) was modified by 50μM EDTA (LDL + 
EDTA), 100 mM methylglyoxal (MG-LDL), 100 mM glycolaldehyde (GA-LDL) or 100 mM glucose, 
in the presence or absence of 1 μM Cu2+ (gLDL ± Cu2+) for 7 days, at 37 °C. After 7 days of incubation 
all modified LDLs were subject to column chromatography. Two types of LDL acetylation were used 
in these studies; modification by 2 μl acetic anhydride/mg of protein (AcLDL(2)), or the usual 6 μl 
acetic anhydride/mg protein (AcLDL(6)). Cells were exposed to the modified LDL for 24 or 96 hr, 
with the media and 125I-LDL replaced at 48 hr. This was followed by a 24 hr exposure to LDL-free 
chase media, containing 1 mg/ml BSA instead of serum. Media was then collected and cells exposed to 
0.01% trypsin for 60 min, before cell lysis. Percent apo B remaining was determined from the 
difference between 0 and 24 hr chase values of non-degraded apo B (cell lysate TCA-precipitable 
radioactive material). Data are mean ± SEM from 3 or more experiments with triplicate samples. * 
Indicates significant difference (P < 0.05), and # indicates p = 0.1, between the percent apo B 
remaining for the 24 and 96 hr LDL exposure conditions, by Students t-test. 
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 In summary, under the conditions used in this study, it appears that once apo B 
from modified LDL has accumulated intracellularly, it is only slowly turned 
over/degraded. Thus, in cells exposed to 125I-LDL for 96 hr, and then a 24 hr chase, 
only 42 % or less of the intracellular apo B is subsequently degraded over 24 hr. In 
analogous studies where the HMDM are exposed to 125I-LDL for 24hr, up to 56 % of 
the intracellular apo B is degraded. This suggests the cells cope better with smaller 
modified protein insults. However, the increased intracellular levels of apo B, seen in 
cells exposed to LDL modified by glycolaldehyde or acetylation suggest perturbations 
in normal cell metabolism. 
 
7.4  Discussion 
Iodination of protein Tyr residues is a well-used technique to label the apo B 
in LDL to examine cellular handling [127, 145-147, 152, 162, 163]. In each of these 
published works it was assumed that the iodination does not significantly affect the 
characteristics of the LDL. A recent study by Sobal et al has however reported that 
the iodination of LDL, using the iodine monochloride method employed in this study, 
resulted in increased fragmentation and a 4.5-fold increase in REM [423]. However 
the calculated REM values for the LDL samples used in the studies reported in this 
Chapter, were not significantly different from those for the unlabelled LDL 
experiments, regardless of whether the LDL was modified or not. This suggests that 
the study by Sobal et al perhaps employed pro-oxidative conditions and/or was 
subject to other problems. The calculated specific activities of the iodinated LDL 
were within the range of other published work [147, 152, 167, 379, 380]. Therefore 
the 125I-LDL was considered to be modified to a similar extent to the LDL used in the 
non-radioactive experiments and hence no further LDL characterisation experiments 
were performed. 
The different modifications of LDL employed in this study did not affect 
HMDM cell death or protein values. Cell death did increase over the chase time in the 
turnover experiments, but this was under 12 % in all conditions and did not appear to 
markedly affect the observed behaviour. In analogous studies, using this method with 
resident mouse peritoneal macrophages, the reported values did not exceed 10 % over 
a 24 hr chase period [152], consistent with the present work. Cell protein was also not 
affected by the different modifications of LDL employed, but a decrease in overall 
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 protein levels with time was detected in the accumulation studies. This is probably 
due to the extra handling and washing steps that the cells were exposed to. The cell 
protein levels were however consistent in HMDM exposed to different modifications 
of LDL throughout the consequent chase studies. These data on cell death and protein 
levels concur with the results reported in Chapter 6 where these values were 
unchanged, regardless of which LDL modification the cells were exposed to. 
The cells used in the current studies were exposed to various glycated LDLs, 
and a suitable incubation control; LDL plus EDTA. This LDL was shown to have a 
low rate of degradation compared to some other modifications of LDL. Henriksen et 
al reported low degradation values when macrophages were exposed to control LDL. 
Thus in macrophages exposed to 125I-LDL for 5 hr, at 50 μg protein/ml, the extent of 
degradation of apo B was ~ 2 ng LDL protein/μg cell protein for resident mouse 
peritoneal macrophages, and ~ 0.5 ng LDL protein/μg cell protein for J774 cells 
[147]. A study by Goldstein et al where resident mouse peritoneal macrophages were 
exposed to 125I-LDL for 5 hr at 50 μg/ml, resulted in ≤ 0.5 ng LDL protein/μg cell 
protein degraded [127]. In another study by Jessup et al using resident mouse 
peritoneal macrophages and control LDL at 10 μg/ml for 24 hr, ~ 1.25 ng LDL 
protein/μg cell protein being degraded [152]. In HMDM exposed to native 125I-LDL 
for 5 hr degradation values have been reported to be < 0.5 ng LDL protein/μg cell 
protein [163]. Another HMDM study using 100 μg/ml 125I-LDL and a 20 hr cell 
exposure time reported apo B degradation values at ~ 2 ng LDL protein/μg cell 
protein [165]. In the studies reported in this Chapter the degradation of apo B in 
HMDM exposed to LDL incubated with EDTA, at 50 μg protein/ml, for 24 hr was ~ 
1.7 ng LDL protein/μg cell protein, and increased with increasing LDL exposure time 
to ~ 7 ng LDL protein/μg cell protein at 96 hr. The values obtained in the current 
study are therefore at the higher range of the reported numbers, though in these 
current studies the cells were generally exposed to higher concentrations of 125I-LDL 
for longer than in these previous reports. 
Low levels of intracellular apo B were observed in cells exposed to 125I-LDL 
incubated with EDTA. This is consistent with the small difference between the levels 
of endocytosed LDL, and degraded LDL, across all time points. In the studies in this 
Chapter ~ 0.5 ng LDL protein/μg cell protein was found intracellularly in cells 
exposed to LDL for 24 hr and  ~ 1 ng LDL protein/μg cell protein for cells exposed to 
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 LDL for 96 hr. In the Goldstein et al study up to 0.4 ng LDL protein/μg cell protein 
accumulated intracellularly over 5 hr [127] and in the study by Jessup et al 
intracellular apo B was less than 0.1 ng LDL protein/μg cell protein [152]; in both 
studies mouse peritoneal macrophages were employed. A HMDM study reported 
intracellular apo B values of ~ 2 ng LDL protein/μg cell protein after a 20 hr exposure 
to 100 μg/ml LDL [165]. Therefore the results in this Chapter are consistent with 
other published work demonstrating low levels of intracellular apo B after exposure to 
control LDL.  
Jessup et al reported on the turnover of apo B from native LDL in a 24 hr 
chase period and found that most of the intracellular material was degraded within 4 
hr in mouse peritoneal macrophages [152]. This is not consistent with the studies in 
this Chapter, which found after 24 hr of exposure to 125I-LDL and a subsequent 24 hr 
chase, 62 % of the intracellular apo B was still remaining. These differences may be 
due to different cell types (resident mouse peritoneal macrophages versus HMDM) or 
the different concentrations of LDL used (10 versus 50 μg protein/ml media). The 
study by Jessup et al also reported that most of the extracellular material was 
precipitable by TCA under the conditions employed, which was not seen in the 
current studies with HMDMs reported in this Chapter; this is perhaps suggestive of 
cell death or retroendocytosis in this previous work [152]. 
 Acetylated LDL was degraded in much greater quantities, than control LDL. 
The extent of degradation of apo B in the 24 hr studies was ~ 35 ng LDL protein/μg 
cell protein for cells exposed to acetylated LDL modified by 6 μl acetic anhydride/mg 
protein and ~ 17 ng LDL protein/μg cell protein for HMDM exposed to LDL 
modified by 2 μl acetic anhydride/mg protein. In the 96 hr studies, the amount of apo 
B degraded was ~ 90 ng LDL protein/μg cell protein. This trend of increased 
degradation of acetylated LDL, when compared to native LDL, has been in reported 
in other studies [127, 151, 152, 163, 175]. However these previous studies report 
degradation values of ≤ 12 ng LDL protein/μg cell protein [127, 152, 163], except for 
two studies which report degradation values of 40-70 ng LDL protein/μg cell protein 
[151, 175]. Possible reasons for these differences include the use of different 
macrophage cell types, lower concentrations of LDL, shorter LDL exposure times and 
possible differences in the extent of acetylation. Of these studies only one has 
included any characterisation of the acetylated LDL. The acetylated LDL used in this 
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 previous work was modified using 2 μl acetic anhydride/mg protein and exposed to 
the cells for 24 hr [152]; this procedure was also employed in the current study. 
However the less modified acetylated LDL in the studies reported in this Chapter still 
had a higher REM (~ 4) than that in this published work (REM 1.7) and the cells were 
exposed to more LDL (10 versus 50 μg protein/ml media). This may explain why the 
HMDMs used in the current study, though exposed to less modified acetylated LDL 
still degraded more material (~ 17 ng LDL protein/μg cell protein) when compared to 
the study by Jessup et al (~ 9 ng LDL protein/μg cell protein) [152]. A study by 
Sparrow et al which also reported higher levels of degraded apo B (~ 28 ng LDL 
protein/μg cell protein) in mouse peritoneal macrophages using highly-modified 
acetylated LDL, with 80 % of lysine residues modified [131]. These results support 
the hypothesis that the differences between all the studies discussed may be due to 
variations in the extent of acetylation. 
  HMDM accumulated intracellular apo B from acetylated LDL, which was 
consistent with the differences between the levels of endocytosed and degraded apo 
B. In the 24 hr studies up to ~ 3 ng LDL protein/μg cell protein accumulated 
intracellularly and in the 96 hr studies this increased to ~ 7 ng LDL protein/μg cell 
protein. These values are again higher than other published values; up to 1.2 ng LDL 
protein/μg cell protein (in [127]) and up to 4 ng LDL protein/μg cell protein (in 
[152]). The turnover of apo B from acetylated LDL occurred at a slow rate in the 
current studies. In the 24 hr studies ~ 60 % of the intracellular apo B remained at the 
end of the chase period, and in the 96 hr studies this was ~ 80 %. In the study by 
Jessup et al, it was reported, as seen with native LDL, that the small intracellular 
pools of apo B were nearly all degraded after 4 hr of chase media [152]. However this 
may again be due to differences in cell types and the level of modification of the 
LDL. 
 There were no significant differences in the parameters measured between 
LDL modified by glycolaldehyde or acetylation, using 6 μl acetic anhydride/mg 
protein. Increased levels of endocytosis, degradation and intracellular accumulation of 
apo B was found in cells exposed to glycolaldehyde-modified LDL, as compared to 
HMDM exposed to control LDL. Other studies have reported increased degradation 
of apo B from glycolaldehyde-modified LDL. With resident mouse peritoneal 
macrophages ~ 3 ng LDL protein/μg cell protein was degraded after exposure to 
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 glycolaldehyde-modified LDL at 20 μg/ml for 5 hr [162]. In another study using 
HMDM, ~ 2 ng LDL protein/μg cell protein was degraded in cells exposed to 50 
μg/ml glycolaldehyde-modified LDL for 5 hr [163]. These numbers are lower than 
found in this Chapter, however, the LDL used in these previous studies, when 
compared to the LDL used in the experiments in this Chapter, was modified with 4-6 
fold less glycolaldehyde and cell exposure was for shorter time periods. There does 
not seem to be any previous data on the intracellular accumulation and turnover of 
apo B from glycolaldehyde-modified LDL. However work, using the reactive 
aldehyde malondialdehyde to modify LDL, demonstrated increased endocytosis, 
degradation and intracellular accumulation in macrophages after exposure to this 
modified LDL [152]. 
Modification of LDL by methylglyoxal and subsequent HMDM exposure 
results in apo B degradation and endocytosis values higher than those observed for 
control LDL, but lower than observed for LDL modified by glycolaldehyde or 
acetylation (using 6 μl acetic anhydride/mg protein). However, intracellular apo B 
levels were not significantly increased over control LDL levels, and after a 24 hr 
chase period decreased by a similar amount to that observed with control LDL (65 % 
of the intracellular apo B remaining). Schalkwijk et al have previously examined the 
effect of methylglyoxal-modified 125I-LDL on macrophages, however the conditions 
and parameters were very different to those used in this study [167]. There seems to 
be little other work reported to compare the work in this Chapter to, but the pattern of 
methylglyoxal-modified LDL having a greater effect than control LDL, and less of an 
effect than LDL modified by acetylation or glycolaldehyde, is consistent with the 
pattern of cholesteryl ester accumulation observed in Chapters 4 and 6. 
The modification of LDL by glucose, in the presence or absence of Cu2+, did 
not result in any significant increases in endocytosis, degradation or intracellular 
accumulation of apo B, as compared to control LDL. There were also no differences 
in cellular handling of the glucose plus Cu2+ modified LDL, when compared to 
glucose-modified LDL alone. This may have been expected, as oxidation of LDL 
leads to increased degradation and intracellular accumulation of apo B [131, 147, 
152]. However as discussed in earlier Chapters of this thesis, the glucose plus Cu2+-
modified LDL was not significantly oxidised and in the characterisation studies 
(Chapter 3), found not to be significantly different from LDL modified by glucose in 
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 the absence of Cu2+. Increased HMDM degradation and intracellular accumulation of 
glucose-modified has been reported by Lopes-Virella, as compared to control LDL 
but, as discussed previously (Section 6.4) it is probable that this LDL was 
glycoxidised, and not just glycated, and thus the LDL was behaving in manner more 
reminiscent of oxidised LDL, than glycated LDL [165]. Kawamura et al reported that 
glucose-modified LDL was degraded more slowly than native LDL, however no 
numerical data was reported for these studies, nor whether any differences were 
significant [163]. 
 There were no significant differences detected in the current study in the levels 
of surface-bound apo B between glycated LDLs and the control LDL in HMDM. 
Surface-bound ligand, as determined by material removed from cells using 0.01 % 
trypsin, does not seem to have been previously examined with any other glycated 
LDLs. Increased surface-bound apo B has been reported in macrophages exposed to 
oxidised LDL [152], but as already discussed the LDL used in the current experiments 
is not significantly oxidised (Chapter 3). Surface-bound material was also reported to 
increase when cells were exposed to 1000 μM myricetin-modified LDL, however this 
modification of LDL led to aggregates larger than the cells themselves, and thus the 
cells seemed unable to internalise the LDL [152]. In the HMDM exposed to a 24 hr 
chase period after 96 hr exposure to glucose-modified LDL the lowest apo B turnover 
values were obtained with ~ 85 % remaining at the end of the chase period.  
 The high rates of endocytosis and degradation of apo B from LDL modified 
by acetylation and glycolaldehyde are hypothesised to be due to the high affinity of 
these modified forms of LDL for macrophage scavenger receptors [127, 162, 163]. 
Methylglyoxal-modified LDL has also been shown to be recognised by macrophage 
receptors [167], but the apo B data obtained in this work and the corresponding 
cholesteryl ester studies (reported in Chapter 6), indicate this modification of LDL 
may not have as high an affinity for macrophage scavenger receptors as acetylated 
LDL. Lopes-Virella et al have reported that glucose-modified LDL is also recognised 
by macrophage scavenger receptors [165], but the LDL used was probably 
oxidised/glycoxidised, and oxidised LDL has been shown to have a high affinity for 
macrophage scavenger receptors [133, 147].  
All these forms of glycated LDLs could be ligands for AGE receptors 
(discussed in Section 1.3.3.e), for example RAGE [295], p60 or p90 [292], and 
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 perhaps under different intracellular regulation to the classical LDL and macrophage 
scavenger receptor pathways [296]. This may explain the high retention (~85 %) of 
apo B from glucose-modified LDL in HMDM after a 24 hr chase period. Thus 
different receptor pathways, as well as possible different mechanisms and kinetics of 
modification of LDL by methylglyoxal, glycolaldehyde or glucose  (Chapter 3) may 
explain the pattern of apo B metabolism by HMDM. 
Accumulation of oxidised or modified proteins has been reported to have a 
variety of cellular effects. It has been shown that moderately oxidised proteins are 
more sensitive to proteolytic attack [177, 235], and are endocytosed more quickly 
than native proteins, which in turn are more quickly removed than heavily oxidised 
proteins [236-238]. Pyrraline-modified albumin has been shown to accumulate in 
macrophages due to decreased cellular degradation rates and a reduced susceptibility 
of this AGE-modified protein to lysosomal proteolytic enzymes [276]. Apo B from 
oxidised LDL has been shown to accumulate in secondary lysosomes in macrophages 
due to inefficient degradation [379]. This may be explained partly by the resistance of 
oxidatively-modified apo B to cathepsins [380]. In our laboratory 
glycated/glycoxidised proteins have been shown to inhibit a number of intracellular 
enzymes including LDH, GAPDH, glutathione reductase [357], and some of the 
lysosomal cathepsins (Jingmin Zeng et al, unpublished results). Inhibition of the latter 
species may be particular importance in apo B turnover.  
AGE-RAGE interactions have been reported to lead to activation of 
macrophages and production of pro-inflammatory cytokines [74]. Secretion of TNF-
α, IL-1Β, PDGF and insulin growth factor-1 may also occur after macrophages 
internalise and degrade AGE-modified proteins [280]. Glycated or glycoxidised LDL 
has also been shown to be a potent immunogen, stimulating antibodies that don’t react 
with native LDL [275]. The consequences of accumulation of glycated apo B in 
macrophages, and the role of these materials in atherosclerosis needs to be examined 
further. 
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 7.5  Conclusions 
HMDM do not metabolise the apo B from different glycated LDLs at the same 
rate, and the order of greatest to least effects of the modified LDL is similar to that 
observed in the cholesteryl ester studies (Chapter 6). HMDM exposed to 
glycolaldehyde-modified LDL demonstrate increased endocytosis, degradation and 
intracellular accumulation of apo B, at levels comparable to those observed with some 
forms of acetylated LDL. HMDM exposed to methylglyoxal-modified LDL showed 
lower levels of endocytosis and degradation of apo B, than cells exposed to 
glycolaldehyde-modified LDL, but rates greater than that observed for HMDM 
exposed to control LDL. Exposure of HMDM to LDL modified by glucose (in the 
presence or absence of Cu2+) did not result in significantly different rates of apo B 
endocytosis, degradation or intracellular accumulation, when compared to control 
LDL. However, under all conditions, 44-85 % of the apo B is retained after the 24 hr 
chase period, regardless of which form of glycated LDL the HMDM were exposed to. 
In many disease states, including diabetes and atherosclerosis, accumulation of 
oxidised and AGE-modified proteins is seen [229, 239, 241, 243, 245]; as discussed 
in Sections 1.3.3 and 1.3.3.a. apo B has been shown to accumulate in normal human 
aortae as well as in atherosclerotic plaques [104]. Thus the studies reported in this 
Chapter demonstrate a potential pathway for (glycated) apo B to accumulate in 
atherosclerotic lesions via macrophage uptake. This apo B accumulation in 
macrophage cells occurs under the same conditions that significant cholesteryl ester 
accumulation is observed and suggests a perturbation of normal cell metabolism. 
Further studies are needed to examine this. 
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8 CHAPTER 8: GENERAL OVERVIEW 
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 8.1  Prelude 
The purpose of the research undertaken in this thesis was to examine the effects of 
glycated/glycoxidised LDL on arterial cell types, especially on macrophage foam cell 
formation. A number of studies have implicated glycation and glycoxidation reactions, 
and the resulting AGE formation in diabetes-induced atherosclerosis [80, 82, 84-87, 90, 
229, 241, 243-245]. However, although glycation and glycoxidation reactions and the 
formation of AGEs are implicated in atherosclerosis, the mechanisms behind the 
increased atherosclerosis observed in people with diabetes are not completely defined. 
Previous work has shown that LDL may be subject to glycation/glycoxidation reactions 
[164, 166, 242, 258-260]. Glycation/glycoxidation of LDL can affect its cellular 
catabolism and the degradation of such particles in vivo [260, 262-265]. LDL from 
people with diabetes [166] or LDL subjected to glycation/glycoxidation reactions [162-
165, 167, 267, 269, 271], can be recognised by macrophage scavenger receptors, 
resulting in macrophage foam cell formation. 
However, many of the studies reporting macrophage foam cell formation after 
exposure to glycated/glycoxidised LDLs are not ideal. For example some of these 
studies have used poorly characterised LDL particles, some have only indirectly 
quantified cellular levels of cholesteryl esters, and some have assumed that 125I-LDL 
metabolism (with the 125I label present on Tyr residues) is representative of cellular 
handling of both the lipid and protein components of LDL. There is also little reported 
data on the effects of glycated/glycoxidised LDL on other arterial cell types, such as 
endothelial and smooth muscle cell types. Therefore the research undertaken in this 
thesis has been undertaken to examine the effect of well-characterised glycated LDL 
particles on arterial cells, especially in regards to foam cell formation. In the following 
Sections the results reported in this thesis are summarised, with the potential 
implications considered, as well as discussion of avenues for possible further 
investigation. 
 
8.2  Covalent Protein Modification of Apolipoprotein B in Low-
Density Lipoproteins exposed to Glucose, Methylglyoxal and 
Glycolaldehyde 
In Chapter 3 it was demonstrated that glycation of LDL was possible, without 
significant accompanying formation of oxidation products. Glycation of LDL by 
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 glucose, methylglyoxal and glycolaldehyde resulted in increases of the net negative 
charge, aggregation/crosslinking, and the loss of key amino acid residues, of the apo B 
protein. These changes occurred without significant loss of cholesterol and cholesteryl 
esters in the LDL particles and without significant formation of protein and lipid 
oxidation products, such as DOPA, o-Tyr, 7-ketocholesterol and cholesteryl ester 
hydro(pero)xides. Consistent with this, was the lack of detectable radical formation and 
antioxidant (α-tocopherol) depletion that may have occurred with lipid or protein 
oxidation reactions. However, the covalent modification of apo B by glucose, 
methylglyoxal and glycolaldehyde differed in the rate, nature and extent of 
modification. 
Incubation with glucose, in the presence or absence of Cu2+, gave rise to the least 
modified LDL, of the three modifying agents used under the conditions examined. After 
2 weeks of modification of LDL by 100 mM glucose, at 37 ºC, the REM of the LDL 
was only increased by ~ 0.5 compared to control LDL incubated for the same time 
period, the extent of aggregation/crosslinking was less than the other glycated LDLs, 
and of the three amino acid residues quantified only loss/modification of Arg residues 
was significant. The loss of the Arg residues could be due to the covalent modification 
of Arg residues, with this resulting in crosslinking and increases in the net negative 
charge of the particles. Modification of Arg residues in glucose-modified LDL is 
consistent with a study on known AGEs reporting greater levels of plasma and tissue 
Arg-derived AGEs, than those from Lys residues, in vivo [198]. Minimal modification 
of Lys residues in LDL from people with diabetes has also been reported [260], 
indicating that the glycated LDL used in these studies is to some degree consistent with 
in vivo glycated LDL. 
2+The modification of LDL with 100 mM glucose and 1 μM Cu , did not result in 
greater modification of the particles, when compared to LDL modified by glucose in the 
absence of Cu2+. A number of studies have shown that the glycoxidation of isolated 
proteins is dependent on, and/or catalysed by, metal ions in the presence of oxygen 
[194, 195, 217]. This dependence has also been reported for the modification of lipid 
and protein components in LDL by glucose [188, 268-271, 361]. The previous studies 
that have reported a stimulatory effect of glucose on Cu2+-mediated LDL oxidation used 
higher ratios of Cu2+: LDL (ranging from 1.25:1 to 31:1) [268, 271, 335, 361], than that 
employed in the present study (0.5:1). The low levels of Cu2+ used in this study are 
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2+closer to in vivo levels of Cu  found in diseased and healthy human artery samples (~ 7 
and 2 pmol/mg tissue respectively) [364].  
 Methylglyoxal has been reported to be more reactive than glucose with protein 
targets [209, 210, 357]. Modification of LDL by 10-100 mM methylglyoxal, for up to 2 
weeks at 37 º C, resulted in faster and greater changes in the overall negative charge of 
the particles, crosslinking/aggregation and losses in Arg, Lys and Trp residues of apo B, 
when compared to glucose-modified LDL. The loss of Arg and Lys residues in these 
studies is consistent with the overall increase in the negative charge of the particles, as 
well as the reports of methylglyoxal-induced Lys and Arg crosslinks, such as 
methylglyoxal-lysine dimer (MOLD), CEL, argpyrimidine and imidazolone products 
[196, 198, 210, 212]. Methylglyoxal is well documented to be elevated in people with 
diabetes [225, 227], and methylglyoxal-derived products have been reported to occur in 
patients with diabetes, at levels higher than other known AGEs [198].  Thus, the 
modification of proteins by methylglyoxal is likely to be of significance in vivo. The 
loss of Trp residues in these studies appears to be a novel result and could potentially be 
another site that AGEs need to be characterised for. 
 Glycolaldehyde is another aldehyde that has been reported to be very reactive 
with LDL [162], with its products reported to be present in atherosclerotic lesions [246]. 
Modification of LDL by 1-100 mM glycolaldehyde, for up to 2 weeks at 37 º C, resulted 
in faster and greater changes in the overall negative charge of the particles, 
crosslinking/aggregation and losses in Lys and Trp residues of apo B, when compared 
to glucose- and methylglyoxal-modified LDL. However, Arg residues of the apo B 
protein were more rapidly lost with methylglyoxal, than glycolaldehyde. This is an 
agreement with other previously published work that indicates Arg residues are a 
preferred target for methylglyoxal [167, 210, 373] and Lys residues for glycolaldehyde 
[162, 224]. Possible products that may have been formed on the Lys residues of 
glycolaldehyde-modified LDL include CML, N6-{2-[(5-amino-5-
carboxypentyl)amino]-2-oxoethyl}lysine (GOLA) and N6-glycoloyllysine (GALA) 
[213, 214], though this was not examined in this study. 
Overall these studies show that it is possible to generate well-characterised LDL 
particles that have significant covalent modification or glycation, in the absence of 
significant levels of oxidation. The reaction of low-molecular-mass aldehydes with 
proteins may be more significant for the formation of AGE-modified proteins in disease 
states, than glucose reactions with proteins. The concentrations of glucose and 
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 methylglyoxal used in these studies were supraphysiological, however the possible 
subendothelial entrapment of lipoproteins, as per the ‘response to retention’ hypothesis 
[33, 34, 39-41, 103, 104, 119], provides a potential mechanism for similar modification 
to occur in vivo, as lipoproteins could be exposed to lower concentrations of glucose 
and the aldehydes for longer time periods. The subendothelial entrapment of LDL 
would also allow for longer modification times of these particles compared to the 2 day 
circulation time of LDL in plasma [102]. Thus, the longer incubation times utilised in 
some of these studies (e.g. 14 days) may be of relevance in vivo. These studies also 
provided well-characterised LDL to examine what effect glycated, rather than 
glycoxidised, LDL has on cellular metabolism in arterial cells. 
 
8.3  The Effect of Low-Density Lipoprotein Modified by Glucose, 
Methylglyoxal and Glycolaldehyde on Arterial Cell Types 
Arterial cells were exposed to the glycated LDLs discussed in the preceding 
Section. Endothelial cells (HUVEC) were exposed to the glycated LDLs for 48 hr, with 
no significant effect found on cellular viability, proliferation, and cholesterol and 
cholesteryl ester levels, when compared to cells exposed to control LDLs. Cellular 
cholesteryl ester levels increased in all cells exposed to LDLs, when compared to cells 
not exposed to LDL, however theses increases occurred regardless of whether cells 
were exposed to control or glycated LDLs. A7r5 rat aortic smooth muscle cells, whether 
serum deprived or not, were exposed to glycated LDLs for 24 hr with no significant 
effects found on cellular viability, proliferation and free cholesterol levels. The levels of 
cholesteryl esters in smooth muscle cells were below detection limits with the methods 
utilised, indicating that smooth muscle cells do not become model foam cells upon 
exposure to glycated LDLs, under the conditions used in these studies. However, these 
studies do not rule out possible perturbations in endothelial or smooth muscle 
metabolism due to exposure to these glycated LDLs, that may be pro-atherogenic, such 
as the release of cytokine, adhesion and growth factor molecules [14, 29, 280, 351, 352, 
405, 409, 418, 419], or altered rates or extents of cellular apoptosis [27, 288]. 
J774A.1 and HMDM cellular viability, proliferation and free cholesterol levels 
were not affected upon exposure to glycated LDLs under the conditions used. However 
significant increases in cholesteryl ester levels were observed in macrophages, upon 
exposure to some of the glycated LDLs, and thus the formation of model lipid-laden 
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 (foam) cells. Significantly increased cholesteryl ester levels were found in both human 
and mouse macrophages exposed to glycolaldehyde-modified LDL. With J774A.1 cells 
24 hr of LDL modification by glycolaldehyde was sufficient for macrophage scavenger 
receptor recognition and cellular accumulation of cholesteryl esters. Exposure of 
macrophages to LDL modified by methylglyoxal for 7-14 days, also resulted in 
significant cellular accumulation of cholesteryl esters, however this was not to the 
extent observed in cells exposed to glycolaldehyde-modified LDL, even when the 
modification time of LDL by methylglyoxal was extended. Differences were observed 
in the mouse and human macrophage handling of methylglyoxal-modified LDL. For the 
same level of LDL modification by methylglyoxal, HMDM accumulated more 
cholesteryl esters than the J774A.1 murine macrophage-like cells. This may have 
occurred due to the different exposure times of macrophages to the glycated LDLs (24 
hr for J774A.1 cells versus 96 hr for HMDM) or differences in lipid metabolism 
between mouse and human derived macrophages [395, 422]. Neither human or mouse 
macrophages accumulated significant cholesteryl esters upon exposure to glucose-
modified LDL, suggesting this LDL was not modified to an extent which was 
recognised by macrophage scavenger receptors. The cholesteryl ester profile in 
macrophages exposed to glycated LDLs differed to the cholesteryl ester profile 
observed for the modified LDL to which it was exposed. Thus for the LDL particles 
there was a 2-fold greater level of cholesteryl linoleate than oleate, whereas these esters 
were found at similar levels in the LDL-exposed macrophages. It has been previously 
shown that once LDL is taken up by macrophages it undergoes a continual esterification 
and hydrolysis cycle, with this potentially resulting in different cholesteryl ester ratios 
when compared to the original LDL [31, 36, 129].  
Further studies with human macrophages showed that some of the glycated LDLs 
were endocytosed and degraded more quickly than others, and that the differences in the 
endocytosis and degradation rates resulted in cellular accumulation of the covalently 
modified apo B. Glycolaldehyde-modified LDL was endocytosed and degraded, by 
macrophages, in significantly greater amounts than LDL modified by methylglyoxal, or 
glucose in the presence or absence of Cu2+. The apo B from glycolaldehyde-modified 
LDL also accumulated in greater amounts in macrophages, when compared to other 
glycated LDLs. Apo B from LDL modified by methylglyoxal was also endocytosed and 
degraded in greater amounts, however significant accumulation did not occur compared 
to control LDLs. Cellular endocytosis, degradation and accumulation of apo B from 
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 LDL modified by glucose was not above control LDL levels. In some studies, after 96 
hr of exposure to modified LDLs, macrophages were exposed to LDL-free media to 
examine the turnover of the accumulated apo B. The accumulated apo B was turned 
over slowly by HMDM, with ≥ 65 % remaining at the end of the chase period, 
regardless of which LDL modification the cells were exposed to. However at the end of 
this chase period intracellular apo B levels were still much higher in cells exposed to 
glycolaldehyde-modified LDL, compared to cells exposed to methylglyoxal- or 
glucose-modified LDL.  
This accumulation of apo B from glycolaldehyde-modified LDL may occur due to 
the resistance of this modified apo B to lysosomal degradation, thus leading to 
intracellular (lysosomal) accumulation as reported for other glycated or modified 
proteins [237, 238, 276] and oxidised LDL [152, 379, 380]. The intracellular 
accumulation of oxidised LDL has partially been explained by its resistance to 
degradation by cathepsins [380]. In our laboratory AGE proteins have also been shown 
to inhibit lysosomal cathepsins (Jingmin Zeng et al, unpublished results). Thus possible 
reasons for the accumulation of AGEs in diabetic tissues may be due to the resistance of 
these modified proteins to proteolysis, that is they may be poorly and/or slowly 
degraded. These concepts need to be examined further. The accumulation of apo B 
within macrophages may also be related to the cholesteryl ester accumulation observed 
under similar conditions, that is, there may be an interdependence of proteolysis on 
lipolysis (or vice versa). For example, Jessup et al postulated from studies with oxidised 
LDL that failure of macrophages to degrade modified apo B may protect LDL 
cholesteryl esters in the core of the particle from lysosomal esterases; or that impaired 
lipolysis of LDL lipids may block proteolysis of apo B as the more hydrophobic regions 
of the apo B are not exposed [152]. Besides possible perturbations in proteolysis and 
lipolysis the internalisation of AGE proteins may also led to other pro-atherogenic 
effects, such as release of cytokines, TNF-α, PDGF, IGF-1 and IL-1β [280]. Thus the 
accumulation of AGE-modified proteins may have significant cellular and atherogenic 
effects. 
 There did appear to be some correlation of cellular accumulation of cholesteryl 
esters and apo B from glycated LDLs, to the rate and extent of modification of the LDL 
particles. Overall, the greater the increase in the overall negative charge, 
aggregation/crosslinking, and amino acid loss/modification of the apo B, the greater the 
accumulation of cholesteryl esters and apo B from glycated LDLs in macrophages. Thus 
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 a greater uptake of methylglyoxal- and glycolaldehyde-modified LDL by macrophages 
was observed than with glucose-modified LDL or control LDLs.  
However there were differences in the cellular uptake of methylglyoxal- and 
glycolaldehyde-modified LDL. These differences in the cellular metabolism of 
methylglyoxal- and glycolaldehyde-modified LDL persisted even when the 
modification time of LDL by methylglyoxal was increased to account for the 
differences in the rate of reactions between methylglyoxal and glycolaldehyde with 
LDL. Upon examination of the extent of amino acid loss/modification, it was observed 
that the loss of Trp and Lys correlated better with cellular accumulation of cholesteryl 
esters and apo B, than Arg loss, REM changes and the extent of apo B 
crosslinking/aggregation. These observations were made on the basis of the observation 
that LDL could be modified in such a way by glycolaldehyde such that only Lys and 
Trp modification occurred and no Arg modification, and cellular cholesteryl ester 
accumulation in macrophages exposed to such modified LDL. This was in contrast to 
the significant Arg loss observed on incubation of LDL with glucose that did not result 
in macrophage cholesteryl ester accumulation. Modification of LDL by methylglyoxal 
also resulted in significant Arg loss, but did not always results in significant 
macrophage cholesteryl ester accumulation. When the modification time of LDL by 
methylglyoxal was increased to account for the slower amino acid residue loss, thereby 
producing comparable Arg, Lys and Trp loss to that observed with the glycolaldehyde-
modified LDL, cholesteryl ester accumulation was still less in cells exposed to the 
methylglyoxal-modified LDL when compared to the glycolaldehyde-modified LDL. 
This is an agreement with previous literature that has reported a dependence, or 
threshold, of macrophage scavenger recognition of Lys modification, which is 
dependent on the type of LDL modification used [145, 146, 162, 389]. Little work has 
been reported previously on the modification of Trp residues and macrophage scavenger 
receptor recognition.  A possible reason for the differences in the cellular handling of 
the aldehyde-modified LDLs is the formation of different products from the key amino 
acids, which may affect macrophage scavenger receptor recognition. Therefore it is 
concluded that the loss of Lys residues (and perhaps Trp residues) per se, and/or the 
products formed from these residues, may be important for macrophage scavenger 
recognition and model foam cell formation.  
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 8.4  Future Directions 
The studies in this thesis have examined the in vitro glycation and glycoxidation 
of LDL by examining the modification of LDL by glucose, methylglyoxal and 
glycolaldehyde. To obtain further detail on the role of protein versus lipid 
oxidation/modification on the glycation of LDL, other molecules that participate in 
glycation and glycoxidation reaction, for example 3-deoxyglucosone and glucosone 
[201, 208, 209], could be examined using the methods detailed in this thesis.  
The modification of LDL was examined by determining the changes in the apo B 
component, such as overall charge, size, protein oxidation product formation and Arg, 
Lys and Trp residue losses. However, it was recently reported that AGE products may 
also arise from modification of Cys residues [196], and thus complete amino acid 
analysis (for example using a pre-column derivitisation reagent, followed by HPLC 
detection [377]) of the glycated apo B would provide information on what amino acid 
residues are involved in the glycation reactions. A number of groups have developed 
techniques for determination of AGE products that could be used to determine what 
AGEs are formed on glycated apo B [196, 198, 303]. These amino acid analyses and 
product studies may provide explanations for the observed increased cellular 
accumulation of cholesteryl esters and apo B from glycolaldehyde-modified LDL, 
compared to methylglyoxal-modified LDL. 
Parameters of lipid oxidation were also examined in the glycated LDLs, such as 
cholesterol and cholesteryl ester loss and the formation of lipid oxidation products, such 
as 7-ketocholesterol. However phospholipids and triglycerides are also present in LDL 
particles (~ 20 and <10 % respectively by mass) [102-107]. AGE products have been 
reported to be formed on the primary amino groups of phospholipids [277], such as 
glucosylated phosphatidylethanolamines in glucose-modified LDL [278].  
Phospholipids can also be subjected to peroxidation [424]. Thus the phospholipids in 
the glycated LDLs used in these studies could have been modified/oxidised and this 
needs to be examined. There are methods available to examine the phospholipid and 
triglyceride content of lipoproteins [425, 426]. 
 If studies are performed examining the modification of LDL by other molecules 
that participate in glycation and glycoxidation reaction (for example 3-deoxyglucosone 
and glucosone [201, 208, 209]), the effects of such modified particles on arterial cell 
types should also be examined. This may aid in determining a comprehensive model of 
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 what changes in glycated LDL results in scavenger receptor recognition and cellular 
effects. 
 In Chapter 4 it was reported that methylglyoxal and glycolaldehyde are toxic to 
macrophages. Work in our laboratory has determined that methylglyoxal and 
glycolaldehyde can affect cellular enzymes, such as LDH, GAPDH and glutathione 
reductase [357], as well as cathepsins (Jingmin Zeng et al, unpublished results). These 
may contribute towards the toxic effects of the aldehydes, however the full reasons 
would be worth elucidating, especially as methylglyoxal is elevated in people with 
diabetes [225, 227] and may add to the apparent cellular dysfunction. 
 Studies with HMDM examined the accumulation and turnover of apo B from 
glycated 125I-LDLs over many time points, but cellular cholesteryl esters were only 
determined at one time point. In Section 8.3 it was discussed how the accumulation of 
apo B within macrophages may be related to the cholesteryl ester accumulation and it 
was proposed there may be an interdependence of proteolysis on lipolysis (or vice 
versa). It would be of interest therefore to know whether the accumulation of apo B and 
cholesteryl esters occurs concurrently, or if one precedes the other. This may have 
implications for the formation of foam cells, and cellular dysfunction, in cells exposed 
to glycated LDLs. 
 Further possible experiments using the glycated 125I-LDLs could include uptake 
and turnover studies of apo B, from the modified LDLs, in endothelial and smooth 
muscle cells. The glycated 125I-LDLs could also be used to determine which cellular 
compartments the apo B accumulates in within macrophages. This again would give 
information on the mechanisms of the cellular dysfunction leading to such protein 
accumulation. Once the site of apo B accumulation is determined further experiments to 
determine why such accumulation occurs in that department could be performed. Apo B 
from oxidised LDL has been reported to accumulated in lysosomes [152, 379, 380], 
perhaps due to its resistance to degradation by cathepsins [380]. 
Likewise the determination of where and how the cholesteryl ester accumulation 
occurs in macrophages also needs to be resolved. The cytostolic accumulation of 
cholesteryl esters could be determined by histological methods, for example using lipid 
staining [267, 427], immunofluorescence techniques [379] or electron microscopy [16], 
as well as subcellular fractionation techniques [154, 379]. If there was significant 
cholesteryl ester accumulation in lysosomes the effects of the glycated apo B on the 
lysosomal cholesteryl ester hydrolases may need to be examined, as their action may be 
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 impaired. The cholesteryl ester accumulation pathway could also be examined using 
inhibitors of ACAT [411]. Another possible future direction could also include whether 
macrophages can efflux the accumulated cholesteryl esters, in the presence of suitable 
cholesterol acceptors such as HDL [128, 129].  
Glycation and glycoxidation reactions can occur on other apolipoproteins 
besides apo B [258]. Using the methods outlined in this thesis other 
glycated/glycoxidised lipoproteins may be characterised and their biological effects 
determined. Thus, for example, it would be of interest to examine the effects of 
glycation on the apo AI and/or apo AII proteins of HDL and thus the consequent effects 
of glycation/glycoxidation on the reverse cholesterol transport pathway (i.e. cholesterol 
efflux from arterial wall cell types). 
 It also needs to be determined what scavenger receptors are responsible for 
cholesteryl ester and apo B accumulation from glycated LDLs. This could be examined 
using peritoneal macrophages obtained from mice lacking in specific scavenger 
receptors [137, 138] and assessing cholesteryl ester and apo B accumulation upon 
exposure to glycated LDLs. Competition studies using proteins with various different, 
but well characterised, modifications could also be used to determine what scavenger 
receptors are involved in the uptake of these glycated LDLs, as there has been some 
previous work reporting which receptors do, and do not, recognise LDL modified by 
acetylation, oxidation or AGEs (reviewed in [134]). 
 Other cellular effects that occur due to the exposure of arterial cells or tissues to 
glycated LDLs could also be examined, especially pro-atherogenic changes. This could 
include studies at a molecular level, such as examining cellular changes in transcription, 
translation and protein expression [139-143]. The cellular release of growth factors, 
cytokines, adhesion molecules, or other pro-atherosclerotic factors could also be studied 
[14, 29, 280, 287, 351, 352, 405, 409, 418, 419], as well as the presence of markers of 
apoptosis [288, 381]. Other possible pro-atherogenic effects of glycated LDLs could be 
increased monocyte adhesion to endothelial cells [414], subendothelial entrapment of 
such modified particles in animal models [34, 119], and cell chemotaxis [8, 22, 285]. 
The work in this thesis has provided a suitable model of foam cell formation 
induced by glycated, but minimally-oxidised LDL. The studies embodied in this thesis 
also provide a pathway to explain the increased atherosclerosis observed in people with 
diabetes; that is glycated LDL induces cholesteryl ester and apo B accumulation in 
macrophages, characteristics of foam cells [16, 49-53, 127]. Therefore we have 
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 developed a model appropriate to study inhibition of the glycation of LDL, and 
subsequent cholesteryl ester and apo B accumulation in macrophages, and thus the 
potential prevention or attenuation of diabetes-induced atherosclerosis. The inhibition of 
the glycation and glycoxidation of LDL, and thus the prevention of cellular uptake of 
these modified particles may have therapeutic benefits. These studies could include the 
addition of inhibitors to the in vitro glycation of LDL, or examining the effect of such 
inhibitors in animal models of diabetes and diabetes-induced atherosclerosis [80, 304, 
305, 428, 429]. Compounds that inhibit (or potentially inhibit) glycation and 
glycoxidation reactions, have been discussed in Section 1.3.4. Work already initiated in 
our laboratory has shown that even incomplete inhibition of the glycation of LDL, by 
carbonyl scavengers such as aminoguanidine, among other types of reagents, can 
completely inhibit cholesteryl ester accumulation in both human and mouse 
macrophages (Fathima Mahroof, Imran Rashid, Naomi Cook, Bronwyn Brown et al, 
unpublished results). These studies highlight that ‘carbonyl stress’, as proposed by 
Baynes et al [256], may indeed promote foam cell formation and atherosclerosis in 
people with diabetes, and may provide potential mechanistic details and intervention 
therapies for diabetes-induced atherosclerosis. 
Overall these studies, and possible future directions discussed in this thesis, may 
contribute to a better, more comprehensive, understanding of foam cell formation from 
glycated/glycoxidised LDLs. These studies demonstrate a mechanism, which may 
contribute to the accelerated atherosclerosis in people with diabetes, and provide a basis 
from which intervention therapies may evolve. 
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